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Established cardiovascular risk factors such as hypertension, hyperlipidemia, diabetes mellitus and 
smoking do not fully explain the occurrence of cardiovascular disease; although the majority of pa-
tients have at least one of these risk factors, a substantial proportion of cases occurs in individuals that 
have none.1 As such, further insight is required into the pathophysiology of cardiovascular disease 
and in factors that may identify individuals at high risk.
One of the most relevant insights in atherosclerosis of the past years is the recognition of the 
role of inflammation.2 Research on inflammatory markers, both experimental and epidemiological, 
has taken flight, and several of these markers have been implicated in cardiovascular disease.3 This 
development was accompanied by an expansion of research on genetic variation that may influence 
inflammatory processes. The field of genetics has rapidly evolved over the last years because of im-
proved technology and methodology in combination with the emergence of large, publicly available 
genetic databases.4
The purpose of this thesis was to expand the knowledge on inflammatory markers and inflam-
matory genes that may play a part in the pathophysiology of cardiovascular disease. We focused on 
factors that have drawn increased attention in the recent years, such as C-reactive protein (CRP) and 
lipoprotein-associated phospholipase A2 (Lp-PLA2), and examined their roles in both atherothrom-
botic disease and in heart failure. Most studies were conducted within the Rotterdam Study, a popula-
tion-based cohort study among 7983 men and women aged 55 years and over living in a well-defined 
suburb of Rotterdam, the Netherlands.5 During a visit of the participants to the research center, blood 
was drawn in order to assess inflammatory markers and genetic variation. Several measures of ath-
erosclerosis were assessed at the research center, and furthermore, participants were followed-up 
for the occurrence of coronary events and heart failure. Specifically, the main research questions we 
examined were as follows.
With regard to inflammation, atherosclerosis and coronary events:
- Is CRP serum level associated with atherosclerosis and coronary events?
- Is variation in the CRP gene and variation in the complement factor H gene associated with coro-
nary events, and do these genes interact to predict disease?
- Is Lp-PLA2 activity associated with atherosclerosis?
With regard to inflammation and heart failure:
- What is the distribution of echocardiographic parameters in an asymptomatic population, and do 
these parameters predict mortality?
- Are the inflammatory markers CRP and Lp-PLA2 associated with the occurrence of heart failure?
The outline of this thesis is as follows. Part I focuses on inflammation and atherosclerotic disease. 
Serum levels of C-reactive protein are investigated in relation to coronary events and atherosclerosis, 
and genetic variation in the C-reactive protein gene and the complement factor H gene is examined in 
relation to coronary events (chapter 2). The associations of lipoprotein-associated phospholipase A2 
activity in plasma with coronary calcification and extracoronary atherosclerosis are described (chapter 
3). Hereafter, other emerging genes and markers which are related to inflammation receive attention; 
genetic variation in the fibrinogen alpha and gamma genes is examined in relation to cardiovascular 
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outcomes, and the association between plasma level of heat shock protein 27 and cardiovascular 
disease is investigated in the Women’s Health Study (chapter 4). Part II focuses on inflammation and 
heart failure. Established cardiovascular risk factors are examined in relation to echocardiographic pa-
rameters, and the association of echocardiographic parameters with all-cause mortality is described. 
Associations of C-reactive protein and lipoprotein-associated phospholipase A2 with heart failure are 
investigated (chapter 5). In Part III, an overview is given of the prevalence of atherosclerosis in the Rot-
terdam Study in both genders (chapter 6). Finally, in the general discussion (chapter 7), methodologi-
cal considerations are addressed, the main findings of this thesis are placed in a broader context, and 
potential clinical implications and directions for future research are discussed.
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Chapter 2
C-reactive protein and complement factor H

19
Chapter 2.1
C-reactive protein level, C-reactive protein 
gene haplotypes, and coronary heart 
disease
Abstract
Aims. C- reactive protein is associated with risk of cardiovascular disease. However, whether C-reac-
tive protein is a marker of severity of cardiovascular disease or actually is involved in its pathogenesis 
remains unknown. We investigated the relation between C-reactive protein haplotypes, representing 
the comprehensive variation of the C-reactive protein gene, and coronary heart disease.
Methods and results. The Rotterdam Study is a prospective population-based study among men and 
women aged 55 years and older. C-reactive protein was associated with risk of coronary heart disease, 
with a multivariate adjusted hazard ratio of 1.9 (95% confidence interval 1.5-2.4) for the highest ver-
sus the lowest quartile. Four C-reactive protein haplotypes were present with overall frequencies of 
32.8%, 31.7%, 29.5%, and 5.9%. C-reactive protein serum levels were significantly different according 
to C-reactive protein haplotypes. C-reactive protein haplotypes were not associated with coronary 
heart disease.
Conclusion. Steady-state C-reactive protein serum level is influenced by C-reactive protein gene hap-
lotypes. Although elevated C-reactive protein level has lately been found to be a consistent and rela-
tively strong risk factor for cardiovascular disease, our study does not support that the common varia-
tion in the C-reactive protein gene has a large effect on the occurrence of coronary heart disease.
Chapter 2.1
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Introduction
C- reactive protein is associated with cardiovascular disease.1 However, whether C-reactive protein 
is merely a marker of severity of cardiovascular disease or actually is involved in its pathogenesis 
remains unknown. Genetic markers offer a possibility to study this.
Evidence has emerged that C-reactive protein may play a pathogenic role in cardiovascular dis-
ease.2 If this is true, genetic variants associated with high C-reactive protein level may be associated 
with greater risk of cardiovascular disease. The genes involved in this regulation remain ill-defined. 
The C-reactive protein gene is likely to play a part, since several studies have demonstrated associa-
tions between single nucleotide polymorphisms (SNPs) in the C-reactive protein gene and C-reactive 
protein level.3-13 Two recent studies have identified comprehensive sets of common C-reactive protein 
gene haplotypes and found associations of these haplotypes with C-reactive protein level.14,15 One of 
these studies has also examined the association between these haplotypes and myocardial infarction 
or ischemic stroke in a nested case-control study within the Physicians’ Health Study cohort,15 but the 
association between C-reactive protein variants and baseline C-reactive protein did not correlate with 
the effects of those variants on clinical cardiovascular events in this study.
SeattleSNPs (part of the National Heart Lung and Blood Institute’s Programs for Genomic Applica-
tions) reports that four C-reactive protein gene haplotypes are present in populations of European 
descent. These haplotypes represent all common variation across the C-reactive protein gene in these 
populations. To further clarify the role of C-reactive protein in coronary heart disease, we set out to 
investigate the relation between these four C-reactive protein gene haplotypes, C-reactive protein 
serum level and coronary heart disease prospectively in all participants of the large, population-based 
Rotterdam Study.
Participants and Methods
Study population and baseline data collection
The present study is part of the Rotterdam Study, a population-based cohort study aimed at assessing 
the occurrence of and risk factors for chronic diseases in the elderly. Objectives and methods of the 
Rotterdam Study have been described in detail elsewhere.16 The Rotterdam Study cohort includes 
7983 men and women aged 55 years and over (78% of the eligible population), living in a well-defined 
suburb of the city of Rotterdam, The Netherlands. The medical ethics committee of Erasmus Medical 
Center, Rotterdam, approved the study. Participants gave written informed consent and permission to 
retrieve information from treating physicians. This study complies with the Declaration of Helsinki.
Baseline data were collected from 1990 until 1993, as described previously.17 A trained interviewer 
visited all participants at home and collected information on current health status, medical history, 
drug use, and smoking, using a computerized questionnaire. Additionally, in 7129 participants, estab-
lished cardiovascular risk factors were measured at the research center.
CRP level, CRP gene haplotypes, and coronary heart disease
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Measurement of C-reactive protein
At baseline, non-fasting blood was collected. All tubes were stored on ice before and after blood 
sampling. High-sensitivity C-reactive protein was determined in serum, which was stored at -20°C 
until performance of the C-reactive protein measurements in 2003-2004. C-reactive protein was mea-
sured using Rate Near Infrared Particle Immunoassay (Immage® Immunochemistry System, Beckman 
Coulter, USA). This system measures concentrations from 0.2 to 1440 mg/l, with a within-run precision 
< 5.0%, a total precision < 7.5% and a reliability coefficient of 0.995.
Genotyping
The Seattle SNPs Program for Genomic Applications has identified 31 SNPs in the C-reactive protein 
gene and has established that, based on SNPs with overall frequencies above 5%, four common C-
reactive protein gene haplotypes are present in 23 unrelated individuals of European descent from 
the CEPH pedigrees (http://pga.gs.washington.edu/data/crp, “visual haplotype” option). These four 
haplotypes can be identified by “haplotype tagging” SNPs. By genotyping three haplotype tagging 
SNPs we were able to infer all four haplotypes and consequently to describe the common variation 
across the C-reactive protein gene (figure 1). These three tagging SNPs were chosen partly based on 
their presence in existing literature and on their proximity to the C-reactive protein gene. Other SNPs 
were also eligible, since a range of SNP trios across the C-reactive protein gene captures the four most 
common haplotypes among European participants.
Figure 1. The C-reactive protein gene, C-reactive protein gene polymorphisms determined in this study 
and common C-reactive protein gene haplotypes.
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All participants were genotyped for the 1184 C>T, 2042 C>T and 2911 C>G SNPs of the C-reactive 
protein gene. The polymorphisms are described in relation to the start of the coding sequence of exon 
1 using the Human May 2004 (hg 17) assembly (http://genome.ucsc.edu). These polymorphisms have 
also been described at http://www.ncbi.nlm.nih.gov/SNP under identification numbers rs1130864 
(1184 C>T), rs1205 (2042C>T) and rs3093068 (2911 C>G).
DNA was extracted according to standard procedures. DNA was solubilized in double-distilled wa-
ter and stored at -20ºC until used for DNA amplification. Genotypes were determined in 2 ng genomic 
DNA with the Taqman allelic discrimination assay (Applied Biosystems, Foster City, CA, USA). Primer 
and probe sequences were optimized by using the SNP assay-by-design service of Applied Biosystems 
(http://store.appliedbiosystems.com). Reactions were performed with the Taqman Prism 7900HT 384 
wells format. Haplotype alleles present in the population were inferred by means of the haplo.em 
function of the program Haplo Stats (http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.
html), which computes maximum likelihood estimates of haplotype probabilities.18,19 Haplotype re-
construction resulted in seven haplotypes, but the fifth, sixth and seventh haplotypes were present in 
<0.001% of the alleles and were therefore not used in the analyses. Haplotype alleles were coded as 
haplotype numbers 1 through 4 in order of decreasing frequency in the population: coding from 1184 
C>T, 2042C>T and 2911 C>G, haplotype 1= C-T-C, 2= T-C-C, 3= C-C-C and 4= C-C-G (figure 1).
Follow-up procedure
Follow-up started at the baseline examination and for the present study lasted until January 1st, 2002. 
Information on fatal and non-fatal cardiovascular endpoints was obtained from general practitioners 
(GPs) and letters and discharge reports from medical specialists.17 Two research physicians indepen-
dently coded all reported events according to the International Classification of Diseases, 10th edition 
(ICD-10).20 In case of disagreement, consensus was reached. A medical expert in cardiovascular dis-
ease, whose judgment was considered final, reviewed all events.
We defined incident coronary heart disease as myocardial infarction, coronary artery bypass graft-
ing (CABG), percutaneous transluminal coronary angioplasty (PTCA) and cardiac death. In identifying 
myocardial infarctions, all available information, which included ECG, cardiac enzyme levels, and the 
clinical judgment of the treating specialist, was used. We defined cardiac death as death from myo-
cardial infarction or other ischemic heart disease (ICD-10: I20-I25), sudden cardiac death (I46), sudden 
death undefined (R96), or death from heart failure (I50).
Population for analysis
C-reactive protein serum levels were available for 6658 participants. C-reactive protein measurements 
were lacking for participants who did not visit the research center (854) and for participants of whom 
no blood was available due to logistic reasons (471). After excluding participants with coronary heart 
disease at baseline (870), defined as a history of myocardial infarction, PTCA or CABG, 5788 partici-
pants were left for the analysis of the association between C-reactive protein serum levels and coro-
nary events.
DNA was available for 6571 participants. Genotyping of all 3 polymorphisms was successful in 
6007 participants. For 5584 of these participants, C-reactive protein serum levels were available. After 
CRP level, CRP gene haplotypes, and coronary heart disease
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excluding participants with coronary heart disease at baseline, 5231 participants were left for the 
analysis of the association between C-reactive protein haplotypes and coronary events.
Data analysis
Linear regression was used to investigate the association between C-reactive protein serum levels and 
established cardiovascular risk factors. After log-transformation of C-reactive protein, the residuals 
were normally distributed with a constant variance.
Subsequently, participants with coronary heart disease at baseline were excluded, and Cox pro-
portional hazards analysis was used to determine the relative risks of coronary heart disease and 
myocardial infarction associated with increasing C-reactive protein quartiles (cut-points 0.9, 1.8 and 
3.5 mg/l). The proportional hazards assumption was tested by drawing log minus log plots of the 
survival function. We adjusted for age and sex (model 1), and subsequently for age, sex, body mass 
index, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, 
and diabetes mellitus (model 2).
Hardy-Weinberg equilibrium of the three C-reactive protein gene polymorphisms was tested using 
a Chi square test. Differences in serum C-reactive protein levels (log transformed) and established car-
diovascular risk factors for the three polymorphisms were examined by using analysis of covariance, 
adjusting for age and sex, categorizing the participants by their genotypes. We used the Bonferroni 
correction to account for multiple testing (three genotypes). All the above analyses were performed 
by using SPSS 11.0 for Windows.
To test the associations of C-reactive protein gene haplotypes with cardiovascular risk factors, 
we used the program Haplo Stats (http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.
html).18,19,21 The probability for each haplotype pair in each individual was assigned and then an indi-
vidual’s phenotype was directly modeled as a function of each inferred haplotype pair, weighed by 
their estimated probability, to account for haplotype ambiguity. The haplo.score function of Haplo 
Stats was used to test the associations. Details on the background and theory of score statistics can be 
found in Schaid et al.21 We adjusted for age and sex and we computed global simulation P-values and 
simulation P-values for each haplotype. The number of simulations was set as 1000.
Since haplo.score does not provide the magnitude of the effect of each haplotype, the associa-
tion between C-reactive protein gene haplotypes and C-reactive protein serum level, coronary heart 
disease and myocardial infarction was investigated by using the haplo.glm function of Haplo Stats.19 
This approach is based on a generalized linear model, and computes the regression of a trait on hap-
lotypes and other covariates. For the analysis regarding the disease outcomes, the haplotype that 
was found to be associated with the lowest serum C-reactive protein levels served as the reference 
category. First, we adjusted for age and sex, and second, we additionally adjusted for body mass in-
dex, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, and 
diabetes mellitus. Haplo.em, haplo.score and haplo.glm were all implemented in the Haplo Stats soft-
ware using the R language.
Values for cardiovascular covariates were missing in less than 4% of participants. These missing val-
ues were handled by single imputation using the expectation-maximization algorithm in SPSS 11.0. 
All tests were two-sided.
Chapter 2.1
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Results
Table 1 shows baseline characteristics of the total cohort and their associations with C-reactive pro-
tein serum level. All studied characteristics, except for total cholesterol, were significantly associated 
with C-reactive protein serum level.
The mean follow-up time was 8.1 years (standard deviation 3.0 years). Among participants without 
history of coronary heart disease, 584 (8.8%) participants experienced incident coronary heart disease 
during follow-up, including 224 myocardial infarctions. Hazard ratios for coronary heart disease and 
myocardial infarction increased significantly across quartiles of C-reactive protein (table 2). When we 
repeated the analysis without excluding participants with coronary heart disease at baseline, the re-
sults did not change materially.
Genotype distributions for the three haplotype tagging SNPs were in Hardy-Weinberg equilibrium. 
Both using the Seattle SNPs website and the HapMap website (http://www.hapmap.org), the SNPs 
were found to lie in one linkage disequilibrium block. The 1184 T allele was present in 31.6% of 12014 
chromosomes, the 2042 T allele in 32.7% and the 2911 G allele in 6.0%. Figure 2 shows differences in 
serum C-reactive protein levels according to the genotype of the three C-reactive protein polymor-
phisms. For all three polymorphisms we observed an allele dose effect. No associations were present 
between genotypes and established cardiovascular risk factors (data not shown). Genotypes were not 
associated with coronary heart disease and myocardial infarction (data not shown).
Haplotype alleles were present in the following frequencies: haplotype 1 (C-T-C) in 32.8%; hap-
lotype 2 (T-C-C) in 31.7%; haplotype 3 (C-C-C) in 29.5%, haplotype 4 (C-C-G) in 5.9%; and remaining 
haplotypes (T-C-G, T-T-C and C-T-G) in less than 0.001%.
Figure 2. Geometric means and 95% confidence intervals of serum levels of C-reactive protein (mg/l) for 
three C-reactive protein gene polymorphisms.
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Table 1. Baseline characteristics of the population and age- and sex-adjusted regression coefficients for 
cardiovascular risk factors, describing the increase in log C-reactive protein per unit increase in each risk 
factor.
Variable
Total
(n=6658)
Regression coefficient
(95% confidence interval) P- value
Age (years)* 69.6±9.2 0.020 (0.017, 0.022) 10-45
Women# 3970 (60%) -0.137 (-0.188, -0.086) 10-7
Body mass index (kg/m2) 26.3±3.7 0.065 (0.058, 0.071) 10-79
Systolic blood pressure (mm Hg) 139±22 0.005 (0.004, 0.006) 10-16
Diastolic blood pressure (mm Hg) 74±12 0.003 (0.002, 0.006) 10-4
Total cholesterol (mmol/l) 6.6±1.2 0.006 (-0.015, 0.027) 0.6
HDL-cholesterol (mmol/l) 1.3±0.4 -0.470 (-0.540, -0.399) 10-38
Diabetes mellitus 704 (11%) 0.321 (0.239, 0.402) 10-14
Smokers
- Never 2289 (35%)
- Current (vs never) 1479 (23%) 0.420 (0.347, 0.493) 10-29
- Former (vs never) 2708 (42%) 0.100 (0.035, 0.164) 10-3
History of myocardial infarction 783 (13%) 0.255 (0.176, 0.333) 10-10
Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts because of missings in the variables. 
Values of continuous variables are expressed as mean ± standard deviation.
* Adjusted for sex. # Adjusted for age
Table 2. Hazard ratios for coronary heart disease and myocardial infarction for quartiles of C-reactive 
protein in participants without history of coronary heart disease at baseline.
Events/ participants
Hazard ratio (95% confidence interval)
Model 1 Model 2
Coronary heart disease
Quartile 1 (<=0.9) 92/ 1450 1.0 (reference) 1.0 (reference)
Quartile 2 (>0.9-1.8) 133/ 1450 1.4 (1.1-1.8) 1.3 (1.0-1.7)
Quartile 3 (>1.8-3.5) 158/ 1446 1.7 (1.3-2.1) 1.5 (1.1-1.9)
Quartile 4 (>3.5) 201/ 1442 2.2 (1.7-2.8) 1.9 (1.5-2.4)
P for trend <0.01 <0.01
Myocardial infarction
Quartile 1 (<=0.9) 32/ 1450 1.0 (reference) 1.0 (reference)
Quartile 2 (>0.9-1.8) 62/ 1450 2.0 (1.3-3.0) 1.8 (1.1-2.7)
Quartile 3 (>1.8-3.5) 67/ 1446 2.2 (1.4-3.3) 1.8 (1.2-2.8)
Quartile 4 (>3.5) 63/ 1442 2.1 (1.4-3.2) 1.7 (1.1-2.7)
P for trend 0.07 0.20
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, and 
diabetes mellitus.
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Table 3. Association of C-reactive protein haplotypes with C-reactive protein serum level.
Variable Coefficient Standard error t P value
Intercept -0.83 0.11 -7.56 10-14
Age 0.02 0.002 12.51 < 10-16
Female sex -0.15 0.03 -5.45 10-7
Haplotype 2 (T-C-C) 0.18 0.02 7.50 10-13
Haplotype 3 (C-C-C) 0.10 0.02 3.99 10-4
Haplotype 4 (C-C-G) 0.28 0.04 6.39 10-10
t statistics and P values were calculated from the coefficients and standard errors within the best-fit multivariable model by the haplo.glm 
function of the Haplo Stats R package. Regression coefficients for each haplotype reflect the difference in mean ln(C-reactive protein) per copy 
relative to haplotype 1, the most frequent haplotype.
Table 4. Age- and sex-adjusted odds ratios for coronary heart disease and myocardial infarction for 
C-reactive protein haplotypes in participants without history of coronary heart disease.
Odds ratio (95% confidence interval)
Coronary heart disease Myocardial infarction
Haplotype 1 (C-T-C) 1.00 (reference) 1.00 (reference)
Haplotype 2 (T-C-C) 0.93 (0.79-1.10) 0.98 (0.76-1.25)
Haplotype 3 (C-C-C) 1.00 (0.85-1.17) 1.16 (0.91-1.48)
Haplotype 4 (C-C-G) 0.84 (0.63-1.13) 1.02 (0.67-1.56)
Figure 3. Relative effects of C-reactive protein gene haplotypes on C-reactive protein serum levels (mg/l).
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* P-value < 10-3. Regression coefficients were estimated with haplo.glm for each haplotype, adjusted for age and sex. Coefficients reflect 
difference in mean ln(C-reactive protein) per copy relative to haplotype 1, the most frequent haplotype. Values were transformed back to normal 
scale. Haplotypes 2, 3 and 4 were all significantly higher than haplotype 1.
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Haplotype 4 was associated with lower BMI (p=0.03), haplotype 1 with higher systolic blood pres-
sure (p=0.04) and haplotype 3 with higher percentage of prevalent myocardial infarction (p=0.04). 
No other associations with cardiovascular risk factors were present (data not shown). All haplotypes 
provided significantly higher C-reactive protein levels than haplotype 1 (table 3). The effect of hap-
lotype on C-reactive protein level, calculated from the regression coefficients, is displayed in figure 
3. Additional adjustment for body mass index, systolic blood pressure, diastolic blood pressure, total 
cholesterol, HDL-cholesterol, smoking, and diabetes mellitus did not materially change the results.
In table 4, age-and sex-adjusted odds ratios for coronary heart disease and for myocardial infarc-
tion are displayed for different C-reactive protein haplotypes. Since haplotype 1 was associated with 
the lowest serum C-reactive protein levels, it served as the reference. For both outcomes, the odds 
ratios for all haplotypes were around one. Additional adjustment for body mass index, systolic blood 
pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, and diabetes mellitus 
did not materially change the point estimates, and neither did repeating the analysis without exclud-
ing participants with coronary heart disease at baseline.
Discussion
In this population-based study, elevated C-reactive protein serum level was a strong and independent 
marker of increased risk of coronary heart disease and myocardial infarction in participants without 
a history of coronary heart disease. C-reactive protein haplotypes were associated with C-reactive 
protein serum levels. However, C-reactive protein haplotypes were not associated with coronary heart 
disease and myocardial infarction.
The approach we used in this study has also been termed “Mendelian randomization”. This ap-
proach has been used recently in studies of C-reactive protein and hypertension and metabolic 
syndrome.8,22 It deals with residual confounding, as alleles of the C-reactive protein gene that influ-
ence C-reactive protein level are transmitted from parent to offspring at random, and factors that 
could confound associations of C-reactive protein level with cardiovascular disease should be evenly 
distributed in those who do, and those who do not, have alleles that cause high C-reactive protein 
level. Furthermore, it deals with reverse causation, because genotype is determined before onset of 
disease.23
The present study uses haplotypes describing the total common variation of the C-reactive protein 
gene. So far, two other studies have used this approach. First, Carlson et al.14 defined all common ge-
netic variation across the C-reactive protein gene region by resequencing the region in a multiethnic 
variation discovery panel (24 African Americans and 23 European Americans), and selected SNPs for 
genotyping in a larger panel (CARDIA study), in which associations between common haplotypes 
and C-reactive protein levels were investigated. Carlson et al. used a population that was partly of 
European descent and partly of African descent, and used all haplotypes that occur in these popula-
tions. We used a population of European descent; therefore, the studies are not strictly comparable. 
In approximation, Carlson et al.’s haplotypes 4, 5 and 7 concur with our haplotypes 3, 2 and 4, respec-
tively, and Carlson et al.’s haplotype 1 and 2 taken together concur with our haplotype 1. Remaining 
haplotypes in the Carlson et al. study were only present in African Americans. Carlson et al. found 
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that their haplotypes 5 and 7 were associated with high C-reactive protein levels, haplotype 1 and 
2 with the lowest levels, and haplotype 4 with intermediate levels. These results are in agreement 
with ours. Furthermore, Carlson et al. did a promoter transcriptional analysis of the C-reactive pro-
tein gene, which suggested that the C-reactive protein haplotype-phenotype associations are at least 
partially attributable to functional changes at promoter sites rs3093062 (SNP 1421 in their paper) and 
rs3091244 (SNP 1440 in their paper).
Secondly, Miller et al. resequenced 192 individuals to ascertain a comprehensive set of common 
variants in the C-reactive protein gene, studied their association with C-reactive protein level in (sub-
sets of ) three cohorts, and also studied their association with myocardial infarction or ischemic stroke 
in a nested case-control study within the Physicians’ Health Study cohort.15 Interestingly, after rese-
quencing this large number of individuals, Miller et al. found a haplotype pattern similar to the pat-
tern of SeattleSNPs. Miller et al’s haplotypes 1, 2 and 5 concur with haplotypes 3, 2 and 4 in our study, 
respectively. There were only two minor differences: Miller et al’s haplotypes 3 and 4 together consti-
tute our haplotype 1, and we did not determine Miller et al’s haplotype 6, but the mean frequency of 
this haplotype was only 2.1%.15 Miller et al’s haplotypes 2 and 5 were associated with higher C-reactive 
protein levels and haplotypes 3 and 4 with lower C-reactive protein levels; these results are again in 
agreement with ours. Also, Miller et al. found that the minor allele of SNP rs2794521 was associated 
with reduced risk of atherothrombotic events. However, this SNP was associated with higher C-reac-
tive protein level, so the association between the C-reactive protein variant and baseline C-reactive 
protein did not correlate with the effect of this variant on clinical cardiovascular events. We did not 
determine this SNP in our study. Our study has the advantage that we had data available on all cases 
and non-cases in a large, population-based cohort.
Remaining studies on C-reactive protein gene haplotypes and risk of cardiovascular events have 
mostly been conducted in smaller numbers of high-risk patients.24-26 The haplotypes used in these 
studies have been constructed without consideration of the patterns of variation across the locus as a 
whole. Remaining studies that have examined the association of C-reactive protein gene haplotypes 
with C-reactive protein levels6,7,12,26,27 are not comparable to our study, because of different polymor-
phisms used to reconstruct the haplotypes and different populations used in terms of health status, 
ethnicity or age. The results of these studies are diverse, some finding associations with C-reactive 
protein levels, and some not. Interesting to note is the finding of Szalai et al.,27 that haplotypes recon-
structed from the -409G/A (rs3093032) and –390C/T/A (rs3091244) C-reactive protein gene promoter 
polymorphisms affect transcription factor binding, alter transcriptional activity, and associate with 
differences in baseline serum C-reactive protein level. According to SeattleSNPs, the latter polymor-
phism is present in all participants with haplotypes 2 and 4 in our study, and therefore it may result 
in functional differences between the haplotypes in our study, leading to different serum C-reactive 
protein levels. Several, mostly smaller, studies have demonstrated associations between various C-
reactive protein SNPs and C-reactive protein levels.3-13 These studies were different in design and were 
conducted in various populations, and are therefore not similar to ours.
In this study, we found an independent association between serum C-reactive protein levels and 
coronary heart disease. Since our earlier report on the role of C-reactive protein in prediction of myo-
cardial infarction in the Rotterdam Study, which was then investigated by means of a nested case-
control study,28 data from 4 more years of follow-up have become available and C-reactive protein has 
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been determined in the total cohort. This may in part explain the difference with the previous results 
that showed a lack of association after multivariable adjustment.
An issue that warrants consideration in this study is that C-reactive protein measurements were 
lacking for 854 participants who did not visit the research center at baseline. These participants gen-
erally had a higher age and worse general health. However, the association that we found between 
C-reactive protein serum level and coronary heart disease is in line with the results from previous 
studies,1 and this suggests that although we cannot entirely exclude the presence of selection bias, it 
is not likely that it has substantially influenced the results.
Although serum C-reactive protein levels were found to influence risk of coronary heart disease 
and C-reactive protein gene haplotypes were found to influence steady state serum C-reactive protein 
levels, no association could be demonstrated between C-reactive protein haplotypes and coronary 
heart disease. Power calculation for the present study shows that, with a power of 80% and an alpha 
of 0.05, in reference to haplotype 1, (the most common haplotype, frequency 32.8%), we were able 
to demonstrate relative risks for coronary heart disease of at least 1.21 (for haplotype 2, frequency 
31.7%).29 Therefore, either there indeed is no association between C-reactive protein gene haplotypes 
and coronary heart disease, or, otherwise, the relative risk is of relatively small magnitude. Application 
of the instrumental variables approach22 to our data is in compliance with the latter; the expected 
relative risks of coronary heart disease for haplotypes 2, 3 and 4, as estimated from the association 
between C-reactive protein serum level with coronary heart disease and the association between 
haplotypes and C-reactive protein serum level, were 1.03 (95% CI 0.90-1.20), 1.02 (95% CI 0.88-1.18) 
and 1.05 (95% CI 0.82-1.36), respectively, as compared to haplotype 1. We were not able to demon-
strate estimates of such small magnitude in the present study. Therefore, the door may still be open 
for a pathophysiological role of C-reactive protein in the development of cardiovascular disease.
Another explanation of the absence of an association in the present study is that baseline C-re-
active protein levels are not solely determined by the variation in the C-reactive protein gene, but 
also by its interaction with several transcription factors induced by regulatory cytokines such as IL-6 
and IL-1β,30 which may have a larger influence on serum C-reactive protein levels. Furthermore, high 
C-reactive protein levels may exert their harmful effects in the acute phase of a coronary event, with 
high peak C-reactive protein levels leading to enhanced infarct size and more complications such 
as arrhythmias.31 Since high C-reactive protein responders may not necessarily have high baseline 
serum C-reactive protein levels, this aspect needs to be studied by means of a study design different 
from ours.
In conclusion, this study confirms that steady-state C-reactive protein serum level is predictive of 
coronary heart disease. Furthermore, it demonstrates that steady-state C-reactive protein serum level 
is influenced by C-reactive protein haplotypes. Although elevated C-reactive protein level has lately 
been found to be a consistent and relatively strong risk factor for cardiovascular disease, our study 
does not support that the common variation in the C-reactive protein gene has a large effect on the 
occurrence of coronary heart disease.
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Chapter 2.2
C-reactive protein level and measures of 
coronary and extracoronary atherosclerosis
Abstract
Aims. Although prospective studies have unequivocally shown that C-reactive protein (CRP) is an 
independent predictor of future cardiovascular events, studies on the association between CRP and 
atherosclerosis have provided inconsistent results. We investigated the association of CRP with extent 
and progression of atherosclerosis in multiple vessel beds in a large, population-based cohort study.
Methods. In the Rotterdam Study, standardized measurements of coronary and extra-coronary ath-
erosclerosis were performed in 1962 persons and 6582 persons, respectively. Progression of extra-
coronary atherosclerosis during a mean follow-up period of 6.4 years was assessed in 3757 persons.
Results. Independent and graded associations were found of CRP with the number of carotid plaques 
and carotid plaque progression (OR 1.72; 95% C.I. 1.14-2.59) for severe progression in participants 
with CRP > 3 mg/dl versus participants with CRP< 1 mg/dl). Similarly, CRP showed an independent 
and graded association with ankle-arm index (AAI) and worsening AAI over the years (OR 1.99; 95% 
C.I. 1.37-2.88) for severe progression in participants with CRP > 3 mg/dl versus participants with CRP< 
1 mg/dl). Although CRP was independently related to the highest level of carotid intima-media thick-
ness (IMT), the association with change in IMT was not significant. Furthermore, there was an inde-
pendent, graded relation between CRP and aortic calcification, but no independent association was 
observed with progression of aortic calcification, nor with the amount of coronary calcification.
Conclusion. In this population-based study, independent and graded associations were present of 
CRP with extent and progression of carotid plaques and AAI, while associations with carotid IMT and 
aortic and coronary calcification were less pronounced.
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Introduction
Multiple prospective studies have unequivocally shown that C-reactive protein (CRP) is an indepen-
dent predictor of future cardiovascular events including myocardial infarction, stroke and peripheral 
vascular disease.1-3 Studies published on the association between CRP and established measures of 
atherosclerosis, however, have provided inconsistent results. In some studies the association was in-
dependently present in the whole study population,2,4-11 in women only12 or in men only.13-16 Other 
studies found a positive association that was lost after adjustment for cardiovascular risk factors.13,17-19 
Several studies did not find any relation between CRP and atherosclerosis.20,21
Studies performed thus far have several limitations. Firstly, most studies are cross-sectional rather 
than longitudinal while inflammation is thought to play an important role in the progression of ath-
erosclerosis.22 Secondly, some studies measured artery calcification which is considered to represent 
stable atherosclerosis, or increased intima-media thickness (IMT) which is thought to reflect early 
atherosclerosis,23 stages in which CRP may play a less important role.22,24 Thirdly, most studies did not 
look at CRP in relation to graded levels of atherosclerosis. Finally, many studies had selected or small 
study populations and most studies examined one vessel bed only.
The Rotterdam Study is a large, prospective, population-based cohort study with standardized 
measurements of atherosclerosis. We studied the association of CRP with extent and progression of 
atherosclerosis in multiple vessel beds. We were able to substantially increase the number of subjects 
available for analysis compared to earlier work on this topic in a limited random sample of the Rot-
terdam Study,6 thus increasing precision leading to stronger conclusions.
Methods
Study population
The Rotterdam Study is a prospective, population-based cohort study including 7983 men and wom-
en ≥55 years of age (response rate 78%). A detailed description of the rationale and design of the 
Rotterdam Study has been given elsewhere.25
Between visit 1 (1990 to 1993) and 3 (1997 to 1999), 1859 (23.3%) participants died and 135 (1.7%) 
were lost to follow-up or not invited due to logistic reasons. Furthermore, 1193 (14.9%) persons did 
not participate in the third visit. At the third visit, 2,063 subjects (response rate 61%) underwent an 
electron beam CT scan (EBT).26 The Medical Ethics Committee of the Erasmus Medical Center Rotter-
dam approved the study, and all participants gave informed consent.
Measurement of CRP
At visits 1 and 3, C-reactive protein was measured in serum using a nephelometric method (Immage; 
Beckman Coulter). This technique has a within-run precision <5.0%, a total precision <7.5%, and a reli-
ability coefficient of 0.995. The serum was kept frozen at –20°C (1990-1993) or –80°C (1997-1999).
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Measures of extent of atherosclerosis
Ultrasonography of both carotid arteries was performed with a 7.5-MHz linear-array transducer and 
a duplex scanner (ATL UltraMark IV, Advanced Technology Laboratories). The common carotid artery, 
carotid bifurcation, and internal carotid artery were examined on both the left and right sides for the 
presence of a plaque. Per location a point was added to a plaque score when this location showed the 
presence of atherosclerotic plaque. Thus, a total plaque score between 0 and 6 was obtained for each 
participant.27 The categories of 0-6 plaques comprised 40.4%, 15.2%, 18.3%, 8.9%, 9.9%, 3.7%, 3.6% of 
the study population, respectively.
Common carotid IMT was determined as the average of near- and far-wall measurements, and the 
average of left and right common carotid IMT was computed.28 For the analyses, IMT was categorized 
into deciles (cut-off values (mm): 0.62, 0.66, 0.70, 0.74, 0.78, 0.81, 0.86, 0.91, 1.00).
Aortic calcification was diagnosed by radiographic detection of calcified deposits in the abdomi-
nal aorta on a lateral abdominal film. Calcification of the posterior abdominal aortic wall was scored 
according to the length of the involved area along the lumbar spine (L1 to L4) with scores of 0 to 5 
corresponding to 0, ≤1, 1.1 to 2.4, 2.5 to 4.9, ≥5.0 to 9.9 and ≥10 cm, respectively. The categories of 0-5 
plaques comprised 33.1%, 9.4%, 26.9%, 17.7%, 10.6%, 2.2% of the study population, respectively.
The ratio of the systolic blood pressure at the ankle (8-MHz continuous-wave Doppler probe (Hunt-
leigh 500D, Huntleigh Technology)) to the systolic blood pressure at the arm (random-zero sphygmo-
manometer) was computed to obtain the ankle-arm index (AAI).4 Because arterial rigidity prevents ar-
terial compression leading to spuriously high values of the AAI, an AAI >1.50 was considered invalid.29 
For the analyses, we used the leg with the lowest value of AAI and categorized AAI into deciles (cut-off 
values: 1.29, 1.23, 1.18, 1.13, 1.09, 1.05, 0.99, 0.91, 0.76).
Coronary calcifications in the epicardial coronary arteries were detected on EBT scans. Imaging 
was performed with a C-150 Imatron scanner (GE-Imatron) as described previously.26 Calcium scores 
were calculated according to Agatston’s method30 and divided into 5 categories: 0-10, >10-100, >100-
500, >500-1000, >1000. The median duration between visit 3 and EBT scanning was 50 days.
Measures of progression of atherosclerosis
Progression of atherosclerosis was computed for each of the 4 extra-coronary measures by subtract-
ing the extent of atherosclerosis at visit 1 from the extent at visit 3. We categorized this new variable 
into no, mild, moderate and severe progression. To ensure comparable categories between the dif-
ferent measures of atherosclerotic progression (i.e. progression of aortic calcification, carotid plaques, 
IMT and AAI), we chose cut-off points for each variable that resulted in more or less the same number 
of subjects in that category (i.e. no, mild, moderate or severe progression) for all progression vari-
ables. We chose to categorize the progression variables instead of analyzing the data in a continuous 
way because we expected a non-linear relation with CRP, assuming the strongest relation with severe 
progression.22,23
For progression of aortic calcification, baseline and follow-up X-ray films were examined in pairs. 
We defined no, mild, moderate, and severe progression of aortic calcification as a progression 0, ≤1, 
1.1 to 2.4, and ≥2.5 cm of aortic calcification along the lumbar spine. None of the participants showed 
a decrease in the extent of aortic calcification. We defined no, mild, moderate, and severe progression 
of carotid plaques as an increase of 0, 1, 2, or ≥3 plaque locations, respectively. Participants with a de-
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crease in plaque score were added to the group with no progression. We based the categories of no, 
mild, moderate and severe progression of the continuous variables IMT and AAI (leg with largest de-
crease) on the 30th, 60th, and 90th percentile of the sample distribution. The mean interval between 
extra-coronary measurements at visits 1 and 3 was 6.4±0.4 years.
Assessment of covariates
At visits 1 and 3, covariates were ascertained using standard procedures as described previously.26,28 
Diabetes mellitus was considered to be present when fasting blood glucose exceeded 7.0 mmol/L, 
non-fasting glucose exceeded 11.0 mmol/L and/or anti-diabetic medication was used. History of car-
diovascular disease included history of myocardial infarction, stroke or presence of peripheral artery 
disease according to the Rose criteria.31
Populations for analyses
The following participants were included: (A) 6582 persons in whom CRP and at least one measure 
of extra-coronary atherosclerosis was assessed at visit 1. Within this group, measurements of carotid 
plaques, IMT, aortic atherosclerosis, and AAI were available for 5267, 4385, 5429 and 5959 participants, 
respectively. (B) 3757 participants in whom information on CRP at visit 1 and at least one measure of 
atherosclerosis at visit 1 and visit 3 were available. Within this group, information on progression of 
carotid plaques, IMT, aortic calcification and AAI was available for 2661, 2301, 2565 and 3298 par-
ticipants, respectively. (C) 1962 participants of visit 3 in whom both CRP and a coronary calcification 
score were obtained.
Statistical analyses
We performed analyses of variance to compute geometric means of CRP for categories of atheroscle-
rosis and used a Student t test to compare categories against the reference group (lowest amount 
of atherosclerosis). Linear regression analysis was used as a test for trend. Because the distribution 
of CRP was highly skewed, log CRP was used for analysis of variance and linear regression analysis. 
Outliers (values > 3*SD of the population distribution of log CRP; study population A: n=25, B: n=4, C: 
n=6) were excluded.
Using multinomial logistic regression analysis, we examined the association of CRP measured at 
visit 1 with mild, moderate, and severe progression of atherosclerosis. CRP was divided in categories 
of <1 mg/L, 1 to 3 mg/L and > 3 mg/L.32 These categories comprised 34%, 42% and 24% of the study 
population, respectively. CRP<1 mg/L served as the reference category. Participants who already had 
the maximum number of carotid plaques at visit 1 were excluded because of lacking ability of pro-
gression (n=52).
In all analyses, we used two models. In model 1, analyses were adjusted for age and sex. In model 
2, we additionally adjusted for smoking status and number of pack-years, systolic and diastolic blood 
pressure, antihypertensive medication, total cholesterol, high-density lipoprotein (HDL) cholesterol, 
cholesterol-lowering medication, body-mass-index (BMI), hormone replacement therapy (for wom-
en), cardiovascular history and, in case of analyses of progression, duration of follow-up and baseline 
level of atherosclerosis. To test whether the relation between CRP and extent or progression of ath-
erosclerosis was different for men and women, we added an interaction term to the regression model 
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(atherosclerosis measure x gender for the linear regression, CRP x gender for the multinomial regres-
sion). If the interaction term was statistically significant (P<0.05), we conducted analyses for men and 
women separately.
Missing data on covariates were imputed by single imputation using the Expectation Maximiza-
tion (EM) algorithm. Values for cardiovascular risk factors were missing mainly due to logistic reasons 
(e.g. absence of sonographers). Analyses were performed with SPSS 11.0 for Windows (SPSS Inc.)
Results
Table 1 displays the baseline characteristics of the 3 study populations. Baseline characteristics of the 
populations with measurements of extra-coronary extent and progression of atherosclerosis were 
assessed at visit 1 (1990-1993) while characteristics of the population with coronary calcification mea-
surement were assessed at visit 3 (1997-1999).
Geometric mean CRP levels (mg/L) for categories of measures of coronary and extra-coronary ath-
erosclerosis are presented in Figure 1. After adjusting for age and sex (model 1), a strong and graded 
increase in CRP level was observed with increasing number of carotid plaques, whereas CRP levels only 
rose across the highest 3 deciles of carotid IMT, corresponding to an IMT above 0.86 mm. A graded 
increase of CRP levels was also seen across incremental categories of aortic calcification. Furthermore, 
CRP levels gradually rose with decreasing AAI, but this was most pronounced in the highest 2 deciles, 
corresponding to an AAI below 0.91. With increasing level of coronary artery calcification, a gradual 
rise in CRP was observed, but this was only modest compared to the extra-coronary measures. After 
multivariable adjustment (model 2), the association between CRP level and extent of atherosclerosis 
was attenuated in the extra-coronary measures but remained statistically significant for the highest 
levels of atherosclerosis. No independent association was found between CRP and coronary artery 
calcification. Tests for trend were all significant except for coronary calcification after multivariable 
adjustment (Fig.1).
Since the interaction term of gender x atherosclerosis level was statistically significant for carotid 
IMT and AAI, we analyzed the relation of CRP with IMT and AAI for men and women separately. For 
both measures, the association between CRP and extent of atherosclerosis showed a similar pattern 
compared to the overall results on IMT and AAI, but was stronger in men than in women (Fig. 2). The 
tests for trend were all significant except for IMT of women after multivariable adjustment: (beta’s ; 
95% C.I.) for model 2 were (0,03 ; 0,01 to 0,05) for men and (0,01 ; -0,01 to 0,03) for women and for AAI 
(0,04 ; 0.03 to 0,06) for men and (0,02 ; 0,01 to 0,03) for women (Fig.2).
Table 2 shows the odds ratios for risk of mild, moderate and severe progression of atherosclerosis 
in comparison to no progression for categories of CRP level. CRP levels >3 mg/L were independently 
related to severe carotid plaque progression and severe decrease in AAI over time. The association 
with progression of aortic calcification was weaker and there was no clear relation between CRP and 
change in carotid IMT. Risk estimates did not change when baseline level of atherosclerosis was not 
included in the model.
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Table 1. Baseline characteristics of the study populations
Variable
Visit 1 Visit 3
Extra-coronary 
atherosclerosis
(n=6582)
Progression of 
atherosclerosis
(n=3757)
Coronary 
atherosclerosis
(n=1962)
Age, y 69.5±9.2 65.7±6.9 71.3±5.7
Male, % 40.6 42.5 46.6
Body-mass-index, kg/m2 26.3±3.7 26.2±3.5 27.0±3.9
Systolic blood pressure, mmHg 139±22 136±21 143±21
Diastolic blood pressure, mmHg 74±12 74±11 76±11
Total cholesterol, mmol/L 6.6±1.2 6.7±1.2 5.7±1.0
HDL cholesterol, mmol/L 1.3±0.4 1.4±0.4 1.3±0.4
Smokers, %
- Current 22.9 21.5 16.0
- Past 42.0 45.2 54.4
Pack-years smokers 22.5 (9.0, 40.0) 21.5 (9.0, 37.5) 18.5 (8.0, 32.2)
Diabetes mellitus, % 11.0 7.2 12.1
Cardiovascular history*, % 16.1 11.2 17.0
Hypertension medication, % 17.8 16.2 28.7
Cholesterol-lowering medication, % 3.3 4.2 19.2
Hormone-replacement therapy, % 15.6 18.8 20.7
Carotid plaque score > 0, % 59.6 42.4 -
Intima-media-thickness, mm 0.80±0.16 0.76±0.14 -
Aortic plaque score > 0, % 66.9 69.2 -
Ankle-arm index 1.05±0.23 1.11±0.18 -
Coronary calcification score > 0, % - - 77.0
CRP, mg/L 1.87 (0.91, 3.64) 1.62 (0.79, 3.06) 2.44 (1.26, 4.45)
Categorical variables are presented as percentage. Continuous values are expressed as mean ± standard deviation. Median (25th, 75th percentiles) 
is presented in case of skewed distribution. *History of cardiovascular disease includes history of myocardial infarction, stroke and/or peripheral 
artery disease.
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Figure 1. Geometric mean C-reactive protein level (mg/L) for categories of carotid plaque, intima-media 
thickness (IMT), aortic calcification, ankle-arm index (AAI) and coronary calcification.
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Model 1: age and sex adjusted. Model 2: additionally adjusted for BMI, systolic and diastolic blood pressure, antihypertensive medication, total 
cholesterol, HDL cholesterol, cholesterol-lowering medication, smoking status, number of pack-years, serum glucose, anti-diabetic medication, 
hormone replacement therapy (for women) and cardiovascular history. *Significantly higher geometric mean C-reactive protein level as 
compared to the reference category (no atherosclerosis) (p<0.05). † p for trend <0.001. ‡ p for trend <0.05.
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Figure 2. Geometric mean CRP level (mg/L) for deciles of intima-media thickness (IMT) and ankle-arm index 
(AAI) in men and women.
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Model 1: age and sex adjusted. Model 2: additionally adjusted for BMI, systolic and diastolic blood pressure, antihypertensive medication, total 
cholesterol, HDL cholesterol, cholesterol-lowering medication, smoking status, number of pack-years, serum glucose, anti-diabetic medication, 
hormone replacement therapy (for women) and cardiovascular history. *Significantly higher geometric mean C-reactive level as compared to the 
reference category (no atherosclerosis) (p<0.05). † p for trend <0.001. ‡ p for trend <0.05.
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Table 2. C-reactive protein in relation to progression of atherosclerosis during 6.4 years of follow-up
Degree of 
progression
Odds ratios (95% CI) Model 1 Odds ratios (95% CI) Model 2
N CRP (mg/L) CRP (mg/L)
Carotid plaques <1 1-3 >3 <1 1-3 >3
Mild 581 1.0 1.06 (0.84-1.33) 1.29 (1.00-1.67) 1.0 1.01 (0.80-1.27) 1.24 (0.94-1.63)
Moderate 318 1.0 1.14 (0.86-1.51) 1.10 (0.79-1.54) 1.0 1.03 (0.77-1.38) 1.02 (0.71-1.46)
Severe 229 1.0 1.36 (0.96-1.93) 1.99 (1.37-2.90) 1.0 1.12 (0.78-1.62) 1.72 (1.14-2.59)
Carotid IMT
Mild 690 1.0 1.31 (1.03-1.68) 1.25 (0.94-1.66) 1.0 1.35 (1.04-1.75) 1.38 (1.01-1.88)
Moderate 690 1.0 1.07 (0.84-1.36) 1.06 (0.80-1.40) 1.0 1.01 (0.78-1.31) 1.05 (0.77-1.44)
Severe 229 1.0 1.21 (0.85-1.73) 1.41 (0.95-2.10) 1.0 0.99 (0.68-1.45) 1.16 (0.74-1.79)
Aortic calcification
Mild 867 1.0 0.95 (0.76-1.19) 1.06 (0.82-1.38) 1.0 0.88 (0.69-1.12) 0.92 (0.68-1.24)
Moderate 731 1.0 1.13 (0.89-1.43) 1.37 (1.05-1.81) 1.0 1.01 (0.78-1.32) 1.14 (0.83-1.57)
Severe 174 1.0 1.38 (0.93-2.04) 1.36 (0.86-2.15) 1.0 1.35 (0.88-2.05) 1.37 (0.82-2.29)
AAI
Mild 989 1.0 0.94 (0.76-1.15) 0.98 (0.78-1.24) 1.0 1.07 (0.86-1.33) 1.29 (0.99-1.69)
Moderate 989 1.0 0.94 (0.76-1.15) 0.96 (0.76-1.22) 1.0 1.07 (0.85-1.36) 1.32 (1.00-1.75)
Severe 329 1.0 1.04 (0.77-1.42) 1.42 (1.02-1.98) 1.0 1.21 (0.87-1.68) 1.99 (1.37-2.88)
Risk estimates are odds ratios (95% confidence intervals) for categories of high C-reactive protein. The category of C-reactive protein < 1 mg/L 
serves as a reference. Categories of no progression for carotid plaque, intima-media thickness (IMT), aortic calcification and ankle-arm index 
(AAI) comprise 1480, 689, 789 and 988 persons, respectively. Model 1: age and sex adjusted. Model 2: additionally adjusted for BMI, systolic 
and diastolic blood pressure, antihypertensive medication, total cholesterol, HDL-cholesterol, cholesterol-lowering medication, smoking status, 
number of pack-years, serum glucose, anti-diabetic medication, hormone replacement therapy (for women), cardiovascular history, extent of 
baseline atherosclerosis and follow-up time.
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Discussion
We found an independent, graded association of CRP with extent and progression of carotid plaques 
and AAI. CRP was independently related to the highest level of carotid IMT, while the association with 
change in IMT was not significant. Although there was an independent, graded relation between CRP 
and aortic calcification, no independent association was found with progression of aortic calcifica-
tion, nor with the amount of coronary calcification.
Relation of CRP with measures of atherosclerosis
Inflammation plays a role in all stages of atherosclerosis. In early stages it is involved in the forma-
tion and progression of atherosclerotic lesions in the intima of the arterial wall. In more advanced 
stages, inflammatory processes become more pronounced and are thought to play an important role 
in plaque vulnerability, rapid progression of plaques, and thrombotic complications.22,33 We found no 
independent association between CRP and coronary calcification. Research on coronary plaque mor-
phology shows that stable plaques are most often calcified, while vulnerable plaques are typically 
not.34 The lack of an independent relation between CRP and coronary calcification, a feature of plaque 
stability, is in line with the finding that CRP plays an important role in plaque vulnerability.24,35
In our study, CRP was only related to the highest levels of IMT. This agrees with the view that inti-
ma-media-thickness represents early stages of atherosclerosis.23
With regard to carotid plaques and AAI, we found that CRP was most strongly related to advanced 
stages of atherosclerosis and to more severe categories of progression. This is in accordance with the 
view that the role of inflammation is more pronounced in advanced stages of atherosclerosis.
In the gender specific analyses, we observed a stronger relation of CRP with carotid IMT and AAI 
in men as compared to women. Whereas the difference could be at least partly explained by the fact 
that women had lower IMT levels than men, AAI levels were comparable between both sexes (data 
not shown).
Results of prior population-based studies
Only a few large population-based studies focused on CRP in relation to quantity of carotid plaque. 
An independent relation was found between CRP and grade of carotid artery stenosis 12 and between 
CRP and amount of carotid plaque.14 The latter study found an association in men only. A Danish 
population-based study did not show an independent relation between CRP and number of carotid 
plaques.21
One population-based study investigated the relation between CRP and levels of carotid IMT and 
found an independent association between CRP and the highest decile of IMT.21 Large population-
based studies on the relation between quartiles of CRP and carotid IMT found associations that were 
lost after adjustment for cardiovascular risk factors.8,12-14,19 One of these studies showed an indepen-
dent relation between CRP and internal but not common carotid IMT.12
Studies on the relation between CRP and levels of AAI are scarce. Folsom et al. showed an indepen-
dent, inverse relation between CRP and AAI in men only.13 However, several large population-based 
studies showed an independent association between CRP and presence of peripheral artery disease 
(AAI<0.9).7,9,10
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The only large, population-based study on the relation between CRP and amount of coronary cal-
cification did not find an independent association.18
Relatively few studies have been performed on the association between CRP and progression 
of atherosclerosis. In a population-based study on carotid artery plaque progression, CRP was only 
related to early stages of plaque progression after 5 years, but not to advanced stages of progres-
sion. However, the number of participants with advanced progression was limited.11 A large study 
on carotid IMT progression over a period of 2 years showed an association between CRP and IMT 
progression that was lost after adjustment for cardiovascular risk factors.17 A study on the effect of 
CRP on decrease in AAI showed an independent association of borderline significance after 5 years 
and a clear independent association after 12 years.5 Furthermore, a previous study on the relation 
between CRP and progression of atherosclerosis among a subgroup of 773 participants of the Rot-
terdam Study showed an independent relation between CRP and progression of carotid plaques, but 
not with change in aortic calcification and AAI over a mean period of 6.4 years.6
In summary, population-based studies on the relation between CRP and quantity of atheroscle-
rosis, although limited in number, generally support independent relations with extent and progres-
sion of carotid plaques and AAI. Furthermore, CRP is found to be associated with the highest level of 
carotid IMT, but not with progression of IMT, or with the amount of coronary calcification. Our findings 
are generally in line with these studies.
Strengths and limitations
This is the largest population-based study to date in which the relation of CRP with extent and pro-
gression of atherosclerosis is examined in multiple vessel beds. However, some methodological is-
sues need to be addressed. Firstly, analyses were conducted among different study populations. In 
analyses of progression of atherosclerosis, responders were younger (mean age difference 8.8 years), 
consisted of a higher percentage of men (42.5% versus 38.2%) and generally had lower levels of car-
diovascular risk factors compared to the non-responders. Although the lower amount of cardiovascu-
lar risk factors may have somewhat limited the range of baseline levels of atherosclerosis, it is unlikely 
that it has affected the validity of the risk estimates. The population with measurements of coronary 
calcification consisted of 61% of the eligibles. A difference between responders and non-responders 
was found in the percentage of men (46.6% versus 37.8%), however no differences were present in 
levels of cardiovascular risk factors.26
Secondly, we attributed differences in the association between CRP and atherosclerosis to differ-
ences in applied measures of atherosclerosis, based on pathophysiological views as described above. 
However, we cannot exclude possible effects of differences in vessel beds.
Finally, in the study on progression we found the strongest relation between CRP and severe pro-
gression of atherosclerosis. However, categories of mild and moderate progression are most suscep-
tible to misclassification. We cannot rule out that associations of CRP with these categories maybe 
diluted by misclassification.
Conclusion
This population-based study shows graded associations of CRP with extent and progression of ath-
erosclerosis. However, the strength of the associations depends on the applied measure of athero-
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sclerosis. We found an independent, graded association between CRP and extent and progression of 
carotid plaques and AAI. Furthermore, CRP was independently related to the highest level of carotid 
IMT, while the association with change in IMT was not significant. Although there was an indepen-
dent, graded relation between CRP and aortic calcification, no independent association was found 
with progression of aortic calcification, nor with the amount of coronary calcification. Our findings are 
generally supported by previous studies on the relation between CRP and quantity of atherosclero-
sis. The inconsistency in the literature on the relation between CRP and atherosclerosis may, at least 
partly, be explained by differences in applied measures of atherosclerosis and lack of quantification.
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Chapter 2.3
A common polymorphism in the 
complement factor H gene and myocardial 
infarction
Abstract
Objectives. This study was designed to investigate the association between a common polymor-
phism (Tyr402His, rs1061170) in the complement factor H (CFH) gene and risk of coronary heart dis-
ease.
Background. The evidence that inflammation is an important mechanism in atherogenesis is grow-
ing. C- reactive protein (CRP), complement factors and complement regulatory factors have all been 
linked to coronary heart disease. The CFH gene is an important regulator of the alternative comple-
ment cascade. We investigated its association with coronary heart disease.
Methods. The study was embedded in the Rotterdam Study, a prospective population-based study 
among men and women aged 55 years and older. 5520 participants without history of coronary heart 
disease were genotyped for the Tyr402His polymorphism of the CFH gene. Cox proportional hazards 
analysis was used to determine risk of myocardial infarction for Tyr402His genotypes.
Results. Mean age among participants was 69.5 years (standard deviation 9.1 years). The overall fre-
quency of the His allele was 36%; genotype frequencies were 41%, 45% and 14% for TyrTyr, TyrHis 
and HisHis, respectively. During a mean follow-up period of 8.4 years, 226 myocardial infarctions oc-
curred. After adjustment for age, gender, established cardiovascular risk factors and CRP level, HisHis 
homozygotes had a hazard ratio of 1.77 (95% confidence interval 1.23-2.55) for myocardial infarction. 
Total cholesterol level, diabetes mellitus and smoking modified the effect. The Tyr402His polymor-
phism was not associated with established cardiovascular risk factors or CRP level.
Conclusions. Our data suggest that the CFH gene determines susceptibility to myocardial infarction. 
This finding underscores the importance of the alternative complement system in cardiovascular 
disease.
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Introduction
Inflammation has been shown to play an important role in cardiovascular disease.1 Both complement 
factors and complement regulatory factors have been linked to atherosclerosis.2 Complement inhibi-
tor factor H (CFH) is a plasma protein that is essential in the regulation of the alternative complement 
pathway. Recently, several studies have found that the Tyr402His (rs1061170) polymorphism in the 
CFH gene is strongly associated with age-related macular degeneration, with relative risks of 2.5-7.4 
for homozygotes.3-7
Complement inhibitor factor H has been suggested to play a part in complement inhibition in ath-
erosclerotic lesions,8 and atherosclerosis has been implicated in the development of age-related mac-
ular degeneration.9 Therefore, the association between the CFH gene polymorphism and age-related 
macular degeneration may at least in part be mediated by atherosclerosis. Research in coronary artery 
specimens suggests that interaction of CFH with proteoglycans may be the mechanism by which 
complement activation in the superficial layer of the coronary intima is controlled.8 Consequently, we 
hypothesize that CFH may play a protective role in the development of coronary heart disease.
Complement inhibitor factor H is encoded by a single gene (HF1) on human chromosome 1q32. 
Several polymorphisms have been identified in the CFH gene, but their potential influence on the 
levels of expression or on the function of CFH is uncertain.10 The Tyr402His polymorphism, represent-
ing a tyrosine-histidine change at amino acid 402, is particularly interesting, since this change is lo-
cated within the cluster of positively charged amino acids implicated in the binding of heparin and 
C-reactive protein (CRP).11 Binding to these factors augments the ability of CFH to down-regulate the 
effect of complement. The substitution of a positively charged histidine for a non-charged hydro-
phobic tyrosine in position 402 may alter the binding properties and have functional implications.10 
These changes may alter CFH’s ability to suppress excess complement activation, ultimately leading 
to complement-related damage to arterial walls and vessel injury.4
We set out to investigate the association between the CFH gene Tyr402His polymorphism and the 
risk of myocardial infarction in the Rotterdam Study, a population-based cohort study in men and 
women aged 55 years and over.
Methods
Study population
The present study is part of the Rotterdam Study, a population-based cohort study aimed at assessing 
the occurrence of and risk factors for chronic diseases in the elderly. Objectives and methods of the 
Rotterdam Study have been described in detail elsewhere.12 The medical ethics committee of Erasmus 
Medical Center, Rotterdam, approved the study. Participants gave written informed consent and per-
mission to retrieve information from treating physicians.
Figure 1 shows a flow chart describing the study population. The Rotterdam Study cohort includes 
7983 men and women aged 55 years and over (78% of the eligible population), living in a well-defined 
suburb of the city of Rotterdam, The Netherlands. Baseline data were collected from 1990 until 1993. 
A trained interviewer visited all subjects at home and collected information using a computerized 
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questionnaire. Additionally, established cardiovascular risk factors were measured at the research 
center in 7129 participants. DNA was available for 6571 subjects. Genotyping was successful in 6345 
participants. After excluding participants with a history of myocardial infarction, percutaneous trans-
luminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) at baseline, 5520 sub-
jects were left for analysis.
Genotyping
The participants were genotyped for the Tyr402His (1277T>C) polymorphism of the CFH gene. This 
polymorphism has been described at http://www.ncbi.nlm.nih.gov/SNP under identification number 
rs1061170.
DNA was extracted with proteinase K and sodium dodecyl sulfate digestion at 37°C overnight and 
purified with phenol-chloroform extractions. The extracted DNA was then precipitated with NaCl at 
4 mol/L and 2 volumes of cold absolute ethanol. DNA was solubilized in double-distilled water and 
stored at –20°C until used for DNA amplification. Genotypes were determined in 2-ng genomic DNA 
with the Taqman allelic discrimination assay (Applied Biosystems, Foster City, California). Primer and 
probe sequences were optimized by using the SNP assay-by-design service of Applied Biosystems (for 
details, see http://store.appliedbiosystems.com). Reactions were performed with the Taqman Prism 
7900HT 384 wells format.
Figure 1. Flow chart describing study population.
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Rotterdam study: 7983 participants
7129 visited the research center
In 6571, DNA was available
In 6345, genotyping was successful
5520 participants
854 participants did not 
visit the research center 
for blood sampling
In 558, no blood sampling due to 
logistic reasons or participant’s refusal, 
or failure of DNA extraction
In 226, genotyping failed
825 subjects with prevalent 
coronary heart disease were
excluded
Study population for the analysis 
of the association between CFH 
genotypes and cardiovascular risk 
factors
Study population for the analysis
of the association between CFH 
genotypes and myocardial infarction
CFH = complement inhibitor factor H; DNA = deoxyribonucleic acid.
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Assessment of covariates
The information obtained during the interview included current health status, medical history (in-
cluding history of PTCA and CABG), drug use, and smoking status. At the research center, height and 
weight were measured and the body mass index was calculated (weight (kg)/height (m2)). Blood pres-
sure was measured at the right brachial artery using a random-zero sphygmomanometer with the 
participant in sitting position. Diabetes mellitus was defined as the use of blood glucose lowering 
medication or a random or post-load serum glucose level >= 11.1 mmol/l.13 C-reactive protein was 
measured in serum, kept frozen at -20 °C, using a nephelometric method (Immage, Beckman Coulter, 
Fullerton, California). A 12-lead resting electrocardiogram (ECG) was recorded with an ACTA electro-
cardiograph (ESAOTE, Florence, Italy) at a sampling frequency of 500Hz, and stored digitally. All ECGs 
were processed by the Modular ECG Analysis System (MEANS14) to obtain ECG measurements and 
interpretations. Myocardial infarction found on ECG was based on criteria partly derived from the 
Minnesota code15 A history of myocardial infarction was considered present in case of a self-report of 
myocardial infarction confirmed by ECG or additional clinical information, or the presence of an ECG 
characteristic of prior myocardial infarction.
Follow-up procedure
Follow-up started at the baseline examination and lasted until January 1st, 2002 for the present study. 
Information on fatal and non-fatal myocardial infarctions for the participants enlisted with the gen-
eral practitioners (GPs) working in the study district (85% of the cohort) was obtained from these 
GPs. Computerized records were sent to the Rotterdam Study data center regularly. Subsequently, re-
search assistants gathered information about these events at the GP offices. All medical records of the 
participants under the care of GPs outside the study area (15% of the cohort) were checked annually 
for possible events. Letters and, in case of hospitalization, discharge reports from medical specialists 
were obtained. With respect to the vital status of participants, information was also obtained regularly 
from the municipal health authorities in Rotterdam. After notification, cause and circumstances of 
death were established by questionnaire from the GPs.
Subsequently, two research physicians independently coded all reported events according to the 
International Classification of Diseases, 10th edition (ICD-10).16 In case of disagreement, consensus was 
reached. Finally, a medical expert in cardiovascular disease, whose judgment was considered final, 
reviewed all events.
In identifying incident myocardial infarctions (ICD-10 code I21), all available information, which 
included ECG, cardiac enzyme levels, and the clinical judgment of the treating specialist, was used. 
Persons with incident silent myocardial infarctions were not identified.
Data analysis
Hardy-Weinberg equilibrium of the Tyr402His polymorphism was tested using a Chi square test. Dif-
ferences in established cardiovascular risk factors for the three genotypes were examined by using 
analysis of covariance, adjusting for age and gender. For age, this analysis was only adjusted for gen-
der, and for gender, this analysis was only adjusted for age. C-reactive protein serum levels were log-
transformed because of their skewed distribution.
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Cox proportional hazards analysis was used to determine the relative risks of myocardial infarction 
associated with Tyr402His genotypes. The proportional hazards assumption was tested by drawing 
log minus log plots of the survival function. In model 1, we adjusted for age and gender, in model 2, 
we adjusted for age, gender, body mass index, systolic blood pressure, diastolic blood pressure, total 
cholesterol, HDL-cholesterol, smoking, and diabetes mellitus, and in model 3, we adjusted for the 
covariates in model 2 and additionally for CRP. Age- and gender-adjusted survival curves were drawn 
showing event-free survival until the occurrence of myocardial infarction. These curves were evalu-
ated at the mean of the covariates (age and gender) in the 5520 subjects used. For age, this was 69.1 
years, for gender, this was 62% women.
Firstly, analyses were performed in all participants. Thereafter, to examine effect modification, sub-
group analyses were performed in strata of age, gender, body mass index, systolic blood pressure, 
diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and CRP level. 
For continuous variables, participants were divided into subgroups according to the median values of 
the variables. Similarly, models 1, 2 and 3, as described above, were used for these subgroup analyses. 
Interaction terms were tested for the Tyr402His polymorphism and each of the covariates we stratified 
on, adjusting for age and gender. For this purpose, the polymorphism was entered into the model 
as a continuous variable with three values, namely homozygotes for the common allele (value 0), 
heterozygotes (value 1) and homozygotes for the rare allele (value 2).
Values for cardiovascular covariates were missing in less than 4% of participants, except for CRP, 
which was missing in 7%. Missing values were handled by single imputation using the expectation-
maximization (EM) algorithm based on age, gender, body mass index, systolic blood pressure, dia-
stolic blood pressure, total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and CRP.
All analyses were performed using SPSS 11.0 for Windows (SPSS Inc., Cary, North Carolina).
Results
Genotype distributions were in Hardy-Weinberg equilibrium. The overall frequency of the His allele 
was 36%; genotype frequencies were 41%, 45% and 14% for TyrTyr, TyrHis and HisHis, respectively. 
Table 1 shows baseline characteristics of all participants in which genotyping was successful. None of 
the studied characteristics, namely age, gender, body mass index, systolic and diastolic blood pres-
sure, hypertension, total and HDL cholesterol, diabetes mellitus, smoking and CRP were associated 
with Tyr402His genotype.
During a mean of 8.4 (standard deviation 2.7) years of follow-up, 226 cases of myocardial infarction 
occurred among participants who had no history of myocardial infarction, CABG or PTCA at base-
line. Follow-up information on myocardial infarction was complete for 5237 out of 5520 participants 
used for the analysis (94.9%). The potential number of person years that could have been contributed 
by these 5520 participants until myocardial infarction, death or the end of the follow-up period was 
46516.7. We were able to observe 46173.5 person years (99.3%) until the date that a participant was 
last know to be alive, myocardial infarction, death or the end of the follow-up period.
In table 2, hazard ratios for myocardial infarction are displayed according to Tyr402His genotype. 
In reference to wild type, heterozygotes had a 14-16% increased risk of myocardial infarction, but 
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Table 1. Baseline characteristics of the total population.
Total (n=6345)
Age (years) 69.5±9.1
Women (%) 60.0
Body mass index (kg/m2) 26.3±3.7
Systolic blood pressure (mm Hg) 139±22
Diastolic blood pressure (mm Hg) 74±11
Total cholesterol (mmol/l) 6.6±1.2
HDL-cholesterol (mmol/l) 1.3±0.4
Diabetes mellitus (%) 10.4
Smokers (%)
- Never 35.5
- Current 22.7
- Former 41.8
History of hypertension (%) 34.3
C-reactive protein (mg/l)* 1.87 (0.90-3.67)
Categorical variables are expressed as percentage. Values of continuous variables are expressed as mean ± standard deviation for total. * Median 
and interquartile range because of skewed distribution. HDL = high-density lipoprotein.
Table 2. Hazard ratios for myocardial infarction according to Tyr402His genotype.
Events/ subjects
Hazard ratio (95% confidence interval)
Genotype Model 1 Model 2 Model 3
All
TyrTyr 81/ 2251 1.00 (reference) 1.00 (reference) 1.00 (reference)
TyrHis 99/ 2509 1.14 (0.85-1.53) 1.16 (0.86-1.55) 1.16 (0.86-1.55)
HisHis 46/ 760 1.72 (1.20-2.47) 1.77 (1.23-2.54) 1.77 (1.23-2.55)
Men
TyrTyr 46/ 863 1.00 (reference) 1.00 (reference) 1.00 (reference)
TyrHis 58/ 924 1.22 (0.83-1.79) 1.25 (0.85-1.84) 1.25 (0.84-1.84)
HisHis 28/ 293 1.82 (1.16-2.96) 1.94 (1.21-3.12) 1.95 (1.21-3.13)
Women
TyrTyr 35/ 1388 1.00 (reference) 1.00 (reference) 1.00 (reference)
TyrHis 41/ 1585 1.03 (0.66-1.62) 1.02 (0.65-1.60) 1.02 (0.65-1.61)
HisHis 18/ 467 1.54 (0.87-2.71) 1.53 (0.86-2.70) 1.54 (0.87-2.73)
Model 1. Adjusted for age and gender; model 2. Adjusted for age, gender, body mass index, systolic blood pressure, diastolic blood pressure, total 
cholesterol, HDL-cholesterol, smoking, and diabetes mellitus; model 3. Adjusted for age, sex, body mass index, systolic blood pressure, diastolic 
blood pressure, total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and C-reactive protein.
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this did not reach statistical significance. After adjustment for age and gender (model 1), HisHis ho-
mozygotes had a hazard ratio of 1.72 (95% CI 1.20-2.47) for developing myocardial infarction. After 
additional adjustment for established cardiovascular risk factors (model 2), the hazard ratio slightly 
increased to 1.77 (95% CI 1.23-2.54). Further adjustment for CRP (model 3) did not change the esti-
mate. When we repeated the analysis without excluding participants with coronary heart disease at 
baseline, the results did not change materially.
The hazard ratios in men and women are also displayed in table 2. After full adjustment (model 
3), male HisHis homozygotes had a hazard ratio of 1.95 (95% CI 1.21-3.13) for developing myocardial 
infarction, whereas for female HisHis homozygotes this was 1.54 (95% CI 0.87-2.73). The latter value 
may not have reached statistical significance due to lack of power in women.
Event-free survival until the occurrence of myocardial infarction is displayed in figure 2. Homozy-
gotes for the rare His allele had a significantly lower event free survival.
Figure 3 displays the effects of potential modifiers of the association between Tyr402His and myo-
cardial infarction in an age- and gender-adjusted subgroup analysis. Overall, risk of myocardial infarc-
tion was increased for HisHis homozygotes in all subgroups. The risk of myocardial infarction was 
considerably higher in participants with total cholesterol levels above the median versus those with 
levels below the median (p for interaction 0.05), in diabetics versus non-diabetics (p for interaction 
Figure 2. Age- and gender-adjusted event-free survival until incident myocardial infarction.
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Figure 3. Age- and gender-adjusted hazard ratios for myocardial infarction according to Tyr402His 
genotype in subgroups, created according to median values for continuous variables.
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0.02), and in current smokers versus former and never smokers (p for interaction 0.06). The risk for sub-
jects with above median CRP levels was somewhat higher, but the interaction did not reach statistical 
significance (p for interaction 0.31). The remaining age- and gender-adjusted interaction coefficients 
of the Tyr402His polymorphism and the covariates upon which we stratified were not significant. Sub-
group analysis with additional adjustment for age, gender, body mass index, systolic blood pressure, 
diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and CRP did 
not materially alter the results.
Discussion
In the present study, the CFH gene Tyr402His polymorphism was associated with an increased risk 
of myocardial infarction in participants without a history of coronary heart disease. Total cholesterol 
levels, diabetes mellitus and smoking modified the effect. The CFH gene Tyr402His polymorphism 
was not associated with established cardiovascular risk factors, or with serum CRP levels. Adjustment 
for these factors did not essentially alter the risk of myocardial infarction. This study was performed 
within a large, prospective, population-based cohort, with lengthy follow-up time and a considerable 
number of incident myocardial infarction cases available for analysis.
Inflammation has been recognized as an important mechanism in coronary heart disease and 
other manifestations of atherosclerosis.1 The complement system contributes to inflammation in the 
arterial intima, and thus may exert unfavourable effects on atherosclerosis.2 The complement system 
contains several plasma and membrane-associated proteins that are organized in three activation 
pathways: the classical, the lectin and the alternative pathway. CFH is a plasma protein that plays an 
important part in the inhibition of the alternative pathway; it restricts the action of complement to ac-
tivating surfaces by binding to C3b, accelerating the decay of the alternative pathway C3-convertase 
(C3bBb) and acting as a cofactor for the factor I-mediated proteolytic inactivation of C3b.10 This mech-
anism allows for activation of the early complement cascade by opsonization and may thereby play 
a protective role; however, complement activation is limited to the C3 level, and does not lead to full 
complement activation with cell lysis and ensuing inflammation.8
Several studies provide evidence for a regulatory role of CFH in the development of atheroscle-
rosis. CFH has been found to be associated with severity of coronary luminal narrowing in patients 
receiving coronary angiography.17 In a study of human atherosclerotic lesions, CFH was observed in 
a large proportion of the lesions.18 Experimental observations have raised the possibility that interac-
tion between proteoglycans and CFH, which co-localize in the superficial layer of the intima, may 
inhibit complement activation in the superficial layer of the arterial intima.8 Furthermore, it has been 
shown that CFH binds to CRP, which may help to inhibit the CRP-dependent alternative complement 
activation pathway induced by damaged tissue.19,20 CRP has been found to be associated with both 
coronary heart disease and age-related macular degeneration.21,22
CFH is encoded by a single gene (HF1) that is part of the Regulator of Complement Activation gene 
cluster on human chromosome 1q32 that encodes several regulatory proteins of the complement 
system. Several polymorphisms have been identified in this gene, but their potential influence on the 
levels of expression or on the function of CFH are uncertain.10 The Tyr402His polymorphism is located 
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within the cluster of positively charged amino acids implicated in the binding of heparin and CRP. 
Binding to either of these partners increases the affinity of CFH for the complement protein C3b,20,23 
augmenting its ability to down-regulate complement’s effect. The substitution of a positively charged 
histidine for a non-charged hydrophobic tyrosine in position 402 may alter the binding properties 
and consequently have functional implications.
Recently, an association of the Tyr402His polymorphism with risk of vascular events could not be 
demonstrated in a nested case-control study within the Physicians’ Health Study.24 The authors report 
that they had the ability to detect, with 80% power, at an alpha of 0.05, a risk ratio of greater than 1.35 
for the His variant for vascular events (myocardial infarction, ischaemic stroke, deep venous thrombo-
sis/ pulmonary embolism, n=685). Therefore, and also based on the effect estimates and confidence 
intervals found, as stated by the authors, a modest risk of vascular events associated with the geno-
types tested could not be fully excluded.
Several aspects of the present study warrant further consideration. One limitation is, that it re-
mains to be investigated whether the Tyr402His variant is the true underlying variant and does not 
represent a marker in complete or partial linkage disequilibrium, either within the CFH gene itself or 
in flanking genes. Still, several arguments support the involvement of the CFH gene and in particular 
the Tyr402His polymorphism in explaining the risk of myocardial infarction. Firstly, the CFH gene is a 
credible candidate, since several studies provide evidence for a regulatory role of CFH in the develop-
ment of atherosclerosis. Secondly, the substitution of a positively charged histidine for a non-charged 
hydrophobic tyrosine theoretically has functional implications for the CFH protein. Finally, haplotype 
reconstruction has implicated this polymorphism in relation to complement-mediated pathogenesis 
of age-related macular degeneration.3,7 Despite these arguments, further research is warranted to dis-
close whether the Tyr402His variant is truly involved in explaining the risk of coronary heart disease. 
While our results are promising, the potential of other variants in the CFH gene to influence coronary 
heart disease risk should be further investigated.
Another limitation of the study is found in the follow-up. We performed a thorough follow-up 
procedure with regard to recognizable myocardial infarction, attaining 94.9% completeness. How-
ever, our follow-up did not contain incident silent myocardial infarction, although patients with silent 
myocardial infarction are in many aspects similar to those with recognized myocardial infarction.25 
The result is that incident silent myocardial infarction cases were missed and have been considered as 
non-cases in the analysis. Since this is non-differential misclassification of the outcome, it should not 
have influenced our results. We present relative risks, which remain the same. Only the risk difference 
between the genotypes could have changed due to this type of misclassification.26
The effect of the Tyr402His polymorphism on risk of myocardial infarction was modified by high 
total cholesterol levels, presence of diabetes mellitus and smoking. These factors all have been shown 
to be pathogens in vessel inflammation.1,27,28 When the alternative complement pathway is activat-
ed by such pathogens, it is plausible that subjects with a genetic susceptibility in CFH such as the 
Tyr402His variant respond with a reduced complement inhibition and thereby increase their risk of 
vessel damage, coronary atherosclerosis and subsequently myocardial infarction. Since the Tyr402His 
polymorphism is located within the cluster of amino acids implicated in the binding of CRP, we also 
expected CRP level to modify the risk of myocardial infarction. Although the risk was slightly higher in 
participants with CRP levels above the median, the interaction with CRP was not significant.
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In conclusion, we have found an association between the CFH gene Tyr402His polymorphism and 
myocardial infarction. This suggests that CFH may play an important role in atherosclerosis, and un-
derscores the importance of the alternative complement system in cardiovascular disease.
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Chapter 2.4
Variation in the complement factor H and 
C-reactive protein genes and myocardial 
infarction
Abstract
Complement factor H (CFH) is an important regulator of the complement cascade. Binding of C-reac-
tive protein (CRP) to CFH augments the ability of CFH to down-regulate the effect of complement in 
atherosclerotic lesions. The CFH Tyr402His polymorphism has been suggested to influence the ability 
of CFH to bind CRP. We hypothesized that the combined presence of unfavorable CRP and CFH genet-
ic profiles is associated with risk of myocardial infarction. The Rotterdam Study is a population-based 
cohort study among 7983 men and women aged ≥ 55 years. The CFH Tyr402His (rs1061170) poly-
morphism was determined (His402 allele = 37%), and using three tagging polymorphisms (rs1130864, 
rs1205, rs3093068), CRP haplotypes were inferred (1=CTC, 2=TCC, 3=CCC, 4=CCG; frequencies 33%, 
32%, 30% and 6%, respectively). Participants were grouped by both CFH genotype (TyrTyr [reference], 
TyrHis, HisHis) and CRP haplotype (haplotype 1 homozygotes [reference], haplotype 2 carriers, hap-
lotype 3 carriers, haplotype 4 carriers), which resulted in a total of 12 groups. CFH His402 homozygotes 
that were also CRP haplotype 3 carriers had an age- and sex-adjusted hazard ratio of 5.9 (95% CI 2.1-
16.5) to develop myocardial infarction compared to the reference group. In conclusion, this popula-
tion-based study suggests that the combined presence of unfavorable CFH and CRP genetic profiles 
is associated with risk of myocardial infarction.
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Introduction
Recently, the complement factor H (CFH) gene and the C-reactive protein (CRP) gene have received 
attention with regard to coronary heart disease risk. CFH is a plasma protein essential in the regula-
tion of the alternative complement pathway1 and has been suggested to play a part in complement 
inhibition in atherosclerotic lesions.2 Binding of CRP to CFH augments the ability of CFH to down-
regulate the effect of complement.3,4 The His402 allele of the functional CFH Tyr402His polymorphism 
(rs1061170) has been suggested to influence the ability of CFH to bind CRP,1 and has recently been 
found to be associated with risk of myocardial infarction in the Rotterdam Study.5 CRP level is a con-
sistent risk factor for cardiovascular disease.6 Steady-state CRP level has been found to be influenced 
by CRP haplotypes.7-9 However, the association between CRP haplotypes and coronary heart disease 
remains controversial. Few studies have been performed on this topic so far, and lack of power may 
play a part in their failure to show a consistent association.8-10 In view of the biological effect of CRP on 
the ability of CFH to down-regulate the effect of complement, we investigated whether the combined 
presence of unfavorable genetic CFH and CRP profiles is associated with risk of myocardial infarction 
in the Rotterdam Study.
Methods
The Rotterdam Study is a population-based cohort study aimed at studying chronic diseases in the 
elderly. Objectives and methods of the Rotterdam Study have been described in detail elsewhere.11 
Briefly, the Rotterdam Study cohort includes 7983 men and women aged 55 years and over (78% of 
the eligible population), living in a well-defined suburb of the city of Rotterdam, The Netherlands. 
Baseline data were collected from 1990 until 1993. A trained interviewer visited all subjects at home 
and collected information using a computerized questionnaire, and established cardiovascular risk 
factors were measured at the research center in 7129 participants, as described in detail previously.5 
DNA was available for 6571 participants. The medical ethics committee of Erasmus Medical Center, 
Rotterdam, approved the study. Participants gave written informed consent and permission to re-
trieve information from treating physicians.
Follow-up started at the baseline examination and for the present study lasted until January 1, 
2005. Information on fatal and non-fatal cardiovascular endpoints was obtained from general practi-
tioners and letters and discharge reports from medical specialists.5 Two research physicians indepen-
dently coded all reported events according to the International Classification of Diseases, 10th edition 
(ICD-10).12 In case of disagreement, consensus was reached. A medical expert in cardiovascular dis-
ease, whose judgment was considered final, reviewed all events. In identifying incident myocardial 
infarctions (ICD-10 code I21), all available information, which included ECG, cardiac enzyme levels, 
and the clinical judgment of the treating specialist, was used.
Participants were genotyped for the Tyr402His (1277T>C, rs1061170) single nucleotide polymor-
phism (SNP) of the CFH gene as described previously.13 This SNP was chosen because of its suggested 
functional properties, mentioned above. Furthermore, we determined CRP haplotypes by genotyping 
the participants for the haplotype tagging SNPs 1184 C>T (rs1130864), 2042 C>T (rs1205) and 2911 
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C>G (rs3093068).9,13 We chose to determine CRP haplotypes in order to make use of the common vari-
ation across the entire CRP gene. CRP haplotypes were inferred by using the program PHASE, which 
implements a Bayesian statistical method for reconstructing haplotypes from population genotype 
data.14
For the analysis, participants were grouped according to both CFH genotype (TyrTyr [reference], 
TyrHis, HisHis) and CRP haplotype (haplotype 1 homozygotes [reference], haplotype 2 carriers, haplo-
type 3 carriers, haplotype 4 carriers), which resulted in 12 groups. Participants homozygous for both 
the common CFH Tyr genotype and the most frequent CRP haplotype 1 were used as the reference 
group. Cox proportional hazards analysis was used to determine the relative risks of myocardial infarc-
tion associated with combinations of Tyr402His genotype and CRP haplotype, adjusted for age and 
sex. The proportional hazards assumption was tested (by drawing log minus log plots of the survival 
function). All analyses were performed using SPSS 11.0 for Windows (SPSS Inc., Cary, North Carolina).
Results
Genotyping was successful for the 4 SNPs within the CRP and CFH genes in 5946 participants. After ex-
cluding participants with history of myocardial infarction, coronary artery bypass grafting or percuta-
neous transluminal coronary angioplasty, 5178 participants were left for analysis. A total of 277 myo-
cardial infarctions occurred during a median follow-up time of 12 (inter-quartile range, 9-13) years. 
Chi-square tests showed that genotype distributions were in Hardy-Weinberg equilibrium in the full 
cohort. The population frequency of the His402 allele was 37%; genotype frequencies were 41%, 45% 
and 14% for TyrTyr, TyrHis and HisHis, respectively. The probability of the CRP haplotypes estimated by 
PHASE was ≥ 0.999 in all individuals. Haplotypes were coded as 1 to 4 in order of decreasing frequency 
in the population (coding from 1184 C>T, 2042 C>T and 2911 C>G: haplotype 1 = C-T-C, haplotype 
2=T-C-C, haplotype 3=C-C-C, and haplotype 4=C-C-G). Frequencies of haplotypes 1, 2, 3 and 4 were 
33%, 32%, 30% and 6%, respectively. These 4 haplotypes described 99.9% of our population.
Baseline characteristics of the study population are shown in table 1. Hazard ratios for developing 
myocardial infarction are displayed in table 2. The reference group had the lowest risk of myocardial 
infarction. Within CFH TyrTyr homozygotes, risk increased in carriers of CRP haplotype 2, 3 and 4. A 
similar increase in risk was seen within CFH HisHis homozygotes. Within CRP haplotype 2, haplotype 3 
and haplotype 4 carriers, CFH HisHis homozygotes carried the highest relative risks. Although within 
the CRP haplotype 1-1 homozygotes, CFH HisHis homozygosity also resulted in a raised relative risk, 
this was not statistically significant. This may have been caused by lack of power. The risk pattern is 
illustrated in figure 1. Additional adjustment for body mass index, systolic and diastolic blood pres-
sure, total and HDL-cholesterol, diabetes mellitus and smoking did not materially change the risk 
estimates.
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Table 1. Baseline characteristics (n=5178).
Variable Value
Age (years) 69.1±9.2
Women 3293 (63.0%)
Body mass index (kg/m2) 26.2±3.7
Systolic blood pressure (mm Hg) 139±22
Diastolic blood pressure (mm Hg) 74±11
Total cholesterol
- (mmol/l) 6.6±1.2
- (mg/dl) 257±47
High-density lipoprotein cholesterol
- (mmol/l) 1.4±0.4
- (mg/dl) 55±16
C-reactive protein (mg/l)* 1.80 (0.86-3.49)
Diabetes mellitus 508 (9.9%)
Smokers
- Never 1879 (37.4%)
- Current 1134 (22.6%)
- Former 2012 (40.0%)
Hypertension (history) 1673 (33.2%)
Values of continuous variables are expressed as mean ± standard deviation. Categorical variables are expressed as count (percentage). Valid 
percentages may vary for some counts because of missing values in the variables.
* Median and interquartile range because of skewed distribution
Figure 1. Complement Factor H genotype, C-reactive protein haplotype and risk of myocardial infarction.
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with haplotype 3 and 4 (3-4) were present in both the 3* and 4* group.
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Discussion
These results suggest that the combined presence of unfavorable genetic CFH and CRP profiles is 
associated with myocardial infarction. To our knowledge, our study is the first to investigate this asso-
ciation. A combined effect of CFH and CRP genetic profiles has previously been found for age-related 
macular degeneration.15 These findings support the biological effect of CRP on CFH previously sug-
gested.4 CFH has the ability to down-regulate the effect of complement in atherosclerotic lesions.2 
CRP is capable to enhance this effect: it has been shown that binding of CRP to CFH is the mechanism 
by which the CRP-dependent alternative pathway, induced by damaged tissue, is counterarrested.4 
The Tyr402His SNP is located within the cluster of amino acids implicated in the binding of CRP, and 
the His402 allele may diminish the binding properties for CRP because of the substitution of a positively 
charged histidine for a non-charged hydrophobic tyrosine.1 The decrease in complement inhibition, 
combined with enhanced activation of the classical complement pathway by increased CRP levels, 
may underlie the large increase in risk of myocardial infarction.
Strengths of the present study include its large size, population-based design, coverage of 99.9% 
of the variation in the CRP gene, occurrence of 277 incident myocardial infarctions, and the thorough 
follow-up procedure. Nevertheless, some aspects of this study warrant further consideration. Firstly, 
although haplotyping was performed for the CRP gene, we only determined one SNP in the CFH gene. 
It remains to be investigated whether this SNP is the true underlying variant and does not represent 
a marker in complete or partial linkage disequilibrium. Still, the Tyr402His SNP is a credible candidate, 
because the substitution of a positively charged histidine for a non-charged hydrophobic tyrosine 
Table 2. Complement factor H genotype, C-reactive protein haplotype and risk of myocardial infarction.
Complement facor H 
genotype
C-reactive protein 
haplotype Cases/ subjects
Hazard ratio (95% confidence 
interval)
TyrTyr 1-1 4/ 200 1.0 (reference)
2* 52/ 1141 2.3 (0.8-6.4)
3* 60/ 1097 2.8 (1.0-7.7)†
4* 14/ 233 3.2 (1.0-9.7)†
TyrHis 1-1 13/ 245 2.8 (0.9-8.7)
2* 60/ 1255 2.5 (0.9-6.8)
3* 59/ 1163 2.7 (1.0-7.4)
4* 8/ 277 1.6 (0.5-5.2)
HisHis 1-1 3/ 76 2.1 (0.5-9.5)
2* 24/ 374 3.4 (1.2-9.8)†
3* 39/ 355 5.9 (2.1-16.5)†
4* 9/ 84 5.1 (1.6-16.5)†
2* = haplotype 2 carriers; 3* = haplotype 3 carriers; 4*=haplotype 4 carriers.
Individuals with haplotype 2 and 3 (2-3) were present in both the 2* and 3* group.
Individuals with haplotype 2 and 4 (2-4) were present in both the 2* and 4* group.
Individuals with haplotype 3 and 4 (3-4) were present in both the 3* and 4* group.
† P < 0.05
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could have functional implications for the CFH protein and furthermore, haplotype reconstruction 
has implicated this SNP in relation to complement-mediated pathogenesis of age-related macular 
degeneration.16,17 Another aspect that merits attention is the fact that our findings are based on one 
single cohort. We did not have an independent reproducibility cohort at our disposal to consolidate 
the findings. The results would be strengthened if confirmed by another, independent, study. Our 
paper may stimulate other research groups to investigate this association.
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Chapter 3.1
Epidemiology of lipoprotein-associated 
phospholipase A2
Introduction 
Inflammation has been shown to play a central role in all phases of the atherosclerotic process.1 
Inflammatory pathways are implicated in early atherogenesis, in the progression of lesions, and in 
thrombotic complications. Clinical studies have shown associations of circulating markers of inflam-
mation, such as C-reactive protein (CRP) and fibrinogen, with cardiovascular events.2,3 Circulating in-
flammatory mediators may not only mark increased risk for cardiovascular events, but also, in some 
cases, may contribute to their pathogenesis. An inflammatory marker that has come under study re-
cently with regard to cardiovascular disease is lipoprotein-associated phospholipase A2 (Lp-PLA2).
Lp-PLA2 belongs to the superfamily of phospholipase A2 enzymes.4 It is a 45-kDa, Ca2+ indepen-
dent protein, up-regulated in atherosclerotic plaques and strongly expressed in macrophages within 
the fibrous cap of rupture prone lesions.5 It is called lipoprotein-associated PLA2 because of its tight 
association with lipoproteins. 80% of the enzyme in human plasma is located on low-density lipopro-
tein (LDL) and around 10% resides on high-density lipoprotein (HDL). In minor amounts, it associates 
with very low-density lipoprotein (VLDL) and lipoprotein(a).6
Lp-PLA2 has been suggested to have both pro-atherogenic and anti-atherogenic properties. When 
first identified, it was named platelet-activating factor acetylhydrolase (PAF-AH) owing to its ability to 
hydrolyze platelet-activating factor (PAF), a potent pro-inflammatory phospholipid. This ability sug-
gests an anti-atherogenic role of Lp-PLA2, supported by research using mouse models.7 However, in 
mice, Lp-PLA2 is predominantly associated with HDL, and therefore the proposed anti-atherogenic 
role of Lp-PLA2 is, at least in part, based on its association with the anti-atherogenic HDL. In addition 
to PAF hydrolysis, Lp-PLA2 can hydrolyze a broad spectrum of substrates including oxidized and po-
lar phosphatidylcholines.8 In humans, Lp-PLA2 is bound predominantly tot LDL cholesterol particles, 
and remains latent until the LDL-cholesterol particles undergo oxidative damage. Hereafter, Lp-PLA2 
cleaves the oxidized phosphatidylcholine into lyso-phosphatidylcholine and free fatty acid metabo-
lites.9 These mediators have been suggested to elicit pro-atherogenic effects.10 These pro-atherogenic 
effects may outweigh the anti-atherogenic effects in humans.
A substantial epidemiologic body of research is emerging on Lp-PLA2 and risk of cardiovascu-
lar disease in humans. First, several, mostly small, case-control studies have suggested that Lp-PLA2 
may play a part in cardiovascular disease.11-18 Hereafter, large cohort studies have examined Lp-PLA2 
in relation to incident cardiovascular events. Furthermore, studies were performed on Lp-PLA2 and 
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measures of atherosclerosis. Finally, Lp-PLA2 genotypes have been used to shed more light on the 
relation between Lp-PLA2 and cardiovascular disease. What follows is an overview of epidemiological 
studies on Lp-PLA2 and cardiovascular outcomes.
Lp-PLA2 and incident cardiovascular events
West of Scotland Coronary Prevention Study (WOSCOPS)
Studies on the association between Lp-PLA2 and incident cardiovascular events are summarized in 
table 1. The first study was performed within WOSCOPS, a trial in which 6595 men who had cholesterol 
levels between 4.5 and 6.0 mmol /l, but who had no history of a myocardial infarction, were randomly 
assigned to receive 40 mg of pravastatin or placebo daily. The present study was a case-control study, 
including 580 men who had an incident coronary event (nonfatal myocardial infarction, death from 
coronary heart disease or revascularization), and 1160 controls matched on age and smoking status.19 
The study showed a relative risk of 1.18 (95% CI 1.05-1.33) per standard deviation (SD) of Lp-PLA2 level 
for having a coronary event after adjustment for age, systolic blood pressure, plasma triglycerides, 
LDL and HDL cholesterol, fibrinogen, white-cell count and CRP. The multivariable adjusted relative risk 
for having a coronary event for the highest versus the lowest quintile of Lp-PLA2 was significant and 
nearly doubled. There was no significant interaction with pravastatin use.
Women’s Health Study (WHS)
The Women’s Health Study is an ongoing randomized, double-blind, placebo-controlled trial of as-
pirin and vitamin E being conducted among 28,263 women aged 45 years and over with no history 
of cardiovascular disease or cancer. For the present study, 123 cases and 123 controls, matched for 
age and smoking status, were selected.20 Cases were defined as study participants who provided a 
baseline blood sample and who subsequently had a cardiovascular event as defined by death due 
to coronary heart disease, non-fatal myocardial infarction or stroke. The mean follow-up period was 
three years. In univariate analyses, baseline levels of Lp-PLA2 were higher among cases than controls 
(mean 1.20 versus 1.05 mg/l, p= 0.016). However, after adjustment for random assignment to aspirin 
or vitamin E, LDL and HDL cholesterol, body mass index, history of hypertension, history of diabetes, 
parental history of myocardial infarction, frequency of exercise and current use of hormone replace-
ment therapy, the effect was minimal and no longer statistically significant.
Atherosclerosis Risk in Communities (ARIC)
The ARIC study is a biracial cohort study of 15,792 men and women 45 to 64 years old, followed up 
for the subsequent development of a coronary heart disease event, including coronary heart disease 
related death. A case-cohort design was constructed, the final sample size for the analysis being 608 
cases and 740 non-cases.21 The age, race and sex adjusted mean level of Lp-PLA2 was higher in cases 
than in non-cases (404 versus 372 μg/l, p< 0.001). Lp-PLA2 levels in the highest tertile were associated 
with increased coronary heart disease risk in a model adjusted for age, sex and race (HR 1.78, 95% CI 
1.33-2.38), however, after additional adjustment for LDL and HDL cholesterol, smoking status, systolic 
blood pressure, diabetes and CRP, the relative risk was attenuated and no longer significant. Further 
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analyses revealed that in individuals with low LDL cholesterol, elevated Lp-PLA2 was associated with 
a significantly higher risk for incident coronary heart disease, even after multivariable adjustment (HR 
2.08, 95% CI 1.20-3.62). No significant associations were seen for individuals with higher LDL choles-
terol.
The association between Lp-PLA2 and ischemic stroke was also evaluated in the ARIC study using 
a case-cohort design.22 Mean Lp-PLA2 levels adjusted for sex, race and age were higher in the 194 
cases than the 766 non-cases (443 vs 374 μg/l). In a model adjusted for age, sex, race, smoking status, 
systolic blood pressure, LDL and HDL cholesterol levels, antihypertensive medication and body mass 
index, Lp-PLA2 levels in the highest tertile were associated with a hazard ratio of stroke of 1.93 (95% 
CI 1.14-3.27).
Monitoring of trends and determinants in cardiovascular disease (MONICA) Augsburg 
Study
The MONICA study consisted of 4022 individuals sampled at random from a mixed urban/rural area. 
The study on Lp-PLA2 was based on 934 men aged 45 to 46 years, followed up for incident fatal or 
nonfatal acute myocardial infarction and sudden cardiac death.23 Lp-PLA2 level was associated with 
an increase in coronary risk, with a hazard ratio of 1.21 (95% CI 1.01-1.45) per SD increase in Lp-PLA2 
after adjustment for age, systolic blood pressure, total cholesterol/HDL cholesterol ratio, physical ac-
tivity, body mass index, smoking, diabetes mellitus, alcohol intake, education and CRP.
Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study comprising 7983 men and 
women aged 55 years or over. For the present investigation, a case-cohort design was used, with 
308 coronary heart disease cases, 110 ischemic stroke cases and a random cohort of 1820 controls.24 
After adjustment for age, sex, body mass index, systolic blood pressure, non-HDL cholesterol, HDL 
cholesterol, diabetes, smoking, cholesterol-lowering medication, CRP, white blood cell count, and al-
cohol consumption, the hazard ratio of coronary heart disease was 1.20 (95% CI 1.04-1.39) per SD of 
Lp-PLA2 activity. The association was present over the entire range of cholesterol levels. For ischemic 
stroke, this hazard ratio was 1.24 (95% CI 1.02-1.52).
Lp-PLA2 and incident cardiovascular events in patients with coronary artery 
disease
Brilakis et al. evaluated the association between Lp-PLA2 level and incidence of major adverse events 
in 504 patients, aged 26-76 years, undergoing clinically indicated coronary angiography.25 The most 
frequent indications for this angiography were acute coronary syndrome, an abnormal nuclear im-
aging study and dyspnoea upon exertion. Major adverse events were defined as death (including 
cardiac death), myocardial infarction, coronary revascularization and stroke. The hazard ratio for ad-
verse events, adjusted for age, gender, smoking history, hypertension, total and HDL cholesterol, trig-
lycerides, and log-CRP, was 1.30 (95% CI 1.06-1.59) per SD of Lp-PLA2, showing that Lp-PLA2 was an 
independent predictor.
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Lp-PLA2 and coronary atherosclerosis
Several studies have examined the association between Lp-PLA2 and coronary artery disease ascer-
tained by coronary angiography (table 2). Shohet et al. did so by means of two case-control stud-
ies.26 First, Lp-PLA2 activity was compared between 72 patients with angiographic evidence of severe 
coronary atherosclerosis and 72 patients with angiographically normal coronary arteries. Cases and 
controls were matched for age and sex. Although Lp-PLA2 activity was slightly higher in cases, no 
significant differences could be demonstrated. To confirm these findings, a second study was under-
taken in which 50 men with documented premature coronary artery disease and apparently healthy 
controls were matched for LDL cholesterol and for age. Again, although Lp-PLA2 activity was slightly 
higher in cases, it was not significantly different between cases and controls.
Caslake et al. performed a case-control study among 48 male subjects with coronary artery disease 
ascertained by coronary angiography, 46 male post myocardial infarction patients and 54 normal age 
matched controls.27 Lp-PLA2 level was found to be associated with stenosis, independently of LDL 
and HDL cholesterol, smoking and systolic blood pressure.
Blankenberg et al. compared 496 coronary artery disease patients of both sexes suffering from 
stable angina pectoris or acute coronary syndrome, who had a lumen reduction > 30% in at least 
one major coronary artery, to 477 healthy control subjects.28 They found that in the entire popula-
tion, Lp-PLA2 activity was borderline associated with the presence of coronary artery disease, but the 
case/control difference seemed mainly present in women. However, when the coronary artery disease 
patients were divided according to stable or unstable angina, Lp-PLA2 activity appeared elevated in 
coronary artery disease patients suffering from acute coronary syndrome in both genders, even after 
controlling for age, body mass index (BMI), ever smoking, history of hypertension, LDL and HDL cho-
lesterol and triglycerides. This association strengthened when excluding subjects receiving statin or 
ACE-inhibitor therapy, and doing so, there was a gradual increase in Lp-PLA2 activity among controls, 
stable angina pectoris patients and patients with acute coronary syndrome present in both genders.
In the above-mentioned study of Brilakis et al. in which adverse events were examined in 504 
patients undergoing clinically indicated angiography, the association between Lp-PLA2 and angio-
graphic coronary artery disease was also examined.25 Although Lp-PLA2 levels were higher in patients 
with more extensive angiographic coronary artery disease, Lp-PLA2 was not independently predic-
tive of angiographic coronary artery disease after adjusting for clinical and lipid variables.
Winkler et al. performed a case-control study in 2454 subjects with angiographically confirmed 
coronary artery disease and in 694 control subjects.29 Lp-PLA2 activity was not associated with coro-
nary artery disease in these subjects. However, after excluding subjects using lipid-lowering drugs 
(leaving 1630 subjects), Lp-PLA2 activity was associated with risk of coronary artery disease, with an 
odds ratio (OR) of 1.85 (95% CI 1.23-2.78) for the highest versus the lowest quartile of Lp-PLA2 activity 
after adjustment for aspirin, β-blockers, digitalis, age, gender, body mass index, smoking, diabetes, 
hypertension, CRP, fibrinogen, white blood cell count, serum amyloid A and LDL-cholesterol.
Finally, Khuseyinova et al. carried out a case-control study using 312 patients with a coronary steno-
sis of >= 50% of luminal diameter of at least one major coronary artery and 479 controls (occasional 
blood donors).30 Mean Lp-PLA2 levels were found to be significantly higher in patients (296.1±122.5 
ng/ml; mean±SD) compared to controls (266.0±109.8 ng/ml) (p<0.0001). After adjustment for age, 
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gender, BMI, smoking status, alcohol intake, school education years, hypertension, diabetes, total and 
HDL cholesterol, the odds ratio of coronary artery disease was 1.84 (95% CI 1.12-2.99) for the highest 
versus the lowest quartile of Lp-PLA2 concentration.
A study on the association between Lp-PLA2 and coronary calcification ascertained by computed 
tomography was performed by Iribarren et al. It was a nested case-control study among participants 
of the Coronary Artery Risk Development in Young Adults (CARDIA) study, an ongoing investigation 
of heart disease risk factors and subclinical coronary artery disease among black and white men and 
women aged 18-30 years.31 Cases (n=266) were those with and controls (n=266) those without evi-
dence of calcified coronary plaque assessed by computed tomography. The age adjusted odds ratio 
of calcified coronary plaque per SD increment was 1.40 (95% CI 1.17 -1.67) and 1.39 (95% CI 1.14-1.70) 
for Lp-PLA
2
 mass and activity, respectively. After adjusting for multiple covariates including LDL and 
HDL cholesterol, triglycerides, and CRP, a statistically significant association remained for Lp-PLA2 
level (OR 1.28 (95% CI 1.03-1.60)) but not for activity (OR 1.09 (95% CI 0.84-1.42)). The reason for the 
differential effect of adjustment may have been the stronger correlation between enzymatic activity 
and LDL-cholesterol (r=0.52) than between enzymatic level with LDL-cholesterol (r=0.39).
Lp-PLA2 and extracoronary atherosclerosis
Campo et al. performed a study among 190 hypercholesterolemic Sicilian individuals, and found no 
association between Lp-PLA2 activity and carotid intima-media thickness (IMT).32 Patients with ab-
normal carotid IMT (>1 mm) had a mean Lp-PLA2 activity of 471.3 U/l, whereas in controls this was 
463.7 U/l, the difference not being statistically significant. Only unadjusted values of mean plasma 
Lp-PLA2 activity for subjects with normal and high carotid IMT were presented in this study. Further-
more, none of the established cardiovascular risk factors was found to be associated with IMT, most 
probably owing to small sample size.
Santos et al. investigated the association between Lp-PLA2 level and ankle-brachial index among 
247 patients referred for lower extremity arterial evaluation.33 In a multiple regression model that 
included univariate predictors of ankle-brachial index (age, hypertension, smoking, fasting plasma 
glucose) and statin use, Lp-PLA2 was a borderline-significant predictor of lower ankle-brachial index 
(p = 0.05).
Genetic polymorphisms affecting Lp-PLA2
Lp-PLA2 is encoded by a gene located at 6p12-p21.1. The gene is organized in 12 exons spanning at 
least 45 kb of DNA sequence.34 In the Japanese, a point mutation, Val279Phe, has been found in exon 
9. This mutation completely abolishes enzymatic activity of Lp-PLA2 in homozygotes, and lowers en-
zymatic activity in heterozygotes compared to wild type. 27% of the Japanese population was found 
to be heterozygous for the mutant allele and 4% was homozygous.34 This mutation has been shown 
to be associated with ischemic stroke, coronary artery disease, atherosclerosis, and abdominal aortic 
aneurysm in Japanese, 35-39 and thus these results suggest that Lp-PLA2 may play a protective role in 
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cardiovascular disease. However, the findings of these studies could not be reproduced in a large-
scale study in 2819 Japanese patients with myocardial infarction and 2242 Japanese controls.40
In white populations, the Val279Phe mutation has not been found. However, several common vari-
ants are present. In vitro, the Ala379Val variant resulted in a 2-fold decrease in the affinity of Lp-PLA2 
for its substrate PAF, resulting in reduced degradation of PAF.41 Abuzeid et al. performed a European 
case-control study, which compared 527 post-myocardial infarction men with 566 age-matched con-
trols.42 Homozygosity for the Val allele was independently associated with lower risk of myocardial 
infarction. Since the Val allele results in lower Lp-PLA2 activity, this study supported the pro-athero-
genic, causal role of Lp-PLA2 in coronary heart disease. These findings do not concur with the findings 
of Ninio et al.43 Using a prospective cohort of 1314 coronary artery disease patients and a group of 
485 healthy controls, they found that the Val allele was associated with an increased Lp-PLA2 activ-
ity. Still, the Val allele was associated with a lower risk of future cardiovascular events and appeared 
less frequent in coronary artery disease cases than in controls. Campo et al. examined the Arg92His, 
Ile198Thr and Ala379Val variants in 190 hypercholesterolemic Sicilian individuals.32 They found no 
associations of these variants with Lp-PLA2 activity, and no associations with carotid IMT > 1 mm. In 
summary, the findings from the genetic studies performed until now appear to be heterogeneous.
Discussion
Recently, a large amount of epidemiological research has emerged on the association between Lp-
PLA2 and cardiovascular disease, overall suggesting an independent, pro-atherogenic role for Lp-
PLA2 in cardiovascular disease. Several issues remain to be further addressed.
The first issue is, whether the effect of Lp-PLA2 on cardiovascular events is truly independent of 
LDL-cholesterol, to which it is bound. The results from WOSCOPS suggested that elevated levels of 
Lp-PLA2 are a strong risk factor for coronary heart disease that is independent of LDL-cholesterol. 
However, in the WHS, after adjusting for LDL-cholesterol, the effect of Lp-PLA2 was minimal and no 
longer statistically significant. A clear reason for the discrepancy of the results from the WHS with the 
results from WOSCOPS could not be found. Use of hormone replacement therapy in the WHS may 
have played a part, however, this was not likely, since prevalence of use did not differ among cases 
and controls, and no effect modification due to this factor was found. Furthermore, statistical power 
may have been low in the WHS due to small sample size (123 cases and 123 controls). Finally, the au-
thors suggested the possibility that the predictive value of Lp-PLA2 may be limited to subjects with 
overt hyperlipidemia, as used in WOSCOPS. However, studies that followed also found associations 
between Lp-PLA2 and cardiovascular disease in non-hyperlipidemic subjects. The ARIC study results 
showed that, in individuals with low LDL cholesterol, elevated Lp-PLA2 was associated with a signifi-
cantly higher risk for incident coronary heart disease, even after multivariable adjustment. In the total 
number of individuals, however, the association was not independent of LDL cholesterol. Differing re-
sults between this study and the two above-mentioned studies were suggested to be attributable to 
the markedly different study populations that were used. What followed was the MONICA study, again 
showing an independent association between Lp-PLA2 and coronary events. Since the average total 
cholesterol level in the MONICA study was lower than in WOSCOPS but higher than in ARIC, this study 
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suggested that Lp-PLA2 has the ability to predict coronary events across all levels of total cholesterol. 
The Rotterdam Study provided further evidence for this by finding associations independent of cho-
lesterol, as did the study by Brilakis et al. Overall, most findings seem to support an independent role 
for Lp-PLA2 in cardiovascular risk prediction.
Another issue is, whether the effect of Lp-PLA2 on cardiovascular events is exerted through ath-
erosclerosis, or whether other mechanisms may contribute. With regard to Lp-PLA2 and coronary 
atherosclerosis, the studies by Caslake et al., Blankenberg et al., Winkler et al. and Khuseyinova et 
al. suggest independent associations, implying that Lp-PLA2 indeed exerts its effect through ath-
erosclerosis. However, the study by Brilakis et al. does not show an independent association with 
coronary atherosclerosis, although in the same study Lp-PLA2 was independently associated with 
cardiovascular events. An explanation for the discordance between the association of Lp-PLA2 with 
angiographic coronary artery disease and the association with adverse events in this study might 
be the concept that molecules that regulate inflammation will not necessarily correlate with plaque 
burden measures, and may represent other characteristics than atherosclerotic mass, such as the in-
flammatory activity within plaques or the degree of plaque destabilization and ongoing ulceration 
or thrombosis. This study raises the question whether Lp-PLA2 truly measures the extent of athero-
sclerosis, or whether it may be a marker of vulnerable plaque activity, which is further supported by 
the fact that Lp-PLA2 is strongly expressed in macrophages within the fibrous cap of rupture prone 
lesions.5 To answer this, further investigation is required. The same issue has been raised with regard 
to C-reactive protein, which, in spite of its ability to predict cardiovascular events, does not seem to 
correlate equally well with atherosclerosis.44
Lp-PLA2 has been suggested to have both pro-atherogenic and anti-atherogenic properties. In 
humans, given that high levels of Lp-PLA2 are associated with cardiovascular events, evidence is 
building up that the pro-atherogenic properties of Lp-PLA2 outweigh the anti-atherogenic proper-
ties. Until now, genetic research appears to yield inconclusive results with regard to this matter. The 
issue may be further resolved by research using Lp-PLA2 inhibitors. Potent Lp-PLA2 inhibitors have 
already been discovered 10 and tested for their ability to lower enzyme activity in plasma and at vas-
cular sites.45 In the future, randomized controlled trial using these compounds may demonstrate the 
consequences of reducing Lp-PLA2 activity.
The final issue that needs to be investigated is a potential gender difference. The results from the 
WHS were not in agreement with studies showing an independent association between Lp-PLA2 
and cardiovascular events, possibly due to gender differences. Lp-PLA2 has been found to be higher 
in men than in women.21,24,25 Furthermore, animal models have shown that estrogen decreases Lp-
PLA2 activity,46 and Lp-PLA2 levels are higher in women not taking hormone replacement therapy 
than among women taking hormone replacement therapy.20 Further research regarding Lp-PLA2 in 
populations stratified by gender, and also by other traditional risk factors such as age, is therefore 
supported.
In summary, studies regarding incident cardiovascular events suggest an independent, pro-athero-
genic role for Lp-PLA2. Studies on coronary atherosclerosis seem to lean into the same direction. With 
regard to extracoronary atherosclerosis, less research has been performed. Genetic studies have yield-
ed heterogeneous results so far. In the future, trials using Lp-PLA2 inhibitors may provide more insight 
into the mechanisms of action of Lp-PLA2 and its usefulness for cardiovascular risk reduction.
Epidemiology of Lp-PLA2
83
References
 1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
 2. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of in-
flammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387-1397.
 3. Danesh J, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular 
mortality: an individual participant meta-analysis. JAMA. 2005; 294: 1799-1809.
 4. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor 
acetylhydrolase. Nature. 1995; 374: 549-553.
 5. Kolodgie F, Burke A, Taye A, et al. Lipoprotein-associated phospholipase A2 is highly expressed in 
macrophages of coronary lesions prone to rupture. Circulation. 2004; 110: 246-247.
 6. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase 
(PAF-AH). Prog Lipid Res. 2003; 42: 93-114.
 7. Sudhir K. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker 
and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab. 2005; 90: 3100-
3105.
 8. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activat-
ing factor acetylhydrolase, generates two bioactive products during the oxidation of low-density 
lipoprotein: use of a novel inhibitor. Biochem J. 1999;338 ( Pt 2):479-487.
 9. Macphee CH, Nelson JJ. An evolving story of lipoprotein-associated phospholipase A2 in atheroscle-
rosis and cardiovascular risk prediction. Eur Heart J. 2005; 26: 107-109.
 10. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, 
epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005; 25: 923-931.
 11. Ostermann G, Ruhling K, Zabel-Langhennig R, Winkler L, Schlag B, Till U. Plasma from atherosclerotic 
patients exerts an increased degradation of platelet-activating factor. Thromb Res. 1987; 47: 279-285.
 12. Satoh K, Imaizumi T, Kawamura Y, et al. Activity of platelet-activating factor (PAF) acetylhydrolase in 
plasma from patients with ischemic cerebrovascular disease. Prostaglandins. 1988; 35: 685-698.
 13. Ostermann G, Lang A, Holtz H, Ruhling K, Winkler L, Till U. The degradation of platelet-activating fac-
tor in serum and its discriminative value in atherosclerotic patients. Thromb Res. 1988; 52: 529-540.
 14. Graham RM, Stephens CJ, Sturm MJ, Taylor RR. Plasma platelet-activating factor degradation in pa-
tients with severe coronary artery disease. Clin Sci (Lond). 1992; 82: 535-541.
 15. Yoshida H, Satoh K, Imaizumi T, et al. Platelet-activating factor acetylhydrolase activity in red blood 
cell-stroma from patients with cerebral thrombosis. Acta Neurol Scand. 1992; 86: 199-203.
 16. Satoh K, Yoshida H, Imaizumi T, Takamatsu S, Mizuno S. Platelet-activating factor acetylhydrolase in 
plasma lipoproteins from patients with ischemic stroke. Stroke. 1992; 23: 1090-1092.
 17. Stephens CJ, Graham RM, Sturm MJ, Richardson M, Taylor RR. Variation in plasma platelet-activating 
factor degradation and serum lipids after acute myocardial infarction. Coron Artery Dis. 1993; 4: 187-
193.
 18. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release 
lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with 
type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 1153-1159.
 19. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an indepen-
dent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl 
J Med. 2000; 343: 1148-1155.
Chapter 3.1
84
 20. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated 
phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 
2001; 38: 1302-1306.
 21. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sen-
sitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and 
women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004; 109: 837-842.
 22. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensi-
tivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the 
Atherosclerosis Risk in Communities Study (ARIC). Arch Intern Med. 2005; 28: 2479-84.
 23. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase 
A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy 
middle-aged men from the general population: results from the 14-year follow-up of a large cohort 
from southern Germany. Circulation. 2004; 110: 1903-1908.
 24. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associ-
ated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005; 
111: 570-575.
 25. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-
associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary 
artery disease, and major adverse events at follow-up. Eur Heart J. 2005; 26: 137-144.
 26. Shohet RV, Anwar A, Johnston JM, Cohen JC. Plasma platelet-activating factor acetylhydrolase activ-
ity is not associated with premature coronary atherosclerosis. Am J Cardiol. 1999; 83: 109-11, A8-9.
 27. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated 
phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coro-
nary artery disease. Atherosclerosis. 2000; 150: 413-419.
 28. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary 
artery disease: results of a cross-sectional analysis. J Lipid Res. 2003; 44: 1381-1386.
 29. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indi-
cates angiographic coronary artery disease independently of systemic inflammation and other risk 
factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005; 111: 980-987.
 30. Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between Lp-PLA2 and coronary artery 
disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. 
Atherosclerosis. 2005; 182: 181-188.
 31. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Jr., Sidney S, Loria CM. Association of lipoprotein-
associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the 
CARDIA study. Arterioscler Thromb Vasc Biol. 2005; 25: 216-221.
 32. Campo S, Sardo MA, Bitto A, et al. Platelet-activating factor acetylhydrolase is not associated with ca-
rotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin Chem. 2004; 50: 2077-
2082.
 33. Santos S, Rooke TW, Bailey KR, McConnell JP, Kullo IJ. Relation of markers of inflammation (C-reactive 
protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial 
index. Vasc Med. 2004; 9: 171-176.
 34. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency. A mis-
sense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest. 1996; 97: 
2784-2791.
Epidemiology of Lp-PLA2
85
 35. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating 
factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke. Stroke. 1997; 28: 2417-2420.
 36. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994--> T missense in exon 9 of the 
plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary 
artery disease in Japanese men. Metabolism. 1998; 47: 177-181.
 37. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma plate-
let-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclero-
sis in a Japanese population. Atherosclerosis. 2000; 150: 209-216.
 38. Unno N, Nakamura T, Kaneko H, et al. Plasma platelet-activating factor acetylhydrolase deficiency is 
associated with atherosclerotic occlusive disease in japan. J Vasc Surg. 2000; 32: 263-267.
 39. Unno N, Nakamura T, Mitsuoka H, et al. Association of a G994 -->T missense mutation in the plasma 
platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. 
Ann Surg. 2002; 235: 297-302.
 40. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymor-
phisms in candidate genes. N Engl J Med. 2002; 347: 1916-1923.
 41. Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhy-
drolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet. 2000; 
66: 1522-1530.
 42. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between the Ala379Val variant of the 
lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of 
Europe. Atherosclerosis. 2003; 168: 283-288.
 43. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene 
haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum 
Mol Genet. 2004; 13: 1341-1351.
 44. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: 
application to clinical and public health practice: A statement for healthcare professionals from the 
Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 
107: 499-511.
 45. Johnson A, Zalewski A, Janmohamed S, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) 
activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel 
pharmacologic intervention: The results of a multicenter clinical study. Circulation. 2004; 110: 590. 
Abstract.
 46. Miyaura S, Maki N, Byrd W, Johnston JM. The hormonal regulation of platelet-activating factor acetyl-
hydrolase activity in plasma. Lipids. 1991; 26: 1015-1020.

87
Chapter 3.2
Lipoprotein-associated phospholipase A2 
activity and coronary calcification
Abstract
Objectives. Although several studies have recently suggested that lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) is an independent predictor of coronary events, only one study has examined the 
association between Lp-PLA2 and coronary calcification, using young adults. We investigated the as-
sociation between Lp-PLA2 activity and coronary calcification assessed by electron-beam computed 
tomography (EBT) in a population of older participants.
Methods and results. The Rotterdam Coronary Calcification Study is a population-based study in 
men and women aged ≥55 years. Coronary calcification assessed by EBT was quantified in a calcium 
score according to Agatston’s method. Lp-PLA2 activity measured in samples collected 7 years be-
fore scanning (n=520) was associated with coronary calcification in men after adjustment for age. 
The odds ratio per standard deviation of Lp-PLA2 activity of having a total calcium score >1000 was 
1.6 (95% confidence interval 1.1-2.4), as compared to a total calcium score ≤100. After adjustment 
for non-HDL and HDL-cholesterol, this association disappeared. In women, the association was less 
consistent. For Lp-PLA2 measured concurrently to scanning (n=703), no association was found with 
coronary calcification.
Conclusions. Lp-PLA2 activity is moderately associated with coronary calcification after adjustment 
for age. The effect of Lp-PLA2 on coronary calcification may be exerted through its effect on LDL-
cholesterol.
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Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has lately gained interest as a predictor of car-
diovascular disease. Several recent studies have found an independent association between Lp-PLA2 
and coronary events.1-4 Basic science implies that the effect of Lp-PLA2 on coronary heart disease is 
exerted through effects of the enzyme on the development of atherosclerosis. Lp-PLA2 hydrolyzes 
oxidatively modified low-density lipoprotein (LDL) by cleaving oxidized phosphatidylcholines, gen-
erating lysophosphatidylcholine and oxidized free fatty acids. Lysophosphatidylcholine and oxidized 
free fatty acids are both chemoattractants for monocytes and may account for a part of the pro-in-
flammatory capacities of oxidized LDL-cholesterol.5
Case-control studies in high-risk participants report independent associations of Lp-PLA2 with an-
giographically documented coronary artery disease.6-9 One case-control study among patients under-
going clinically-indicated coronary angiography found that although Lp-PLA2 mass was associated 
with severity of angiographic coronary artery disease, the association did not persist after adjustment 
for lipids and other cardiovascular risk factors.10
Only one study has been conducted on Lp-PLA2 and coronary calcification. In a nested case-con-
trol study among young adults participating in the CARDIA study, an independent association was 
found of Lp-PLA2 mass with calcified coronary plaque.11 No studies have been reported on Lp-PLA2 
and coronary calcification in older adults. In a population-based cohort study in men and women 
aged ≥55 years, we investigated whether Lp-PLA2 activity is associated with coronary calcification 
detected by electron-beam computed tomography (EBT).
Methods
Study population
The Rotterdam Coronary Calcification Study is designed to study determinants and consequences of 
coronary calcification, detected by EBT. The study is embedded in the Rotterdam Study, a population-
based study aimed at addressing the occurrence of and risk factors for chronic disease in the elderly, 
which started with a baseline visit between 1990 and 1993. All inhabitants of a suburb of Rotterdam, 
aged ≥55 years, were invited (response 78%). The rationale and design of the Rotterdam Study have 
been described elsewhere.12 Follow-up visits took place in 1993 to 1994 and 1997 to 1999. From 1997 
onwards, participants through 85 years of age completing the third phase of the Rotterdam Study 
were invited to participate in the Rotterdam Coronary Calcification Study and to undergo an EBT scan. 
They were scanned from 1997 to 2000. Of the 3371 eligible participants, scans were obtained for 2063 
participants (response 61%). Due to several causes, i.e. metal clips from cardiac surgery, severe arti-
facts and registration errors (ECG, acquisition), image acquisition data could not be reconstructed or 
analyzed in 50 participants. Thus, calcium scores were available for 2013 participants.
Measurements of Lp-PLA2 activity performed at the third phase of the Rotterdam Study, and thus 
concurrently to EBT scanning, were available in a random sample of 703 participants. Of these 703, base-
line measurements of Lp-PLA2 activity could be performed in 520 participants. The median duration 
between risk factor assessment and EBT scanning was 7 years (1990-1993) and 50 days (1997-1999).
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The Medical Ethics Committee of Erasmus MC approved the study, and all participants gave in-
formed consent.
Measurement of Lp-PLA2 activity
Plasma aliquots prepared from blood samples were collected and stored at -80°C, and Lp-PLA2 activ-
ity was measured with a high throughput radiometric activity assay as described in detail previously.1 
Lp-PLA2 activity was expressed as nanomoles of platelet-activating factor hydrolyzed per minute per 
milliliter of plasma samples. Prior to analysis of plasma samples from the Rotterdam Coronary Cal-
cification Study, a pre-study validation was conducted to determine the reliability of the Lp-PLA2 
activity assay. The coefficient of variation (CV) for intra-assay precision ranged from 3.51-8.96%. The 
CV for inter-assay precision ranged from 8.48 -15.08%. Three cycles of freeze-thaw of frozen plasma 
did not result in appreciable loss of activity. The assay was therefore considered suitable for analysis 
of the Rotterdam Coronary Calcification Study samples, which were tested in duplicate. Samples were 
re-tested if the replicate CV was > 25%. The range of detection was 8-150 nmol/min per ml.
Coronary calcification
We assessed coronary calcification in the epicardial coronary arteries detected on EBT scans. Imag-
ing was performed with a C-150 Imatron scanner (Imatron, South San Francisco, CA, USA). Before 
the participants were scanned, they exercised breath holding. From the level of the root of the aorta 
through the heart, 38 images were obtained with 100 ms scan time and 3 mm slice thickness. We ac-
quired images at 80% of the cardiac cycle, using electrocardiogram triggering, during a single breath-
hold. The scanner was calibrated on a daily basis using a water phantom. Quantification of coronary 
calcification was performed with AccuImage software (AccuImage Diagnostics Corporation, South 
San Francisco, CA, USA) displaying all pixels with a density of over 130 Hounsfield Units. Trained scan 
readers were blinded to the clinical data of the participants. The presence of calcification was defined 
as a minimum of two adjacent pixels (area=0.52 mm²) with a density over 130 Hounsfield Units. We 
placed a region of interest around each high-density lesion in the epicardial coronary arteries. The 
peak density in Hounsfield Units and the area in mm² of the individual coronary calcifications were 
calculated. A calcium score was obtained by multiplying each area of interest with a factor indicating 
peak density within the individual area, as proposed by Agatston et al.13 We added the scores for indi-
vidual calcifications, resulting in a calcium score for the entire epicardial coronary system.
Assessment of covariates
The Rotterdam Coronary Calcification Study is embedded in the ongoing Rotterdam Study. There-
fore, information was available on risk factors assessed 7 years before EBT scanning (1990-1993) and 
concurrently to EBT scanning (1997-1999). Apart from blood sampling methods, protocols for the 
interview and clinical examination were identical at both examinations. Information obtained in the 
home interview included current health status, medical history, drug use, and smoking. Clinical mea-
sures were obtained during a visit to the research center. Height and weight were measured and the 
body mass index was calculated (weight (kg)/length (m2)). Blood pressure was measured at the right 
brachial artery using a random-zero sphygmomanometer with the participant in sitting position.
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In 1990–1993 non-fasting blood samples were obtained while in 1997–1999 blood samples were 
obtained after an overnight of fasting. Laboratory techniques were identical for both periods: serum 
total cholesterol was determined by an enzymatic procedure,14 and high-density lipoprotein (HDL) 
cholesterol was measured similarly after precipitation of the non-HDL fraction. Non-HDL cholesterol 
was computed by subtracting HDL cholesterol from total cholesterol. LDL cholesterol was determined 
in fasting blood samples in 120 randomly selected participants (1990-1993) using an enzymatic meth-
od (Roche, Mannheim, Germany). The correlation coefficient between non-HDL cholesterol and LDL-
cholesterol was high (r=0.97, p<0.001). Glucose was determined enzymatically by the Hexokinase 
method. Diabetes was defined as the use of anti-diabetic medication and/or non-fasting glucose 
levels > =11.1 mmol/l (1990–1993) and/or fasting glucose levels >=7.0 mmol/l (1997–1999).15 Using 
a nephelometric method (Immage®, Beckman Coulter), C-reactive protein was measured in blood 
samples, which were kept frozen at -20 °C (1990-1993) and at –80°C (1997-1999).
Statistical analysis
The analysis was performed similarly for the subcohort of 520 participants (1990-1993) and the sub-
cohort of 703 participants (1997-1999). Firstly, we tested for differences between the populations for 
analysis and the remainder of the Rotterdam Coronary Calcification Study by using a t-test for con-
tinuous and a chi-square test for nominal variables. The Mann Whitney test was used for C-reactive 
protein and total calcium score, because their distributions were skewed.
Since male sex is an important determinant of coronary artery calcification,16 all analyses were 
conducted separately in men and women. We performed linear regression analysis to assess the rela-
tionship between Lp-PLA2 activity and total calcium score measured on continuous scales. The distri-
bution of the residuals was highly skewed when we used the total calcium score for this purpose. After 
log-transformation of the total calcium score, the residuals were normally distributed with a constant 
variance. Therefore, log (total calcium score +1) was used for linear regression analysis. We used Lp-
PLA2 activity as the independent variable and the log total calcium score as the dependent variable. 
We computed the increase in log total calcium score per (sex-specific) standard deviation increase of 
Lp-PLA2 activity. Correlations of Lp-PLA2 activity with several cardiovascular risk factors have been 
demonstrated previously in the Rotterdam Study.1 Therefore, we adjusted the analysis: in model 1, we 
adjusted for age; in model 2, we additionally adjusted for non-HDL cholesterol and HDL-cholesterol; 
in model 3, we also added body mass index, systolic blood pressure, diabetes mellitus, smoking, C-
reactive protein, cholesterol lowering medication, and in women hormone replacement therapy.
Subsequently, we set out to investigate whether mean log(calcium scores) differ for tertiles of Lp-
PLA2 activity. For this purpose, we divided Lp-PLA2 activity into sex-specific tertiles (cut-offs in men 
and women 41 and 50 nmol/min per ml and 36 and 46 nmol/min per ml respectively for the 1990-
1993 cohort, and 40 and 48 nmol/min per ml and 34 and 42 nmol/min per ml respectively for the 
1997-1999 cohort), and performed analysis of covariance. Geometric means of the calcium scores and 
their confidence intervals were computed. We used the above-mentioned three models for adjust-
ment.
Finally, to obtain relative risks of having a high calcium score per (sex-specific) standard deviation 
of Lp-PLA2 activity, multinomial regression was used. For this purpose, coronary calcium score was 
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divided into four categories, namely 0 to 100, 101-500, 501-1000 and above 1000. Again, the above 
three models were used for adjustment.
Values for cardiovascular risk factors were missing in less than 2% of participants in both sub-
cohorts, except for C-reactive protein, which was missing in 5% (1990-1993) and diabetes mellitus, 
which was missing in 8% (1997-1999). Missing values were handled by imputing the mean for nor-
mally distributed variables, the median for skewed variables, and the value with the highest preva-
lence for nominal variables. Analyses were performed with SPSS 11.0 for Windows (SPSS, Inc, Chicago, 
IL, USA).
Results
The characteristics of the study population are shown in table 1. The characteristics of both subco-
horts were similar to the characteristics of the remaining population of the Rotterdam Coronary Cal-
cification Study with a few minor exceptions. Participants in the 1990-1993 subcohort had a slightly 
lower systolic blood pressure (133 mm Hg versus 134 mm Hg) and a slightly higher HDL-cholesterol 
(1.38 mmol/l versus 1.35 mmol/l). Participants in the 1997-1999 subcohort had a slightly lower dia-
Table 1. Study population characteristics 7 years before scanning (1990-1993) and concurrently to 
scanning (1997-1999).
Variable
7 years before scanning Concurrently to scanning
Subcohort 
(n=520)
Total 
(n=2013)
Subcohort
(n=703)
Total
(n=2013)
Age (years) 63.8±5.3 64.2±5.5 71.5±5.7 71.3±5.7
Men (%) 45 46 47 46
Women using hormone replacement therapy (%) 16 21 19 22
Body mass index (kg/m2) 26.3±3.4 26.3±3.4 27.0±3.8 27.0±3.9
Systolic blood pressure (mm Hg) 133±19 134±20 142±21 143±21
Diastolic blood pressure (mm Hg) 73±11 74±11 75±11 76±11
Non-HDL cholesterol (mmol/l) 5.4±1.2 5.4±1.2 4.5±0.9 4.4±1.0
HDL-cholesterol (mmol/l) 1.38±0.42 1.35±0.38 1.38±0.39 1.38±0.39
Diabetes (%) 6 6 13 12
Smokers (%)
- Current 23 22 16 16
- Past 48 48 54 54
C-reactive protein (mg/l)* 1.6 (0.8-3.1) 1.6 (0.8-3.1) 2.5 (1.2-4.6) 2.4 (1.3-4.5)
Cholesterol lowering medication (%) 3.7 3.2 13.4 14.5
History of myocardial infarction (%) 8.2 9.5 10.0 11.5
Calcium score* 119 (12-567)# 139 (14-581) 134 (13-578)
Categorical variables are expressed as percentage. Values of continuous variables are expressed as mean ± standard deviation.
*Expressed as median and interquartile range due to the skewed distribution.
#Calcium score measured in 1997-2000 for the subcohort of 520 participants.
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stolic blood pressure (75 mmHg versus 76 mmHg). Mean Lp-PLA2 activity in the 1990-1993 subcohort 
was 44 (standard deviation 11) nmol/min per ml plasma, in the 1997-1999 subcohort this was 42 
(standard deviation 11) nmol/min per ml plasma.
Table 2 provides regression coefficients describing the increase in log calcium score per standard 
deviation increase of Lp-PLA2 activity. After adjustment for age, there was a significant association be-
tween Lp-PLA2 activity measured in samples collected 7 years before EBT scanning and coronary cal-
cification in men. In women, the regression coefficient was of a similar magnitude, but the association 
did not reach statistical significance. When additional adjustment for non-HDL and HDL-cholesterol 
was performed, the association disappeared. Subsequent adjustment for other cardiovascular risk 
factors did not materially change the estimates. In contrast, there was no association between Lp-
PLA2 activity measured concurrently to EBT scanning and coronary calcification. Geometric means of 
calcium scores for tertiles of Lp-PLA2 activity are displayed in figure 1. For Lp-PLA2 activity measured 
in samples collected 7 years before EBT scanning, the calcium score in the highest tertile of Lp-PLA2 
activity was higher than the calcium score in the lowest tertile after adjustment for age in men. This 
association was borderline significant (p=0.052). After adjustment for cholesterol, this difference dis-
appeared. Subsequent adjustment for other cardiovascular risk factors did not further change the 
estimates. For Lp-PLA2 activity measured concurrently to EBT scanning, there were no significant dif-
ferences in calcium scores in tertiles of Lp-PLA2 activity using all three models.
For Lp-PLA2 activity measured in samples collected 7 years before EBT scanning, after adjustment 
for age, in men, the odds ratio per standard deviation of Lp-PLA2 activity of having a total calcium 
score in the highest category was 1.6 (95% confidence interval 1.1-2.4), as compared to a total calcium 
Table 2. Regression coefficients for the increase in log(calcium score) per standard deviation increase of 
lipoprotein-associated phospholipase A2 activity.
Regression coefficient
(95% confidence interval) P-value
Lp-PLA2 measured in samples, collected 7 years before scanning
Men Model 1 0.30 (0.03, 0.58) 0.03
Model 2 -0.02 (-0.33, 0.29) 0.91
Model 3 -0.06 (-0.38, 0.25) 0.70
Women Model 1 0.23 (-0.30, 0.32) 0.08
Model 2 0.01 (-0.03, 0.50) 0.96
Model 3 0.07 (-0.24, 0.37) 0.67
Lp-PLA2 measured concurrently to scanning
Men Model 1 0.07 (-0.32, 0.19) 0.51
Model 2 -0.07 (-0.15, 0.30) 0.62
Model 3 0.06 (-0.19, 0.31) 0.64
Women Model 1 0.01 (-0.22, 0.24) 0.91
Model 2 -0.07 (-0.33, 0.20) 0.63
Model 3 0.03 (-0.24, 0.29) 0.85
Model 1: adjusted for age; model 2: adjusted for age, non-HDL cholesterol and HDL-cholesterol; model 3: adjusted for age, non-HDL cholesterol, 
HDL-cholesterol, body mass index, systolic blood pressure, diabetes mellitus, smoking, C-reactive protein, cholesterol lowering medication and in 
women also for hormone replacement therapy.
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score in the lowest category (table 3). For the second-highest category, this was 1.7 (95% CI 1.1-2.6). 
This association disappeared after additional adjustment for cholesterol. In women, no association 
could be demonstrated. For LpPLA2 activity measured concurrently to EBT scanning, no association 
was found with coronary calcification in both sexes.
Figure 1. Geometric means and 95% confidence intervals of total calcium score for tertiles of Lipoprotein-
associated phospholipase A2 activity.
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Discussion
Although Lp-PLA2 activity has been found to be independently associated with cardiovascular events 
in the Rotterdam Study,1 its association with coronary calcification seems less consistent. Lp-PLA2 ac-
tivity measured in samples collected 7 years before EBT scanning was associated with coronary calcifi-
cation after adjustment for age in men. In women, the association did not reach statistical significance. 
After adjustment for non-HDL cholesterol and HDL-cholesterol, the association disappeared. Lp-PLA2 
activity measured concurrently to EBT scanning was not associated with coronary calcification.
The biological role of Lp-PLA2 in atherogenesis has been studied extensively. By hydrolyzing 
oxidized phospholipids, the enzyme is capable of generating two bioactive lipids, lysophosphatidyl-
choline and oxidized fatty acids, within oxidized LDL. These products are both chemoattractants for 
monocytes, suggesting that Lp-PLA2 has a pro-inflammatory role in atherogenesis.5 However, Lp-
PLA2, also known as platelet-activating factor acetylhydrolase (PAF-AH), is also suggested to have 
anti-inflammatory properties17 by hydrolyzing platelet-activating factor, which plays a role in the 
activation of platelets, monocytes and macrophages.18 The positive association found between Lp-
PLA2 and incident cardiovascular disease1-4 implies that the pro-inflammatory effects outweigh the 
anti-inflammatory effect of the enzyme. The moderate association of Lp-PLA2 activity with coronary 
calcification in men, demonstrated in this study, supports this notion, the disappearance of the as-
sociation after adjustment for cholesterol suggesting that the effect of Lp-PLA2 on coronary calcifica-
tion may be exerted through its effect on LDL-cholesterol. In women, the analysis using calcium score 
Table 3. Odds ratios and 95% confidence intervals for severity of coronary calcification per standard 
deviation of lipoprotein-associated phospholipase A2 activity.
Calcium score
0-100 101-500 501-1000 >1000
Lp-PLA2 measured in samples, collected 7 years before scanning
Men OR (model 1) 1.0 (reference) 1.2 (0.9-1.8) 1.7 (1.1-2.6) 1.6 (1.1-2.4)
OR (model 2) 1.0 (reference) 0.9 (0.6-1.4) 1.3 (0.8-2.3) 1.2 (0.8-1.8)
OR (model 3) 1.0 (reference) 0.9 (0.6-1.4) 1.4 (0.8-2.3) 1.1 (0.7-1.7)
Women OR (model 1) 1.0 (reference) 1.2 (0.9-1.6) 1.0 (0.7-1.5) 1.1 (0.6-1.7)
OR (model 2) 1.0 (reference) 1.0 (0.7-1.4) 0.8 (0.5-1.3) 0.9 (0.5-1.6)
OR (model 3) 1.0 (reference) 1.0 (0.7-1.4) 0.7 (0.4-1.3) 1.0 (0.5-1.8)
Lp-PLA2 measured concurrently to scanning
Men OR (model 1) 1.0 (reference) 1.0 (0.7-1.3) 1.2 (0.9-1.7) 1.2 (0.9-1.6)
OR (model 2) 1.0 (reference) 0.8 (0.6-1.1) 1.1 (0.7-1.6) 1.1 (0.7-1.5)
OR (model 3) 1.0 (reference) 0.8 (0.6-1.2) 1.1 (0.8-1.7) 1.1 (0.8-1.6)
Women OR (model 1) 1.0 (reference) 1.0 (0.8-1.3) 0.9 (0.7-1.3) 0.8 (0.5-1.2)
OR (model 2) 1.0 (reference) 1.0 (0.8-1.4) 0.9 (0.6-1.4) 0.8 (0.5-1.3)
OR (model 3) 1.0 (reference) 1.1 (0.8-1.5) 0.9 (0.6-1.5) 0.9 (0.5-1.6)
Model 1: adjusted for age; model 2: adjusted for age, non-HDL cholesterol and HDL-cholesterol; model 3: adjusted for age, non-HDL cholesterol, 
HDL-cholesterol, body mass index, systolic blood pressure, diabetes mellitus, smoking, C-reactive protein, cholesterol lowering medication and in 
women also for hormone replacement therapy.
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as a continuous variable rendered a regression coefficient of a similar magnitude as in men, but it 
did not reach statistical significance. Failure to demonstrate the association in women in the analysis 
using calcium score as a categorical variable, may have been caused by the fact that less women had 
calcium scores in the high categories.
In the present study, Lp-PLA2 activity was measured in plasma samples drawn 7 years before EBT 
scanning and samples drawn concurrently to EBT scanning. Previously, it has been demonstrated 
within the Rotterdam Coronary Calcification Study that established cardiovascular risk factors mea-
sured 7 years before EBT scanning are strongly associated with the amount of coronary calcification, 
while some of these associations attenuate when risk factors are measured simultaneously to EBT 
scanning.16 This concurs with the observation that the predictive value of cardiovascular risk factors 
attenuates with increasing age,19-21 and may explain why an association was found between Lp-PLA2 
activity measured 7 years before EBT scanning and coronary calcification, while this association was 
not found for Lp-PLA2 activity measured concurrently to EBT scanning. Another explanation may be 
that the strength of the association increases with increasing time between assessment of Lp-PLA2 
activity and the measurement of coronary calcification. A point of mention here is that, in the pres-
ently used subcohorts, total cholesterol level measured 7 years before scanning was independently 
associated with coronary calcification, while for total cholesterol measured concurrently to scanning, 
the association disappeared after multivariable adjustment (data not shown).
Although the independent association of Lp-PLA2 with coronary events has recently been dem-
onstrated in several population-based studies,1-4 the association between Lp-PLA2 and coronary 
atherosclerosis has mostly been examined in case-control studies with high-risk subjects. In a case-
control study among male subjects experiencing symptoms of angina, Lp-PLA2 mass was found to be 
independently associated with positive angiograms.7 This study was performed in a relatively small 
number of high-risk subjects, which were younger than the subjects in our population. Furthermore, 
the severity of disease was not recorded in the study, and angiograms were defined as positive when 
stenotic disease was present, which contrasts with the continuous measures of asymptomatic coro-
nary calcification in our study. Similarly, Lp-PLA2 activity was independently associated with presence 
of coronary artery disease in a case-control study with men and women with presence of an angio-
graphically determined stenosis >30% in at least one major coronary artery experiencing acute coro-
nary syndrome or stable angina and healthy control subjects,8 in a case-control study in patients with 
angiographic evidence of coronary artery disease and in age- and gender-matched blood donors,6 
and among patients hospitalized for coronary angiography who were not using lipid-lowering drugs.9 
Conversely, in a study enrolling 504 patients undergoing clinically indicated coronary angiography, 
Lp-PLA2 mass was found to be associated with severity of angiographically determined coronary ar-
tery disease, but after adjustment for clinical and lipid variables, this association disappeared.10 In-
terestingly, in the same study, an independent relationship was found between Lp-PLA2 and cardio-
vascular events. Although this was also a study in high-risk subjects and the participants used were 
younger than the participants in the Rotterdam Study, these results seem to be in accordance with 
the results of the Rotterdam Study, which also showed that Lp-PLA2 activity was independently asso-
ciated with cardiovascular events1 but was not independently associated with coronary calcification. 
Regarding this issue, it needs to be considered that molecules that regulate inflammation will not 
necessarily correlate with plaque burden measures, as illustrated by inflammatory markers such as 
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C-reactive protein. Although C-reactive protein is associated with coronary events, it has been a less 
consistent predictor of the extent of atherosclerotic disease, and may measure other characteristics 
than atherosclerotic mass, such as the activity of lymphocyte and macrophage populations within 
plaque or the degree of plaque destabilization and ongoing ulceration or thrombosis.22 The same may 
apply to Lp-PLA2.
To our knowledge, only one study has been reported on the association of Lp-PLA2 with coronary 
calcification. In a nested case-control study among CARDIA participants, an independent association 
was found of Lp-PLA2 with calcified coronary plaque in young adults.11 Subjects in the highest tertile 
of Lp-PLA2 mass had a relative risk of 2.15 for coronary artery calcification compared to subjects in 
the lowest tertile of Lp-PLA2 mass. For subjects in the highest tertile of Lp-PLA2 activity, the rela-
tive risk was 2.40 compared to the lowest tertile. After adjustment for cholesterol, the association of 
Lp-PLA2 mass with calcified coronary plaque remained materially the same, and the association of 
Lp-PLA2 activity with calcified coronary plaque attenuated. The reason for the differential effect of 
adjustment may be the stronger correlation between enzymatic activity and LDL-cholesterol (r=0.52) 
than between enzymatic mass with LDL-cholesterol (r=0.39). The finding of an independent associa-
tion between Lp-PLA2 measured concurrently to scanning and coronary calcification in the CARDIA 
study contrasts with our findings. The disappearance of the relation between Lp-PLA2 measured 7 
years before scanning and coronary calcification after adjustment for cholesterol in our study may be 
due to the different age range of the participants (young adults in the CARDIA study, elderly in the 
Rotterdam Study). The complete absence of an association between Lp-PLA2 measured concurrently 
to scanning and coronary calcification in our study may be due to the fact that the age range was 
even higher by this time. Whether the difference in age was the main factor that contributed to the 
observed discrepancy in findings remains to be resolved.
In conclusion, the disappearance of the moderate association of Lp-PLA2 activity with coronary 
calcification after adjustment for cholesterol in this study suggests that the effect of Lp-PLA2 on coro-
nary calcification may be exerted through its effect on LDL-cholesterol. The absence of the associa-
tion while measuring Lp-PLA2 activity concurrently to scanning may be due to attenuation of the 
predictive value of cardiovascular risk factors with increasing age or may indicate a stronger relation 
when Lp-PLA2 is measured longer before the assessment of coronary calcification. Future studies are 
needed to further elucidate the role of Lp-PLA2 in the development of cardiovascular disease.
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Chapter 3.3
Lipoprotein-associated phospholipase A2 
activity and extracoronary atherosclerosis
Abstract
Objective. Lipoprotein-associated phospholipase A2 (Lp-PLA2) may be a new and independent pre-
dictor of cardiovascular events. The effect of Lp-PLA2 may be exerted through effects of the enzyme 
on the development of atherosclerosis. Therefore, we investigated the association between Lp-PLA2 
activity and measures of extracoronary atherosclerosis.
Methods and results. Lp-PLA2 activity was determined in a random sample of 1820 participants 
from the Rotterdam Study, a population-based cohort study in men and women ≥55 years. Common 
carotid intima-media thickness, carotid plaques, ankle-arm index and aortic calcification were exam-
ined. Atherosclerosis status could be assigned in 1609 participants. The age-adjusted odds ratio of 
having atherosclerosis at any site for the highest versus the lowest tertile of Lp-PLA2 activity was 1.86 
(95% CI 1.01-3.43) in men and 1.60 (95% CI 1.08-2.37) in women. After additional adjustment for cho-
lesterol, these associations attenuated or even disappeared. The odds ratios of having atherosclerosis 
at specific sites (carotid arteries and aortic-iliac-femoral tract) followed a similar pattern.
Conclusions. Although Lp-PLA2 has been found to be independently associated with cardiovascular 
events, the association with measures of subclinical extracoronary atherosclerosis found in this study 
strongly attenuated or even disappeared after adjustment for cholesterol.
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Introduction
Recently, several studies suggested that lipoprotein-associated phospholipase A2 (Lp-PLA2) may be 
a new and independent risk factor for cardiovascular disease.1-5 Lp-PLA2 hydrolyzes oxidatively modi-
fied low-density lipoprotein (LDL) by cleaving oxidized phosphatidylcholines, generating lysophos-
phatidylcholine and oxidized free fatty acids. Lysophosphatidylcholine and oxidized free fatty acids 
are both chemoattractants for monocytes and may account for a part of the proinflammatory capaci-
ties of oxidized LDL-cholesterol.6
Although experimental studies imply that the effect of Lp-PLA2 on cardiovascular disease is ex-
erted through effects of the enzyme on the development of atherosclerosis, little population-based 
research has been reported on this topic. Several studies have examined the association between 
Lp-PLA2 and angiographically documented coronary atherosclerosis in case control settings using 
high-risk subjects, most of them finding an independent association,7-10 and one of them finding that 
the association disappeared after adjusting for clinical and lipid variables.11 Furthermore, in a nested 
case-control study among young adults participating in the population-based CARDIA study, an in-
dependent association was found of Lp-PLA2 mass with calcified coronary plaque assessed by com-
puted tomography.12
In a study among 190 hypercholesterolemic Sicilian individuals, no association was found between 
Lp-PLA2 activity and carotid intima-media thickness (IMT).13 However, this was a relatively small study, 
showing only unadjusted values of mean plasma Lp-PLA2 activity for subjects with normal and high 
carotid IMT. In a study among 247 patients referred for lower extremity arterial evaluation, Lp-PLA2 
was a borderline significant predictor of lower ankle-arm index (AAI) after adjustment for convention-
al cardiovascular risk factors and statin use.14 So far, no population-based studies have investigated 
whether Lp-PLA2 activity is associated with measures of extracoronary atherosclerosis. We investi-
gated whether Lp-PLA2 activity is associated with atherosclerosis at different sites of the vascular tree 
in the Rotterdam study.
Methods
Study population
The Rotterdam Study is a prospective population-based cohort study comprising 7983 men and 
women ≥55 years of age. Its overall aim is to investigate the incidence of and risk factors for chronic 
disabling diseases. From 1990 to 1993, all inhabitants of a suburb of the city of Rotterdam aged 55 
years and over were invited to participate in an extensive home interview and two visits to the re-
search center. The overall response was 78%. The Medical Ethics Committee of Erasmus MC approved 
the Rotterdam Study and written informed consent was obtained from all participants. A more de-
tailed description of the Rotterdam Study and the collection of data have been given previously.15
For the present study, a random sample of 1820 participantts was drawn from the source popula-
tion, and in this subcohort, baseline measurements of Lp-PLA2 activity were conducted. Within this 
group, measurements of IMT were available for 1430 participants, and assessment of carotid plaques, 
AAI and aortic calcification for 1435, 1624 and 1259 participants, respectively. Missing measurements 
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were mainly attributable to logistic reasons. Values for cardiovascular risk factors were missing in less 
than 6% of participants.
Measurement of Lp-PLA2 activity
Plasma aliquots prepared from non-fasting blood samples were collected at baseline and stored at 
-80°C, and Lp-PLA2 activity was measured with a high throughput radiometric activity assay. Briefly, 
plasma samples were aliquoted into 96-well microtiter plates and mixed with a substrate solution 
consisting of 0.4 µM [3H]-platelet-activating factor (Specific Activity 21.5 Ci/mmol, Perkin Elmer Life 
Sciences) and 99.6 µM C16-platelet-activating factor (Avanti Polar Lipids Inc) in assay buffer (100mM 
HEPES, 150mM NaCl, 5mM EDTA, pH7.4). The reactions were allowed to proceed at room temperature 
for 5 min before sequestering of the phospholipid substrates by an ice-cold fatty acid-free bovine 
serum albumin solution at a final concentration of 16.1 mg/ml. The BSA-lipid complexes were then 
precipitated with ice-cold trichloroacetic acid at a final concentration of 7.8% and pelleted by cen-
trifugation at ~6,000 g for 15 min at 4°C. Aliquots of the supernatant containing the reaction products 
were transferred to another microplate (Perkin Elmer) and the radioactivity counted in a Topcount liq-
uid scintillation counter (Perkin Elmer Life Sciences) on addition of Microscint-20 scintillation cocktail 
(Perkin Elmer Life Sciences). Lp-PLA2 activity was expressed as nanomoles of platelet-activating factor 
hydrolyzed per minute per ml of plasma samples.
Before analysis of plasma samples from the Rotterdam Study, a pre-study validation was conduct-
ed to determine the reliability of the Lp-PLA2 activity assay. Six plasma samples were tested in tripli-
cate, and the coefficient of variation (CV) for intra-assay precision ranged from 3.51-8.96%. To assess 
inter-assay precision, six plasma samples were tested on three occasions, and CV ranged from 8.48 
to15.08%. Three cycles of freeze-thaw of frozen plasma did not result in appreciable loss of activity. 
The assay was therefore considered suitable for analysis of the Rotterdam Study samples, which were 
tested in duplicate. Samples were re-tested if the replicate CV was > 25%. The range of detection was 
8-150 nmol/min/ml.
Measures of atherosclerosis
Ultrasonography of both carotid arteries was performed with a 7.5 MHz linear-array transducer and 
a duplex scanner (ATL UltraMark IV, Advanced Technology Laboratories, Bethel, Washington, USA). 
Measurements of the common carotid IMT involved regions of the common carotid arteries proximal 
to the carotid bulb, starting at a distance of 1 cm from the bulb. IMT was determined as the average 
of mean near- and far-wall measurements, computing the average of left and right common carotid 
IMT.16 We considered carotid IMT below 1 mm as absence of atherosclerosis according to this mea-
surement.
The internal carotid artery, carotid bifurcation, and common carotid artery were examined both 
left and right for the presence of plaques. Plaques were defined as a focal widening relative to adja-
cent segments, with the protrusion into the lumen composed either of only calcified deposits or a 
combination of calcification and non-calcified material.16 The anterior and posterior wall were evalu-
ated for the presence of a plaque. Carotid plaques were dichotomized into presence or absence of 
carotid plaques.
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Using a random zero sphygmomanometer, sitting blood pressure was measured at the right upper 
arm. The average of two measurements obtained at one occasion was used. Systolic blood pressure 
at the ankles (posterior tibial artery) was measured in supine position with a random zero sphygmo-
manometer and an 8 MHz continuous wave Doppler probe (Huntleigh 500D, Huntleigh Technology, 
Bedfordshire, UK). The ratio of the systolic blood pressure at the ankle to the systolic blood pressure 
at the arm was computed to obtain the AAI. For the analyses, we used the lowest value of two legs. 
Values of the AAI larger than 1.50 were considered invalid.17 We considered AAI above 0.90 as absence 
of atherosclerosis according to this measurement.
Aortic calcification was diagnosed by radiographic detection of calcified deposits in the abdomi-
nal aorta on a lateral abdominal film.18 Aortic calcification was dichotomized into presence or absence 
of aortic calcification.
Based on the above four measurements, we assigned atherosclerosis status to the participants. 
Atherosclerosis status could be assigned to 1609 participants, which were subsequently used for the 
analysis. Participants without atherosclerosis were defined as those with either three or four measures 
of atherosclerosis available, which all showed absence of atherosclerosis. Presence of atherosclerosis 
was defined as presence of atherosclerosis at any site measured.
Furthermore, presence of atherosclerosis was classified according to the two vessel beds involved, 
being the carotid arteries and the aortic-iliac-femoral tract. Atherosclerosis in the carotid arteries was 
defined as IMT > 1 mm or presence of carotid plaques, and atherosclerosis in the aortic-iliac-femoral 
tract was defined as AAI < 0.9 or presence of aortic calcification. Atherosclerosis in both the carotid 
arteries and the aortic-iliac-femoral tract was defined as IMT > 1 mm or presence of carotid plaques 
concomitant with AAI < 0.9 or presence of aortic calcification.
Assessment of covariates
At baseline, covariates were ascertained using standard procedures as described previously.4 C-re-
active protein was measured using a nephelometric method (Immage, Beckman Coulter) in serum 
which was kept frozen at -20 °C. This system has a within-run precision < 5.0%, a total precision < 7.5% 
and a reliability coefficient of 0.995. To compute the correlation between total cholesterol and LDL-
cholesterol, we determined LDL-cholesterol in a random sample of 42 subjects using an enzymatic 
method (Roche, Mannheim, Germany). The correlation coefficient between total cholesterol and LDL-
cholesterol was high (r=0.91, p<0.001).
Statistical analysis
First, we tested for differences between the subcohort used for analysis and the remainder of the 
Rotterdam Study, by using a t-test for continuous and a chi-square test for dichotomous variables. Be-
cause the distribution of C-reactive protein was skewed, the Mann Whitney test was used for this vari-
able. Second, age-adjusted (except for age) and sex-adjusted (except for sex) correlation coefficients 
were computed for the association of age, sex and cardiovascular risk factors with Lp-PLA2.
Lp-PLA2 activity was divided into tertiles using cut-off values of 39 and 48 nmol/min/ml. Because 
gender differences may exist for Lp-PLA2 activity, we also did sex-specific analyses, using sex-specific 
tertiles (cut-offs 37 and 47 nmol/min/ml for women and 41 and 51 nmol/min/ml for men). We used bi-
nary logistic regression to examine the association between tertiles of Lp-PLA2 activity and presence 
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of any sign of atherosclerosis in men and women. In model 1, we adjusted for age. In model 2, total 
cholesterol and HDL-cholesterol were added. In model 3, body mass index, systolic blood pressure, 
diabetes, smoking, cholesterol lowering medication and C-reactive protein were entered additionally 
for men, and for women, hormone replacement therapy was also added. We used multinomial logistic 
regression to examine the association between tertiles of Lp-PLA2 activity and presence of athero-
sclerosis in the carotid arteries, the aortic-iliac-femoral tract, or both, in men and women. Again, three 
models were constructed as described above.
Missing values for cardiovascular risk factors were handled by imputing the mean for normally 
distributed variables, the median for skewed variables, and the value with the highest prevalence for 
nominal variables. A sensitivity analysis was performed to investigate whether the results changed 
when only subjects with complete information on all covariates were used.
Results
The characteristics of the subcohort used for the analysis were similar to the baseline characteristics 
of the remaining population of the Rotterdam Study with a few minor exceptions. Subjects in the 
subcohort were slightly younger (68.8 versus 71.0 years of age), had a slightly lower mean systolic 
blood pressure (138 versus 140 mm Hg) and diastolic blood pressure (73 versus 74 mm Hg), a slightly 
higher total cholesterol level (6.7 versus 6.6 mmol/l) and a somewhat lower prevalence of myocardial 
infarction (11% versus 14%). Table 1 shows the baseline characteristics of the participants according 
to sex and atherosclerosis status.
Lp-PLA2 activity was positively associated with male sex (Spearman correlation coefficient r=0.16), 
body mass index (r=0.074), systolic blood pressure (r=0.070), and total cholesterol (r=0.42). An inverse 
association was present with HDL cholesterol (r= -0.28). Lp-PLA2 activity was not significantly associ-
ated with age, diabetes, smoking, and CRP.
In table 2, the association between Lp-PLA2 activity and presence of atherosclerosis in all partici-
pants and in men and women separately is displayed. A total of 303 participants were classified as 
not having atherosclerosis, 1306 participants were classified as having atherosclerosis. After adjusting 
for age and sex, the overall odds ratio of having atherosclerosis was 1.77 (95% CI 1.26-2.50) for the 
highest compared with the lowest tertile of Lp-PLA2 activity. In men, the age-adjusted odds ratio was 
1.86 (95% CI 1.01-3.43), and in women, it was 1.60 (95% CI 1.08-2.37). After adjustment for total and 
HDL cholesterol, the effect disappeared; what was left was a non-significant, attenuated odds ratio of 
1.40 (95% CI 0.70-2.77) in men. Additional adjustment for body mass index, systolic blood pressure, 
diabetes, smoking, cholesterol lowering medication, C-reactive protein and for women, hormone re-
placement therapy, did not materially alter the risk estimates. The middle versus the lowest tertile of 
Lp-PLA2 did not show any association with atherosclerosis.
Table 3 shows odds ratios of presence of atherosclerosis in the carotid arteries, the aortic-iliac-
femoral tract, or both, according to tertiles of Lp-PLA2 activity. The age- and sex-adjusted odds ratio 
for having aortc-iliac-femoral atherosclerosis was 1.97 (95% CI 1.34-2.90) for the highest versus the 
lowest tertile of Lp-PLA2 activity in all participants. In men, the corresponding age-adjusted odds 
ratio was 1.95 (95% CI 0.98-3.87), and in women, it was 1.70 (95% CI 1.08-1.13). These associations 
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Table 1. Baseline characteristics of the study population.
All
(n=1609)
No atherosclerosis Atherosclerosis
Men
(n=83)
Women 
(n=220)
Men
(n=543)
Women 
(n=763)
Age (years) 68.8±8.7 63.6±6.9 64.1±7.0 69.0±8.1 70.6±9.1
Hormone replacement therapy (%) 20 14
Body mass index (kg/m2) 26.2±3.6 25.2±2.6 26.5±3.6 25.5±3.1 26.6±3.9
Systolic blood pressure (mm Hg) 138±22 132±18 128±20 139±22 141±22
Diastolic blood pressure (mm Hg) 73±11 75±11 71±10 74±11 73±11
Total cholesterol (mmol/l) 6.7±1.2 6.3±1.2 6.7±1.1 6.4±1.1 7.0±1.3
HDL-cholesterol (mmol/l) 1.3±0.35 1.3±0.3 1.5±0.4 1.2±0.3 1.4±0.4
Diabetes mellitus (%) 10 7 3 10 12
Smokers (%)
- Current 24 22 12 29 24
- Past 41 60 33 62 26
Cholesterol lowering medication (%) 2.2 0.0 0.4 3.0 2.5
C-reactive protein (mg/l)* 1.78 (0.93-
3.58)
1.54 (0.70-
3.49)
1.41 (0.65-
2.73)
1.90 (0.97-
3.95)
1.82 (1.00-
3.57)
Lp-PLA2 activity (nmol/min/ml plasma) 45±12 44±10 41±10 48±11 44±12
History of myocardial infarction (%) 11 1 3 18 9
Carotid intima-media thickness (mm) 0.80±0.17 0.74±0.11 0.69±0.10 0.86±0.18 0.80±0.16
IMT > 1 mm (%) 10 0 0 18 10
Ankle-arm index 1.05±0.23 1.22±0.14 1.13±0.12 1.05±0.24 1.00±0.24
AAI < 0.90 (%) 19 0 0 21 26
Carotid plaques† (%) 59 0 0 78 72
Aortic calcification‡ (%) 71 0 0 86 84
Categorical variables are expressed as percentage. Values of continuous variables are expressed as mean ± standard deviation. *Expressed as 
median and interquartile range because of skewed distribution; †percentage of subjects with ≥1 carotid plaques; ‡percentage of subjects with 
aortic calcification.
Table 2. Odds ratios (ORs) and 95% confidence intervals for presence of atherosclerosis for tertiles of Lp-
PLA2 activity in all subjects, men and women.
Total (n=1609) Men (n= 626) Women (n=983)
Second vs first tertile Lp-PLA2
OR (model 1) 1.02 (0.75-1.38) 1.10 (0.63-1.93) 1.24 (0.85-1.80)
OR (model 2) 0.71 (0.51-0.99) 0.92 (0.51-1.66) 0.82 (0.54-1.23)
OR (model 3) 0.71 (0.50-1.00) 0.92 (0.51-1.69) 0.83 (0.54-1.28)
Third vs first tertile Lp-PLA2
OR (model 1) 1.77 (1.26-2.50) 1.86 (1.01-3.43) 1.60 (1.08-2.37)
OR (model 2) 1.00 (0.67-1.48) 1.40 (0.70-2.77) 0.78 (0.49-1.25)
OR (model 3) 1.04 (0.69-1.57) 1.42 (0.71-2.86) 0.83 (0.54-1.28)
Model 1, adjusted for age (and sex when appropriate); model 2, adjusted for age (and sex when appropriate), total cholesterol level and HDL-
cholesterol level; model 3, adjusted for age (and sex when appropriate), total cholesterol level, HDL-cholesterol level, body mass index, systolic 
blood pressure, diabetes, smoking, cholesterol lowering medication, C-reactive protein, and for women also hormone replacement therapy.
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disappeared after adjustment for total and HDL-cholesterol. The odds ratios for carotid atherosclero-
sis were somewhat lower and did not reach statistical significance. Again, these were attenuated by 
adjustment for cholesterol. A strong association was found with having both carotid and aortc-iliac-
femoral atherosclerosis; the overall age- and sex-adjusted odds ratio for the highest versus the lowest 
tertile of Lp-PLA2 activity was 1.97 (95% CI 1.34-2.90). For men and women, the age-adjusted odds 
ratios were 2.04 (95% CI 1.06-3.95) and 1.82 (95% CI 1.15-2.88), respectively. Again, the associations 
disappeared after adjustment for total and HDL-cholesterol.
Table 3. Odds ratios (ORs) and 95% confidence intervals for severity of carotid plaques for tertiles of Lp-
PLA2 activity in men and women.
No 
atherosclerosis
Carotid 
atherosclerosis
Aortic-iliac-
femoral 
atherosclerosis
Carotid and 
aortic-iliac-femoral 
atherosclerosis
Total n=303 n=299 n=446 n=561
Second vs first tertile Lp-PLA2
OR (model 1) 1.00 (ref ) 0.73 (0.49-1.08) 1.15 (0.81-1.65) 1.13 (0.79-1.61)
OR (model 2) 1.00 (ref ) 0.55 (0.36-0.84) 0.81 (0.55-1.18) 0.75 (0.51-1.10)
OR (model 3) 1.00 (ref ) 0.55 (0.36-0.84) 0.80 (0.54-1.19) 0.76 (0.50-1.13)
Third vs first tertile Lp-PLA2
OR (model 1) 1.00 (ref ) 1.31 (0.87-1.99) 1.97 (1.34-2.90) 1.97 (1.34-2.90)
OR (model 2) 1.00 (ref ) 0.84 (0.52-1.36) 1.11 (0.71-1.73) 1.01 (0.65-1.58)
OR (model 3) 1.00 (ref ) 0.86 (0.53-1.40) 1.15 (0.73-1.82) 1.10 (0.69-1.75)
Men n=83 n=117 n=167 n=259
Second vs first tertile Lp-PLA2
OR (model 1) 1.00 (ref ) 1.00 (0.51-1.95) 1.29 (0.68-2.42) 1.02 (0.55-1.89)
OR (model 2) 1.00 (ref ) 0.97 (0.48-1.96) 1.04 (0.53-2.04) 0.81 (0.42-1.55)
OR (model 3) 1.00 (ref ) 0.93 (0.45-1.90) 1.08 (0.55-2.13) 0.83 (0.42-1.61)
Third vs first tertile Lp-PLA2
OR (model 1) 1.00 (ref ) 1.50 (0.73-3.08) 1.95 (0.98-3.87) 2.04 (1.06-3.95)
OR (model 2) 1.00 (ref ) 1.46 (0.65-3.28) 1.39 (0.64-3.00) 1.36 (0.65-2.86)
OR (model 3) 1.00 (ref ) 1.40 (0.62-3.17) 1.39 (0.64-3.03) 1.39 (0.65-2.96)
Women n=220 n=182 n=279 n=302
Second vs first tertile Lp-PLA2
OR (model 1) 1.00 (ref ) 0.79 (0.48-1.29) 1.43 (0.93-2.22) 1.42 (0.91-2.22)
OR (model 2) 1.00 (ref ) 0.55 (0.33-1.94) 0.96 (0.60-1.53) 0.89 (0.55-1.44)
OR (model 3) 1.00 (ref ) 0.58 (0.33-0.99) 0.94 (0.57-1.54) 0.92 (0.55-1.55)
Third vs first tertile Lp-PLA2
OR (model 1) 1.00 (ref ) 1.24 (0.76-2.03) 1.70 (1.08-1.13) 1.82 (1.15-2.88)
OR (model 2) 1.00 (ref ) 0.67 (0.38-1.20) 0.84 (0.49-1.44) 0.81 (0.47-1.39)
OR (model 3) 1.00 (ref ) 0.69 (0.37-1.22) 0.86 (0.49-1.51) 0.86 (0.48-1.55)
Model 1, adjusted for age (and sex when appropriate); model 2, adjusted for age (and sex when appropriate), total cholesterol level and HDL-
cholesterol level; model 3, adjusted for age (and sex when appropriate), total cholesterol level, HDL-cholesterol level, body mass index, systolic 
blood pressure, diabetes, smoking, cholesterol lowering medication, C-reactive protein, and for women also hormone replacement therapy.
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Performing the analysis using only subjects with complete information on all covariates did not 
materially change the results.
Discussion
Lp-PLA2 activity has been found previously to be independently associated with cardiovascular 
events in the Rotterdam Study.4 In the present study, Lp-PLA2 activity was associated with extracoro-
nary atherosclerosis at different sites of the arterial tree after adjustment for age and sex. However, 
after adjustment for total cholesterol and HDL-cholesterol, the associations between Lp-PLA2 activity 
and measures of atherosclerosis strongly attenuated or even disappeared.
The inconsistency between the association of Lp-PLA2 with clinical and subclinical atherosclerosis 
merits attention. First, the atherosclerosis measurements need to be evaluated. This study was per-
formed within the Rotterdam Study, a large population-based study in subjects ≥55 years of age. We 
used several techniques to measure atherosclerosis. Ultrasound was used to measure the IMT of the 
common carotid artery and to detect plaques in the common carotid artery, bifurcation and internal 
carotid artery. We took x-ray films to assess the amount of aortic calcification, which has been shown 
to be a highly specific technique for the measurement of aortic intimal atherosclerosis,19 and we used 
AAI as a measure of lower extremity atherosclerosis. The measures of carotid, aortic and lower ex-
tremity atherosclerosis have all shown to be associated with cardiovascular risk factors and risk of 
cardiovascular events and are considered to be measures of generalized atherosclerosis.16,20-23 In a 
previous study we found that C-reactive protein is independently associated with all these measures 
of atherosclerosis.24 This suggests that measures of atherosclerosis were determined appropriately in 
our study.
Second, it needs to be considered that molecules that regulate inflammation will not necessarily 
correlate with plaque burden measures, as illustrated by inflammatory markers such as C-reactive pro-
tein. Although C-reactive protein is associated with coronary events, it has not been a good predictor 
of the extent of atherosclerotic disease, and may measure other characteristics than atherosclerotic 
mass, such as the activity of lymphocyte and macrophage populations within plaque or the degree 
of plaque destabilization and ongoing ulceration or thrombosis.25 The same may apply to Lp-PLA2. In 
a study enrolling 504 patients undergoing clinically indicated coronary angiography, Lp-PLA2 mass 
was found to be associated with severity of angiographically determined coronary artery disease.11 
However, after adjustment for clinical and lipid variables, this association disappeared. In the same 
study, LpPLA2 was independently associated with coronary events. Furthermore, Lp-PLA2 has been 
found to be independently associated with cardiovascular events in the West of Scotland Coronary 
Prevention Study (WOSCOPS), Atherosclerosis Risk in Communities (ARIC), Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA), and Rotterdam studies,1-5 and univariately associ-
ated in the Women’s Health Study.26 Also, Lp-PLA2 was found to be independently associated with a 
positive history of coronary artery disease in a small randomized controlled trial.27
Lp-PLA2 is bound to LDL-cholesterol and therefore highly correlated with LDL-cholesterol levels. 
In the present study, no LDL-cholesterol levels were available and therefore we adjusted for total cho-
lesterol levels. Because of the high correlation between LDL and total cholesterol in a random sample 
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in the present study and because the correlation between Lp-PLA2 and total cholesterol in our study 
was even higher than that of Lp-PLA2 with LDL-cholesterol in the WOSCOPS1 and the ARIC study,2 we 
believe that we adjusted sufficiently for LDL-cholesterol. Furthermore, whereas residual confounding 
would lead to an overestimation of the effect, we no longer observed an association between Lp-
PLA2 activity and measures of atherosclerosis after adjustment for total and HDL-cholesterol, showing 
that adjustment for total cholesterol exerts its effect on the risk estimates.
Few studies have been reported on the association between Lp-PLA2 and extracoronary athero-
sclerosis. In a study among 190 hypercholesterolemic Sicilian individuals, no association was found 
between Lp-PLA2 activity and a carotid IMT >1 mm.13 However, this was a small study in high-risk sub-
jects, and only unadjusted values of mean plasma Lp-PLA2 activity for patients with normal and high 
carotid IMT were presented. Sex-specific values were not given. Furthermore, none of the established 
cardiovascular risk factors was found to be associated with IMT in this study, most likely because of 
small sample size. In a study among 247 patients referred for lower extremity arterial evaluation, Lp-
PLA2 was a borderline significant predictor of lower AAI after adjustment for conventional cardiovas-
cular risk factors and statin use.14
Several studies have examined the association between Lp-PLA2 and angiographically document-
ed coronary atherosclerosis in case control settings using high-risk subjects, most of them finding an 
independent association,7-10 and one of them finding that the association disappeared after adjust-
ing for clinical and lipid variables.11 Furthermore, in a nested case-control study among young adults 
participating in the population-based CARDIA study, an independent association was found of Lp-
PLA2 mass with calcified coronary plaque assessed by computed tomography.12 These studies have 
been conducted in various populations and were different in design, and are therefore not strictly 
comparable to our study. Discrepancies between these studies and our study may be attributable to 
different sites of the atherosclerosis measurements (coronary versus extracoronary), use of high-risk 
subjects in the case-control studies and differences in the age range of the participants.
In conclusion, although Lp-PLA2 activity has been found to be independently associated with car-
diovascular events in the Rotterdam Study, the association with measures of subclinical extracoro-
nary atherosclerosis found in this study strongly attenuated or even disappeared after adjustment 
for cholesterol. Future studies are needed to further elucidate the role of Lp-PLA2 in the stages of the 
atherosclerotic process and the development of cardiovascular disease.
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Chapter 4.1
Fibrinogen gene haplotypes and 
cardiovascular disease
Abstract
Fibrin network structure has been correlated with coronary disease. Fibrinogen γ and α (FGG and FGA) 
gene haplotypes (chromosome 4q28) may be associated with fibrin network structure, and thereby 
with rigidity of the fibrin clot and sensitivity of the fibrin clot to the fibrinolytic system. Through these 
mechanisms they may influence risk of cardiovascular disease. We set out to investigate the relation 
between combined fibrinogen FGG and FGA gene haplotypes, representing the common variation 
of the fibrinogen FGG and FGA genes, coronary events and measures of coronary and extracoronary 
atherosclerosis. The study was embedded in the Rotterdam Study, a prospective population-based 
study among men and women aged ≥ 55 years. Common haplotypes were studied using seven tag-
ging SNPs across a 30-kb region with the FGG and FGA genes. Incident coronary events were regis-
tered, and carotid intima-media thickness, carotid plaques, ankle-arm index, aortic calcification and 
coronary calcification were assessed. Seven haplotypes with frequencies >1% covered 97.5% of the 
genetic variation. In 5,667 participants without history of coronary heart disease, 733 coronary heart 
disease cases occurred during a median follow-up time of 11.9 years. Fibrinogen gene haplotypes 
were not associated with coronary events. Fibrinogen gene haplotypes did not show a consistent 
association with measures of coronary and extracoronary atherosclerosis. In conclusion, fibrinogen 
FGG and FGA gene haplotypes are not associated with coronary events, coronary atherosclerosis or 
extracoronary atherosclerosis. Confirmation of these findings by future population-based studies is 
warranted.
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Introduction
Fibrinogen is an important coagulation factor, acting as an adhesive protein essential for platelet ag-
gregation as well as forming insoluble fibrin fibers in the final stage of the blood coagulation cas-
cade.1 Several prospective epidemiological studies have demonstrated an independent association 
between fibrinogen level and cardiovascular disease. This has recently been confirmed in a large, in-
dividual participant meta-analysis.2
Fibrinogen may contribute to the progression of atherosclerosis through several potential 
pathophysiological mechanisms, whose roles are still unclear.3 One of the mechanisms that have been 
gaining attention lately is the effect of changes in the structure of the fibrin network, because a cor-
relation has been demonstrated between fibrin structure and coronary disease.4,5 A possible underly-
ing mechanism is the relationship between fibrin structure and hypofibrinolysis.6 Fibrin structure is 
in part determined by genetic influences.7,8 Therefore, genetic variants altering fibrinogen structure 
and function and consequently fibrin structure may provide an opportunity to further investigate the 
involvement of fibrinogen in atherogenesis.
The fibrinogen molecule consists of two sets of three different peptide chains- Aα, Bβ and γ chains- 
encoded by three genes, fibrinogen γ (FGG), α (FGA) and β (FGB), located in a region of approximately 
50 kb on chromosome 4q.9 Various single nucleotide polymorphisms (SNPs) have been identified in 
the fibrinogen genes, which may result in heterogeneity in circulating fibrinogen and fibrin clot struc-
ture. A weak association of the Ala312 allele of the Thr312Ala (rs6050) SNP in the FGA gene with low fi-
brin gel porosity and fibre-mass:length ratio has been reported in survivors of myocardial infarction.10 
Later, this allele has been found to be associated with clots having large fibrin fibres and increased 
stiffness.11 This allele has also been associated with increased post-stroke mortality and pulmonary 
embolism.12,13 The T allele of the 10034C/T (rs2066865) SNP in the FGG gene may affect the sensitivity 
of the fibrin clot to the fibrinolytic system by altering the proportion of the γ’ chains as a result of more 
frequent cleavage of pre-mRNAs and increased splicing, and an FGG haplotype containing this allele 
has been found to be associated with risk of deep venous thrombosis.14 Haplotypes based on FGG 
SNP rs1049636 and FGA SNP rs2070011 have been associated with risk of myocardial infarction in a 
case-control setting.15 The rs2070011 SNP in FGA is an independent determinant of fibrin gel porosity 
and modulates the relation between plasma fibrinogen concentration and fibrin clot porosity.16
The above findings suggest that fibrinogen FGG and FGA haplotypes may affect the formation 
of the fibrin network structure and consequently the sensitivity of the fibrin clot to the fibrinolytic 
system. Through these mechanisms they may influence risk of coronary heart disease. We set out to 
investigate the association between common variations in the fibrinogen FGG and FGA genes and 
coronary heart disease in the Rotterdam Study, a large, prospective, population-based cohort study.
Methods
Study population and baseline data collection
The Rotterdam Study is a population-based cohort study aimed at assessing the occurrence of and 
risk factors for chronic diseases in the elderly. Objectives and methods have been described in detail 
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elsewhere.17 The cohort includes 7,983 men and women aged 55 years and over (78% of the eligible 
population), living in a well-defined suburb of the city of Rotterdam, The Netherlands. The medical 
ethics committee of Erasmus Medical Center, Rotterdam, approved the study. Participants gave writ-
ten informed consent and permission to retrieve information from treating physicians.
Baseline data were collected from 1990 until 1993, as described previously.18 All participants were 
visited by a trained interviewer. Additionally, in 7,129 participants, established cardiovascular risk fac-
tors were measured at the research center. Fibrinogen measurements were done in a random sample 
of 2,968 participants. Platelet poor plasma was frozen in liquid nitrogen and stored at –80°C. Fibrino-
gen levels were derived from the clotting curve of the prothrombin time assay using Thromborel S 
as a reagent on an automated coagulation laboratory (ACL 300, Instrumentation Laboratory). The 
coefficient of variation was 5%.
Genotyping
The Seattle SNPs Program for Genomic Applications19 has identified various SNPs in the fibrinogen 
genes based on 23 unrelated individuals of European descent from the CEPH pedigrees and has con-
structed haplotypes based on this dataset. We combined the four haplotypes of the FGG gene and 
the five haplotypes of the FGA gene and determined tagging SNPs needed to describe this combined 
FGG-FGA haplotype structure. All participants were genotyped for seven tagging SNPs (figure 1). We 
numbered the SNPs in relation to the transcription start site, in accordance with the Human Genome 
Organisation guidelines (www.gene.ucl.ac.uk/nomenclature/guidelines.html). In the Seattle SNPs 
program, SNP numbering was based on GenBank accession number AF350254 (FGG) and AF361104 
(FGA), containing the fibrinogen gene sequences of Seattle SNPs. Our SNP number 4288 corresponds 
Figure 1. Schematic depiction of haplotypes based on FGG and FGA in the study population (n=6514).
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to Seattle number 5836, 6326 to 7874, 7792 to 9340, -58 to 2224, 1374 to 3655, 1526 to 3807, and 
4253 to 6534. These SNPs have also been described at http://www.ncbi.nlm.nih.gov/SNP under the 
appropriate rs numbers (figure 1).
Genotypes were determined in 2-ng genomic DNA with the Taqman allelic discrimination assay 
(Applied Biosystems, Foster City, CA, USA). Reactions were performed with the Taqman Prism 7900HT 
in 384-wells format. Haplotypes present in the population were inferred by means of the haplo.em 
function of the program Haplo Stats (http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.
html), which computes maximum likelihood estimates of haplotype probabilities.20,21 Only haplotypes 
with frequencies >1% were used in the analysis. These seven haplotypes were coded as haplotype 
numbers 1 through 7 in order of decreasing frequency in the population.
Measures of extracoronary and coronary atherosclerosis
Several non-invasive measurements of extracoronary atherosclerosis were conducted at baseline. A 
detailed description of the procedures has been given previously.22 Briefly, ultrasonography of both 
the left and the right carotid artery was performed according to the protocol of the Rotterdam Study 
and mean common carotid intima-media thickness (IMT) was determined. The left and right common 
carotid arteries, bifurcations and internal carotid arteries were evaluated for the presence of athero-
sclerotic lesions (plaques), resulting in a plaque score between 0 and 6. The ratio of systolic blood 
pressure at the ankles to the systolic blood pressure at the arm was computed to obtain the ankle-arm 
index (AAI). Aortic calcification was diagnosed by radiographic detection of calcified deposits in the 
abdominal aorta. The extent of aortic calcification was scored according to the length of the involved 
area of the posterior wall, with scores 0-5 corresponding to 0, <1, 1-2.4, 2.5-4.9, 5.0-9.9 and ≥10 cm.
From 1997 onwards, participants through 85 years of age completing the third phase of the Rotter-
dam Study were invited to participate in the Rotterdam Coronary Calcification Study and to undergo 
electron-beam computed tomography (EBCT) scans to assess coronary calcification in the epicardial 
coronary arteries, as described in detail previously.23 The calcium score was obtained as proposed by 
Agatston et al.24
Follow-up procedure
Follow-up started at the baseline examination and for the present study lasted until January 1st, 2005. 
Information on fatal and non-fatal cardiovascular endpoints was obtained from general practitioners 
and letters and discharge reports from medical specialists.18 Reported events were coded accord-
ing to the International Classification of Diseases, 10th edition (ICD-10).25 We defined incident coro-
nary heart disease as myocardial infarction, coronary artery bypass grafting (CABG), percutaneous 
transluminal coronary angioplasty (PTCA) and cardiac death. In identifying myocardial infarctions, all 
available information, which included ECG, cardiac enzyme levels, and the clinical judgment of the 
treating specialist, was used. We defined cardiac death as death from myocardial infarction or other 
ischemic heart disease (ICD-10: I20-I25), sudden cardiac death (I46), sudden death undefined (R96), or 
death from heart failure (I50).
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Population for analysis
Figure 2 shows a flow chart describing the population for analysis. After excluding participants with 
coronary heart disease at baseline (history of myocardial infarction, PTCA or CABG), 5,667 partici-
pants were left for the analysis of the association between fibrinogen gene haplotypes and incident 
coronary events. Measurements of IMT, carotid plaques, AAI and aortic calcification at baseline were 
available in limited numbers of participants, mainly because of logistic reasons such as limited avail-
ability of research assistants (figure 2). Coronary calcification was measured in a subset of participants 
completing the third phase of the Rotterdam Study. Genotyping was successful in 1,877 of these par-
ticipants.
Figure 2. Flow chart describing the study population.
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Data analysis
Hardy-Weinberg equilibriums of the SNPs were tested using Chi square tests. Associations between 
individual SNPs and coronary heart disease and myocardial infarction were examined using Cox pro-
portional hazards models in SPSS 11.0.
Associations between fibrinogen gene haplotypes and age, sex, body mass index (BMI), systolic 
blood pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, diabetes mellitus, and 
fibrinogen plasma level were examined using the haplo.glm function of the program Haplo Stats 
(http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.html).20,21,26 Haplo.glm is based on a 
generalized linear model and computes the regression of a trait on haplotypes and other covariates. 
Haplotype 1 had the highest frequency and served as the reference category. The haplo.score func-
tion of Haplo Stats was used to test the association between fibrinogen gene haplotypes and smok-
ing, which was entered as an ordinal variable (never, former, current). Details on the background and 
theory of score statistics can be found in Schaid et al.26 We adjusted the analyses for age and sex. Using 
haplo.score, we computed simulation P-values for each haplotype to account for multiple testing. The 
number of simulations was set at 1,000.
The association between fibrinogen-gene haplotypes and coronary heart disease and myocardial 
infarction was investigated by using the haplo.glm function. Again, haplotype 1 served as the refer-
ence category. First, we adjusted for age and sex, and second, we additionally adjusted for body mass 
index, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking, 
and diabetes mellitus. The analysis was repeated without excluding participants with coronary heart 
disease at baseline. The analysis was also repeated examining FGG and FGA haplotypes separately.
The associations between fibrinogen haplotypes and IMT, carotid plaques, AAI, aortic calcifica-
tion and coronary calcification were examined using haplo.score. This non-parametric approach was 
chosen because the distributions of AAI and coronary calcification were skewed and difficult to nor-
malize, and carotid plaques and aortic calcification were ordinal variables, which can be dealt with by 
haplo.score. Subsequently, atherosclerosis measures were dichotomized; IMT > 1 mm, carotid plaque 
score ≥ 4, AAI < 0.9, aortic calcification ≥ 5 cm and coronary calcification score > 1,000 were used as 
the outcomes in regression analysis using haplo.glm. Again, two models were used for adjustment.
Values for cardiovascular covariates were missing in less than 4% of participants. These missing val-
ues were handled by single imputation using the expectation-maximization algorithm in SPSS 11.0. 
Haplo.em, haplo.score and haplo.glm were all implemented in the Haplo Stats software using the R 
language. All tests were two-sided.
Results
Table 1 shows baseline characteristics of the study population. Mean age was 69.5 years and 59% was 
female. Among participants without history of coronary heart disease and with successful genotyp-
ing, median follow-up time was 11.9 years (interquartile range 7.9-12.9 years) and incident coronary 
heart disease occurred in 733 participants during follow-up, including 303 myocardial infarctions.
DNA was available in 6,571 participants. Failure of genotyping for individual SNPs occurred in 2.9 
to 4.7%. Genotype distributions for the seven haplotype tagging SNPs were in Hardy-Weinberg equi-
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librium (table 2). Individual SNPs were not significantly associated with coronary heart disease and 
myocardial infarction (data not shown). Notably, this was also the case for the Thr312Ala SNP in FGA. 
Heterozygotes and Ala312 homozygotes had hazard ratios of 1.00 (95% CI 0.86-1.17) and 0.96 (95% CI 
0.72-1.29), respectively, of developing coronary heart disease. For myocardial infarction, the relative 
risk was somewhat increased, but not significant; it was 1.15 (95% CI 0.91-1.47) and 1.19 (95% CI 0.77-
1.83), for heterozygotes and Ala312 homozygotes, respectively.
The FGG and FGA SNPs are located on chromosome 4q28. According to the HapMap website 
(http://www.hapmap.org), they lie in two linkage disequilibrium blocks spanning approximately 30 
kb of genomic DNA. However, linkage disequilibrium between these two blocks is very high, with a 
D’of 0.94. Therefore, we combined haplotypes of both genes. Haplotype reconstruction resulted in 
twenty-four FGG-FGA haplotypes in the Rotterdam Study population. Seven haplotypes had frequen-
cies >1%, and together these seven haplotypes covered 97.5% of the genetic variation. The structures 
of these haplotypes and their frequencies are displayed in figure 1.
Haplotypes 2 and 5 were associated with lower BMI, with beta coefficients of –0.28 (95% CI, –0.50, 
-0.06; p=0.01) kg/m2 per allele copy and –0.18 (95% CI –0.35, -0.01; p=0.03) kg/m2 per allele copy, 
respectively. Haplotype 3 was associated with lower diastolic blood pressure, with a beta coefficient 
of –0.62 (95% CI, -1.08, -0.17; p=0.007) mmHg per allele copy. In view of the number of variables we 
examined, this significance level was not particularly high; the associations lost significance after ad-
justment for multiple comparisons. Haplotypes were not associated with age, sex, total cholesterol, 
HDL cholesterol, diabetes mellitus, history of myocardial infarction, or smoking (data not shown). The 
regression model became unstable when systolic blood pressure was examined. Therefore we used 
haplo.score, and no association was found with systolic blood pressure (data not shown).
Haplotype 4 was associated with higher fibrinogen plasma level. Haplotype 4 resulted in a fibrino-
gen plasma level of 3.21 (95% CI 3.15-3.27) g/l, as compared to a level of 3.13 g/l for haplotype 1 
Table 1. Baseline characteristics of the study population (n=6514).
Variable
Age (years) 69.5±9.2
Women 3871 (59%)
Body mass index (kg/m2) 26.3±3.7
Systolic blood pressure (mm Hg) 139±22
Diastolic blood pressure (mm Hg) 74±11
Total cholesterol (mmol/l) 6.6±1.2
HDL-cholesterol (mmol/l) 1.3±0.4
Diabetes mellitus 669 (10%)
Smokers
- Never 2244 (34%)
- Current 1441 (22%)
- Former 2649 (41%)
History of myocardial infarction 760 (13%)
Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts because of missing values in the variables. 
Values of continuous variables are expressed as mean ± standard deviation.
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(reference) (p=0.02). Other fibrinogen haplotypes were not significantly associated with fibrinogen 
plasma level (data not shown).
In table 3, age-and sex-adjusted odds ratios for coronary heart disease and for myocardial in-
farction are displayed for different fibrinogen haplotypes. For both outcomes, the odds ratios for all 
haplotypes were around one. Additional adjustment for cardiovascular risk factors did not materially 
change the point estimates, and neither did repeating the analysis without excluding participants 
with coronary heart disease at baseline. When FGG and FGA haplotypes were analyzed separately, 
also, no associations were found with coronary events (data not shown).
Table 4 displays the associations between fibrinogen haplotypes and IMT, carotid plaques, AAI, 
aortic calcification and coronary calcification. Haplotype 3 was associated with lower IMT (p=0.03). 
However, haplotype 3 was not associated with other measures of atherosclerosis. Haplotype 4 was as-
sociated with lower amount of aortic calcification (p=0.01). Although the direction of the associations 
of this haplotype with the other measures of atherosclerosis was consistent, none of the other asso-
ciations was significant. Of note is, that the protective direction of the associations of haplotype 4 with 
measures of atherosclerosis was not in accordance with the association of haplotype 4 with higher 
fibrinogen plasma level. Remaining haplotypes did not show significant associations with measures 
of atherosclerosis.
Table 2. Frequencies of SNPs in the study population (n=6514).
Gene SNP Genotype n (%)
Minor allele 
frequency
P-value HWE 
Chi square
FGG 4288G>A,
rs2066860
GG 5897(92.6) A = 3.7% 0.31
GA 464 (7.3)
AA 6 (0.1)
6326G>A,
rs2066861
GG 3457(54.6) A = 26.0% 0.46
GA 2460 (38.8)
AA 417 (6.6)
7792T>C,
rs1049636
TT 3159(49.5) C = 29.4% 0.15
TC 2694(42.2)
CC 526 (8.2)
FGA -58G>A,
rs2070011
GG 2346(36.8) A = 39.1% 0.27
GA 3075 (48.3)
AA 951 (14.9)
1374G>A,
rs2070014
GG 4348(68.7) A = 17.2% 0.77
GA 1795 (28.3)
AA 190 (3.0)
1526T>C,
rs2070016
TT 4829 (75.6) C = 12.8% 0.93
TC 1418 (22.8)
CC 103 (1.6)
4253A>G,
rs6050
(Thr312Ala)
AA 3272 (52.2) G (Ala312)= 27.6% 0.61
AG 2521 (40.3)
GG 470 (7.5)
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Using IMT > 1 mm, severe carotid plaques, AAI < 0.9 and severe aortic calcification as outcomes in 
haplo.glm did not result in significantly raised or lowered odds ratios, using either model for adjust-
ment (data not shown). Using coronary calcification score > 1000 as the outcome, haplotype 4 result-
ed in an odds ratio of 0.70 (95% CI 0.49-0.99), p=0.05. This association was borderline significant after 
multivariable adjustment and was in accordance with the direction of the association seen in table 4.
Discussion
In this population-based study, fibrinogen FGG-FGA haplotypes were not associated with coronary 
events. Furthermore, fibrinogen haplotypes did not show a consistent association with measures of 
coronary and extracoronary atherosclerosis.
Strengths of the present study include its population-based nature, coverage of 97.5% of the varia-
tion in the FGG and FGA genes, occurrence of 733 incident coronary events, and availability of several 
Table 3. Associations between fibrinogen haplotypes and coronary events, adjusted for age and sex 
(n=5667).
Haplotype Frequency
Odds ratio (95% confidence interval)
Coronary heart disease Myocardial infarction
Haplotype 1 26.5% 1.00 (reference) 1.00 (reference)
Haplotype 2 25.6% 1.01 (0.86-1.18) 1.06 (0.85-1.31)
Haplotype 3 16.6% 0.93 (0.78-1.11) 0.83 (0.64-1.09)
Haplotype 4 12.3% 1.01 (0.83-1.23) 0.90 (0.88-1.20)
Haplotype 5 11.6% 1.14 (0.95-1.39) 1.01 (0.76-1.34)
Haplotype 6 3.6% 1.06 (0.77-1.45) 1.19 (0.77-1.85)
Haplotype 7 1.3% 0.95 (0.57-1.59) 1.68 (0.92-3.08)
Table 4. Fibrinogen haplotypes and measures of extracoronary and coronary atherosclerosis, adjusted for 
age and sex.
Haplo-
type
Intima-media 
thickness Carotid plaques Ankle-arm index Aortic calcification
Coronary
calcification
Score 
statistic P-value
Score 
statistic P-value
Score 
statistic P-value
Score 
statistic P-value
Score 
statistic P-value
1 0.67 0.50 -0.60 0.57 -0.13 0.89 -0.08 0.93 0.38 0.72
2 1.02 0.30 0.17 0.87 -0.34 0.72 -0.20 0.82 0.16 0.86
3 -2.15 0.03 0.07 0.94 1.56 0.11 0.22 0.82 0.23 0.83
4 -0.84 0.39 -1.52 0.13 0.31 0.76 -2.54 0.01 -1.09 0.28
5 0.59 0.57 1.28 0.18 -1.38 0.16 1.46 0.14 -0.28 0.80
6 0.08 0.93 0.85 0.38 0.43 0.66 1.16 0.24 0.29 0.76
7 1.52 0.14 1.55 0.13 0.33 0.72 1.12 0.27 -0.99 0.31
P-values in the table were obtained using haplo.score, after 1000 simulations.
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non-invasive measures of coronary and extracoronary atherosclerosis. Nevertheless, several aspects 
of this study warrant further consideration. First, because we wanted to examine structural aspects of 
fibrinogen in our study, and FGG and FGA, not FGB, are expected to be involved in this matter, we did 
not determine FGB haplotypes. Second, we chose to combine FGG and FGA haplotypes in the analysis 
although linkage disequilibrium between these two regions was not complete, D’ being 0.94. Third, 
effects of gene haplotypes on multifactorial diseases may generally be expected to be of modest 
magnitude. Therefore, although 733 coronary events were available for analysis, we cannot exclude 
the possibility that statistical power in our study was insufficient to uncover a potential association. 
Power calculation for the present study shows that, with a power of 80% and an alpha of 0.05, in 
reference to haplotype 1 (the most common haplotype, frequency 26.4%), we were able to demon-
strate a relative risk of coronary heart disease (n=733) of at least 1.29 and a relative risk of myocardial 
infarction (n=303) of at least 1.49 (both for haplotype 2, frequency 25.6%). The true association may 
be smaller than this. Fourth, not all participants had complete information on all 4 measures of ex-
tracoronary atherosclerosis presented in this study. Although we cannot exclude the possibility that 
health-related issues have also played a role, missing data were predominantly because of logistic rea-
sons and are unlikely to have affected our results. Furthermore, coronary calcification was assessed in 
a subset of participants through 85 years of age that reached the third phase of the Rotterdam Study 
(1997-1999). We need to bear in mind that these participants had somewhat different characteristics 
because of the time that had elapsed since the baseline examination in 1990-1993.23 However, we 
consider it unlikely that this could have affected the association between fibrinogen haplotypes and 
coronary calcification.
Fibrinogen level is a consistent risk factor for cardiovascular disease.2 Lately, structural aspects of 
fibrinogen have gained attention as risk factors for cardiovascular disease.27 Collet et al. have dem-
onstrated that fibrin network architecture is the most important factor in determining rates of fibrin-
olysis.6 This could provide an explanation for the finding that men who had suffered from myocardial 
infarction at young age have a clot structure with decreased fibrin gel porosity.4,5 Similar findings have 
been documented in conditions such as peripheral vascular disease, diabetes and hypercholester-
olemia, which on their turn are associated with coronary artery disease.28,29
Investigation of fibrinogen genes has mostly focused on FGB SNPs, some of which have been found 
to be associated with fibrinogen level and coronary artery disease.30-32 However, fibrin structure is also 
in part determined by genetic influences. This is supported by a twin study,7 and a study that has dem-
onstrated that healthy male relatives of patients with premature coronary artery disease have a pro-
thrombotic clot structure characterized by reduced permeability.8 Several SNPs in the fibrinogen FGG 
and FGA genes have been shown to result in heterogeneity in fibrin clot structure and have been asso-
ciated with both venous and arterial thrombosis. Firstly, some evidence of an association of the Ala312 
allele of the Thr312Ala (rs6050) SNP in the FGA gene with low fibrin gel porosity and fibre-mass:length 
ratio has been reported in survivors of myocardial infarction.10 Later, this allele has been found to 
be associated with clots having large fibrin fibres and increased stiffness.11 This allele has also been 
associated with increased post-stroke mortality and pulmonary embolism.12,13 In the present study, 
when analyzed separately, the Ala312 allele resulted in an increased, but not significant, hazard ratio for 
myocardial infarction, namely 1.19 (95% CI 0.77-1.83), for Ala312 homozygotes. Furthermore, our haplo-
types 2 and 7, which contained the Ala312 allele, were not associated with adverse outcomes.
Fibrinogen gene haplotypes and cardiovascular disease
123
Secondly, the T allele of the 10034C/T (rs2066865) SNP in the FGG gene may affect the sensitiv-
ity of the fibrin clot to the fibrinolytic system by altering the proportion of the γ’ chains, and an FGG 
haplotype containing this allele has been found to be associated with risk of deep venous thrombosis 
by Uitte de Willige et al. in the Leiden Thrombophilia Study.14 They noted that the FGA Thr312Ala 
(rs6050) SNP is in strong, but not complete, linkage disequilibrium with the FGG haplotype associated 
with thrombosis (D’ =0.97). Uitte de Willige et al were unable to identify the rs6050 SNP as an inde-
pendent risk factor, and suggested that the risk associated with this polymorphism may be caused 
by linkage disequilibrium with the unfavorable FGG haplotype they identified. In the present study, 
we did not determine the rs2066865 SNP. According to the Seattle SNPs haplotype pattern, this SNP 
was present in our haplotype 2. As mentioned above, this haplotype was not associated with cardio-
vascular disease. In view of their above-mentioned results, Uitte de Willige et al. studied the associa-
tion between FGG gene haplotypes and myocardial infarction in the “Study of Myocardial Infarctions 
Leiden”(SMILE), a population-based case-control study.33 However, they had to conclude that none of 
the four common FGG gene haplotypes, including the haplotype that increased thrombosis risk, has 
a strong effect on the risk of myocardial infarction, and they stated that this was in line with studies 
on other prothrombotic factors that affect the risk of venous thrombosis but have small or no effects 
on arterial disease.
Furthermore, Mannila et al. studied the association between fibrinogen gene haplotypes and 
myocardial infarction in the Stockholm Coronary Artery Risk Factor (SCARF) study, a case-control 
study of factors predisposing to premature myocardial infarction in 377 postinfarction patients and 
387 healthy individuals.15 Their main finding was that haplotypes based on the FGG SNP rs1049636 
and FGA SNP rs2070011 were associated with risk of myocardial infarction. Limitations of the study 
included the retrospective design and the fact that only parts of the FGG, FGA and FGB genes were 
examined. In a subsequent study, Mannila et al. further strengthened their findings by reporting that 
the rs2070011 SNP appeared to be an independent determinant of fibrin gel porosity and that it 
modulated the relation between plasma fibrinogen concentration and fibrin clot porosity.16 In the 
present study, the rs1049636 and rs2070011 SNPs showed no associations with adverse outcomes 
when analyzed separately. Furthermore, our haplotype 5 contains the rare alleles of both these SNPs, 
and this haplotype did not show any association with events nor with measures of atherosclerosis.
In short, our results are concordant with the results of Uitte de Willige et al.,33 showing no signifi-
cant associations between fibrinogen haplotypes and myocardial infarction. We could not reproduce 
the findings of Mannila et al. that haplotypes based on rs2070011 and rs1049636 are associated with 
risk of myocardial infarction.15 This discrepancy may have arisen because of differences in study popu-
lation (mean age in the Rotterdam Study was 69.5 years versus 53.0 in the SCARF study, 60% versus 
18% was female) and the fact that the SCARF study was designed to study determinants of premature 
myocardial infarction, whereas the Rotterdam Study was designed to examine myocardial infarction 
in a general population. Whether these differences were the main factors that contributed to the ob-
served discrepancy in findings remains to be resolved.
In conclusion, in this large, prospective, population-based cohort study, FGG and FGA fibrinogen 
haplotypes were not associated with coronary events, coronary calcification or extracoronary athero-
sclerosis. Confirmation of these findings by future population-based studies and subsequent pooling 
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of the results of these studies may render adequate statistical power to provide a final answer in 
this matter.
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Chapter 4.2
Heat shock protein 27 and cardiovascular 
disease
Abstract
Aims. Heat shock protein 27 (HSP27) has been hypothesized to be a potential biomarker of athero-
thrombosis. However, no prospective studies have yet been performed to investigate the association 
between HSP27 plasma level and incident cardiovascular events among initially healthy individuals.
Methods and results. Plasma levels of HSP27 were evaluated at baseline among 255 initially healthy 
participants in the Women’s Health Study who subsequently developed myocardial infarction, stroke, 
or cardiovascular death during a follow-up period of up to 5.9 years (cases) and among an equal num-
ber of age and smoking matched women who remained free of cardiovascular disease over the same 
time period (controls). Overall, HSP27 plasma levels were inversely associated with age (Spearman 
correlation coefficient r= -0.258, P < 0.001), but not with other established cardiovascular risk factors. 
Conditional logistic regression analysis showed no significant association of baseline HSP27 plasma 
level with future cardiovascular disease; the odds ratio for the upper versus the lower tertile of HSP27 
level at baseline was 0.99 (95% confidence interval 0.62-1.57, P for trend = 0.99).
Conclusion. In this prospective study of initially healthy women, baseline HSP27 plasma level was not 
associated with incident cardiovascular events.
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Introduction
Heat shock proteins (HSPs) are molecular chaperones that protect against stress stimuli including 
heat shock, oxidized low-density lipoprotein (LDL), mechanical stress, oxidants and cytokine stimu-
lation.1 Their primary function is to fulfill chaperoning activity: as new proteins are being produced 
by ribosomes, HSPs assist in correct folding of polypeptide chains into functional protein, and after a 
stress event, HSPs assist in refolding or degradation of damaged or denatured proteins.2
HSPs are divided into several families according to molecular weight, including the 110, 90, 70, 60, 
and 40 kDa families, the small HSPs such as HSP27, and the HSP10 family. HSPs have been implicated 
in the pathogenesis of several disease processes. In relation to atherosclerosis, HSPs from the HSP60 
and HSP70 families have been most widely investigated.1,2 Recently, however, cardiovascular atten-
tion has also focused on HSP27, which is known to have chaperoning activity, to inhibit F-actin polym-
erization, to protect against apoptosis and to be involved in the presentation of oxidized proteins to 
the proteosome degradation machinery.3 Specifically, using atherosclerotic carotid endarterectomy 
samples and control endarteries, we demonstrated that HSP27 secretion correlates negatively with 
atherosclerotic plaque complexity by comparing the complicated versus the non-complicated adja-
cent area from the same specimen and control endarteries. We also reported reduced HSP27 plasma 
levels in atherosclerotic patients compared with healthy subjects.4 Park et al. used the same strategy 
but examined the tissue compartment, and also reported that HSP27 expression is increased in the 
normal-appearing vessel adjacent to atherosclerotic plaque compared to both the plaque core area 
and the reference arteries.5 By contrast, however, they reported that HSP27 plasma level was increased 
in acute coronary syndrome patients compared to normal reference subjects.
Taken together, these two recent studies raise the possibility that HSP27 may serve as a marker 
for atherothrombosis. To further evaluate this hypothesis, we performed a prospective, nested case-
control study to examine whether baseline levels of HSP27 among initially healthy individuals are 
associated with future cardiovascular event rates.
Methods
Study design
We used a prospective nested case-control design within the Women’s Health Study, a recently com-
pleted randomized, double-blind, placebo-controlled trial of low-dose aspirin and vitamin E in the pri-
mary prevention of cardiovascular disease and cancer in US female healthcare professionals. Eligible 
participants were apparently healthy women, aged 45 years or older, who were free of self-reported 
cardiovascular disease or cancer at study entry (1992–1995). Baseline characteristics of participants 
of the Women’s Health Study have been described in detail previously.6 At the time of enrollment, 
participants gave written informed consent, completed questionnaires on demographics, medical 
history, medication, and lifestyle factors, and were asked to provide a blood sample. The study was 
approved by the institutional review board of the Brigham and Women’s Hospital (Boston, Mass). The 
study complies with the Declaration of Helsinki.
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Participants were prospectively followed for a composite end point of first-ever major cardiovascu-
lar event (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death). Medical records 
were obtained for all women in whom a cardiovascular end point was reported to occur and were 
reviewed in a blinded fashion by an end-points committee of physicians. Myocardial infarction was 
confirmed if symptoms met World Health Organization criteria and if the event was associated with 
abnormal levels of cardiac enzymes or diagnostic electrocardiograms. A confirmed stroke was defined 
as a new neurologic deficit of sudden onset that persisted for at least 24 hours. Death was confirmed 
to be from cardiovascular causes on the basis of an examination of autopsy reports, death certificates, 
medical records and information obtained from the next of kin or other family members.
For each cardiovascular disease case, a control matched by age, smoking status and length of fol-
low-up was chosen among those subjects who remained free of cardiovascular disease at the time the 
index event occurred in the case participant. The control participants were selected from those who 
remained event-free up to the date that the dataset was closed for selection of study participants. For 
the present investigation, 255 incident cardiovascular disease case-control pairs were identified. Out 
of the total of 255 case subjects, 111 were diagnosed with myocardial infarction, another 111 were 
diagnosed with stroke, and 33 were confirmed to have died from cardiovascular causes. In this nested 
case-control analysis, the maximum length of follow-up was 5.9 years.
Blood collection and laboratory evaluation
EDTA blood samples were obtained at the time of enrollment and stored in vapor phase liquid nitro-
gen (–170°C). For each of the 255 case and control subjects in this study, samples were thawed and 
analyzed in a core laboratory certified by the National Heart, Lung, and Blood Institute/Centers for 
Disease Control and Prevention Lipid Standardization Program.
HSP27 plasma levels were measured with an enzyme-linked immunosorbent assay (ELISA) from 
Calbiochem (San Diego, CA). This assay employs the quantitative sandwich enzyme immunoassay 
technique. Briefly, a monoclonal antibody specific for HSP27 was pre-coated onto a microtitre plate. 
Samples, standards and controls were incubated along with a polyclonal HSP27 antibody in the mi-
crotitre plate. After incubation and a wash step, a horseradish peroxidase enzyme/IgG antibody con-
jugate was added. After another incubation and wash to remove unbound substances, an enzyme 
substrate was added and color was generated that was proportional to the amount of HSP27 present 
in the sample. Assays were run in duplicate and were repeated if the replicate coefficient of variation 
was >10%. The interassay coefficient of variation of the assay at concentrations of 2.2 and 26.3 ng/mL 
was 10.8 and 9.3%, respectively. The range of detection was 1 to 800 ng/mL.
Total and high-density lipoprotein (HDL) cholesterol were assayed directly with reagents from 
Genzyme Corporation (Cambridge, Mass) and Roche Diagnostics (Indianapolis, Ind) with the use of 
a Hitachi 911 autoanalyzer. CRP was measured with a high-sensitivity immunoturbidimetric assay on 
the Hitachi 917 autoanalyzer (Roche Diagnostics, Indianapolis, Ind.), with the use of reagents and cali-
brators from Denka Seiken (Tokyo, Japan). Fibrinogen was measured with an immunoturbidimetric 
assay, which is a mass-based assay with international standards (Kamiya Biomedical, Seattle, Wash.). 
sICAM-1 was measured using an enzyme-linked immunosorbent assay (R & D Systems, Minneapolis, 
Minn.).
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Statistical analysis
We first evaluated differences in baseline characteristics between case and control groups using 
paired t-tests for normally distributed, continuous variables, Wilcoxon signed-ranks tests for continu-
ous variables with skewed distributions, McNemar tests for dichotomous variables, and marginal ho-
mogeneity tests for variables with more than two categories.
Second, we examined associations between HSP27 plasma level and baseline characteristics of 
the control participants. Specifically, we calculated means, medians and proportions of the baseline 
characteristics according to tertiles of HSP27 level at baseline. We used ln-transformed, continuous 
plasma level of HSP27 as the independent variable and tested for trends by using linear regression 
for continuous variables, logistic regression for dichotomous variables, and multinomial regression 
for variables with more than two categories. Furthermore, we computed Spearman correlation coef-
ficients between HSP27 plasma level and baseline characteristics using both the cases and the control 
subjects.
To address the predictive value of baseline HSP27 levels, we calculated the relative risk of future 
cardiovascular events associated with HSP27 plasma level by logistic regression analysis, conditional 
on the matching on age, smoking (never, former, current) and length of follow-up. HSP27 plasma level 
was divided into tertiles based on the distribution in the control subjects and the lowest tertile was 
used as the reference category. Analysis for trend was performed by entering ln transformed HSP27 
plasma level into the model as a continuous variable. Furthermore, we investigated the presence of 
a threshold effect by dichotomizing HSP27 plasma level based on the 50th, 75th, and 90th percentiles 
in the control subjects and entering it into the model. We used several levels of adjustment. Model 1 
was matched on age, smoking and length of follow-up. In model 2, we additionally adjusted for BMI, 
systolic blood pressure, hypertension, total cholesterol, HDL cholesterol, hyperlipidemia and diabetes 
mellitus. In model 3, we added C-reactive protein, exercise, alcohol intake, menopausal status, and 
hormone replacement therapy to the variables in model 2.
To examine effect modification, we stratified the above analysis on age (below and above the me-
dian), BMI (< 25, ≥ 25-30, ≥ 30 kg/m2), hypertension, hyperlipidemia, diabetes mellitus, smoking (nev-
er, former, current), CRP (≤ 3 and > 3 mg/l), fibrinogen (below and above the median) and sICAM-1 
(below and above the median). In these latter analyses, matching was broken to obtain enough 
power for the stratified analyses. Interaction terms were computed by entering the variables into the 
conditional logistic regression model as continuous variables (with values of 1, 2, 3 for variables with 
3 categories and values 1, 2, 3, 4 for variables with 4 categories).
All analyses were conducted with SPSS 13.0 for Windows (SPSS Inc., Cary, North Carolina). A two-
tailed probability value of 0.05 was considered a statistically significant result.
Results
Baseline characteristics of cases and controls are shown in Table 1. As anticipated, cases had a sig-
nificantly higher prevalence of established cardiovascular risk factors. Notably, CRP, fibrinogen and 
sICAM-1 levels were also significantly higher in cases compared to controls. The distribution of HSP27 
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plasma level was right-skewed and median levels were similar in cases and controls (19.6 vs 18.6 ng/
ml, p=0.58) (Table 1).
Table 2 displays baseline characteristics of controls according to tertiles of HSP27 plasma level. Age 
was inversely associated with HSP27 plasma level; mean age decreased from 63.4 in the lowest tertile 
of HSP27 to 58.0 in the highest tertile of HSP27 (P for trend < 0.001). No significant trends were pres-
ent in the remaining baseline characteristics. Spearman correlation coefficients are shown in table 
3. HSP27 plasma level was significantly correlated with age (r= -0.258, P<0.001). Diabetes mellitus 
showed a borderline significant correlation (r= -0.087, P=0.051). Correlation coefficients between the 
remaining characteristics and HSP27 plasma level were small and did not reach statistical significance. 
Adjustment for age did not materially change the estimates (data not shown), although it made the 
correlation with diabetes mellitus reach statistical significance (r= -0.098, P=0.027).
Odds ratios for cardiovascular disease are displayed in Table 4. No trend was found when ln trans-
formed HSP27 plasma level was entered into the logistic regression model (odds ratio 1.00, 95% con-
fidence interval 0.83-1.21, P = 0.99). The odds ratio of developing cardiovascular disease for the high-
est versus the lowest tertile of HSP27 plasma level was 0.99 (95% confidence interval 0.62-1.57). The 
risk estimates did not change materially when adjusted for other cardiovascular risk factors (Table 
4, Models 2 and 3). We found no threshold effect when we dichotomized HSP27 plasma level based 
Table 1. Baseline characteristics of cases and controls.
Variable Controls (n=255) Cases (n=255) P-value
Age (y) 61.0±8.7 61.0±8.7 MV
Body mass index (kg/m2) 25.5±4.4 27.0±5.2 0.001
Systolic blood pressure (mmHg) 127±14 135±16 < 0.001
Diastolic blood pressure (mmHg) 78±9 80±9 0.004
Hypertension (%) 30.6 55.7 < 0.001
Total cholesterol (mg/dl) 214±37 224±43 0.009
LDL cholesterol (mg/dl) 126±32 133±38 0.04
HDL cholesterol (mg/dl) 54±15 48±15 < 0.001
Hyperlipidemia (%) 36.9 46.3 0.04
Diabetes mellitus (%) 2.0 13.7 < 0.001
Smoking (%) MV
- Never 42.0 42.0
- Past 35.7 35.7
- Current 22.4 22.4
C-reactive protein (mg/l) 2.3 (0.9-4.0)* 3.2 (1.6-6.1)* < 0.001
Fibrinogen (mg/dl) 375 (324-417)* 390 (333-452)* 0.02
sICAM (ng/ml) 354 (310-399)* 378 (326-447)* 0.002
Heat shock protein 27 (ng/ml) 18.6 (11.6-36.2)* 19.6 (9.7-39.3)* 0.58
Categorical variables are expressed as percentage. Continuous variables are expressed as mean ± standard deviation. P-values were obtained by 
paired samples t-test, Wilcoxon signed-ranks test, McNemar test or Marginal Homogeneity, whichever was appropriate.
MV=matching variable
*Median and inter-quartile range because of skewed distribution.
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Table 2. Baseline characteristics according to tertiles of HSP27 plasma level among control subjects.
Variable
Tertiles of HSP27
P for trend
1 (n=85)
≤ 13.6 ng/ml
2 (n=85)
>13.6 to 28.7 ng/ml
3 (n=85)
> 28.7 ng/ml
Age (y) 63.4±9.1 61.6±8.4 58.0±7.7 < 0.001
Body mass index (kg/m2) 25.2±3.7 25.9±4.9 25.4±4.6 0.89
Systolic blood pressure (mmHg) 129±16 127±13 124±12 0.32
Diastolic blood pressure (mmHg) 78±10 78±9 77±9 0.37
Hypertension (%) 32.9 34.1 24.7 0.81
Total cholesterol (mg/dl) 210±39 216±36 217±36 0.65
LDL cholesterol (mg/dl) 124±32 127±32 128±33 0.66
HDL cholesterol (mg/dl) 51±13 55±16 55±17 0.42
Hyperlipidemia (%) 40.0 38.8 31.8 0.22
Diabetes mellitus (%) 3.5 1.2 1.2 0.41
Smoking (%)
- Never 47.1 40.0 38.8 Reference
- Past 28.2 41.2 37.6 0.37
- Current 24.7 18.8 23.5 0.38
C-reactive protein (mg/l) 2.4 (1.0-4.1)* 2.3 (0.8-4.1)* 2.2 (0.9-4.0)* 0.71†
Fibrinogen (mg/dl) 353 (321-414)* 376 (323-417)* 386 (329-420)* 0.52†
sICAM (ng/ml) 347 (307-393)* 351 (314-390)* 368 (309-422)* 0.42†
Categorical variables are expressed as percentage. Continuous variables are expressed as mean ± standard deviation. P for trend was obtained 
by linear, logistic or multinomial regression, whichever was appropriate. *Median and inter-quartile range because of skewed distribution. 
†Variables were ln transformed to test for trend.
Table 3. Correlation between HSP27 plasma level and baseline characteristics for all subjects.
Variable Spearman correlation coefficient P-value
Age -0.258 <0.001
Body mass index -0.009 0.84
Systolic blood pressure -0.051 0.25
Diastolic blood pressure -0.008 0.86
Hypertension -0.016 0.72
Total cholesterol 0.015 0.73
LDL cholesterol 0.020 0.66
HDL cholesterol 0.064 0.16
Hyperlipidemia 0.004 0.92
Diabetes mellitus -0.087 0.05
Smoking -0.013 0.77
C-reactive protein -0.021 0.64
Fibrinogen 0.009 0.85
sICAM 0.011 0.82
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on the 50th, 75th, and 90th percentiles in the control subjects and entered it into the model (data not 
shown).
When we entered interaction terms into the model, we found a possible interaction of HSP27 level 
and hyperlipidemia (P for interaction= 0.043). Stratification on hyperlipidemia resulted in a higher 
risk of cardiovascular disease associated with HSP27 level in hyperlipidemic subjects. However, the 
odds ratios did not reach statistical significance. No interactions were found with other characteristics, 
including lipid profile.
Discussion
Contrary to our a priori hypothesis, in this prospective study, we found no association between base-
line HSP27 plasma level and risk of future cardiovascular events among initially healthy women. Fur-
ther, although HSP27 was inversely associated with age, it was not associated with other established 
cardiovascular risk factors.
HSPs represent the response of cells of the vessel wall to various stressors, including atherosclerosis 
risk factors.7 They fulfill chaperoning activity, and they appear to be important in preventing damage 
and in cellular repair processes after injury.8 HSPs have also been shown to regulate cell apoptosis.9 
On the other hand, HSPs may also play a part in atherogenesis.1,2 When cells are dying, intracellular 
HSPs are released into intercellular spaces to form soluble HSPs. HSP60 and 70 have been shown to 
bind to Toll-like receptor 4/CD14 complex, which is a soluble HSP receptor, resulting in expression of 
adhesion molecules by endothelial cells, in proliferation of smooth muscle cells, and in induction of 
several pro-inflammatory cytokines by macrophages. These inflammatory processes all contribute to 
the development of atherosclerosis.1 Furthermore, HSPs may serve as a link between infections and 
the atherosclerotic process. Infection with agents that contain homologous HSP proteins, such as for 
instance Chlamydia pneumoniae, could induce an anti-self response against HSPs expressed by en-
dothelial cells of stressed arteries through molecular mimicry in susceptible individuals.2
In the past years, HSPs have been gaining interest in atherosclerosis research. HSPs from the HSP60 
and HSP70 families and antibodies against these HSPs have been most widely investigated. Correla-
tions have been reported between several of these factors and cardiovascular risk factors such as 
LDL cholesterol and hypertension, and psychosocial measures such as socio-economic status and 
Table 4. HSP27 plasma level and risk of cardiovascular disease.
HSP27 (ng/ml)
Odds ratio (95% confidence interval)
Model 1 Model 2 Model 3
Tertile 1
Tertile 2
Tertile 3
Reference
0.67 (0.43-1.04)
0.99 (0.62-1.57)
Reference
0.67 (0.39-1.16)
1.14 (0.63-2.06)
Reference
0.53 (0.29-0.98)
1.06 (0.55-2.05)
Continuous, ln transformed 1.00 (0.83-1.21) 1.02 (0.81-1.29) 0.96 (0.74-1.24)
Model 1: Matched on age, smoking (never, former, current) and length of follow-up
Model 2: Model 1, additionally adjusted for BMI, systolic blood pressure, hypertension, total cholesterol, HDL cholesterol, hyperlipidemia, 
diabetes mellitus
Model 3: Model 2, additionally adjusted for exercise, alcohol use, menopausal status, hormone replacement therapy, C-reactive protein.
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psychological stress.10-12 Furthermore, several of these factors have been associated with carotid dis-
ease and ischemic stroke,10,13,14 with presence and severity of coronary atherosclerosis,15,16 and with 
restenosis after percutaneous transluminal coronary angioplasty.17 They have also been associated 
with aortic disease and peripheral vascular disease.18-20 More recently, increased concentrations of 
circulating HSP70 have been associated with low risk of coronary artery disease and with decreased 
intima-media thickness in hypertensive patients.21,22
However, little has been published on HSP27 in relation to atherosclerosis.3 With regard to the 
cardiovascular system, HSP27 has been reported to be differentially expressed in left ventricular sam-
ples from normal and failing dog myocardium.23 Mice overexpressing HSP27 were protected from 
lethal ischemia/reperfusion injury compared to their negative littermates.24 Increased expression of 
HSP27 protected against ischemic injury in adult rat cardiomyocytes.25 HSP27 was reported to act as 
an anti-apoptotic protein against doxorubicin, a chemotherapeutic drug that has may cause dilative 
cardiomyopathy and congestive heart failure.26 Also, expression of a specific diphosphorylated form 
of HSP27 was present in healthy blood vessels as opposed to vessels with cardiac allograft vasculopa-
thy in patients who had undergone cardiac transplantaion.27 Recently, it was reported that intracel-
lular HSP27 allowed protection against plasmin-induced anoikis in human vascular smooth muscle 
cells and was inversely localized with apoptotic cells within culprit atherosclerotic carotid plaques.28 
The role of HSP27 in the extracellular compartment remains unclear; exogenously added HSP27 was 
shown to prevent neutrophil apoptosis,29 but did not have any effect on plasmin-induced apoptosis 
in vascular smooth muscle cells.28
To our knowledge, two clinical studies of HSP27 and atherosclerosis have previously been report-
ed. In the first, we used atherosclerotic carotid and femoral endarterectomy samples and mammary 
and radial control endarteries to demonstrate that HSP27 secretion is decreased in atherosclerotic 
plaques compared with control arteries.4 Furthermore, secretion was barely detectable in complicated 
plaques. To confirm the hypothesis that plasma protein content can reflect arterial wall secretion, in 
the same study we measured soluble HSP27 level in the plasma of patients with carotid stenosis and 
healthy controls, and showed that HSP27 plasma levels were decreased in atherosclerotic patients. 
In the second study, Park et al. compared HSP27 expression in carotid plaque core areas, normal-ap-
pearing areas from the same vessel specimens, and nonatherosclerotic renal and internal mammary 
reference arteries. Confirming the results obtained by us,4,28 they reported that HSP27 expression is 
increased in the normal-appearing vessel adjacent to atherosclerotic plaque compared to both the 
plaque core area and the reference arteries.5 Contrary to the higher HSP27 expression, the phospho-
rylation of HSP27, which downregulates chaperone action and resistance against oxidative stress,3 
was decreased in the normal-appearing areas. Furthermore, in the same study Park et al. reported that 
HSP27 plasma levels were increased in acute coronary syndrome patients compared to normal refer-
ence subjects. They also demonstrated that plasma level of HSP27 was significantly correlated with 
serum level of total cholesterol (r=0.254, P< 0.05), and was not correlated with age, gender, smoking, 
diabetes mellitus and hypertension.
In contrast with the two above-mentioned reports, no association was found between HSP27 
plasma level and cardiovascular disease in the present study. To evaluate this discrepancy, strengths 
as well as limitations of our study should be considered. The present study is part of a large prospec-
tive cohort whose methods have been evaluated repeatedly.30,31 In the nested case-control sample 
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we used, cases had a higher prevalence of traditional risk factors such as hypertension and hyperlipi-
demia, as expected. Levels of blood biomarkers such as CRP and fibrinogen were also significantly 
higher in cases compared to controls. Consequently, we expect that a true difference in HSP27 level 
between cases and controls, if present, would have been demonstrated. The quality of the HSP27 as-
say should also be addressed. The precision of the assay was monitored; the interassay coefficient of 
variation ranged from 9.3% to 10.8%, and assays were run in duplicate and repeated if the replicate 
coefficient of variation was >10%. In view of these points, we consider it unlikely that the results of the 
present study are methodologically flawed.
Given this situation, the possibility that HSP27 plasma level might not closely reflect the secretion 
of HSP27 from atherosclerotic plaques should be considered as an alternative explanation for our 
results. If we address the hypothesis that HSP27 may be degraded by culprit atherosclerotic plaque,28 
it is unlikely that variations in HSP27 plasma level could be detected until the disease is advanced, 
as demonstrated in patients with a mean age of nearly 70 years with carotid atherosclerosis.4 In this 
regard, we have recently observed increased plasma levels of proteolytic markers of neutrophil activa-
tion in these patients with carotid atherosclerosis.32
Another possibility is that HSP27 plasma level rises in the acute phase of ischemic events, as shown 
for HSP70,33 in which case raised plasma level would not precede cardiovascular disease. This would 
help to explain the results found by Park et al., who used acute coronary syndrome patients and drew 
blood within 24 hours from presentation to the emergency department.5 The study design we used, 
with blood collection at baseline, does not allow demonstration of such an association.
Strengths of our study include the prospective study design, inclusion of 255 cases of cardiovascu-
lar disease and the availability of detailed information on cardiovascular risk factors and several inter-
related biomarkers, which made a profound analysis of the biomarker of interest possible. As such, 
apart from adjusting the analysis of the association between HSP27 plasma level and cardiovascular 
events for potential confounders, we were able to investigate whether HSP27 is associated with CRP 
and fibrinogen, inflammatory markers that may serve as measures for presence of infection, which on 
its part could play a role in the induction of HSPs. We were also able to test the hypothesis that HSPs 
may result in expression of adhesion molecules by endothelial cells by investigating whether HSP27 
is associated with sICAM-1.
Our study included female health care professionals who were mostly white and apparently 
healthy at study initiation. Therefore, the results may not be applicable to other populations such as 
those with advanced atherosclerosis or acute coronary syndrome, or men, especially since HSP27 has 
been shown to have an estrogen response element in its promoter.34,35 Nonetheless, the present study 
does not support an association between baseline HSP27 plasma level and incident cardiovascular 
disease. Furthermore, it does not support associations between HSP27 plasma level and established 
cardiovascular risk factors, with the exception of an inverse correlation with age. Confirmation of 
these findings by other prospective studies is warranted.
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Chapter 5.1
Cardiovascular risk factors and 
echocardiographic parameters
Abstract
Background. Insight into echocardiographic parameters in the general population may facilitate ear-
ly recognition of ventricular dysfunction, reducing the population morbidity and mortality of heart 
failure. We examined the distribution of structural, systolic and diastolic echocardiographic param-
eters and their associations with cardiovascular risk factors in the Rotterdam Study.
Methods and Results. The Rotterdam Study is a population-based cohort study in men and women 
aged ≥ 55 years. Participants with prevalent heart failure, myocardial infarction and atrial fibrillation 
and flutter were excluded. Structural, systolic and diastolic parameters were assessed using two-di-
mensional, M-mode and Doppler echocardiography. Echocardiograms were available in 4425 partici-
pants. Structural parameters were generally larger in men, and most consistently associated with age, 
body mass index and blood pressure in both sexes. Prevalence of moderate and poor left ventricular 
systolic function was 2.8 and 1.1 %, respectively, in men, and 1.7 and 0.4%, respectively, in women. 
Age, body mass index and blood pressure were most consistently associated with systolic function. 
Doppler peak E and peak A velocities were higher in women than in men, and E/A ratio was lower in 
women than in men. Age and diastolic blood pressure were most consistently associated with E/A 
ratio in both sexes.
Conclusions. Ventricular systolic and diastolic dysfunction was present in asymptomatic individuals. 
Selected established cardiovascular risk factors were associated with structural, systolic and diastolic 
parameters. The value of echocardiography in the identification of individuals with preclinical ven-
tricular dysfunction warrants further investigation.
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Introduction
Heart failure is an important health problem. Its prevalence is increasing, in part because of improved 
treatment of patients with heart failure and increased survival of patients with myocardial infarction.1 
Since heart failure is primarily a condition in the elderly, the aging of the population also contributes 
to its increasing prevalence. Although in most patients, abnormalities of systolic and diastolic dys-
function coexist,1it has been shown that persons with normal ejection fraction can have impaired dia-
stolic function.2 Also of note is, that persons with a very low ejection fraction may be asymptomatic; 
this has been termed preclinical systolic dysfunction.3
It has been recognized that therapeutic interventions introduced even before the appearance of 
left ventricular dysfunction or symptoms can reduce the population morbidity and mortality of heart 
failure.1,4 This underlines the importance of early recognition of preclinical ventricular dysfunction. 
Echocardiography, which has become a common method to assess ventricular function, may be use-
ful to gain more insight into this matter. To its advantage, it is noninvasive and comprehensive. As a 
consequence, echocardiography has been used in several population-based studies to examine the 
prevalence and determinants of systolic and diastolic dysfunction in the community3,5-9 and to inves-
tigate the predictive value of echocardiographic parameters for heart failure, cardiovascular disease 
and mortality.3,7,10-13
The growing importance of insight into echocardiographic characteristics of the general popu-
lation has prompted us to perform echocardiography in the Rotterdam Study, a population-based 
study in men and women aged 55 years and over. The purpose of the present report is to describe the 
distribution of structural, systolic and diastolic echocardiographic parameters in our study popula-
tion and to examine the associations of established cardiovascular risk factors with these echocardio-
graphic parameters.
Methods
Study population
The study was performed within the framework of the Rotterdam Study, a population-based cohort 
study aimed at assessing the occurrence of and risk factors for chronic diseases in the elderly.14 Base-
line visits of the Rotterdam Study took place in 1990-1993. All inhabitants of a suburb of Rotterdam 
aged 55 years and over were invited and 7983 agreed to participate (response 78%). Follow-up visits 
took place in 1993 to 1994 and 1997 to 1999. In 2000-2001, the cohort was extended with 3011 partic-
ipants from the same suburb (response 67%), also aged 55 years and over. For the present study, data 
collection took place from 2002-2005. Within this period, the participants from the original cohort 
completed their fourth center visit (n=3550), and the participants of the extended cohort completed 
their second center visit (n=2389). Of these, 3052 and 2235, respectively, underwent cardiac echocar-
diography. The large majority of missing echocardiograms was explained by incidental absence of 
echocardiographers. Participants with prevalent heart failure (n=304), prevalent myocardial infarc-
tion, (n=561), and atrial fibrillation (n=124) or atrial flutter (n=13) at the time of echocardiography 
were excluded from the analysis. This led to the exclusion of a total of 862 persons and consequently 
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resulted in a total of 4425 participants available for analysis. The medical ethics committee of Erasmus 
Medical Center, Rotterdam, approved the study. Participants gave written informed consent and per-
mission to retrieve information from treating physicians.
Assessment of cardiovascular risk factors and prevalent disease
A trained interviewer visited all participants at home and collected information on current health 
status, medical history, drug use, and smoking, using a computerized questionnaire. Participants were 
categorized as current, past and never smokers. Clinical measures were obtained during a visit at 
the study center. Height and weight were measured and the body mass index (BMI) was calculated 
(weight (kg)/height (m)2). Blood pressure was measured at the right brachial artery using a random-
zero sphygmomanometer with the participant in sitting position. Serum total cholesterol and high-
density lipoprotein (HDL) cholesterol were obtained using an automatic enzymatic procedure (Hi-
tachi 911, Roche CHOD PAP). Diabetes mellitus was defined as the use of antidiabetic medication or 
a fasting glucose level of ≥7 mmol/l.15 Presence of symptomatic heart failure at the time of echocar-
diography was assessed by using a validated score similar to the definition of heart failure of the Eu-
ropean Society of Cardiology, as described previously,16 and the information needed was obtained by 
screening of all medical records of general practitioners (GPs) in retrospect for the occurrence of heart 
failure and obtaining letters and discharge reports from medical specialists when a case was found. A 
history of myocardial infarction was considered present when myocardial infarction was detected by 
screening GP medical records and reviewing letters and discharge reports from medical specialists, 
or when an ECG characteristic of prior myocardial infarction was detected during a follow-up visit. 
Presence of atrial fibrillation or atrial flutter at the time of echocardiography was assessed with elec-
trocardiography by applying the Modular ECG Analysis System (MEANS), which has been extensively 
evaluated,17,18 and is characterized by a high sensitivity (96.6%) and a high specificity (99.5%) in cod-
ing arrhythmias.19 For a small sample of participants, ECGs were not available at the time this report 
was written because of logistic problems and were approximated by using ECGs from the previous 
examination (year 2000-2001).
Echocardiography
For each participant, an echocardiogram was obtained. The first 2188 echocardiograms were per-
formed with a commercially available ultrasonography system (AU3 Partner, Esaote Biomedica, with 
a 3.5/2.5 MHz transducer). The following 3099 echocardiograms were performed with another com-
mercially available system (Acuson Cypress, with a 3V2c transducer). A standardized protocol was 
used, including two-dimensional scanning in the parasternal long axis view, parasternal short axis 
view, apical view and subcostal view, M-mode scanning in the parasternal long axis view, and pulsed 
wave Doppler scanning in the apical four chamber view.20 Echocardiograms were recorded onto VHS 
tape and assessed at the reading center, which was located at Erasmus Medical Center.
Several structural parameters were assessed.21 Left atrium diameter, left ventricular end systolic di-
mension (LVES), left ventricular end diastolic dimension (LVED), end diastolic interventricular septum 
thickness and end-diastolic left ventricular posterior wall thickness were measured in the parasternal 
long axis view using M-mode with two-dimensional guidance. With regard to systolic parameters, 
fractional shortening at the endocardium was calculated as (LVED-LVES)/LVED*100%.21 Global left 
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ventricular systolic function was qualitatively assessed, without quantitative measurement, from the 
two-dimensional echocardiogram and classified as normal, fair, moderate or poor. Furthermore, dia-
stolic parameters were measured.22 Pulsed Doppler recordings of transmitral filling velocity were per-
formed in the apical 4-chamber view, with the sample volume placed in the mitral valve orifice near 
the tips of the leaflets. Doppler peak E and peak A velocities were averaged over 3 cycles. E/A ratio was 
computed by dividing Doppler peak E velocity by Doppler peak A velocity. Early mitral valve velocity 
deceleration time was measured as the time between the peak E wave and the upper deceleration 
slope extrapolated to the zero baseline.
Echocardiograms were made and read by 4 trained echocardiographers. To assess intra-reader and 
inter-reader agreement, 32 participants were examined in duplicate. For continuous variables, overall 
median percent intra-reader and inter-reader measurement variabilities were calculated as the ab-
solute measurement difference divided by the average of the two measurements, multiplied by 100. 
Overall median intra-reader and inter-reader variabilities for left ventricular end-diastolic dimension 
were 3% and 4%, respectively. For left ventricular end-systolic dimension both variabilities were 6%, 
and for fractional shortening both were 8%. Overall median intra-reader and inter-reader variabilities 
for E/A ratio were 15% and 18%, respectively, and for deceleration time both were 16%. Finally, the 
percentage agreement for categorization of left ventricular systolic function as normal or other than 
normal was 82% within readers and 86% between readers.
Statistical analysis
We calculated means, medians and proportions of cardiovascular risk factors and echocardiographic 
characteristics in men and women. Differences between the sexes were tested with t-tests, chi square 
tests and Mann-Whitney tests where appropriate.
Subsequently, we investigated the association between cardiovascular risk factors and echocardio-
graphic parameters. We performed linear regressions with age, BMI, systolic blood pressure, diastolic 
blood pressure, total cholesterol, HDL-cholesterol, diabetes mellitus and smoking as independent 
variables and structural echocardiographic parameters (diameter of left atrium, left ventricular end-
systolic dimension, left ventricular end-diastolic dimension, interventricular septum thickness, left 
ventricular posterior wall thickness), systolic parameters (fractional shortening) and diastolic param-
eters (mitral valve inflow peak E velocity, mitral valve inflow peak A velocity, E/A ratio and mitral valve 
inflow deceleration time) as dependent variables. Continuous independent variables were examined 
per standard deviation increase. For some of the dependent variables, the distribution of the residuals 
was skewed. After log-transformation of these variables, the residuals were normally distributed with 
a constant variance. To make the regression coefficients more informative, units of dependent vari-
ables were multiplied by 10-2. The analysis was performed separately in men and women. We adjusted 
for age and type of ultrasonography system used, and subsequently, we also adjusted the analysis of 
each risk factor for all other risk factors and also for use of diuretics, beta-blockers, ACE inhibitors, lipid 
lowering drugs and heart rate.
We used analysis of covariance to compare risk factors according to categories of qualitatively 
assessed left ventricular systolic function and categories of E/A ratio and diastolic function. We cat-
egorized E/A ratio and deceleration time according to cut points used in previous reports.3,23 Normal 
diastolic function was defined as E/A ratio between 0.75 and 1.50 and deceleration time between 150 
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ms and 240 ms. Impaired relaxation was defined as E/A ratio < 0.75 and deceleration time > 240 ms. 
Restrictive diastolic dysfunction was defined as E/A ratio > 1.50 and deceleration time < 150 ms. Par-
ticipants were required to have both Doppler criteria consistent with impaired relaxation or restrictive 
dysfunction to be classified. Participants with one abnormal criterion were classified as indeterminate 
rather than as normal.
All analyses were performed using SPSS 11.0. Values for cardiovascular covariates were missing in 
less than 3% of participants, except for BMI, which was missing in 5.5%. Missing values were handled 
by single imputation using the expectation-maximization algorithm in SPSS 11.0. All tests were two-
sided.
Results
Table 1 shows the distribution of cardiovascular risk factors in men and women. Women were sig-
nificantly older than men, although this was a clinically modest difference of 1.1 years. In table 2, 
the distribution of echocardiographic characteristics is displayed in men and women. All character-
istics showed significant differences across the sexes; in general, structural parameters were larger in 
men, systolic function was worse in men, and with regard to diastolic function, E/A ratio was lower in 
women.
For reasons of conciseness, the multivariable results are presented in the tables. Table 3 demon-
strates the multivariable-adjusted associations between cardiovascular risk factors and structural pa-
rameters assessed by echocardiography. Overall, age, BMI, systolic blood pressure and diastolic blood 
Table 1. Population characteristics.
Variable Men (n=1736) Women (n=2689) P-value
Age (years) 70.8 ± 7.0 71.9 ± 7.5 < 0.001
Body mass index (kg/m2) 27.2 ± 3.4 27.7 ± 4.5 < 0.001
Systolic blood pressure (mmHg) 148 ± 20 151 ± 22 < 0.001
Diastolic blood pressure (mmHg) 81 ± 11 79 ± 11 < 0.001
Total cholesterol (mmol/l) 5.4 ± 0.9 5.9 ± 0.9 < 0.001
HDL-cholesterol (mmol/l) 1.3 ± 0.3 1.6 ± 0.4 < 0.001
Diabetes mellitus (%) 13.4 12.7 0.49
Smoking < 0.001
- Never (%) 13.4 43.1
- Former (%) 68.2 42.8
- Current (%) 18.4 14.0
Use of diuretics (%) 5.4 11.8 < 0.001
Use of beta blockers (%) 11.9 15.6 < 0.001
Use of ACE-inhibitors (%) 11.2 11.0 0.79
Use of lipid-lowering drugs (%) 11.2 11.9 0.52
Categorical variables are expressed as percentage. Continuous variables are expressed as mean ± standard deviation. T-tests and chi square tests 
were used where appropriate.
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pressure were significantly associated with most structural parameters in men and women. Age, BMI 
and systolic blood pressure generally showed positive associations, with the exception of an inverse 
association of age with left ventricular end diastolic dimension in women. Diastolic blood pressure 
showed inverse associations with left atrium diameter in men and women. Furthermore, total choles-
terol showed associations with selected parameters. The age- and ultrasonography system adjusted 
results demonstrated additional associations between HDL-cholesterol and diabetes mellitus and 
most structural parameters (inverse and positive associations, respectively), which disappeared after 
further adjustment (data not shown).
In table 4, associations with fractional shortening are displayed. Age, BMI and diastolic blood pres-
sure were inversely and independently associated with fractional shortening in men and women. Sys-
tolic blood pressure showed an independent, positive association in women; in men, the regression 
coefficient was comparable but did not reach statistical significance. The age- and ultrasonography 
system adjusted results were similar (data not shown). Table 5 shows associations of risk factors with 
left ventricular systolic function. Overall, the results were in accordance with table 4. Age was higher 
in men and women with fair and moderate function than in those with normal function. BMI was also 
significantly higher in men and women with fair function. Systolic blood pressure was lower in men 
with fair function than in men with normal function. In women, systolic blood pressure decreased and 
diastolic blood pressure increased according to systolic function categories.
Table 2. Echocardiographic characteristics.
Variable Men (n=1736) Women (n=2689) P-value
Structural parameters
Left atrium diameter (mm) 42 ± 5 39 ± 5 < 0.001
Left ventricular end systolic dimension (mm) 32 (29-36)* 29 (27-32)* < 0.001
Left ventricular end diastolic dimension (mm) 53 ± 5 49 ± 5 < 0.001
Interventricular septum thickness (mm) 8 (8-10)* 8 (7-9)* < 0.001
Left ventricular posterior wall thickness (mm) 8 (7-8)* 7 (7-8)* < 0.001
Systolic parameters
Fractional shortening 38 ± 7 40 ± 6 < 0.001
Left ventricular systolic function < 0.001
- Normal (%) 55.0 64.9
- Fair (%) 41.0 33.1
- Moderate (%) 2.8 1.7
- Poor (%) 1.1 0.4
Diastolic parameters
Mitral valve inflow peak E (m/s) 0.63 ± 0.15 0.66 ± 0.16 < 0.001
Mitral valve inflow peak A (m/s) 0.72 ± 0.16 0.80 ± 0.17 < 0.001
Mitral valve inflow deceleration time (ms) 219 ± 47 211 ± 45 < 0.001
E/A ratio 0.86 (0.71-1.00)* 0.81 (0.70-1.00)* < 0.001
*Median and inter-quartile range because of skewed distribution.
Categorical variables are expressed as percentage. Continuous variables are expressed as mean ± standard deviation. T-tests, chi square tests and 
Mann-Whitney tests were used where appropriate.
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Table 3. Multivariable adjusted regression coefficients for risk factors, describing the increase in structural 
parameters (with their appropriate units) per (sex-specific) standard deviation increase of the risk factors.
Variable
Diameter of 
left atrium 
(mm*10-2)
Left ventricular 
end-systolic 
dimension 
(mm*10-2), log 
transformed
Left 
ventricular 
end-diastolic 
dimension 
(mm*10-2)
Interventricular 
septum 
thickness 
(mm*10-2), log 
transformed
Left ventricular
posterior wall 
thickness 
(mm*10-2), log 
transformed
Men
Age (years) 39.9 (12.0, 67.9)† 1.54 (0.64, 2.43)‡ -27.5 (-55.5, 
4.54)
2.68 (1.54, 3.82)‡ 1.67 (0.67, 2.67)†
Body mass index 
(kg/m2)
203 (177, 229)‡ 3.06 (2.23, 3.89)‡ 126 (99.7, 151)‡ 3.03 (2.02, 4.04)‡ 3.10 (2.23, 3.98)‡
Systolic blood 
pressure (mmHg)
50.2 (21.0, 79.5)‡ 0.54 (-3.89, 1.48) 57.9 (28.7, 
87.1)‡
1.79 (0.60, 2.97)† 2.13 (1.10, 3.17)‡
Diastolic blood 
pressure (mmHg)
-18.8 (-48.4, 10.8) -0.05 (-1.00, 0.89) -44.7 (-74.1, 
-15.3)†
2.20 (1.00, 3.39)‡ 0.33 (-0.71, 1.38)
Total cholesterol 
(mmol/l)
-11.6 (-36.5, 13.4) -0.16 (-0.96, 0.64) -1.65 (-26.5, 
23.2)
1.06 (-2.07, -0.05)* -0.99 (-1.88, 
-0.11)*
HDL-cholesterol 
(mmol/l)
4.06 (-21.1, 29.2) -0.07 (-0.87, 0.74) 17.6 (-7.57, 
42.7)
-0.44 (-1.46, 5.80) -0.14 (-1.03, 0.75)
Diabetes mellitus -3.21 (-75.1, 68.7) 1.04 (-1.25, 3.34) 34.0 (-37.7, 106) 2.74 (-0.17, 5.65) -1.06 (-3.61, 1.49)
Current smoking -39.5 (-100.6, 
21.6)
0.87 (-1.08, 2.28) -10.3 (-50.8, 
71.4)
2.28 (-0.20, 4.76) 1.89 (-0.28, 4.05)
Women
Age (years) 47.9 (26.0, 69.8)‡ 0.50 (-0.17, 1.17) -37.4 (-58.1, 
-16.7)‡
4.06 (3.26, 4.86)‡ 2.18 (1.44, 2.91)‡
Body mass index 
(kg/m2)
147 (126, 167)‡ 2.86 (2.24, 3.49)‡ 116 (96.4, 135)‡ 4.00 (3.25, 4.74)‡ 2.92 (2.24, 3.60)‡
Systolic blood 
pressure (mmHg)
34.4 (10.1, 58.6)† 0.03 (-0.71, 0.78) 32.9 (10.1, 
55.7)†
1.40 (0.51, 2.28)† 0.68 (-0.13, 1.49)
Diastolic blood 
pressure (mmHg)
-27.9 (-51.2, 
-4.50)†
1.00 (0.29-1.72)† 6.77 (-15.3, 
28.8)
0.97 (0.11, 1.83)* 0.78 (-229, 1.57)
Total cholesterol 
(mmol/l)
-2.19 (-21.5, 17.2) -0.70 (-1.29, 
-0.11)†
-27.2 (-45.4, 
-9.00)†
0.74 (0.03, 1.44)* -0.28 (-0.93, 0.37)
HDL-cholesterol 
(mmol/l)
-12.0 (-31.6, 7.56) -0.03 (-0.63, 0.56) 4.51 (-13.9, 
22.9)
-0.93 (-1.64, 
-0.21)*
0.05 (-0.60, 0.70)
Diabetes mellitus 13.9 (-43.7, 71.5) 1.08 (-0.67, 2.83) 62.5 (8.76, 116)* 0.96 (-1.14, 3.06) 2.17 (0.25, 4.10)*
Current smoking -87.8 (-141, 
-34.7)†
0.73 (-0.87, 2.34) 19.1 (-30.3, 
68.5)
1.32 (-0.60, 3.25) 2.32 (0.56, 4.08)*
* 0.01< p <0.05, † 0.001< p <0.01, ‡ P<0.001.
All models are adjusted (where appropriate) for ultrasonography system, age, BMI, systolic and diastolic blood pressure, total and HDL 
cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors, lipid lowering drugs and heart rate.
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Table 4. Multivariable adjusted regression coefficients for risk factors, describing the increase in fractional 
shortening (% *10-2) per (sex-specific) standard deviation increase of the risk factors.
Fractional shortening (% *10-2)
Variable Men Women
Age (years) -125 (-163, -87.1)‡ -77.5 (-106, -49.6)‡
Body mass index (kg/m2) -39.4 (-74.4, -4.34)* -26.1 (-52.0, -0.13)*
Systolic blood pressure (mmHg) 34.3 (-4.94, 73.6) 36.4 (5.52, 67.3)*
Diastolic blood pressure (mmHg) -54.3 (-93.9, -14.6)† -47.6 (-77.3, -17.8)†
Total cholesterol (mmol/l) 6.11 (-27.7, 39.9) 10.3 (-14.3, 34.9)
HDL-cholesterol (mmol/l) 20.0 (-14.0, 53.9) 3.59 (-21.2, 28.3)
Diabetes mellitus -51.8 (-148.6, 45.0) 9.65 (-63.1, 82.4)
Current smoking -41.8 (-124, 40.6) -32.9 (-99.5, 33.7)
* 0.01< p <0.05, † 0.001< p <0.01, ‡ P<0.001.
All models are adjusted (where appropriate) for ultrasonography system, age, BMI, systolic and diastolic blood pressure, total and HDL 
cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors, lipid lowering drugs and heart rate.
Table 5. Population characteristics according to left ventricular systolic function, multivariable adjusted.
Variable
Left ventricular systolic function
Normal Fair Moderate Poor
Men n=938 n=699 n=48 n=19
Age (years) 69.7 72.0‡ 73.6‡ 72.0
Body mass index (kg/m2) 26.9 27.5‡ 26.7 27.5
Systolic blood pressure (mmHg) 149 147* 148 143
Diastolic blood pressure (mmHg) 81 82 82 83
Total cholesterol (mmol/l) 5.4 5.4 5.5 5.2
HDL-cholesterol (mmol/l) 1.33 1.31 1.30 1.39
Diabetes mellitus (%) 13.0 12.3 21.4 20.7
Current smoking (%) 16.6 21.1* 13.9 19.4
Women n=1725 n=879 n=44 n=10
Age (years) 70.8 73.5‡ 76.5‡ 71.4
Body mass index (kg/m2) 27.5 28.1‡ 28.2 25.8
Systolic blood pressure (mmHg) 152 150† 144† 140*
Diastolic blood pressure (mmHg) 79 80‡ 81* 81
Total cholesterol (mmol/l) 5.9 5.9 5.6* 5.4
HDL-cholesterol (mmol/l) 1.58 1.57 1.52 1.49
Diabetes mellitus (%) 11.9 14.0 6.5 11.8
Current smoking (%) 13.8 14.8 20.1 20.0
* 0.01< p <0.05, † 0.001< p <0.01, ‡ P<0.001, compared to normal left ventricular systolic function.
All models are adjusted (where appropriate) for ultrasonography system, age, BMI, systolic and diastolic blood pressure, total and HDL 
cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors, lipid lowering drugs and heart rate.
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Table 6 demonstrates the multivariable-adjusted associations between cardiovascular risk factors 
and diastolic echocardiographic parameters. Age and diastolic blood pressure were inversely and 
significantly associated with E/A ratio in men and women, whereas systolic blood pressure showed 
no association. BMI was positively and significantly associated with E/A ratio in women; in men, the 
regression coefficient was of similar magnitude but did not reach significance. Age- and ultrasonogra-
phy system adjusted analyses also showed inverse associations between BMI and systolic blood pres-
sure and E/A ratio in both sexes; however, these did not persist after additional adjustment (data nor 
shown). Categorization of E/A ratio confirmed the associations of lower E/A ratio with higher age and 
diastolic blood pressure in both sexes (table 7). Of note is that it also showed significantly lower sys-
tolic blood pressure in women with E/A ratio < 0.75. In table 8 characteristics are shown according to 
categories of left ventricular diastolic function. In accordance with table 6 and 7, higher age was asso-
Table 6. Multivariable adjusted regression coefficients for risk factors, describing the increase in diastolic 
parameters (with their appropriate units) per (sex-specific) standard deviation increase of the risk factors.
Variable Mitral valve inflow 
peak E (m/s*10-2), 
log transformed
Mitral valve 
inflow peak A 
(m/s*10-2)
Mitral valve inflow 
deceleration time 
(ms*10-2)
E/A ratio (*10-2), 
log transformed
Men
Age (years) -3.06 (-3.88, -2.23)‡ 3.29 (2.43, 4.15)‡ 1315 (1047, 1583)‡ -10.1 (-11.4, -8.70)‡
Body mass index (kg/m2) 1.45 (0.67, 2.22)‡ 2.46 (1.66, 3.26)‡ 6.71 (-241, 255) -1.16 (-2.42, 0.11)
Systolic blood pressure 
(mmHg)
4.02 (3.16, 4.88)‡ 4.05 (3.15, 4.95)‡ -162 (-442, 117) 0.48 (-0.94, 1.90)
Diastolic blood pressure 
(mmHg)
-3.80 (-4.68, -2.93)‡ -2.03 (-2.95, -1.12)‡ 259 (-26.7, 544) -3.43 (-4.88, -1.98)‡
Total cholesterol (mmol/l) -0.26 (-1.00, 0.47) 0.33 (-4.31, 1.09) 290 (55.0, 525)* -0.79 (-2.01, 0.43)
HDL-cholesterol (mmol/l) 0.01 (-0.73, 0.76) 0.08 (-0.69, 0.86) -136 (-375, 104) 0.04 (-1.17, 1.25)
Diabetes mellitus 2.58 (0.45, 4.70)* 3.98 (1.77, 6.20)‡ 306 (-382, 995) -2.66 (-6.16, 0.85)
Current smoking -0.47 (-2.26, 1.32) 1.27 (-0.61, 3.14) 316 (-267, 890) -2.73 (-5.71, 0.24)
Women
Age (years) -2.24 (-2.94, -1.54)‡ 4.09 (3.37, 4.81)‡ 1049 (842, 1256)‡ -9.90 (-11.0, -8.82)‡
Body mass index (kg/m2) 0.43 (-0.22, 1.08) 1.90 (1.23, 2.56)‡ 38.8 (-154, 232) -1.59 (-2.59, -0.60)†
Systolic blood pressure 
(mmHg)
3.43 (2.65, 4.20)‡ 3.73 (2.94, 4.53)‡ -423 (-650, -195)‡ 0.95 (-0.24, 2.14)
Diastolic blood pressure 
(mmHg)
-3.18 (-3.93, -2.43)‡ -1.52 (-2.29, -0.76)‡ 184 (-35.8, 403) -3.61 (-4.76, -2.46)‡
Total cholesterol (mmol/l) -0.48 (-1.10, 0.14) -0.04 (-0.67, 0.59) 146 (-34.4, 327) -0.61 (-1.56, 0.33)
HDL-cholesterol (mmol/l) 0.06 (-0.57, 0.68) -0.55 (-1.19, 0.08) -106 (-289, 76.9) 1.28 (0.32, 2.24)†
Diabetes mellitus 2.04 (0.19, 3.90)* 2.28 (0.39, 4.18)* 469 (-75.5, 1013) 0.78 (-2.05, 3.61)
Current smoking -1.54 (-3.25, 0.16) -0.89 (-2.61, 0.84) 447 (-50.7, 945) -0.84 (-3.41, 1.73)
* 0.01< p <0.05, † 0.001< p <0.01, ‡ P<0.001.
All models are adjusted (where appropriate) for ultrasonography system, age, BMI, systolic and diastolic blood pressure, total and HDL 
cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors, lipid lowering drugs and heart rate.
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ciated with impaired relaxation in men and women. Diastolic blood pressure was significantly higher 
in women with impaired relaxation compared to women with normal diastolic function. In men with 
impaired relaxation, diastolic blood pressure, although higher, did not reach statistical significance. 
Finally, systolic blood pressure was significantly lower in women with impaired relaxation.
Discussion
Summarizing, in this study, we have examined structural, systolic and diastolic echocardiographic 
parameters and their associations with cardiovascular risk factors in a population-based cohort. Struc-
tural parameters were generally larger in men, and larger values were most consistently associated 
with higher values of age, BMI and systolic blood pressure in both sexes. Although we had excluded 
participants with prevalent heart failure, myocardial infarction, and atrial fibrillation and flutter, mod-
erate or poor left ventricular systolic function was found to be present in the participants, albeit with a 
modest prevalence (a total of 3.9% of men and 2.1% of women). Higher age, higher BMI, lower systolic 
and higher diastolic blood pressure were most consistently associated with worse systolic function. 
Table 7. Population characteristics according to E/A ratio, multivariable adjusted.
Variable
E/A ratio
E/A < 0.75 0.75≤ E/A≤ 1.50 E/A > 1.50
Men n=457 n=1183 n=29
Age (years) 73.5‡ 69.7 69.2
Body mass index (kg/m2) 27.2 27.2 27.2
Systolic blood pressure (mmHg) 147 148 149
Diastolic blood pressure (mmHg) 82† 81 80
Total cholesterol (mmol/l) 5.4 5.4 5.2
HDL-cholesterol (mmol/l) 1.31 1.32 1.33
Diabetes mellitus (%) 14.7 12.1 16.0
Current smoking (%) 29.9 18.0 11.3
Women n=824 n=1730 n=36
Age (years) 74.6‡ 70.4 69.7
Body mass index (kg/m2) 27.9 27.6 26.9
Systolic blood pressure (mmHg) 149† 151 152
Diastolic blood pressure (mmHg) 81‡ 79 77
Total cholesterol (mmol/l) 6.0 5.9 5.7
HDL-cholesterol (mmol/l) 1.55* 1.59 1.59
Diabetes mellitus (%) 11.6 12.6 21.9
Current smoking (%) 14.6 14.4 13.0
* 0.01< p <0.05, † 0.001< p <0.01, ‡ P<0.001, compared to 0.75≤ E/A≤ 1.50.
All models are adjusted (where appropriate) for ultrasonography system, age, BMI, systolic and diastolic blood pressure, total and HDL 
cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors, lipid lowering drugs and heart rate.
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With regard to diastolic parameters, we found that Doppler peak E and peak A velocities were larger 
in women than in men, but that E/A ratio was lower in women than in men. Higher age and higher 
diastolic blood pressure were most consistently associated with lower E/A ratio in both sexes.
Strengths of the present study include its population-based nature, its large size, and its stan-
dardized assessment of risk factors and echocardiographic characteristics. Nevertheless, several is-
sues warrant consideration. First, we used global left ventricular function assessed qualitatively from 
two-dimensional images, without quantitative measurement of the ejection fraction. This approach 
is easily obtainable and reflects the routine procedure in echocardiography laboratories. Prior stud-
ies have reported that the reproducibility and accuracy of visual assessments are as good as those of 
quantitative methods,24,25 and similar visual assessments have also been used in other studies such as 
the Framingham Study.13 Furthermore, we have also measured fractional shortening which is a quan-
titative measure and also an indicator of systolic function. Associations of risk factors with fractional 
shortening showed a pattern similar to associations with qualitatively assessed left ventricular func-
Table 8. Population characteristics according to left ventricular diastolic function, multivariable adjusted.
Variable
Left ventricular diastolic function
Normal,
0.75≤E/A≤1.50
150≤DT≤240
Impaired 
relaxation,
E/A<0.75
DT>240
Restrictive,
E/A>1.50
DT<150
Indeterminate
(Other 
combination of E/A 
and DT)
Men n=882 n=196 n=5 n=564
Age (years) 69.3 74.1‡ 69.4 71.5‡
Body mass index (kg/m2) 27.3 27.2 27.0 27.1
Systolic blood pressure (mmHg) 148 147 143 147
Diastolic blood pressure (mmHg) 81 82 84 82*
Total cholesterol (mmol/l) 5.4 5.4 6.0 5.4
HDL-cholesterol (mmol/l) 1.32 1.28 1.36 1.32
Diabetes mellitus (%) 12.0 13.5 29.6 13.5
Current smoking (%) 17.0 18.5 0.0 20.0
Women n=1373 n=275 n=8 n=905
Age (years) 70.2 76.0‡ 71.0 72.6‡
Body mass index (kg/m2) 27.6 27.7 24.3* 27.8
Systolic blood pressure (mmHg) 151 148† 159 151
Diastolic blood pressure (mmHg) 79 81‡ 76 79*
Total cholesterol (mmol/l) 5.9 6.0 5.6 5.9
HDL-cholesterol (mmol/l) 1.59 1.55 1.60 1.57
Diabetes mellitus (%) 12.56 15.4 50.4‡ 11.0
Current smoking (%) 13.8 16.0 0.0 15.0
* 0.01< p <0.05, † 0.001< p <0.01, ‡ P<0.001, compared to normal left ventricular diastolic function.
E/A = E/A ratio. DT = deceleration time. All models are adjusted (where appropriate) for ultrasonography system, age, BMI, systolic and diastolic 
blood pressure, total and HDL cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors, lipid lowering drugs and 
heart rate.
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tion. This suggests that assessment of left ventricular systolic function was performed appropriately 
in our study.
Second, we categorized diastolic function solely according to E/A ratio and deceleration time, 
while additional measures such as pulmonary venous flow or Doppler tissue imaging are needed to 
distinguish the pseudonormal pattern from normal diastolic function.26 We were not able to assess 
such additional measures because of constraints in examination time available per participant, inher-
ent to large-scale population-based research. Furthermore, several different recommendations have 
been issued for categorization of diastolic function based on E/A ratio and deceleration time.27,28 We 
based our categorization on recent reports.3,23 The use of only two criteria resulted in a substantive 
group of participants with “indeterminate” diastolic function (33%). Furthermore, only 0.3% of the 
population fell into the restrictive category, which made this group inadequately small for drawing 
statistically powered conclusions. When we made the criteria more stringent (E/A ratio < 0.50 or > 1.50 
and deceleration time < 150 or > 280), percentages of the study population in the impaired relaxation, 
restrictive, and indeterminate categories were 0.3%, 0.3%, and 13.1%, respectively. From the above, it 
is clear that the choice of cut-points complicates the estimation of the prevalence of diastolic dysfunc-
tion. However, the categorization may still be a useful addition when examining the associations of 
risk factors with diastolic parameters.
Finally, we should bear in mind that some of the echocardiographic measurements displayed 
considerable variability. Inter-reader and intra-reader measurement variabilities for E/A ratio and de-
celeration time reflect the practical difficulties involved in estimating Doppler peak E velocity and 
Doppler peak A velocity. In contrast, intra-reader and inter-reader variability of structural and systolic 
parameters was in a much lower range.
Previously, fractional shortening has been measured in a subset of 2267 participants of the Rotter-
dam Study.29 In accordance with the present study, fractional shortening was found to be somewhat 
higher in women (40±7%) than in men (38±8%). However, no significant association was found with 
age.
The distribution of echocardiographic parameters and their associations with cardiovascular risk 
factors have previously been examined in several population-based studies. The Cardiovascular Health 
Study has reported a prevalence of left ventricular ejection fraction abnormalities of 6.3% in men and 
1.8% in women. Sex, age, hypertension and clinical coronary heart disease were the only indepen-
dent predictors of left ventricular ejection fraction abnormalities.8 In the same study, Doppler early 
and late diastolic left ventricular filling velocities were importantly related to sex, age, blood pressure 
and also to height, weight and heart rate.30 In accordance with our study, women had higher early 
and late diastolic velocities than men, and diastolic blood pressure was inversely related and systolic 
blood pressure was positively related to Doppler early and late velocities. The Olmsted County study 
has reported a prevalence of 6.0% of systolic dysfunction, defined as an ejection fraction of ≤50%.3 
Furthermore, the prevalence of mild, moderate and severe diastolic dysfunction was 20.8%, 6.6% and 
0.7%, respectively (definitions of mild and severe diastolic dysfunction roughly corresponding to our 
impaired relaxation and restrictive categories, respectively). The prevalence of diastolic dysfunction 
increased with age, was more common in participants with cardiovascular disease, diabetes, or sys-
tolic dysfunction, and was equally common in men and women. The Framingham study has reported 
a prevalence of 5.1% of abnormally low fractional shortening (≤30%) measured by M-mode echocar-
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diography in 1493 men.12 Later, they reported a prevalence of visually estimated ejection fraction ≤ 
50% without having a history of heart failure of 6% in men and 0.8% in women.13 Furthermore, this 
study has reported that E/A ratio is associated with age, sex, systolic blood pressure, heart rate, PR in-
terval and left ventricular systolic function in a subset of 127 randomly selected, normal subjects.5 The 
Strong Heart study has reported that left ventricular systolic dysfunction, defined as ejection fraction 
≤54%, was present in 14% of the subjects and that is was independently associated with male sex, 
hypertension, overweight, overt heart failure and coronary heart disease, and less consistently with 
older age and diabetes.6 With regard to diastolic parameters, 16% of the participants had E/A ratio < 
0.6 and 3% had E/A ratio >1.5. Sex, age, BMI, systolic and diastolic blood pressure, heart rate, diabetes, 
baseline coronary heart disease and heart failure showed associations with abnormal E/A ratio (< 
0.6 or > 1.5). The above underlines that prevalence of systolic and diastolic dysfunction varies across 
studies, probably in part due to differences in population characteristics and definitions of ventricular 
dysfunction. Nevertheless, associations of age, sex, and blood pressure with ventricular dysfunction 
appear to be rather consistent across studies.
In conclusion, we have found that moderate and poor left ventricular systolic function was pres-
ent in asymptomatic men and women participating in the Rotterdam Study. With regard to diastolic 
parameters, we found that E/A ratio was on average lower in women than in men. Higher age, BMI 
and diastolic blood pressure and lower systolic blood pressure were most consistently associated with 
worse systolic function in both sexes. Higher age and diastolic blood pressure were most consistently 
associated with lower E/A ratio in both sexes. Further research is warranted to investigate the value of 
echocardiography in identification of individuals with preclinical ventricular dysfunction.
Chapter 5.1
156
References
 1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Man-
cini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr., 
Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato 
JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic 
Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Associa-
tion Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the 
Evaluation and Management of Heart Failure): developed in collaboration with the American Col-
lege of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed 
by the Heart Rhythm Society. Circulation. 2005;112:e154-235.
 2. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart 
failure with a normal ejection fraction: is measurement of diastolic function necessary to make the 
diagnosis of diastolic heart failure? Circulation. 2001; 104: 779-82.
 3. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic 
and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure 
epidemic. JAMA. 2003; 289: 194-202.
 4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with 
reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992; 327: 685-91.
 5. Benjamin EJ, Levy D, Anderson KM, Wolf PA, Plehn JF, Evans JC, Comai K, Fuller DL, Sutton MS. Deter-
minants of Doppler indexes of left ventricular diastolic function in normal subjects (the Framingham 
Heart Study). Am J Cardiol. 1992; 70: 508-15.
 6. Devereux RB, Roman MJ, Paranicas M, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Rodehef-
fer RJ, Cowan LD, Howard BV. A population-based assessment of left ventricular systolic dysfunction 
in middle-aged and older adults: the Strong Heart Study. Am Heart J. 2001; 141: 439-46.
 7. Devereux RB, Roman MJ, Palmieri V, Liu JE, Lee ET, Best LG, Fabsitz RR, Rodeheffer RJ, Howard BV. 
Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong 
Heart Study. Am Heart J. 2003; 146: 527-34.
 8. Gardin JM, Siscovick D, Anton-Culver H, Lynch JC, Smith VE, Klopfenstein HS, Bommer WJ, Fried L, 
O’Leary D, Manolio TA. Sex, age, and disease affect echocardiographic left ventricular mass and sys-
tolic function in the free-living elderly. The Cardiovascular Health Study. Circulation. 1995; 91: 1739-
48.
 9. Xie X, Gidding SS, Gardin JM, Bild DE, Wong ND, Liu K. Left ventricular diastolic function in young 
adults: the Coronary Artery Risk Development in Young Adults Study. J Am Soc Echocardiogr. 1995; 8: 
771-9.
 10. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and 
diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. 
J Am Coll Cardiol. 2001; 37: 1042-8.
 11. Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, Devereux RB. Mitral ra-
tio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly 
adults: the Strong Heart Study. Circulation. 2002; 105: 1928-33.
 12. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and sys-
tolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J 
Cardiol. 1992; 70: 1180-4.
Cardiovascular risk factors and echocardiographic parameters
157
 13. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left 
ventricular systolic dysfunction in the community. Circulation. 2003; 108: 977-82.
 14. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in 
the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991; 7: 403-22.
 15. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes 
Care. 2003;26 Suppl 1:S5-20.
 16. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Strick-
er BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis 
of heart failure The Rotterdam Study. Eur Heart J. 2004; 25: 1614-9.
 17. van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG analysis system MEANS. 
Methods Inf Med. 1990; 29: 346-53.
 18. Willems JL, Abreu-Lima C, Arnaud P, van Bemmel JH, Brohet C, Degani R, Denis B, Gehring J, Graham 
I, van Herpen G, et al. The diagnostic performance of computer programs for the interpretation of 
electrocardiograms. N Engl J Med. 1991; 325: 1767-73.
 19. Kors JA, van Herpen G, Wu J, Zhang Z, Prineas RJ, van Bemmel JH. Validation of a new computer 
program for Minnesota coding. J Electrocardiol. 1996;29 Suppl:83-8.
 20. Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, Sahn DJ, Schiller NB, Tajik A, Teichholz 
LE, Weyman AE. Report of the American Society of Echocardiography Committee on Nomenclature 
and Standards in Two-dimensional Echocardiography. Circulation. 1980; 62: 212-7.
 21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, 
Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimension-
al echocardiography. American Society of Echocardiography Committee on Standards, Subcommit-
tee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358-67.
 22. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification 
of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomencla-
ture and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 
2002; 15: 167-84.
 23. Ommen SR, Nishimura RA. A clinical approach to the assessment of left ventricular diastolic function 
by Doppler echocardiography: update 2003. Heart. 2003;89 Suppl 3:iii18-23.
 24. Amico AF, Lichtenberg GS, Reisner SA, Stone CK, Schwartz RG, Meltzer RS. Superiority of visual versus 
computerized echocardiographic estimation of radionuclide left ventricular ejection fraction. Am 
Heart J. 1989; 118: 1259-65.
 25. Jensen-Urstad K, Bouvier F, Hojer J, Ruiz H, Hulting J, Samad B, Thorstrand C, Jensen-Urstad M. Com-
parison of different echocardiographic methods with radionuclide imaging for measuring left ven-
tricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy. Am J 
Cardiol. 1998; 81: 538-44.
 26. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of dia-
stolic function. J Am Coll Cardiol. 1998; 32: 865-75.
 27. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J. 
1998; 19: 990-1003.
 28. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of 
left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc 
Echocardiogr. 1997; 10: 246-70.
Chapter 5.1
158
 29. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of 
heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur 
Heart J. 1999; 20: 447-55.
 30. Gardin JM, Arnold AM, Bild DE, Smith VE, Lima JA, Klopfenstein HS, Kitzman DW. Left ventricular 
diastolic filling in the elderly: the cardiovascular health study. Am J Cardiol. 1998; 82: 345-51.
159
Chapter 5.2
Echocardiographic parameters and 
mortality
Abstract
Background. Even when heart failure has not yet become clinically manifest, preclinical ventricular 
dysfunction may be present, and therapeutic interventions introduced at this time may reduce mor-
bidity and mortality. However, data on the predictive value of echocardiographic characteristics in the 
general population remain relatively scarce.
Methods. The Rotterdam Study is a population-based cohort study in men and women aged ≥ 55 
years. Participants with prevalent heart failure, myocardial infarction and atrial fibrillation and flutter 
at the time of echocardiography were excluded. Structural, systolic and diastolic parameters were 
assessed using two-dimensional, M-mode and Doppler echocardiography. Echocardiograms were 
available in 4425 participants.
Results. During a mean follow-up of 3.0 years, 226 participants died. Increased left ventricular mass 
was an independent risk factor for all-cause mortality, particularly in men (hazard ratio per standard 
deviation of natural log transformed left ventricular mass, 1.20 (95% CI, 1.01-1.43)). Fractional shorten-
ing and left ventricular systolic function did not show a clear association with mortality. E/A ratio < 
0.75 was an independent risk factor in men (age-adjusted hazard ratio 1.82 (95% CI 1.23-2.69)). This 
was further reflected by diastolic function: impaired relaxation was a risk factor in men, but not in 
women.
Conclusions. Structural and diastolic echocardiographic parameters are associated with all-cause 
mortality in an asymptomatic population. However, the evidence is still inadequate to support the 
usefulness of echocardiography for screening to identify asymptomatic individuals with preclinical 
ventricular dysfunction.
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Introduction
Heart failure has been shown to entail an increased risk of mortality.1 This issue is gaining importance 
because the burden of heart failure is steadily increasing, in part as a result of better treatment of car-
diovascular disease and of the aging of the population.2 Even when heart failure has not yet become 
clinically manifest, preclinical ventricular dysfunction may be present.3 It has been recognized that 
therapeutic interventions introduced even before the appearance of left ventricular dysfunction or 
symptoms may reduce morbidity and mortality.2
The above underlines the value of early recognition of preclinical abnormalities. Echocardiography 
may be useful for this purpose, and may also be useful to gain more insight into which of these pre-
clinical features predispose to earlier mortality. Important advantages of echocardiography include its 
noninvasive and comprehensive nature. As a consequence, the predictive value of echocardiographic 
measures for occurrence of heart failure, cardiovascular disease and for mortality has been investi-
gated within several population-based studies, such as the Framingham Study, Cardiovascular Health 
Study, The Strong Heart Study and the Olmsted County study.3-13 Nonetheless, data on the predictive 
value of echocardiographic characteristics in the general population still remain relatively scarce.
To expand the current knowledge on echocardiographic parameters that may increase risk of 
death in the general population, we have performed a comprehensive investigation of structural, 
systolic as well as diastolic echocardiographic parameters in relation to all-cause mortality within a 
population-based cohort study in men and women aged 55 years and over.
Methods
Study population
The study was performed within the framework of the Rotterdam Study, a population-based cohort 
study aimed at assessing the occurrence of and risk factors for chronic diseases in the elderly.14 Base-
line visits of the Rotterdam Study took place in 1990-1993. All inhabitants of a suburb of Rotterdam 
aged 55 years and over were invited and 7983 agreed to participate (response 78%). Follow-up visits 
took place in 1993 to 1994 and 1997 to 1999. In 2000-2001, the cohort was extended with 3011 partic-
ipants from the same suburb (response 67%), also aged 55 years and over. For the present study, data 
collection took place from 2002-2005. Within this period, the participants from the original cohort 
completed their fourth center visit (n=3550), and the participants of the extended cohort completed 
their second center visit (n=2389). Of these, 3052 and 2235, respectively, underwent cardiac echocar-
diography. Missing echocardiograms were largely caused by the absence of echocardiographers. 
Participants with prevalent heart failure (n=304), myocardial infarction, (n=561), or atrial fibrillation 
(n=124) or atrial flutter (n=13) at the time of echocardiography were excluded from the analysis; this 
led to the exclusion of a total of 862 persons and consequently resulted in a total of 4425 participants 
available for analysis. The medical ethics committee of Erasmus Medical Center, Rotterdam, approved 
the study. Participants gave written informed consent and permission to retrieve information from 
treating physicians.
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Echocardiography
For each participant, an echocardiogram was obtained. The first 2188 echocardiograms were per-
formed with a commercially available ultrasonography system (AU3 Partner, Esaote Biomedica, with 
a 3.5/2.5 MHz transducer). The following 3099 echocardiograms were performed with another com-
mercially available system (Acuson Cypress, with a 3V2c transducer). A standardized protocol was 
used, including two-dimensional scanning in the parasternal long axis view, parasternal short axis 
view, apical view and subcostal view, M-mode scanning in the parasternal long axis view, and pulsed 
wave Doppler scanning in the apical four chamber view.15 Echocardiograms were recorded onto VHS 
tape and assessed at the reading center, which was located at Erasmus Medical Center.
Several structural parameters were assessed.16 Left atrium diameter, left ventricular end systolic 
dimension (LVES), left ventricular end diastolic dimension (LVED), end diastolic interventricular sep-
tum thickness (IVST) and end-diastolic left ventricular posterior wall thickness (PWT) were measured 
in the parasternal long axis view using M-mode with two-dimensional guidance. Left ventricular 
mass (grams) was calculated as 0.80(1.04*((IVST+LVED+PWT)3-LVED3))+0.6, according to Devereux et 
al.17 With regard to systolic parameters, fractional shortening at the endocardium was calculated as 
(LVED-LVES)/LVED*100%.16 Global left ventricular systolic function was qualitatively assessed, without 
quantitative measurement, from the two-dimensional echocardiogram and classified as normal, fair, 
moderate or poor. Furthermore, diastolic parameters were measured.18 Pulsed Doppler recordings 
of transmitral filling velocity were performed in the apical 4-chamber view, with the sample volume 
placed in the mitral valve orifice near the tips of the leaflets. Doppler peak E and peak A velocities were 
averaged over 3 cycles. E/A ratio was computed by dividing Doppler peak E velocity by Doppler peak 
A velocity. Early mitral valve velocity deceleration time was measured as the time between the peak E 
wave and the upper deceleration slope extrapolated to the zero baseline.
Echocardiograms were made and read by 4 trained echocardiographers. To assess intra-reader and 
inter-reader agreement, 32 participants were examined in duplicate. For continuous variables, overall 
median percent intra-reader and inter-reader measurement variabilities were calculated as the ab-
solute measurement difference divided by the average of the two measurements, multiplied by 100. 
Overall median intra-reader and inter-reader variabilities for left ventricular end-diastolic dimension 
were 3% and 4%, respectively. For left ventricular end-systolic dimension both variabilities were 6%, 
and for fractional shortening both were 8%. Overall median intra-reader and inter-reader variabilities 
for E/A ratio were 15% and 18%, respectively, and for deceleration time both were 16%. Finally, the 
percentage agreement for categorization of left ventricular systolic function as normal or other than 
normal was 82% within readers and 86% between readers.
Assessment of cardiovascular risk factors and prevalent disease
A trained interviewer visited all participants at home and collected information on current health 
status, medical history, drug use, and smoking, using a computerized questionnaire. Clinical measures 
were obtained during a visit at the study center using standard procedures.19 Presence of symptom-
atic heart failure at the time of echocardiography was assessed by using a validated score similar to 
the definition of heart failure of the European Society of Cardiology, as described previously,20 and 
the information needed was obtained by screening of all medical records of general practitioners 
(GPs) in retrospect for the occurrence of heart failure and obtaining letters and discharge reports from 
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medical specialists when a case was found. Prevalent myocardial infarction was considered present 
when myocardial infarction was detected by screening GP medical records and reviewing letters and 
discharge reports from medical specialists, or when an ECG characteristic of prior myocardial infarc-
tion was detected during a follow-up visit. Presence of atrial fibrillation or atrial flutter at the time 
of echocardiography was assessed with electrocardiography by applying the Modular ECG Analysis 
System (MEANS), which has been extensively evaluated,21,22 and is characterized by a high sensitivity 
(96.6%) and a high specificity (99.5%) in coding arrhythmias.23 For a small sample of participants, ECGs 
were not available at the time this report was written because of logistic problems and were approxi-
mated by using ECGs from the previous examination (year 2000-2001).
Follow-up procedure
Information on vital status of the Rotterdam Study participants was obtained from general practi-
tioner medical records and from municipal records. Follow-up for all-cause mortality started at the 
echocardiographic examination and for the present study was complete until February 21, 2007.
Statistical analysis
We calculated means, medians and proportions of cardiovascular risk factors and echocardiographic 
characteristics in men and women. To investigate the association between echocardiographic param-
eters and all-cause mortality, we used Cox proportional hazards models. The proportional hazards 
assumption was tested by drawing log minus log plots of the survival function or by adding interac-
tion terms involving time to the models where appropriate. Diameter of left atrium, left ventricular 
end-systolic dimension, left ventricular end-diastolic dimension, interventricular septum thickness, 
left ventricular posterior wall thickness, left ventricular mass, fractional shortening, mitral valve inflow 
E-peak, mitral valve inflow A-peak, E/A ratio and mitral valve inflow deceleration time were entered as 
independent variables. Variables were natural log transformed when their distributions were skewed. 
Hazard ratios were computed per standard deviation increase in the independent variables. E/A ratio 
was also entered as a categorical variable with cut-points 0.75 and 1.50.3,24 In model 1, we adjusted for 
age, sex and type of ultrasonography system, and in model 2, we adjusted for age, sex, type of ultra-
sonography system, body mass index, systolic blood pressure, diastolic blood pressure, total choles-
terol, HDL-cholesterol, diabetes mellitus, smoking, use of diuretics, beta-blockers, ACE inhibitors and 
lipid lowering drugs, and heart rate. The analysis was repeated in men and women separately.
Left ventricular systolic and diastolic function were entered into the Cox proportional hazards 
model as categorical variables. We categorized diastolic function according to cut points used in 
previous reports.3,24 Normal diastolic function was defined as E/A ratio between 0.75 and 1.50 and 
deceleration time between 150 ms and 280 ms. Impaired relaxation was defined as E/A ratio < 0.75 
and deceleration time > 280 ms. Restrictive diastolic dysfunction was defined as E/A ratio > 1.50 and 
deceleration time < 150 ms. Participants were required to have both Doppler criteria consistent with 
impaired relaxation or restrictive dysfunction to be classified. Participants with one abnormal crite-
rion were classified as indeterminate rather than as normal.
All analyses were performed using SPSS 11.0. Values for cardiovascular covariates were missing in 
less than 3% of participants, except for BMI, which was missing in 5.5%. Missing values were handled by 
single imputation using the expectation-maximization algorithm in SPSS 11.0. All tests were two-sided.
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Results
Table 1 shows baseline characteristics in men and women. All echocardiographic characteristics 
showed significant differences across the sexes; in general, structural parameters were larger in 
men, systolic function was worse in men, and with regard to diastolic function, E/A ratio was lower 
in women.
During a mean follow-up time of 3.0 (standard deviation, 1.0) years, death occurred in 226 persons. 
In table 2, hazard ratios of all-cause mortality, adjusted for age, sex and type of ultrasonography sys-
tem, are shown. The structural parameters interventricular septum thickness and left ventricular pos-
terior wall thickness were significantly and positively associated with all-cause mortality. After stratify-
ing on sex, the hazard ratio for interventricular septum thickness remained of similar magnitude in 
both sexes but lost significance in women, whereas left ventricular posterior wall thickness no longer 
showed an association in women. Left ventricular mass was positively associated with all-cause mor-
tality in the total population and in men, but not in women. The estimates did not materially change 
after multivariable adjustment.
With regard to systolic parameters, fractional shortening did not show a significant association 
with all-cause mortality (table 2). As for qualitatively assessed left ventricular systolic function, risk 
of all-cause mortality was increased in participants with poor systolic function, but the risk estimates 
did not reach statistical significance (table 3). Overall survival at the end of follow-up in persons with 
normal, fair, moderate and poor systolic function was 96.6%, 92.4%, 92.4% and 89.7%, respectively.
As to diastolic parameters, E/A ratio showed a significant and inverse association with all-cause 
mortality in the total population (table 2). After stratification on sex, this effect only remained present 
in men. Accordingly, after categorization of E/A ratio, E/A ratio < 0.75 was associated with an increased 
risk of mortality in men. In women, E/A ratio > 1.50 resulted in an increased but non-significant risk 
(table 4). Furthermore, impaired relaxation was also associated with an increased risk in men, while 
a restrictive pattern was associated with an increased risk in both men and women (table 4). Overall 
survival at the end of follow-up in persons with normal, impaired and restrictive diastolic function 
was 97%, 91.0% and 76.9%, respectively. Results remained essentially the same after multivariable 
adjustment.
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Table 1. Baseline characteristics.
Variable All (n=4425) Men (39%) Women (61%) P-value
Age (years) 71.4 ± 7.3 70.8 ± 7.0 71.9 ± 7.5 < 0.001
Body mass index (kg/m2) 27.5 ± 4.1 27.2 ± 3.4 27.7 ± 4.5 < 0.001
Systolic blood pressure (mmHg) 150 ± 21 148 ± 20 151 ± 22 < 0.001
Diastolic blood pressure (mmHg) 80 ± 11 81 ± 11 79 ± 11 < 0.001
Total cholesterol (mmol/l) 5.7 ± 1.0 5.4 ± 0.9 5.9 ± 0.9 < 0.001
HDL-cholesterol (mmol/l) 1.5 ± 0.4 1.3 ± 0.3 1.6 ± 0.4 < 0.001
Diabetes mellitus (%) 12.9 13.4 12.7 0.49
Smoking < 0.001
- Never (%) 31.5 13.4 43.1
- Former (%) 52.7 68.2 42.8
- Current (%) 15.8 18.4 14.0
Use of diuretics (%) 9.3 5.4 11.8 < 0.001
Use of beta blockers (%) 14.1 11.9 15.6 < 0.001
Use of ACE-inhibitors (%) 11.1 11.2 11.0 0.79
Use of lipid-lowering drugs (%) 11.6 11.2 11.9 0.52
Left atrium diameter (mm) 40 ± 5 42 ± 5 39 ± 5 < 0.001
Left ventricular end systolic dimension (mm) 30 (28-34)* 32 (29-36)* 29 (27-32)* < 0.001
Left ventricular end diastolic dimension (mm) 51 ±5 53 ± 5 49 ± 5 < 0.001
Interventricular septum thickness (mm) 8 (7-9)* 8 (8-10)* 8 (7-9)* < 0.001
Left ventricular posterior wall thickness (mm) 7 (7-8)* 8 (7-8)* 7 (7-8)* < 0.001
Left ventricular mass (g) 140 (117-167)* 157 (135-187)* 130 (110-151)* < 0.001
Fractional shortening (%) 39 ± 7 38 ± 7 40 ± 6 < 0.001
Left ventricular systolic function < 0.001
- Normal (%) 61.0 55.0 64.9
- Fair (%) 36.2 41.0 33.1
- Moderate (%) 2.1 2.8 1.7
- Poor (%) 0.7 1.1 0.4
Mitral valve inflow peak E (m/s) 0.65 ± 0.16 0.63 ± 0.15 0.66 ± 0.16 < 0.001
Mitral valve inflow peak A (m/s) 0.77 ± 0.17 0.72 ± 0.16 0.80 ± 0.17 < 0.001
Mitral valve inflow deceleration time (ms) 214 ± 46 219 ± 47 211 ± 45 < 0.001
E/A ratio 0.83 (0.71-1.00)* 0.86 (0.71-1.00)* 0.81 (0.70-1.00)* < 0.001
*Median and inter-quartile range because of skewed distribution.
Categorical variables are expressed as percentage. Continuous variables are expressed as mean ± standard deviation. P-values are for differences 
between men and women. T-tests, chi square tests and Mann-Whitney tests were used where appropriate.
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Table 2. Hazard ratios for all-cause mortality per standard deviation of echocardiographic parameters 
(natural log transformed when appropriate).
Variable
Hazard ratio per standard deviation (95% confidence interval)
Model 1 Model 2
All Men Women All Men Women
Left atrium diameter (mm) 0.94 (0.82-
1.08)
0.94 (0.78-
1.12)
0.96 (0.80-
1.15)
0.96 (0.83-
1.11)
0.99 (0.81-
1.21)
0.96 (0.78-
1.17)
Left ventricular end systolic 
dimension (mm)‡
1.02 (0.89-
1.17)
1.03 (0.85-
1.23)
1.01 (0.85-
1.21)
1.03 (0.89-
1.18)
1.04 (0.86-
1.27)
1.00 (0.83-
1.20)
Left ventricular end diastolic 
dimension (mm)
0.98 (0.86-
1.13)
1.01 (0.85-
1.21)
0.96 (0.80-
1.15)
0.99 (0.86-
1.14)
1.04 (0.86-
1.26)
0.96 (0.80-
1.16)
Interventricular septum 
thickness (mm)‡
1.21 (1.06-
1.38)†
1.25 (1.03-
1.51)*
1.20 (0.99-
1.46)
1.21 (1.05-
1.39)†
1.26 (1.02-
1.54)*
1.20 (0.97-
1.47)
Left ventricular posterior wall 
thickness (mm)‡
1.13 (1.00-
1.29)*
1.21 (1.02-
1.44)*
1.07 (0.88-
1.28)
1.12 (0.98-
1.27)
1.19 (0.99-
1.43)
1.05 (0.87-
1.28)
Left ventricular mass (g)‡ 1.15 (1.01-
1.31)*
1.20 (1.01-
1.43)*
1.09 (0.91-
1.31)
1.16 (1.01-
1.34)*
1.24 (1.02-
1.51)*
1.10 (0.91-
1.34)
Fractional shortening (%) 0.94 (0.83-
1.08)
0.95 (0.78-
1.15)
0.95 (0.79-
1.13)
0.95 (0.83-
1.08)
0.94 (0.77-
1.15)
0.97 (0.81-
1.16)
Mitral valve inflow peak E (m/s) 1.01 (0.89-
1.16)
0.94 (0.78-
1.13)
1.08 (0.91-
1.29)
0.98 (0.86-
1.12)
0.89 (0.73-
1.08)
1.06 (0.89-
1.27)
Mitral valve inflow peak A (m/s) 1.11 (0.98-
1.26)
1.19 (1.03-
1.37)*
1.00 (0.83-
1.21)
1.10 (0.97-
1.25)
1.16 (0.99-
1.36)
1.02 (0.84-
1.23)
Mitral valve inflow deceleration 
time (ms)
0.98 (0.86-
1.12)
1.07 (0.89-
1.29)
0.89 (0.74-
1.07)
0.99 (0.87-
1.12)
1.07 (0.89-
1.28)
0.92 (0.76-
1.10)
E/A ratio ‡ 0.87 (0.75-
1.00)*
0.75 (0.61-
0.91)†
1.02 (0.84-
1.23)
0.85 (0.74-
0.98)*
0.75 (0.62-
0.92)†
0.98 (0.80-
1.19)
Model 1. Adjusted for age and type of ultrasonography system (and sex where appropriate).
Model 2. Adjusted for age, type of ultrasonography system, sex (where appropriate), body mass index, systolic blood pressure, diastolic blood 
pressure, total cholesterol, HDL-cholesterol, diabetes mellitus, smoking, heart rate, use of diuretics, beta-blockers, ACE inhibitors and lipid 
lowering drugs and heart rate.
* 0.01< p <0.05; † p <0.01; ‡ Natural log transformed because of skewed distribution.
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Discussion
In summary, in this population-based study, we have examined structural, systolic and diastolic 
echocardiographic parameters and their associations with all-cause mortality. Increased left ventricu-
lar mass was an independent risk factor, particularly in men. Fractional shortening and left ventricular 
systolic function did not show a clear association. Low E/A ratio was an independent risk factor in 
men. This was further reflected by diastolic function: impaired relaxation was a risk factor in men, but 
not in women.
Strengths of the present study include its population-based nature, its large size, and its stan-
dardized assessment of risk factors and echocardiographic characteristics. Nevertheless, several is-
sues warrant consideration. First, we used global left ventricular function assessed qualitatively from 
two-dimensional images, without quantitative measurement of the ejection fraction. This approach 
is easily obtainable and reflects the routine procedure in echocardiography laboratories. Prior stud-
ies have reported that the reproducibility and accuracy of visual assessments are as good as those of 
quantitative methods,25,26 and similar visual assessments have also been used in other studies such as 
the Framingham Study.13 Furthermore, we also measured fractional shortening which is a quantitative 
indicator of systolic function. Second, we categorized diastolic function solely according to E/A ratio 
and deceleration time, while additional measures such as pulmonary venous flow or Doppler tissue 
imaging are needed to distinguish the pseudonormal pattern from normal diastolic function.27 Also, 
several different recommendations have been issued for categorization of diastolic function based on 
E/A ratio and deceleration time.28,29 We based our criteria for diastolic dysfunction on recent reports.3,24 
Table 3. Hazard ratios for all-cause mortality per category of left ventricular systolic function.
Systolic function
All Men Women
Cases/
subjects HR (95% CI)
Cases/
subjects HR (95% CI)
Cases/
subjects HR (95% CI)
Model 1
Normal 91/ 2662 1.00 (ref.) 36/ 938 1.00 (ref.) 55/ 1724 1.00 (ref.)
Fair 119/ 1578 1.21 (0.91-1.61) 67/ 699 1.34 (0.88-2.03) 52/ 879 1.14 (0.76-1.69)
Moderate 7/ 92 0.90 (0.42-1.97) 5/ 48 1.05 (0.40-2.70) 2/ 44 0.69 (0.17-2.84)
Poor 3/ 29 1.74 (0.55-5.52) 2/ 19 1.48 (0.35-6.15) 1/ 10 3.16 (0.44-23.0)
Model 2
Normal 91/ 2662 1.00 (ref.) 36/ 938 1.00 (ref.) 55/ 1724 1.00 (ref.)
Fair 119/ 1578 1.22 (0.92-1.62) 67/ 699 1.46 (0.96-2.22) 52/ 879 1.08 (0.73-1.61)
Moderate 7/ 92 0.95 (0.44-2.08) 5/ 48 1.22 (0.47-3.17) 2/ 44 0.70 (0.17-2.91)
Poor 3/ 29 1.85 (0.58-5.93) 2/ 19 1.68 (0.40-7.14) 1/ 10 3.94 (0.54-29.0)
HR= Hazard ratio, CI= Confidence interval
Model 1. Adjusted for age and type of ultrasonography system (and sex where appropriate).
Model 2. Adjusted for age, type of ultrasonography system, sex (where appropriate), body mass index, systolic blood pressure, diastolic blood 
pressure, total cholesterol, HDL-cholesterol, diabetes mellitus, smoking, heart rate, use of diuretics, beta-blockers, ACE inhibitors and lipid 
lowering drugs and heart rate.
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The use of only two criteria complicated classification of diastolic dysfunction. It resulted in a substan-
tial group of participants with “indeterminate” diastolic function, and results pertaining to the “restric-
tive pattern” category were based on very small numbers of participants. However, E/A ratio can by 
itself be used as an approximation of diastolic function, permitting classification of all participants. 
Finally, lack of power prevented us from examining incident cardiovascular disease and incident heart 
failure as endpoints at this point in time.
The association of echocardiographic measures with mortality has been investigated in several 
other population-based studies. Structural parameters have been examined in the Cardiovascular 
Health Study.9 In accordance with this study, we did not find an association of left atrium diameter 
Table 4. Hazard ratios for all-cause mortality per category of E/A ratio and left ventricular diastolic 
function.
Variable
All Men Women
Cases/
subjects HR (95% CI)
Cases/
subjects HR (95% CI)
Cases/
subjects HR (95% CI)
E/A ratio
Model 1
0.75-1.50 105/ 2912 1.00 (ref.) 53/ 1183 1.00 (ref.) 52/ 1729 1.00 (ref.)
< 0.75 103/ 1281 1.47 (1.11-1.95)* 56/ 457 1.82 (1.23-2.69)† 47/ 824 1.18 (0.78-1.78)
> 1.50 5/ 65 1.81 (0.74-4.44) 1/29 0.87 (0.12-6.31) 4/ 36 2.61 (0.94-7.25)
Model 2
0.75-1.50 105/ 2912 1.00 (ref.) 53/ 1183 1.00 (ref.) 52/ 1729 1.00 (ref.)
< 0.75 103/ 1281 1.49 (1.12-1.98)† 56/ 457 1.79 (1.20-2.65)† 47/ 824 1.26 (0.83-1.93)
> 1.50 5/ 65 1.55 (0.62-3.88) 1/ 29 0.71 (0.09-5.28) 4/ 36 2.29 (0.79-6.62)
Diastolic function
Model 1
Normal 67/ 2254 1.00 (ref.) 33/ 882 1.00 (ref.) 34/ 1372 1.00 (ref.)
Impaired relaxation 42/ 471 1.55 (1.03-2.33)* 28/ 196 2.09 (1.23-3.57)† 14/ 275 1.01 (0.53-1.93)
Restrictive pattern 3/ 13 6.89 (2.15-22.1)† 1/ 5 17.0 (2.26-127)† 2/ 8 5.64 (1.34-23.8)*
Indeterminate 92/ 1469 1.49 (1.08-2.05)* 43/ 564 1.43 (0.90-2.27) 49/ 905 1.55 (0.99-2.41)
Model 2
Normal 67/ 2254 1.00 (ref.) 33/ 882 1.00 (ref.) 34/ 1372 1.00 (ref.)
Impaired relaxation 42/ 471 1.55 (1.04-2.33)* 28/ 196 2.03 (1.19-3.46)* 14/ 275 1.08 (0.56-2.09)
Restrictive pattern 3/ 13 7.23 (2.16-24.2)† 1/ 5 22.6 (2.74-187)† 2/ 8 4.89 (1.10-21.8)*
Indeterminate 92/ 1469 1.49 (1.08-2.05)* 43/ 564 1.36 (0.85-2.16) 49/ 905 1.57 (1.01-2.46)*
HR= Hazard ratio, CI= Confidence interval
Model 1. Adjusted for age and type of ultrasonography system (and sex where appropriate).
Model 2. Adjusted for age, type of ultrasonography system, sex (where appropriate), body mass index, systolic blood pressure, diastolic blood 
pressure, total cholesterol, HDL-cholesterol, diabetes mellitus, smoking, heart rate, use of diuretics, beta-blockers, ACE inhibitors and lipid 
lowering drugs.
* 0.01< p <0.05; † p <0.01
Chapter 5.2
168
with mortality in our study. Our finding of a positive association of end diastolic interventricular sep-
tum thickness and end diastolic left ventricular posterior wall thickness with mortality confirms the 
associations found in the Cardiovascular Health Study. These associations may reflect the association 
between left ventricular mass and mortality, found in the Cardiovascular Health Study, as well as the 
Framingham Study4 and the present study. In contrast with the Cardiovascular Health Study, we did 
not find a significant association of left ventricular end systolic dimension with all-cause mortality.
In the present study, we did not find a significant association of fractional shortening and left ven-
tricular systolic function with all-cause mortality. Investigation of left ventricular systolic function was 
complicated by a modest prevalence of moderate and poor function and consequently low numbers 
of events in these categories. The Framingham Study, Cardiovascular Health Study, the Strong Heart 
Study and the Olmsted County study have examined the impact of systolic parameters on all-cause 
mortality. The Framingham Study reported an independent association between asymptomatic left 
ventricular dysfunction, ascertained by visual assessment of echocardiograms, and all-cause mortal-
ity. 13 The discrepancy with our study may in part have been caused by selection bias in our study; the 
Framingham Study had up to 12 years of follow-up (mean 5 years), whereas in our study mean follow-
up was 3.0 years, and participants who came to the research center may have been less likely to die in 
the first years of follow-up, because they were still relatively healthy. This may have attenuated some 
associations. The Cardiovascular Health Study also reported an independent association between ejec-
tion fraction assessed by echocardiography and all-cause mortality.7 The fact that the participants of 
the Cardiovascular Health Study were on average ten years older than the Rotterdam Study participants 
may have contributed to this discrepancy.30 The Strong Heart Study also reported an independent as-
sociation of ejection fraction, measured from echocardiographic left ventricular linear dimensions, with 
all-cause mortality.12 The difference with our study may at least in part have been caused by differences 
in study population, since the Strong Heart Study comprises American Indians with high prevalence of 
diabetes and obesity. Within residents of Olmsted County, low ejection fraction was found to be associ-
ated with increased all-cause mortality.3 However, this analysis was only adjusted for age and sex.
With regard to diastolic measures, Bella et al demonstrated within the Strong Heart Study that E/A 
ratio >1.5 was associated with an increase in all-cause mortality, as was E/A ratio <0.6, the latter not 
independent of covariates.11 In the Olmstedt County study, diastolic dysfunction, detected using Dop-
pler examination of mitral inflow and pulmonary venous inflow and Doppler tissue imaging of the 
mitral annulus, was predictive of all-cause mortality, independent of age, sex and ejection fraction.3 
In the present study, in the entire cohort, E/A ratio <0.75 was independently associated with all-cause 
mortality. After stratification by gender, this association remained present in men but attenuated 
in women. This may reflect gender differences in the occurrence of heart failure. Categorization of 
diastolic function accordingly revealed increased risk for impaired relaxation in men. Furthermore, it 
revealed an increased risk for a restrictive pattern in both men and women, although the confidence 
intervals were wide because of low power in this category.
In conclusion, our study supports the associations of selected structural and diastolic echocardio-
graphic parameters with all-cause mortality in an asymptomatic population. However, in view of the 
low prevalence of ventricular dysfunction in our study population, the evidence is still inadequate to 
support the usefulness of echocardiography for screening to identify asymptomatic individuals with 
preclinical ventricular dysfunction who may benefit from early treatment.
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Chapter 5.3
C-reactive protein level and heart failure
Abstract
Background. Experimental studies have shown that the known biological effects of proinflamma-
tory cytokines could explain many aspects of the syndrome of heart failure. The inflammatory marker 
that presently seems most suitable to assess inflammation is C-reactive protein (CRP). This study was 
designed to investigate the association between serum CRP levels, as determined by high-sensitivity 
assay, and the occurrence of heart failure.
Methods. Serum CRP levels were available from 6437 men and women without heart failure, aged 
≥55 years, from the prospective population-based Rotterdam Study. Cox proportional hazards analy-
sis was used to determine risk of heart failure for sex-specific quartiles of CRP.
Results. CRP levels in the highest versus the lowest quartile showed increased hazard ratios of inci-
dent heart failure. The age-and sex-adjusted hazard ratio was 2.64 (95% confidence interval 2.04-3.43) 
for all participants. For men, the age adjusted hazard ratio was 4.37 (2.87-6.66), and for women, 1.86 
(1.32-2.62). The interaction term of CRP with sex was highly significant. After additional adjustment 
for established cardiovascular risk factors, the association attenuated slightly in men and substantially 
in women, becoming 3.73 (2.40-5.78) and 1.42 (0.99-2.03), respectively. Excluding participants with 
prevalent coronary heart disease and accounting for incident coronary heart disease resulted in a 
further attenuation of the hazard ratios, which was proportionately larger in men than in women.
Conclusions. CRP is strongly and independently associated with occurrence of heart failure in men. In 
women, the association is weaker and does not persist after accounting for established cardiovascular 
risk factors.
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Introduction
Recently, inflammatory markers have been implicated as predictors of heart failure. Experimental 
studies have shown that the known biological effects of proinflammatory cytokines could explain 
many aspects of the syndrome of heart failure, such as left ventricular dysfunction, pulmonary edema 
and the process of left ventricular remodeling, including myocyte hypertrophy and progressive myo-
cyte loss through apoptosis.1
The inflammatory marker that presently seems most suitable to assess inflammation is C-reactive 
protein (CRP).2 Elevated CRP levels have been associated with an adverse prognosis in patients with 
heart failure,3-5 and elevated CRP levels have shown to be predictive of the development of heart 
failure in high-risk participants.6,7
Few population-based studies have examined the association between CRP and heart failure. In 
the Cardiovascular Health Study, increased CRP was an independent predictor of heart failure, the 
association persisting after adjustment for clinically prevalent as well as subclinical atherosclerotic 
disease.8 The Framingham Heart Study demonstrated that participants with CRP serum levels of ≥5 
mg/l experienced a significantly increased risk of heart failure, even after adjustment for prevalent 
cardiovascular disease and the occurrence of myocardial infarction during follow-up.9 This study was 
limited by the use of a low-sensitivity CRP assay. Finally, in the Health ABC study, high levels of CRP 
independently predicted the incidence of events of heart failure.10 In this study, incident heart failure 
was defined as any overnight hospitalization with this diagnosis, which does not account for all heart 
failure cases in a population.
These studies suggest that elevated levels of CRP precede heart failure. We sought to expand the 
evidence by examining the relation between CRP levels, as determined by high-sensitivity assay, and 
the occurrence of heart failure, in the Rotterdam Study, a prospective population-based cohort study 
in men and women aged ≥55 years.
Methods
Study population and baseline data collection
The present study is part of the Rotterdam Study, a population-based cohort study aimed at assessing 
the occurrence of and risk factors for chronic diseases in the elderly. Objectives and methods of the 
Rotterdam Study have been described in detail elsewhere.11 The Rotterdam Study cohort includes 
7983 men and women aged ≥55 years (78% of the eligible population), living in a well-defined sub-
urb of the city of Rotterdam, the Netherlands. Baseline data were collected from 1990 until 1993. The 
obtained information included current health status, medical history, drug use and smoking.
In addition, in 7129 participants, established cardiovascular risk factors were determined at the re-
search center according to standard procedures, as described previously.12 These included body mass 
index, blood pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, diabetes mellitus, 
and presence of angina pectoris according to the Rose questionnaire.13 Electrocardiograms (ECGs) 
were recorded and processed by the Modular ECG Analysis System14 to obtain ECG measurements 
and interpretations. Myocardial infarction found on ECG was based on a set of criteria partly derived 
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from the Minnesota code.15 A history of myocardial infarction was considered present in case of a self-
report of myocardial infarction confirmed by ECG or additional clinical information, or the presence of 
an ECG characteristic of prior myocardial infarction.
The medical ethics committee of Erasmus Medical Center, Rotterdam, approved the study. Par-
ticipants gave written informed consent and permission to retrieve information from treating physi-
cians.
Population for analysis
The Rotterdam Study comprises 7983 participants. Two hundred fifty-four participants were excluded 
because of prevalent heart failure at baseline, five because of unclear heart failure status, and four 
because of missing heart failure status, leaving 7720 participants. Within this group, CRP levels were 
available for 6437 participants, which were used for analysis. CRP measurements were lacking for par-
ticipants who did not visit the research center and for participants of whom no blood was available 
due to logistic reasons. Values for cardiovascular covariates were missing in <14% of participants, and 
these missing values were handled by single imputation using an expectation-maximization algo-
rithm.
In further analyses, participants with coronary heart disease at baseline, defined as a history of 
myocardial infarction, percutaneous transluminal coronary angioplasty or coronary artery bypass 
grafting, were additionally excluded, yielding a group of 6881, in which CRP levels were available for 
5691 participants.
Measurement of CRP
At baseline, a venipuncture was performed by application of minimal stasis with a 21-gauge Butterfly 
needle with tube (Surflo winged infusion set, Terumo, Tokyo, Japan). Non-fasting blood was collected, 
and all tubes were stored on ice before and after blood sampling. High-sensitivity CRP was deter-
mined in serum, which was stored at -20°C until performance of the CRP measurements in 2003 to 
2004. CRP was measured using Rate Near Infrared Particle Immunoassay (Immage Immunochemistry 
System, Beckman Coulter, Fullerton, CA). This system measures concentrations from 0.2 to 1440 mg/l, 
with a within-run precision < 5.0%, a total precision < 7.5% and a reliability coefficient of 0.995.
Heart failure assessment
Assessment of prevalent heart failure at baseline in the Rotterdam Study has been described in detail 
elsewhere.16,17 Briefly, a validated score was used, which was similar to the definition of heart failure of 
the European Society of Cardiology.18 Furthermore, databases containing hospital discharge diagno-
ses from all hospitals in the Netherlands as of January 1, 1991, and all medical records from general 
practitioners in the area were screened in retrospect. Using these three methods, information on the 
presence of heart failure at baseline was available for all participants.
Follow-up started at the baseline examination and for the present study ended on January 1, 2000. 
Cases of incident heart failure were obtained by continuously monitoring participants of the Rotter-
dam Study for the occurrence of heart failure during follow-up through automated linkage with files 
from general practitioners. All available data on these events, including hospital discharge letters, 
were copied from the medical records. Furthermore, verified hospital discharge diagnoses were used 
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for case finding, gathered from all hospitals in the Netherlands as described above. The date of inci-
dent heart failure was defined as the day of the first occurrence of symptoms suggestive of heart fail-
ure, obtained from the medical records, or the day of receipt of a first prescription for a loop diuretic 
or an angiotensin-converting enzyme inhibitor, whichever came first.
The diagnosis of heart failure was classified as definite, probable, possible or unlikely. Only definite 
and probable cases were included in the analysis. In accordance with the criteria of the European 
Society of Cardiology,18 definite heart failure was defined as a combination of heart failure diagnosed 
by a medical specialist and the presence of typical symptoms of heart failure, such as breathlessness 
at rest or during exertion, ankle edema, and pulmonary crepitations, confirmed by objective evidence 
of cardiac dysfunction (chest x-ray, echocardiography). Probable heart failure was defined as heart 
failure diagnosed by a general practitioner, with at least 2 typical symptoms suggestive of heart fail-
ure, and at least 1 of the following: history of cardiovascular disease, response to treatment for heart 
failure, or objective evidence of cardiac dysfunction, whereas symptoms could not be attributed to 
another underlying disease. Two research physicians independently classified all information on po-
tential heart failure events. If there was disagreement, a consensus was reached in a separate session. 
Finally, a cardiologist verified all probable and possible cases, and all cases in which the 2 physicians 
could not reach consensus. If the cardiologist disagreed with the research physicians, the cardiolo-
gist’s judgment was considered decisive.
Statistical analysis
Firstly, age-adjusted means or proportions for baseline characteristics were computed by analysis of 
covariance for men and women with and without incident heart failure. For this purpose, CRP was 
log-transformed because of its skewed distribution. Secondly, to allow for the demonstration of a pos-
sibly non-linear association, CRP was categorized into quartiles with cut-points 0.9, 1.9, and 3.6 mg/l 
and Cox proportional hazards analysis was performed to determine the hazard ratio of heart failure. 
Participants in the lowest quartile of CRP served as the reference group. P for trend was obtained by 
entering CRP into the Cox proportional hazards models as a continuous variable. Participants were 
censored at the time of occurrence of heart failure, death or the end of the study period. The propor-
tional hazards assumption was tested by drawing log minus log plots of the survival function, which 
confirmed that the assumption was met. In model 1, we adjusted for age and sex. In model 2, we 
additionally adjusted for body mass index, hypertension, total cholesterol, HDL-cholesterol, smoking, 
diabetes mellitus and angina pectoris. Analyses were performed in all participants, and furthermore 
separate analyses were performed in men and women using sex-specific quartiles of CRP. While ex-
ploring the data in this way, we noted that remarkable differences were present in the hazard ratios 
between men and women. Thus, we tested interaction between CRP and gender using a Cox model 
containing sex, CRP and the product term of sex and CRP, entering CRP as a continuous variable. This 
interaction was similarly tested with additional adjustment for age, body mass index, hypertension, 
total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and angina pectoris.
Finally, we excluded participants with presence of coronary heart disease at baseline. We per-
formed Cox proportional hazards analysis, censoring participants at the time of occurrence of heart 
failure, death or the end of the study period, or occurrence of coronary heart disease (myocardial in-
farction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting) if this took 
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place before the occurrence of heart failure. Once more, we divided CRP into quartiles, the cut-points 
now being 0.9, 1.8 and 3.5 mg/L. In model 1, we adjusted for age and sex. In model 2, we adjusted for 
age, sex, body mass index, hypertension, total cholesterol, HDL-cholesterol, smoking, diabetes mel-
litus and angina pectoris. Similarly, analyses were first performed in all participants, and subsequently 
separate analyses were performed in men and women using sex-specific CRP quartiles. Analyses were 
performed with SPSS 11.0 for Windows (SPSS, Inc, Chicago, IL).
Results
Baseline characteristics and follow-up
Table 1 shows baseline characteristics of the total study population (n=6437) and for cases and non-
cases in men and women. The mean age of the total study population was 69.3 years and 40% were 
men. In both sexes, age, body mass index, systolic blood pressure, hypertension, smoking, history of 
myocardial infarction and C-reactive protein were significantly different in cases and noncases. Total 
cholesterol and diabetes mellitus were significantly different in cases and noncases in men but not in 
women, whereas diastolic blood pressure and HDL-cholesterol were significantly different in women 
but not in men.
Table 1. Baseline characteristics of the study population, crude for total population and age-adjusted for 
men and women.
Variable
Total 
population
(n=6437)
Men (n=2601)
P-value
Women (n=3836)
P-value
Cases
(n=262)
Non-
cases
(n=2339)
Cases
(n=289)
Non-
cases
(n=3547)
Age (years) 69.3±9.1 73.2 67.7 <0.001 77.8 69.5 <0.001
Body mass index (kg/m2) 26.2±3.7 26.3 25.6 <0.001 27.6 26.6 <0.001
Systolic blood pressure (mm Hg) 139±22 143 138 0.003 144 140 0.003
Diastolic blood pressure (mm 
Hg)
74±12 75 75 0.296 75 73 0.036
Hypertension (%) 33.9 39.1 28.7 0.001 47.0 35.8 <0.001
Total cholesterol (mmol/l) 6.6±1.2 6.5 6.3 0.004 6.8 6.8 0.981
HDL-cholesterol (mmol/l) 1.4±0.4 1.2 1.2 0.237 1.4 1.4 0.009
Smokers (%)
- Never 34.2 4.8 8.5 0.042 48.2 54.3 0.049
- Current 22.4 33.8 29.6 0.174 25.0 17.7 0.003
- Former 40.6 61.4 61.9 0.891 26.9 28.0 0.682
Diabetes mellitus (%) 10 19.8 8.9 <0.001 13.3 10.0 0.074
C-reactive protein (mg/l)* 1.9 (0.9-3.6) 3.0 1.9 <0.001 2.2 1.8 0.001
History of myocardial infarction 
(%)
10.4 33.2 14.6 <0.001 14.5 7.0 <0.001
Categorical variables are expressed as percentage. Values of continuous variables are expressed as mean ± standard deviation.
*Median and interquartile range for total because of skewed distribution.
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The mean follow-up time until occurrence of heart failure, death or study end was 6.5 years (stan-
dard deviation 2.4 years). During follow-up 551 incident cases of heart failure occurred.
C-reactive protein and risk of heart failure
After adjustment for age and sex, the risk of developing heart failure increased with increasing quartiles 
of CRP, with a hazard ratio of 2.64 (95% confidence interval (CI) 2.04-3.43) for the highest compared to 
the lowest quartile in the total population (table 2). The interaction between sex and CRP was highly 
significant (p=0.02, and p=0.01 after adjustment for established cardiovascular risk factors). In men, 
a hazard ratio of 4.37 (95% CI 2.87-6.66) was reached in the highest compared to the lowest quartile. 
In women, the hazard ratios were lower; they did not reach statistical significance in the second and 
third quartiles and became 1.86 (95% CI 1.32-2.62) in the highest quartile. After additional adjustment 
for established cardiovascular risk factors, the estimates declined moderately, providing a hazard ratio 
of 2.08 (95% CI 1.58-2.74) for the highest compared to the lowest quartile in the general population. 
Adjustment for established cardiovascular risk factors resulted in a larger proportionate decline of the 
risk estimates in women than in men, the multivariable-adjusted hazard ratio for the highest com-
pared to the lowest quartile of CRP falling from 1.86 (95% CI 1.32-2.62) to 1.42 (95% CI 0.99-2.03) in the 
former and from 4.37 (95% CI 2.87-6.66) to 3.73 (95% CI 2.40-5.78) in the latter.
Table 2. Hazard ratios with 95% confidence intervals for developing heart failure in quartiles of C-reactive 
protein levels.
Model 1 Model 2
Events/ participants Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Total
Quartile 1 76/ 1610 1.00 (reference) 1.00 (reference)
Quartile 2 117/ 1612 1.41 (1.05-1.88) 1.28 (0.95-1.71)
Quartile 3 135/ 1607 1.55 (1.17-2.05) 1.32 (0.99-1.76)
Quartile 4 223/ 1608 2.64 (2.04-3.43) 2.08 (1.58-2.74)
P for trend <0.001 <0.001
Men
Quartile 1 27/ 650 1.00 (reference) 1.00 (reference)
Quartile 2 53/ 652 1.77 (1.11-2.81) 1.61 (1.01-2.58)
Quartile 3 65/ 649 2.21 (1.41-3.46) 1.84 (1.16-2.92)
Quartile 4 117/ 650 4.37 (2.87-6.66) 3.73 (2.40-5.78)
P for trend <0.001 <0.001
Women
Quartile 1 48/ 959 1.00 (reference) 1.00 (reference)
Quartile 2 65/ 967 1.23 (0.85-1.79) 1.12 (0.77-1.64)
Quartile 3 69/ 952 1.20 (0.83-1.74) 1.01 (0.69-1.47)
Quartile 4 107/ 958 1.86 (1.32-2.62) 1.42 (0.99-2.03)
P for trend <0.001 0.010
Model 1 was adjusted for age and sex (when appropriate). Model 2 was adjusted for age, sex (when appropriate), body mass index, hypertension, 
total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and angina pectoris.
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After exclusion of participants with coronary heart disease at baseline and additionally censor-
ing participants at the occurrence of coronary heart disease before heart failure during follow-up, 
the hazard ratios attenuated compared to the hazard ratios found for the total cohort (table 3). The 
multivariable-adjusted hazard ratio for the highest compared to the lowest quartile of CRP in men 
declined from 3.73 (95% CI 2.40-5.78) to 2.64 (95% CI 1.54-4.53), whereas in women, the proportionate 
decline was smaller, ranging from 1.42 (95% CI 0.99-2.03) to 1.39 (95% CI 0.92-2.12).
Additional adjustment for cardiac medication and antithrombotic and serum lipid-reducing agents 
did not materially change the results.
Additional analyses
To determine which covariates were responsible for the decline of the risk estimates after adjustment 
for established cardiovascular risk factors in women, we added body mass index, hypertension, total 
cholesterol, HDL-cholesterol, smoking, diabetes mellitus and angina pectoris to model 1 (CRP with 
age) one at a time, excluding participants with prevalent coronary heart disease. Adding hyperten-
sion yielded hazard ratios of 1.2 (95% CI 0.8-1.8), 1.2 (95% CI 0.8-1.8) and 1.7 (95% CI 1.1-2.5) for the 
second, third and fourth quartile of CRP, respectively; adding body mass index resulted in hazard 
Table 3. Hazard ratios with 95% confidence intervals for developing heart failure in quartiles of C-reactive 
protein levels in participants without prevalent coronary heart disease.
Model 1 Model 2
Events/ participants Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Total
Quartile 1 59/ 1423 1.00 (reference) 1.00 (reference)
Quartile 2 94/ 1423 1.24 (0.87-1.75) 1.14 (0.80-1.62)
Quartile 3 106/ 1426 1.36 (0.97-1.90) 1.17 (0.82-1.65)
Quartile 4 157/ 1419 2.16 (1.58-2.96) 1.71 (1.23-2.38)
P for trend <0.001 <0.001
Men
Quartile 1 22/ 537 1.00 (reference) 1.00 (reference)
Quartile 2 40/540 1.32 (0.75-2.34) 1.30 (0.72-2.32)
Quartile 3 41/ 534 1.45 (0.83-2.54) 1.29 (0.72-2.29)
Quartile 4 69/ 536 3.02 (1.82-5.00) 2.64 (1.54-4.53)
P for trend <0.001 <0.001
Women
Quartile 1 37/ 887 1.00 (reference) 1.00 (reference)
Quartile 2 54/ 888 1.20 (0.78-1.87) 1.10 (0.71-1.72)
Quartile 3 64/ 883 1.24 (0.81-1.91) 1.05 (0.68-1.62)
Quartile 4 89/ 886 1.81 (1.21-2.70) 1.39 (0.92-2.12)
P for trend <0.005 0.042
Model 1 was adjusted for age and sex (when appropriate). Model 2 was adjusted for age, sex (when appropriate), body mass index, hypertension, 
total cholesterol, HDL-cholesterol, smoking, diabetes mellitus and angina pectoris.
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ratios of 1.1 (95% CI 0.7-1.7), 1.1 (95% CI 0.7-1.7) and 1.6 (95% CI 1.0-2.4), respectively; and adding 
HDL-cholesterol resulted in hazard ratios of 1.2 (0.8-1.8), 1.2 (0.8-1.8) and 1.7 (1.2-2.6), respectively. 
Adding the remaining risk factors did not materially change the risk estimates.
Furthermore, both for men and women, age, body mass index, hypertension, total cholesterol, HDL-
cholesterol, smoking, diabetes mellitus and angina pectoris were entered into the Cox proportional 
hazards model by forward selection. Doing so, in women, age (p<0.001), hypertension (p=<0.001), 
body mass index (p=0.01) and current smoking (p=0.01) remained in the model, whereas in men, age 
(p<0.001), diabetes mellitus (p<0.001), and angina pectoris (p<0.001) remained in the model.
Discussion
In the present population-based study, CRP was a strong predictor of heart failure. The association 
persisted after exclusion of participants with coronary heart disease at baseline and after account-
ing for incident coronary heart disease in the follow-up period. The interaction between CRP and 
sex was highly significant. In men, the association was stronger than in women. After adjustment for 
established cardiovascular risk factors, in men, the association proved to be independent, whereas in 
women, the association strongly attenuated and lost statistical significance.
The strengths of our study include its population-based nature and the availability of >500 inci-
dent heart failure cases. Furthermore, a high-sensitivity CRP assay was used, giving us the possibility 
to examine steady-state CRP levels in the low reference range. Standardized assessment of various 
cardiovascular risk factors at baseline enabled us to account for possible confounding. Finally, we 
were able to account for incident coronary heart disease in our analysis.
There are several reasons for examining the association of inflammatory markers with heart fail-
ure.1 Firstly, the biological role of inflammatory markers in the development of heart failure has been 
studied extensively, and the results suggest that many aspects of the syndrome of heart failure could 
be explained by the known biological effects of proinflammatory cytokines. These aspects include 
left ventricular dysfunction, pulmonary edema, left ventricular remodeling, myocyte hypertrophy, 
progressive myocyte loss through apoptosis and endothelial dysfunction. Furthermore, expression of 
cytokines is in direct relation to worsening New York Heart Association functional classification, which 
is very similar to the expression of the classic neurohormones (e.g., angiotensin II and norepinephrine) 
that are believed to play an important role in disease progression in heart failure. Moreover, there is 
growing evidence that critical interactions are present between inflammatory mediators and the me-
diators of the classic neurohormonal systems, and that many of the conventional therapies for heart 
failure may work, at least in part, through the modulation of proinflammatory cytokines.
Various analytes have been used to examine the association between inflammation and cardiovas-
cular disease. However, only some of them are currently employable in clinical settings after consider-
ation of the stability of the analyte, the commercial availability of assays, the standardization of those 
assays to allow comparison of results and the precision of the assays as measured by the coefficient 
of variation. Presently, comparison of the various inflammatory markers with respect to the above-
mentioned characteristics favors CRP from the clinical chemistry perspective.2
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Recent research has implied that CRP is associated with heart failure. Elevated CRP levels have 
been shown to result in an adverse prognosis in heart failure patients,3-5 and elevated CRP levels seem 
to be predictive of the development of heart failure in high-risk participants.6,7
Until now, few population-based studies have examined the association between CRP and heart 
failure. Within the Cardiovascular Health Study cohort, which is based on Medicare eligibility lists at 
four locations, increased CRP was an independent predictor of heart failure in participants without 
prevalent heart failure.8 The association persisted after adjustment for clinically prevalent as well as 
subclinical atherosclerotic disease, and for incident coronary heart disease. The Framingham Heart 
Study demonstrated that participants with CRP serum levels ≥5 mg/L experienced a significantly in-
creased risk of heart failure, even after adjustment for prevalent cardiovascular disease and the oc-
currence of myocardial infarction on follow-up.9 However, this study was limited by the use of a low-
sensitivity CRP assay, and therefore could not discriminate between CRP levels in the low reference 
range. Finally, in the Health ABC study, high levels of CRP independently predicted the incidence of 
events of heart failure.10 However, in this study, incident heart failure was defined as any overnight 
hospitalization for this diagnosis, which does not account for all heart failure cases in a population. 
Furthermore, although participants with cardiovascular disease at baseline were excluded, there was 
no adjustment for incident cardiovascular disease.
In all of the above-mentioned studies, sex-specific relative risks of developing heart failure were 
not provided. However, there is evidence that there are gender differences in heart failure. Women are 
more likely to have preserved left ventricular systolic function; systolic dysfunction is more common 
in men and diastolic dysfunction tends to occur more often in women. Heart failure that occurs after 
myocardial infarction is characterized by profound ventricular dilation, wall thinning, increased heart 
size, eccentric hypertrophy and systolic dysfunction. Heart failure that occurs due to long-standing 
hypertension is characterized by (concentric) left ventricular hypertrophy, increased myocardial mass 
and diastolic dysfunction, especially in the early stages. Therefore, men have coronary artery disease 
as an underlying factor for heart failure more frequently than women. Women are more likely to have 
hypertension as an underlying factor.19,20 In the present study, gender differences in the association 
between CRP and risk of heart failure were found. In women, the risk estimates were lower, and fur-
thermore, adjustment for established cardiovascular risk factors resulted in a larger proportionate 
decline of the risk estimates. This suggests that some of the established risk factors for which we 
adjusted may play a larger part in the development of heart failure in women than in men. Separate 
evaluation of the risk factors in women and application of a forward selection model implicated hy-
pertension and body mass index. This concurs with the higher prevalence of diastolic dysfunction 
generally found in women. Contrastingly, applying forward selection in men resulted in a model that 
included angina pectoris and diabetes mellitus, suggesting that coronary heart disease, and thus sys-
tolic dysfunction, may be important in the development of heart failure in men. Moreover, although 
men and women were found to have equal risks of coronary heart disease for increasing CRP levels 
(data not shown), the hazard ratios for developing heart failure in men declined after accounting for 
prevalent and incident coronary heart disease, whereas in women, the proportionate decline was 
much smaller. Once again this suggests that in men, coronary heart disease may play a more im-
portant part in the development of heart failure than in women. In summary, these results may be a 
reflection of gender differences in the etiology of heart failure.
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Some aspects of this study warrant further consideration. Firstly, serum samples had been stored 
for approximately ten years at -20ºC before CRP measurements were carried out. We compared these 
CRP measurements with CRP measurements in serum that had been stored at -80ºC in a random 
sample of 29 participants. Although the median CRP serum level was somewhat lower in -20ºC serum, 
Spearman’s correlation coefficient for the association between CRP serum level in -20ºC samples and 
-80ºC samples was highly significant (correlation coefficient 0.99; p<0.001). Therefore, associations 
should be unaffected. Secondly, CRP measurements were lacking for 1283 out of 7720 participants 
at risk for heart failure. These participants were mainly persons who did not come to the research 
center at baseline. In these participants, 176 cases of heart failure occurred (13.7%), versus 551 cases 
in 6437 participants with CRP measurements available (8.6%). These 1283 participants were older, 
consisted for a higher percentage of women, had a lower percentage of current smokers, and had a 
higher prevalence of myocardial infarction. We believe that the higher heart failure incidence in these 
participants may be attributable to their higher age and worse health status. However, we consider 
it unlikely that this could have affected the difference we found between the sexes in the association 
of CRP with heart failure.
In conclusion, CRP is strongly and independently associated with occurrence of heart failure in 
men. In women, the association does not persist after accounting for established cardiovascular risk 
factors. The results of this study provide further support for the hypothesis that CRP may participate 
in the development and progression of heart failure, and suggest that the association between CRP 
and heart failure is different in men and women, possibly reflecting gender differences in the etiology 
of heart failure.
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Chapter 5.4
Lipoprotein-associated phospholipase A2 
activity and heart failure
Abstract
Aims. Evidence is accumulating that inflammation plays a role in the pathophysiology of heart failure. 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has pro-inflammatory properties. We investigat-
ed whether Lp-PLA2 activity is associated with heart failure.
Methods and results. Lp-PLA2 activity was determined in a random sample of 1820 subjects from 
the Rotterdam Study, a population-based cohort study among persons aged 55 years and over. Dur-
ing a mean follow up of 6.7 years, 94 heart failure cases occurred. We excluded participants with heart 
failure or coronary heart disease at baseline and we accounted for incident coronary heart disease 
during follow-up. We used Cox proportional hazards models to compute hazard ratios adjusted for 
age, sex, non-HDL cholesterol, HDL cholesterol, body mass index, systolic blood pressure, diastolic 
blood pressure, hypertension, diabetes mellitus, smoking and C-reactive protein. The hazard ratio per 
unit increase of Lp-PLA2 activity was 1.03 (95% confidence interval, 1.01 to 1.05), P for trend = 0.011. 
Hazard ratios for the second, third and fourth quartiles were 1.06 (0.55 to 2.04), 1.43 (0.73 to 2.81) 
and 2.33 (1.21 to 4.49), respectively, using the lowest quartile of Lp-PLA2 activity as the reference 
category.
Conclusion. This study suggests that Lp-PLA2 activity is independently associated with incident 
heart failure.
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Introduction
During the last fifteen years, an interest has developed for the potential role of inflammatory media-
tors in the pathofysiology of heart failure. Associations have been found between elevated inflamma-
tory markers, such as interleukin-61, tumor necrosis factor-α2 and C-reactive protein (CRP)3 and con-
gestive heart failure. It has been shown that inflammatory mediators may influence left ventricular 
remodeling, left ventricular function and pulmonary edema.4,5 Furthermore, a correlation has been 
found between high blood levels of these inflammatory markers and worsening functional NYHA 
class, increased hospitalization rates and poorer survival of heart failure patients.6
Recently, several studies have found an independent association between the inflammatory mark-
er lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of coronary heart disease.7-11 Lp-PLA2 
is an enzyme that circulates in the blood bound to low density lipoprotein (LDL) cholesterol. The en-
zyme has pro-inflammatory properties because of its capacity to hydrolyze oxidized phospholipids.12 
However, it is also suggested to have anti-inflammatory properties because of its ability to hydrolyze 
platelet-activating factor.13,14 The relationship found between Lp-PLA2 and coronary heart disease 
suggests that the pro-inflammatory properties of Lp-PLA2 outweigh its anti-inflammatory proper-
ties.
To our knowledge no studies have yet been conducted on Lp-PLA2 as a predictor of heart failure. 
Therefore, we investigated the association between Lp-PLA2 and risk of heart failure in the Rotterdam 
Study, a population-based cohort study among men and women aged 55 years and over.
Methods
Rotterdam Study
The Rotterdam Study is a population-based cohort study comprising 7983 men and women aged 55 
years and over. Its overall aim is to assess the occurrence of and risk factors for chronic diseases in the 
elderly. A detailed description of the objectives and methods of the Rotterdam Study has been given 
elsewhere.15 All residents of a Rotterdam suburb aged 55 and over were invited to participate in the 
study and 78% participated. Baseline measurements started in 1990 and were completed in 1993.
The Medical Ethics Committee of Erasmus Medical Center, Rotterdam, approved the study. All par-
ticipants gave written informed consent. This study complies with the Declaration of Helsinki.
Study Population
Lp-PLA2 activity was determined in a random subcohort of 1820 subjects. Prevalent heart failure 
cases at baseline (n = 47) were excluded for the current analysis. In addition, 183 subjects were ex-
cluded because they had a history of myocardial infarction, a history of coronary artery bypass graft-
ing (CABG) or a history of percutaneous transluminal coronary angioplasty (PTCA) at baseline, leaving 
1590 subjects, who were used for analysis.
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Measurement of Lp-PLA2 activity
Plasma aliquots prepared from non-fasting blood samples were collected at baseline and stored at 
-80°C. Lp-PLA2 activity was measured with a high throughput radiometric activity assay, as described 
in detail previously.11 Lp-PLA2 activity was expressed as nanomoles of platelet-activating factor hy-
drolyzed per minute per millilitre of plasma samples.
Prior to analysis of plasma samples from the Rotterdam Study, a pre-study validation was con-
ducted to determine the reliability of the LpPLA2 activity assay. Six plasma samples were tested in 
triplicate, and the coefficient of variation (CV) for intra-assay precision ranged from 3.51-8.96%. To 
assess inter-assay precision, six plasma samples were tested on three occasions, and CV ranged from 
8.48 -15.08%. Three cycles of freeze-thaw of frozen plasma did not result in appreciable loss of activity. 
The assay was therefore considered suitable for analysis of the Rotterdam Study samples, which were 
tested in duplicate. Samples were re-tested if the replicate CV was > 25%. The range of detection was 
8-150 nmol/min per mL.
Measurement of covariates at baseline
At baseline, a trained interviewer visited all participants at home using a computerized questionnaire. 
The information obtained included current health status, medical history, drug use and smoking 
behavior. Additionally, established cardiovascular risk factors were measured at the research center. 
Height and weight were measured and the body mass index was calculated (weight (kg)/height2 (m)). 
Blood pressure was measured at the right brachial artery with a random-zero sphygmomanometer 
with the participant seated. We defined hypertension as a systolic blood pressure ≥160 mmHg or a 
diastolic blood pressure ≥100 mmHg or the use of blood pressure lowering medication with an indi-
cation for hypertension.
Non-fasting blood samples were drawn and total cholesterol and high-density lipoprotein (HDL) 
cholesterol were measured within two weeks, as described previously.16 Non-HDL cholesterol was 
computed by subtracting HDL cholesterol from total cholesterol. LDL cholesterol was determined in 
fasting blood samples in 120 randomly selected subjects by use of an enzymatic method (Roche). We 
calculated Pearson’s correlation coefficient to compute the correlation of non-HDL cholesterol with 
LDL cholesterol, r = 0.97, P < 0.001.We defined diabetes mellitus as a random or post load glucose 
level ≥11.1 mmol/l or the use of blood glucose lowering medication.17 Using a nephelometric method 
(Immage, Beckman Coulter), we measured CRP in blood samples kept frozen at –20°C.
A 12-lead resting electrocardiogram (ECG) was recorded with an ACTA electrocardiograph (ESAOTE, 
Florence, Italy) at a sampling frequency of 500Hz, and stored digitally. All ECGs were processed by the 
Modular ECG Analysis System (MEANS) to obtain ECG measurements and interpretations.18 Myocar-
dial infarction found on ECG was based on a comprehensive set of criteria that partly derive from the 
Minnesota code.19 A history of myocardial infarction was considered present in case of a self-report 
of myocardial infarction confirmed by electrocardiography (ECG) or additional clinical information, 
or the presence of an ECG characteristic of prior myocardial infarction. In identifying incident myo-
cardial infarctions (ICD-10 code I21), all available information, which included ECG, cardiac enzyme 
levels, and the clinical judgment of the treating specialist, was used. Revascularization procedures 
were identified by review of hospital discharge letters from the medical specialist.
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Ascertainment of heart failure cases
Assessment of prevalent heart failure at the baseline examination in the Rotterdam Study has been 
described in detail earlier.20,21 Briefly, a validated score was used, similar to the definition of heart fail-
ure of the European Society of Cardiology.22 This score was based on the presence of at least two 
symptoms suggestive of heart failure (shortness of breath, ankle swelling and pulmonary crepita-
tions) or use of medication for the indication of heart failure, in combination with objective evidence 
of cardiovascular disease.
Information on the presence of heart failure at baseline was obtained for all participants using 
either of the following three methods: interview questions on indication of cardiovascular medica-
tion and breathlessness, linkage of the Rotterdam Study database to a database containing hospital 
discharge diagnoses from all hospitals in the Rotterdam area as of 1 January 1991, and screening of 
all medical records in retrospect for the occurrence of heart failure in the majority of participants of 
the Rotterdam Study.
For the present study, follow-up started at the baseline examination, from 1990 till 1993 and was 
complete until 1 January 2000. Follow-up has been described in detail previously.21 Briefly, cases of 
incident heart failure were obtained by continuously monitoring participants of the Rotterdam Study 
for the occurrence of heart failure during follow-up through automated linkage with files from gen-
eral practitioners. Each participant’s medical record was fully screened for incident heart failure. All 
available data on these events, such as hospital discharge letters and notes from general practitio-
ners, were copied from the medical records. Apart from this systematic follow-up procedure, we used 
verified hospital discharge diagnoses for case finding, gathered from all hospitals in the Rotterdam 
area as described above. The diagnosis of heart failure was classified as definite, probable, possible or 
unlikely.21 Two research physicians independently classified all information on potential heart failure 
events. If there was disagreement, a consensus was reached in a separate session. Finally, a cardiolo-
gist verified all probable and possible cases, and all cases in which the two physicians could not reach 
consensus. If the cardiologist disagreed with the research physicians, the cardiologist’s judgement 
was considered decisive. The research physicians and the cardiologist based their decisions on the 
same data. Only definite and probable cases were included in the analyses.
Statistical analysis
To compare the baseline characteristics of the random sub-cohort to the remainder of the Rotter-
dam Study we used a χ2 test for dichotomous variables, a t-test for continuous variables and a Mann-
Whitney test for CRP, because its distribution was skewed. We used ANCOVA to display age- and sex 
adjusted baseline characteristics of the participants in different Lp-PLA2 activity quartiles. We log-
transformed CRP because of its skewed distribution and we computed the geometric mean. We com-
puted the standard deviation and interquartile range from the standard error. To compute P-value for 
trend for the baseline characteristics, we used logistic regression for dichotomous variables and linear 
regression for continuous variables. In both cases, continuous plasma values of Lp-PLA2 activity were 
used as the independent variable.
We used Cox proportional hazards models to evaluate the association of Lp-PLA2 activity with risk 
of heart failure. Subjects were censored at the time of occurrence of either heart failure, death or at 
the end of the study period. Furthermore, we censored subjects at the time of occurrence of myocar-
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dial infarction, PTCA or CABG if these took place before the occurrence of heart failure, to account for 
coronary heart disease. The proportional hazards assumption was tested by drawing log minus log 
plots of the survival function, which confirmed that the assumption was met. In model 1 we adjusted 
for age and sex. Lp-PLA2 is tightly associated with lipoproteins; in humans it is predominantly located 
on LDL, and to a smaller extent on HDL. Because these factors were most likely to be confounders, in 
model 2, we additionally adjusted for non-HDL cholesterol and HDL cholesterol. In model 3 we addi-
tionally adjusted for body mass index, systolic blood pressure, diastolic blood pressure, hypertension, 
smoking status, diabetes mellitus and C-reactive protein. First, we entered the continuous plasma val-
ues of Lp-PLA2 activity into the models, to obtain the hazard ratio for heart failure per unit increase in 
Lp-PLA2 activity. By this means we also obtained the P for trend. Second, to allow for the demonstra-
tion of a possibly non-linear association, we made quartiles of Lp-PLA2 activity, with cut-points 35.9, 
42.9 and 50.8 nmol/min per mL plasma and used the lowest quartile as the reference category.
To compare survival time until the occurrence of heart failure in the quartiles of Lp-PLA2 activity, C-
reactive protein and non-HDL cholesterol we made event free survival curves adjusted for age and sex.
We conducted a subgroup analysis to compare the association between Lp-PLA2 activity and 
heart failure in subjects with a non-HDL cholesterol level below and above the median (cutpoint 5.20 
mmol/L). Lp-PLA2 was dichotomized in this analysis using the median as cutoff point (42.9 nmol/min 
per mL plasma). We adjusted for age, sex, HDL cholesterol, body mass index, systolic blood pressure, 
diastolic blood pressure, hypertension, smoking status, diabetes mellitus and CRP. We did a similar 
subgroup analysis in strata of C-reactive protein (cutpoint 1.79 mg/L), adjusting for non-HDL choles-
terol instead of C-reactive protein in the Cox proportional hazards model.
To test for interaction between Lp-PLA2 activity and non-HDL cholesterol and CRP, we entered 
interaction terms into the model using continuous values of Lp-PLA2 activity instead of quartiles of 
Lp-PLA2 activity and using non-HDL cholesterol and CRP as continuous variables. In this analysis we 
adjusted for age and sex.
Values for covariates were missing in <3%, except for C-reactive protein (6% missing values). We 
used single imputation based on expectation maximization to handle missing values.
Results
The mean follow-up time until censoring was 6.7 years (standard deviation 2.3 years). During follow-
up, 113 incident heart failure cases occurred. Of these cases, 19 were preceded by coronary heart 
disease. Therefore, 94 incident cases of heart failure were left for analysis.
Table 1 shows the baseline characteristics of the total random cohort and the remainder of the 
Rotterdam Study. The characteristics of the random cohort were similar to the remainder of the Rot-
terdam Study except for age, systolic blood pressure and hypertension. Subjects in the random co-
hort were slightly younger (69.1 versus 71.1 years), had a lower systolic blood pressure (138.2 mm Hg 
versus 139.9 mm Hg) and had a lower prevalence of hypertension (33.1% versus 37.1%). Table 2 shows 
the baseline characteristics of participants in different quartiles of Lp-PLA2 activity adjusted for age 
and sex (when appropriate) and the P-value for trend. In all linear regression models we used, the 
residuals were normally distributed with a constant variance. Quartiles with a higher Lp-PLA2 activity 
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Table 1. Baseline characteristics of the study population.
Variable
Random Cohort
(n = 1820)
Remainder Rotterdam Study
(n = 6163)
P-value
Age, years 69.1 ± 9.1 71.1 ± 9.9 <0.01
Men, % 38.3 39.1 0.55
Body mass index, kg/m2 26.2 ± 3.7 26.3 ± 3.8 0.30
Systolic blood pressure, mm Hg 138.2 ± 22.3 139.9 ± 22.4 <0.01
Diastolic blood pressure, mm Hg 73.3 ± 11.2 73.8 ± 11.8 0.12
Hypertension, % 33.1 37.1 <0.01
Non-HDL cholesterol, mmol/L 5.30 ± 1.24 5.24 ± 1.23 0.10
HDL-cholesterol mmol/L 1.35 ± 0.38 1.34 ± 0.37 0.38
Diabetes mellitus, % 9.8 10.7 0.31
Smokers, %
- Current 23.0 22.5 0.68
- Former 41.7 40.4 0.34
- Never 35.3 37.0 0.18
CRP, mg/L* 1.78 (0.90-3.59) 1.93 (0.92-3.71) 0.07
Continuous variables are expressed as mean ± standard deviation. Categorical variables are expressed as percentage.
* Median and interquartile range because of skewed distribution.
Table 2. Baseline characteristics according to quartiles of Lp-PLA2 activity.
Variables Quartile 1 Quartile 2 Quartile 3 Quartile 4
P-value 
for trend
Age, years 68.6 ±9.1 69.7 ±9.0 68.8 ±9.0 69.5 ±9.1 0.29
Men, % 27.1 35.2 42.0 48.9 <0.01
Body Mass Index, kg/m2 25.8 ±3.6 26.1 ±3.6 26.5 ±3.6 26.5 ±3.6 <0.01
Systolic blood pressure, mm Hg 135.9 ±21.5 138.4 ±21.4 137.7 ±21.4 140.8 ±21.5 <0.01
Diastolic blood pressure, mm Hg 72.8 ±11.2 73.8 ±11.2 73.4 ±11.2 73.3 ±11.2 0.84
Hypertension, % 29.0 30.7 33.3 39.5 <0.01
Non-HDL cholesterol, mmol/L 4.49 ±1.09 5.13 ±1.08 5.53 ±1.06 6.06 ±1.08 <0.01
HDL-cholesterol mmol/L 1.50 ±0.36 1.38 ±0.36 1.28 ±0.36 1.25 ±0.36 <0.01
CRP, mg/L* 1.67 (1.62-1.73) 1.69 (1.64-1.75) 1.83 (1.77-1.89) 1.97 (1.91-
2.04)
<0.01
Diabetes, % 8.8 9.6 11.0 10.0 0.18
Smokers, %
- Current 24.5 20.6 22.5 24.3 0.76
- Former 42.7 44.0 42.7 37.5 0.10
- Never 32.8 35.4 34.8 38.2 0.05
Continuous variables are expressed as mean ± standard deviation. Categorical variables are expressed as percentage. All (geometric) means and 
percentages are adjusted for age and sex, except for age (only adjusted for sex) and sex (only adjusted for age).
*Geometric mean and interquartile range because of skewed distribution.
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contained a higher percentage of men and hypertensive participants. They had a significantly higher 
body mass index, systolic blood pressure, non-HDL cholesterol and CRP. HDL-cholesterol was lower in 
participants within higher quartiles of Lp-PLA2 activity.
Lp-PLA2 activity was associated with risk of heart failure (Table 3). After adjustment for age and 
sex, the hazard ratio for heart failure per unit increase in Lp-PLA2 activity was 1.02 (95% confidence 
interval (CI) 1.00-1.03), P = 0.026. After additional adjustment for non-HDL cholesterol and HDL cho-
lesterol, this was 1.02 (95% CI 1.00-1.04), P = 0.024, and after additional adjustment for known car-
diovascular risk factors, 1.03 (95% CI 1.01-1.05), P = 0.011. Participants in the second, third and fourth 
quartiles of Lp-PLA2 activity had a hazard ratio of 0.99 (95% CI 0.52-1.86), 1.27 (95% CI 0.68-2.40), 
1.93 (95% CI 1.09-3.42), respectively, for heart failure, using the first quartile of Lp-PLA2 activity as the 
reference category and adjusting for age and sex. Using model 2, this was 1.01 (95% CI 0.53-0.92), 1.34 
(0.69-2.60) and 2.16 (95% CI 1.13-4.11), respectively. Using model 3, this further increased to 1.06 (95% 
CI 0.55-2.04), 1.43 (95% CI 0.73-2.81) and 2.33 (95% CI 1.21-4.49), respectively.
The event-free survival curve according to quartiles of Lp-PLA2 activity shows that the survival 
time until the occurrence of heart failure was higher in the lowest quartile than in the highest quartile 
(Figure 1). The curve also illustrates that the difference in risk between quartiles 1 and 4 is rather 
consistent over time. Figure 2 and 3 show the event free survival curve of C-reactive protein and non-
HDL cholesterol, respectively. Although C-reactive protein was significantly related to the event free 
survival time, no clear association was found for non-HDL cholesterol.
Figure 4 shows the results of our subgroup analyses. The hazard ratios for heart failure associated 
with Lp-PLA2 activity for the subgroups below and above the median of non-HDL cholesterol level 
were 1.89 (95% CI 1.05-3.39) and 1.77 (95% CI 0.83-3.79), respectively. The hazard ratio was somewhat 
larger in subjects with a non-HDL cholesterol below the median, but no significant interaction was 
found between Lp-PLA2 activity and non-HDL cholesterol (P for interaction = 0.817) in relation to risk 
of heart failure. The hazard ratio for the subjects with a CRP below the median was 3.83 (95% CI 1.64-
8.93), which was higher than the hazard ratio for the subjects with CRP above the median, namely 
1.26 (95% CI 0.71-2.23). However, the interaction term for Lp-PLA2 activity and CRP was not significant 
(P for interaction = 0.364).
Table 3. Hazard ratios for heart failure according to quartiles of Lp-PLA2 activity
Lp-PLA2 Cases/ Hazard Ratio (95% confidence interval)
(nmol/min per mL) Subjects Model 1 Model 2 Model 3
Unit increase 94/ 1590 1.02 (1.00-1.03) 1.02 (1.00-1.04) 1.03 (1.01-1.05)
P-value for trend 0.026 0.024 0.011
Quartile 1 18/ 397 1 (reference) 1 (reference) 1 (reference)
Quartile 2 20/ 398 0.99 (0.52-1.86) 1.01 (0.53-1.92) 1.06 (0.55-2.04)
Quartile 3 21/ 398 1.27 (0.68-2.40) 1.34 (0.69-2.60) 1.43 (0.73-2.81)
Quartile 4 35/ 397 1.93 (1.09-3.42) 2.16 (1.13-4.11) 2.33 (1.21-4.49)
Model 1 adjusted for age and sex; model 2 adjusted for age, sex, non-HDL cholesterol and HDL cholesterol; model 3 adjusted for age, sex, non-
HDL cholesterol, HDL cholesterol, body mass index, systolic blood pressure, diastolic blood pressure, hypertension, diabetes mellitus, smoking 
status and C-reactive protein.
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Figure 1. Survival time until the occurrence of heart failure according to quartiles of Lp-PLA2, adjusted for 
age and sex.
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Figure 2. Survival time until the occurrence of heart failure according to quartiles of C-reactive protein 
(CRP), djusted for age and sex.
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Figure 3. Survival time until the occurrence of heart failure according to quartiles of non-HDL cholesterol, 
adjusted for age and sex.
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Discussion
In the present population-based cohort study, Lp-PLA2 activity was an independent predictor of 
heart failure. The association persisted after we adjusted for known cardiovascular risk factors and 
C-reactive protein. A significant trend was seen, and subjects in the highest quartile had no less than 
a doubled risk of developing heart failure compared to subjects in the lowest quartile, even though 
we excluded subjects with prevalent coronary heart disease at baseline and censored subjects with 
incident coronary heart disease during follow-up. This suggests that the association found between 
Lp-PLA2 activity and heart failure is independent of coronary heart disease.
To our knowledge, this is the first study performed on the association between Lp-PLA2 and risk 
of heart failure. The present study is a population-based prospective cohort study, which guards our 
study from selection and recall bias. Strengths of our study include the ability to account for possible 
Figure 4. Hazard ratios for heart failure associated with Lp-PLA2 activity in strata of non-HDL cholesterol 
level and C-reactive protein.
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confounding by incorporating established cardiovascular risk factors into the statistical models. Fi-
nally, we were able to account for prevalent and incident coronary heart disease in our analysis.
The pathophysiology of heart failure is complex. While heart failure was once merely considered 
to be a cardiocirculatory impairment, now it is known that the neuroendocrine system is involved. 
Evidence is accumulating that inflammation also plays a direct role in the pathophysiology of heart 
failure. In former studies several inflammatory markers, such as interleukin-61, tumor necrosis factor-
α2 and C-reactive protein3, have been associated with incidence of heart failure. Inflammatory media-
tors have been found to affect left ventricular remodeling, left ventricular dysfunction, pulmonary 
edema, fetal gene expression and cardiomyopathy.4,5 Finally, a correlation has been found between 
high blood levels of inflammatory markers and poorer prognosis in heart failure patients.6
In the Atherosclerosis Risk in Communities study, an association between Lp-PLA2 and incident 
coronary heart disease was present after adjustment for age, sex and race. After further adjustments 
for cardiovascular risk factors, the association was only present in subjects with a low LDL cholesterol.9 
Our subgroup analysis showed that the association found between Lp-PLA2 activity and heart failure 
is present in subjects with a non-HDL cholesterol level below the median as well as in subjects with 
a non-HDL cholesterol level above the median, although in the latter group the association lacked 
significance. The association between Lp-PLA2 and heart failure was much stronger in subjects with 
a C-reactive protein level below the median than in subjects with a C-reactive protein level above the 
median. We have no explanation for this difference in risk estimates. The interaction between Lp-PLA2 
and C-reactive protein was not significant, so the difference may be due to chance.
Several studies have investigated the association between LDL cholesterol and heart failure.23-25 
Although the Framingham Study found a positive relation,26 subsequent studies were not able to 
confirm this. In our study, we also failed to find a clear relation between non-HDL cholesterol and 
risk of heart failure. Lp-PLA2 is an enzyme bound to LDL cholesterol and therefore Lp-PLA2 activity 
is highly correlated with LDL cholesterol levels. In the present study, we found that the association of 
Lp-PLA2 with heart failure was independent of non-HDL cholesterol. We used non-HDL cholesterol for 
adjustment, since no measurements of LDL cholesterol were available. Because of the high correla-
tion between LDL cholesterol and non-HDL cholesterol in a random sample of our cohort (r = 0.97, P < 
0.001), we believe that residual confounding by LDL cholesterol cannot explain our results.11
In conclusion, our findings suggest that Lp-PLA2 activity is independently associated with risk of 
heart failure. Our study provides further evidence inflammation is involved in the etiology of heart 
failure.
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The female advantage in cardiovascular 
disease
Abstract
The female advantage in coronary heart disease occurrence is not completely understood. To charac-
terize gender differences in cardiovascular disease by vascular site, the authors compared degrees of 
coronary, carotid, peripheral, and aortic atherosclerosis in men and women aged ≥55 years from the 
population-based Rotterdam Study (Rotterdam, the Netherlands). Data were collected between 1997 
and 2000. A subset of 2,013 participants had data on both coronary calcification and one or more 
measures of extracoronary atherosclerosis, including intima-media thickness (IMT), carotid plaques, 
ankle-arm index (AAI), and aortic calcification. The multivariable adjusted male:female odds ratios for 
calcium score > 1,000 were 7.8 (95% confidence interval (CI): 3.2, 19.3), 5.4 (95% CI: 2.8, 10.2), and 3.0 
(95% CI: 1.7, 5.2) in the lowest, middle, and highest age tertiles, respectively. For IMT > 1.0 mm, severe 
carotid plaques, AAI < 0.90, and severe aortic calcification, ratios did not decline with age. Overall 
multivariable-adjusted male:female odds ratios for these measures were 2.9 (95% CI: 2.0, 4.1), 2.0 (95% 
CI: 1.4, 2.8), 0.9 (95% CI: 0.7, 1.3), and 1.0 (95% CI: 0.8, 1.5), respectively. The authors conclude that 
the gender difference in atherosclerosis is larger in the coronary vessels than in other vascular beds. 
Remarkably, it is absent in the aorta and the lower-extremity vessels. Factors causing this site-specific 
gender difference require further investigation.
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Introduction
After two decennia of rigorous research, the remarkable gender difference in coronary heart disease 
occurrence is still not completely understood. It cannot be fully explained by risk factors such as life-
style, lipid profile, and blood pressure.1 The hypothesis that estrogen carries a cardioprotective ef-
fect is still being debated and could not be proven in large randomized controlled trials on estrogen 
therapy.2,3 Although the gender difference is also present to a much smaller extent for stroke and 
peripheral artery disease, it is most prominent for coronary heart disease.4-9 This suggests that gender 
differences in cardiovascular disease may differ according to vascular sites. Autopsy studies support 
such a differential gender effect.10-13 Although studies have been performed in living populations to 
examine gender differences in atherosclerosis at single vascular sites,14-17 to our knowledge, no stud-
ies have been performed in living populations to compare gender differences in atherosclerosis at 
different sites of the vascular tree. To further characterize gender differences in cardiovascular disease 
according to various vascular sites, we compared degrees of coronary, carotid, aortic, and periph-
eral atherosclerosis between men and women in participants aged 55 years or more in a population-
based cohort study.
Materials and Methods
Study population
This study was embedded in the Rotterdam Study, a population-based study aimed at addressing 
the occurrence of and risk factors for chronic diseases in the elderly. The rationale and design of the 
Rotterdam Study have been described elsewhere.18 The study started with a baseline examination 
conducted between 1990 and 1993, which included 7,983 men and women aged 55 years or more 
(78 percent of the eligible population) living in a well-defined suburb of the city of Rotterdam, the 
Netherlands. Follow-up visits took place in 1993–1994 and 1997–1999. From 1997 onwards, partici-
pants through 85 years of age who completed the third phase of the Rotterdam Study were invited to 
participate in the Rotterdam Coronary Calcification Study and to undergo electron-beam computed 
tomography for assessment of coronary calcification in the epicardial coronary arteries.19 The medical 
ethics committee of Erasmus Medical Center, Rotterdam, approved the study. Participants gave writ-
ten informed consent and permission to retrieve information from treating physicians.
Coronary calcification
Imaging was performed with a C-150 Imatron scanner (Imatron, South San Francisco, California), and 
has been described in detail previously.19 Briefly, quantification of coronary calcification was per-
formed with AccuImage software (AccuImage Diagnostics Corporation, South San Francisco, Califor-
nia) displaying all pixels with a density of over 130 Hounsfield Units. A calcium score was obtained as 
proposed by Agatston et al.20 We added the scores for individual calcifications, resulting in a calcium 
score for the entire epicardial coronary system. A calcium scores above 1,000 was considered the 
outcome measure. Interobserver reliability for calcium scoring has been found to be excellent, with 
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correlation coefficients for calcium scores obtained by different observers being greater than 0.99 and 
only small differences in absolute calcium scores being observed.21
Measures of extracoronary atherosclerosis
During the third phase of the Rotterdam Study (1997–1999), several noninvasive measurements of 
atherosclerosis were conducted. A detailed description of the procedures used has been given pre-
viously.22 Ultrasonography of both carotid arteries was performed according to the protocol of the 
Rotterdam Study. Measurements of common carotid intima-media thickness (IMT) involved regions 
of the common carotid arteries proximal to the carotid bulb, starting at a distance of 1 cm from the 
bulb. IMT was determined as the average of mean near- and far-wall measurements, computing the 
average of left and right common carotid IMT. We considered carotid IMT above 1.0 mm to be high 
carotid IMT. In a reproducibility study of IMT measurements carried out among 80 participants of the 
Rotterdam Study, intraclass correlation coefficients between ultrasonographers, readers, and visits to 
the study center were 0.63, 0.88, and 0.74, respectively.23
The left and right common carotid arteries, bifurcations, and internal carotid arteries were evalu-
ated for the presence of atherosclerotic lesions (plaques). A plaque was defined as a focal widening 
relative to adjacent segments, with protrusion into the lumen. The anterior and posterior walls were 
evaluated and the number of affected locations counted. This resulted in a plaque score between 0 
and 6. Carotid plaque scores of 4 or greater were considered severe. A reproducibility study among 166 
Rotterdam Study participants on the assessment of plaques in the carotid bifurcation revealed kappa 
values of 0.59 for the left carotid artery, 0.65 for the right carotid artery, and 0.60 for plaques in either 
side.24 These findings were statistically significant (p < 0.001) and indicated moderate agreement.
Using a random-zero sphygmomanometer, sitting blood pressure was measured at the right up-
per arm, and systolic blood pressure at both ankles (posterior tibial artery) was measured in the su-
pine position. We computed the ratio of systolic blood pressure at the ankles to systolic blood pres-
sure at the arm to obtain the ankle-arm index (AAI). For the current analyses, we used the lowest 
measurement. Because of possible measurement artifacts reflecting the presence of rigid or calcified 
walls, participants with AAIs greater than 1.5 were excluded. AAIs smaller than 0.90 were considered 
anomalous.
Aortic calcification was diagnosed by radiographic detection of calcified deposits in the abdomi-
nal aorta. Lateral abdominal radiographs were made from a fixed distance with the participant seated. 
Calcifications in the abdominal aorta were classified as present when linear densities were seen in an 
area parallel and anterior to the lumbar spine. The extent of aortic calcification was scored accord-
ing to the length of the involved area of the posterior wall, with scores 0–5 corresponding to 0, <1.0, 
1.0–2.4, 2.5–4.9, 5.0–9.9, and ≥10.0 cm. Severe aortic calcification was considered present when the 
length of the area was 5 cm or more. A comparison study conducted in our department involving 
computed tomography among 56 subjects showed that abdominal calcification could be detected 
radiographically in 32 subjects; in all but one of these subjects, calcification was located in the aorta 
on the corresponding computed tomography images.25
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Assessment of covariates
A trained interviewer visited all participants at home and collected information using a computer-
ized questionnaire. Information obtained included current health status, medical history, smoking, 
and medication use, including use of hormone replacement therapy. Clinical measurements were 
obtained during a visit to the research center. Height and weight were measured, and body mass in-
dex (weight (kg)/height (m)2) was calculated. Blood pressure was measured at the right brachial artery 
using a random-zero sphygmomanometer with the participant in a sitting position. Blood samples 
were obtained after overnight fasting. Serum total cholesterol level was determined by an enzymatic 
procedure, and high density lipoprotein (HDL) cholesterol was measured similarly after precipitation 
of the non-HDL fraction.26 Glucose was determined enzymatically by the hexokinase method. Diabe-
tes was defined as the use of antidiabetic medication and/or a fasting glucose level ≥7.0 mmol/liter 
and/or a nonfasting glucose level ≥11.1 mmol/liter.27 Using a nephelometric method (Immage; Beck-
man Coulter, Inc., Fullerton, California), C-reactive protein was measured in serum samples, which 
were kept frozen at −80°C.
Population for analysis
Of the 3,371 participants who completed the third phase of the Rotterdam Study and were eligible 
for electron-beam computed tomography scanning, scans were obtained for 2,063 participants (a 
response of 61 percent). For several reasons (i.e., metal clips from cardiac surgery, severe artifacts, 
and registration errors (electrocardiogram, acquisition), image acquisition data could not be recon-
structed or analyzed for 50 participants. Thus, calcium scores were available for 2,013 participants. 
The present study was conducted in these participants. In this group, IMT, carotid plaque scores, AAI, 
and aortic calcification measurements were available for 1,859, 1,736, 1,926, and 1,753 participants, 
respectively. The analysis was repeated excluding participants with prevalent cardiovascular disease; 
prevalent myocardial infarction, stroke, heart failure, and angina pectoris and claudicatio intermittens, 
both diagnosed by Rose questionnaire,28 were present in 255, 71, 74, 138, and 64 of the 2,013 partici-
pants, respectively. Their exclusion resulted in exclusion of 468 participants, leaving 1,545 participants 
for whom calcium scores were available. In this group, IMT, carotid plaque scores, AAI, and aortic calci-
fication measurements were available for 1,432, 1,341, 1,490, and 1,347 participants, respectively.
Statistical analysis
In the statistical analysis, we first tested for differences in baseline characteristics between men and 
women. For this purpose, we used t tests for continuous variables and chi-squared tests for categori-
cal variables. A Mann-Whitney U test was used for C-reactive protein because of the skewed data 
distribution. Second, we examined the associations of baseline characteristics with measures of ath-
erosclerosis in men and women using linear regression, adjusting for age.
Subsequently, participants were stratified according to gender and age. Age, ranging from 61 to 
85 years, was divided into tertiles (61–67, 68–73, and 74–85 years). Mean values were computed for 
IMT and AAI, and median values were computed for coronary calcium score, carotid plaque score, and 
aortic calcification score because of their skewed distributions, for men and women in strata of age. 
Using logistic regression, male:female odds ratios were calculated for having coronary calcification 
above 1,000, IMT > 1.0 mm, severe carotid plaques, AAI < 0.90, or severe aortic calcification in different 
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age tertiles. In model 1, we adjusted for age. In model 2, we additionally adjusted for body mass index, 
systolic and diastolic blood pressure, total and HDL cholesterol, smoking, diabetes mellitus, C-reactive 
protein, hormone replacement therapy in women, and use of diuretics, beta-blockers, angiotensin-
converting enzyme inhibitors, and lipid-lowering drugs (defined as those with World Health Organi-
zation Anatomical-Therapeutic-Chemical (ATC) code C10; www.whocc.no/atcddd). Analyses were re-
peated after excluding participants with prevalent myocardial infarction, stroke, heart failure, angina 
pectoris, and claudicatio intermittens.
Values for cardiovascular covariates were missing in less than 4 percent of participants, except for 
the presence of diabetes mellitus, for which 6.8 percent of values were missing. These missing values 
were handled by single imputation using an expectation-maximization algorithm. Analyses were per-
formed using SPSS 11.0 for Windows (SPSS, Inc., Chicago, Illinois).
Results
Table 1 shows baseline characteristics of the study population. Mean age was 71.3 years, and the 
population consisted of 46 percent men and 54 percent women. Men had a significantly lower body 
mass index, significantly higher systolic and diastolic blood pressures, significantly lower total and 
HDL cholesterol levels, and significantly higher prevalences of smoking and diabetes mellitus than 
Table 1. Baseline characteristics of the study population.
Variable Total Men Women p value
No. or 
mean
% No. or 
mean
% No. or 
mean
%
No. and % of subjects 2,013 100 933 46 1,080 54
Mean age (years) 71.3 (5.7)* 71.2 (5.6) 71.3 (5.8) 0.77
Mean body mass index† 27.0 (3.9) 26.5 (3.2) 27.4 (4.4) <0.001
Mean systolic blood pressure (mmHg) 143 (21) 144 (21) 142 (21) 0.04
Mean diastolic blood pressure (mmHg) 76 (11) 77 (11) 75 (11) <0.001
Mean total cholesterol level (mmol/liter) 5.8 (1.0) 5.8 (0.9) 6.0 (0.9) <0.001
Mean high density lipoprotein cholesterol level 
(mmol/liter)
1.4 (0.4) 1.2 (0.3) 1.5 (0.4) <0.001
Smoking status (%)
- Never smoker 30 10 47
- Current smoker 16 18 15 <0.001
- Former smoker 54 72 39
Diabetes mellitus (%) 14 16 12 0.01
Median‡ C-reactive protein level (mg/liter) 2.5 (1.3–4.5) 2.6 (1.3–4.6) 2.4 (1.3–4.4) 0.37
Use of hormone replacement therapy (%) 21
Mean age (years) at last menstrual period 48.8 (5.2)
* Numbers in parentheses, standard deviation. † Weight (kg)/height (m)2. ‡ The median value and interquartile range are presented because of 
the skewed distribution of the data.
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did women. Age and C-reactive protein level were similar in men and women. Associations of base-
line characteristics with coronary calcium score, IMT, and AAI showed similar patterns in men and 
women (table 2). For carotid plaques, current smoking and diabetes were significant risk factors in 
men, whereas in women, they did not reach statistical significance (table 3). For aortic calcification, 
systolic blood pressure was a significant risk factor in men but did not reach statistical significance in 
women (table 4).
Figure 1 shows median coronary calcium score, mean IMT, median carotid plaque score, mean AAI, 
and median aortic calcification score according to age and gender. Median coronary calcium score 
was higher in men than in women in all age categories. A similar, though less pronounced, pattern 
was seen for IMT and carotid plaque score. For AAI and aortic calcification score, the pattern was more 
heterogeneous, with less obvious differences between men and women.
Crude percentages of participants with atherosclerosis, according to gender and age, are shown 
in figure 2 for each of the vascular locations. For all four measures of atherosclerosis, percentages 
of participants with high degrees of atherosclerosis increased with increasing age. Percentages with 
severe coronary calcification, IMT > 1.0 mm, and severe carotid plaques were notably higher in men 
than in women.
Table 5 shows numbers of cases and participants in gender and age categories and male:female 
odds ratios as computed by logistic regression. Coronary calcification showed the highest male:female 
odds ratios as compared with the other measures of atherosclerosis. The age-adjusted male:female 
odds ratios for having a calcium score above 1,000 in the two lowest age tertiles were 6.9 (95 percent 
Table 2. Age-adjusted regression coefficients for risk factors, describing the increase in log calcium score, 
intima-media thickness and ankle arm index per standard deviation increase of the cardiovascular risk 
factors, adjusted for age.
Variable
Log coronary calcium score Intima-media thickness Ankle arm index
Men Women Men Women Men Women
Body mass index 0.24 (0.11, 
0.37)
0.19 (0.06, 
0.32)
0.03 (0.02, 
0.04)
0.01 (0.001, 
0.02)
0.01 (-0.01, 
0.02)
0.01 (0.00, 
0.02)
Systolic blood 
pressure
0.19 (0.06, 
0.33)
0.11 (-0.03, 
0.25)
0.04 (0.03, 
0.06)
0.04 (0.03, 
0.04)
-0.05 (-0.07, 
-0.04)
-0.04 (-0.05, 
-0.04)
Diastolic blood 
pressure
0.02 (-0.11, 
0.16)
0.00 (-0.14, 
0.14)
0.01 (0.003, 
0.03)
0.01 (0.001, 
0.02)
0.00 (-0.01, 
0.01)
-0.01 (-0.02, 
0.00)
Total cholesterol -0.05 (-0.19, 
0.08)
0.07 (-0.06, 
0.21)
0.01 (0.00, 
0.03)
0.00 (-0.01, 
0.01)
-0.01 (-0.02, 
0.01)
0.00 (-0.01, 
0.01)
HDL-cholesterol -0.04 (-0.18, 
0.09)
-0.23 (-0.37, 
-0.09)
-0.01 (-0.02, 
-0.00)
-0.01 (-0.02, 
-0.00)
0.01 (-0.001, 
0.02)
0.01 (0.001, 
0.02)
Smoking (ever) 0.55 (0.12, 
0.99)
0.61 (0.35, 
0.88)
0.03 (-0.004, 
0.07)
0.01 (-0.01, 
0.03)
-0.04 (-0.08, 
0.01)
-0.03 (-0.05, 
-0.01)
Diabetes mellitus 0.56 (0.20, 
0.93)
0.84 (0.42, 
1.26)
0.05 (0.02, 
0.08)
0.02 (0.00, 
0.05)
-0.05 (-0.08, 
-0.01)
-0.01 (-0.05, 
0.01)
C-reactive 
protein*
0.20 (0.07, 
0.33)
0.16 (0.02, 
0.29)
0.02 (0.01, 
0.03)
0.01 (0.002, 
0.02)
-0.03 (-0.04, 
-0.02)
0.00 (-0.01, 
0.01)
* Log transformed because of skewed distribution.
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confidence interval (CI): 3.4, 13.9) and 7.4 (95 percent CI: 4.3, 12.7), showing that the men had a sub-
stantially higher degree of coronary calcification than the women. In the highest age tertile, the odds 
ratio declined to 2.7 (95 percent CI: 1.8, 4.0). The odds ratios for IMT, carotid plaques, AAI, and aortic 
Table 3. Association between baseline characteristics and presence of severe carotid plaques in men and 
women adjusted for age.
Variable
Men Women
No severe 
carotid 
plaques
Severe 
carotid 
plaques
P for 
trend
No severe 
carotid 
plaques
Severe 
carotid 
plaques
P for 
trend
Body mass index (kg/m2) 26.3 26.4 0.80 27.2 26.8 0.86
Systolic blood pressure 
(mm Hg)
142 150 < 0.001 142 143 0.002
Diastolic blood pressure 
(mm Hg)
77 77 0.49 75 73 0.65
Total cholesterol (mmol/l) 5.5 5.6 0.04 6.0 6.1 0.26
HDL-cholesterol (mmol/l) 1.3 1.3 0.40 1.5 1.4 0.68
Smoking
- Former (%) 72.6 69.7 0.55 37.5 45.2 0.07
- Current (%) 15.9 26.2 <0.001 12.9 23.9 0.20
Diabetes mellitus (%) 13.4 20.8 0.001 10.6 14.8 0.13
C-reactive protein (mg/l) 2.2* 2.8* <0.001 2.1* 2.7* 0.01
* Geometric mean because of skewed distribution.
Table 4. Association between baseline characteristics and presence of severe aortic calcification in men 
and women, adjusted for age.
Variable
Men Women
No severe 
aortic 
calcification
Severe 
aortic 
calcification
P for 
trend
No severe 
aortic 
calcification
Severe 
aortic 
calcification
P for 
trend
Body mass index (kg/m2) 26.4 26.7 0.05 27.3 27.8 0.35
Systolic blood pressure (mm 
Hg)
143 146 0.001 142 143 0.13
Diastolic blood pressure 
(mm Hg)
77 76 0.997 75 73 0.48
Total cholesterol (mmol/l) 5.6 5.6 0.44 6.1 6.1 0.48
HDL-cholesterol (mmol/l) 1.3 1.3 0.04 1.5 1.4 <0.001
Smoking
- Former (%) 71 76 0.86 38.1 44.0 0.56
- Current (%) 17.7 16.9 <0.001 12.7 20.1 <0.001
Diabetes mellitus (%) 14.6 23.5 0.03 10.7 18.9 0.03
C-reactive protein (mg/l) 2.2* 2.7* 0.01 2.2* 2.6* <0.001
* Geometric mean because of skewed distribution.
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Figure 1. Measures of atherosclerosis according to gender (stripes, men; dots, women) and age tertile.
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Figure 2. Crude percentages of participants with severe atherosclerosis at various vascular locations, 
according to gender (stripes, men; dots, women) and age tertile.
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calcification did not show an evident decline with increasing age, and the overall age-adjusted odds 
ratios for these measures were 2.6 (95 percent CI: 2.0, 3.4), 2.7 (95 percent CI: 2.0, 3.5), 1.3 (95 percent 
CI: 1.0, 1.7), and 1.3 (95 percent CI: 1.0, 1.6), respectively.
Adjustment for established cardiovascular disease risk factors, C-reactive protein level, hormone 
replacement therapy, and use of cardiac medication changed the estimates slightly. Multivariable ad-
justed odds ratios are displayed in figure 3. This figure emphasizes that the gender difference in severe 
coronary calcification is particularly present at lower age; at high age, the difference is less marked as 
compared with other measures of atherosclerosis.
Table 5. Male:female odds ratios for atherosclerosis among all participants and by age tertile.
Age tertile
Total1 (61–67 years) 2 (68–73 years) 3 (74–85 years)
Coronary calcification > 1,000
 No. of men 49/308* 88/321 87/304 224/933
 No. of women 10/364 17/349 48/367 75/1,080
 Male:female OR† (model 1)‡ 6.9 (3.4, 13.9)§ 7.4 (4.3, 12.7) 2.7 (1.8, 4.0) 4.4 (3.3, 5.8)
 Male:female OR (model 2)¶ 7.8 (3.2, 19.3) 5.4 (2.8, 10.2) 3.0 (1.7, 5.2) 4.3 (3.0, 6.3)
Intima-media thickness > 1.0 mm
 No. of men 41/282 60/301 108/278 209/861
 No. of women 13/334 42/322 58/342 113/998
 Male:female OR (model 1) 4.2 (2.2, 8.0) 1.7 (1.1, 2.6) 3.1 (2.1, 4.5) 2.6 (2.0, 3.4)
 Male:female OR (model 2) 4.7 (2.0, 11.2) 1.6 (0.9, 2.9) 4.1 (2.4, 7.1) 2.9 (2.0, 4.1)
Severe carotid plaques
 No. of men 37/268 62/274 84/263 183/805
 No. of women 17/319 31/298 47/314 95/931
 Male- to-female OR (model 1) 2.8 (1.5, 5.2) 2.6 (1.6, 4.1) 2.7 (1.8, 4.0) 2.7 (2.0, 3.5)
 Male:female OR (model 2) 2.2 (1.0, 4.7) 2.4 (1.3, 4.3) 1.8 (1.1, 3.2) 2.0 (1.4, 2.8)
Ankle-arm index < 0.90
 No. of men 28/302 55/309 76/285 159/896
 No. of women 36/353 45/336 64/341 145/1,030
 Male:female OR (model 1) 0.9 (0.5, 1.5) 1.4 (0.9, 2.1) 1.6 (1.1, 2.3) 1.3 (1.0, 1.7)
 Male:female OR (model 2) 0.9 (0.5, 1.7) 1.0 (0.6, 1.7) 1.0 (0.6, 1.8) 0.9 (0.7, 1.3)
Severe aortic calcification
 No. of men 36/273 58/277 86/269 180/819
 No. of women 31/321 59/296 80/317 170/934
 Male:female OR (model 1) 1.4 (0.8, 2.4) 1.1 (0.7, 1.6) 1.4 (1.0, 2.0) 1.3 (1.0, 1.6)
 Male:female OR (model 2) 1.4 (0.7, 2.8) 0.8 (0.5, 1.4) 1.2 (0.7, 2.0) 1.0 (0.8, 1.5)
* Number of cases/total number of participants. † OR, odds ratio. ‡ Adjusted for age. § Numbers in parentheses, 95% confidence interval.
¶ Adjusted for age, body mass index, systolic and diastolic blood pressure, total and high density lipoprotein cholesterol, smoking, diabetes 
mellitus, C-reactive protein, hormone replacement therapy, and use of diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and 
lipid-lowering drugs.
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When we repeated the analysis after excluding participants with prevalent myocardial infarction, 
stroke, heart failure, angina pectoris, and claudicatio intermittens, the pattern of the risk estimates did 
not materially change (table 6).
Table 6. Male:female odds ratios for atherosclerosis in participants without prevalent myocardial 
infarction, cerebrovascular accident, heart failure, angina pectoris,* or claudicatio intermittens,* among all 
participants and by age tertile.
Age tertile Total
1 (61–67 years) 2 (68–73 years) 3 (74–85 years)
Coronary calcification > 1,000
 No. of men 28/249† 44/218 30/184 102/651
 No. of women 5/327 10/287 25/280 40/894
 Male:female OR‡ (model 1)§ 8.4 (3.2, 22.1)¶ 7.0 (3.4, 14.3) 2.0 (1.1, 3.5) 4.1 (2.8, 6.1)
 Male:female OR (model 2)# 11.3 (3.3, 38.9) 5.6 (2.4, 13.3) 2.7 (1.2, 6.1) 4.7 (2.9, 7.7)
Intima-media thickness > 1.0 mm
 No. of men 30/230 38/210 56/167 124/607
 No. of women 8/299 38/264 33/262 79/825
 Male:female OR (model 1) 5.5 (2.5, 12.2) 1.3 (0.8, 2.2) 3.5 (2.2, 5.7) 2.6 (1.9, 3.5)
 Male:female OR (model 2) 6.8 (2.4, 19.4) 1.5 (0.8, 2.9) 6.1 (3.0, 12.5) 3.1 (2.1, 4.7)
Severe carotid plaques
 No. of men 28/220 35/189 40/159 103/568
 No. of women 11/286 21/246 26/241 58/773
 Male- to-female OR (model 1) 3.6 (1.8, 7.5) 2.5 (1.4, 4.4) 2.8 (1.6, 4.8) 2.9 (2.0, 4.0)
 Male:female OR (model 2) 3.4 (1.3, 8.8) 2.5 (1.2, 5.3) 1.9 (0.9, 4.0) 2.2 (1.4, 3.4)
Ankle-arm index < 0.90
 No. of men 18/245 31/211 32/175 81/631
 No. of women 30/319 36/278 47/262 113/859
 Male:female OR (model 1) 0.8 (0.4, 1.4) 1.2 (0.7, 1.9) 1.0 (0.6, 1.7) 1.0 (0.7, 1.4)
 Male:female OR (model 2) 0.8 (0.4, 1.8) 0.7 (0.4, 1.4) 0.7 (0.4, 1.5) 0.7 (0.5, 1.1)
Severe aortic calcification
 No. of men 24/224 37/188 42/161 103/573
 No. of women 23/289 42/240 55/245 120/774
 Male:female OR (model 1) 1.4 (0.8, 2.5) 1.1 (0.7, 1.9) 1.2 (0.8, 2.0) 1.2 (0.9, 1.7)
 Male:female OR (model 2) 1.9 (0.8, 4.3) 0.8 (0.4, 1.6) 1.4 (0.7, 2.6) 1.2 (0.8, 1.7)
* As assessed by Rose questionnaire.  † Number of cases/total number of participants. ‡ OR, odds ratio. § Adjusted for age. ¶ Numbers in 
parentheses, 95% confidence interval. # Adjusted for age, body mass index, systolic and diastolic blood pressure, total and high density 
lipoprotein cholesterol, smoking, diabetes mellitus, C-reactive protein, hormone replacement therapy, and use of diuretics, beta-blockers, 
angiotensin-converting enzyme inhibitors, and lipid-lowering drugs.
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Discussion
This study demonstrates that the gender difference in atherosclerosis in the coronary vessels is large, 
that it is particularly high in younger participants, and that it remains present at older ages. The gen-
der difference in the coronary vessels is strikingly larger than in the other studied vascular beds. The 
gender difference in carotid atherosclerosis is also substantial, yet smaller and less consistent. Re-
markably, differences in the aorta and the lower extremity vessels are virtually absent. The difference 
in gender ratio between sites is not explained by differences in cardiovascular disease risk factors.
Strengths of the present study include its population-based nature, its large size, the availability 
of several noninvasive measures of extracoronary atherosclerosis in combination with a noninvasive 
measure of coronary atherosclerosis, and standardized assessment of risk factors. Nevertheless, some 
issues warrant consideration.
First, in the assessment of coronary calcium, 61 percent of the invited population participated. In 
general, slight differences were present between responders and nonresponders, such as the younger 
age of the scanned population (mean age difference, 1.7 years) and the relatively higher proportion of 
men in the scanned population (46.3 percent vs. 37.8 percent).19 Female participants in electron-beam 
computed tomography scanning more frequently were former smokers (38.9 percent vs. 33.4 percent) 
than nonparticipants. Male participants in electron-beam computed tomography scanning were also 
Figure 3. Male:female odds ratios for different measures of atherosclerosis according to age tertile.
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more frequently former smokers (72.2 percent vs. 66.9 percent) than nonparticipants. Furthermore, 
they had a somewhat higher body mass index (26.5 vs. 26.1) and a somewhat higher diastolic blood 
pressure (77 mmHg vs. 76 mmHg). Additional missing values for the other measures of atherosclero-
sis in the scanned population were missing for logistic reasons, and therefore were considered to be 
missing at random. Any differences in cardiovascular disease risk factors between participants and 
nonparticipants in these measurements were also of very small magnitude. Although we think it is 
unlikely that selection bias occurred, we cannot fully exclude the possibility of a slight underestima-
tion or overestimation of the studied associations.
Second, although interobserver reproducibility of coronary calcium scoring has been found to be 
excellent,14 when interpreting our results, it must be noted that the measures of extracoronary athero-
sclerosis have lower reproducibility. Still, it has been shown that measurement of IMT is highly repro-
ducible23 and measurement of carotid plaques is moderately reproducible.24 Radiographic detection 
of aortic calcification has been validated.25 Reproducibility of AAI measurements is dependent on the 
standardization of the technique and the experience of the personnel;29-30 both were optimized in the 
Rotterdam Study.
Finally, the definition of peripheral arterial disease is conventionally stated as an AAI < 0.90.31-33 
However, using the cutpoint of 0.90 in both men and women assumes equal sensitivity for arterial 
obstruction, whereas in truth it may differ between the genders. It was not possible for us to examine 
the association of AAI with true arterial obstruction in our population empirically. The disadvantage 
of choosing a gender-specific cutpoint in an attempt to approximate equal sensitivity in men and 
women is that this may potentially introduce a new bias into the gender estimates. Therefore, we used 
the cutpoint of 0.90 in the analysis. In line with this thinking, we applied the frequently used absolute 
cutpoint of 1.0 mm for IMT in the analyses.34,35 Furthermore, the meaning of mean AAI (figure 1) in a 
population may be questioned; while the interpretation of a low AAI as indicative of arterial obstruc-
tion has been validated, the meaning of the mean AAI is less clear. However, AAI has been suggested 
to have an association with cardiovascular disease across its entire range,36-38 which supports the pos-
sibility that AAI may be used as a continuous variable.
The differential gender effect for vascular sites was demonstrated in autopsy studies several de-
cades ago.10-13 Present studies demonstrate the prominence of the gender difference in coronary heart 
disease.4 The gender difference in diseases which originate in other vascular beds, such as stroke and 
peripheral artery disease, is not nearly as large.5-9 In the present study, we found that the male:female 
odds ratio for severe coronary calcification was almost 8 in the lowest age tertile and diminished with 
increasing age. The large male:female ratio is in accordance with prior data;39 the incidence of hospi-
talization for a first myocardial infarction in the Netherlands results in a male-to female ratio of 4.2 in 
the age category 50–59 years, diminishing to 1.2 in persons aged 90 years or older. Furthermore, in 
the present study, the overall male:female odds ratio was somewhat lower for IMT > 1.0 mm and se-
vere carotid plaques, with values of approximately 3 and 2, respectively. Prior data have demonstrated 
that the male:female ratio for cerebral infarction ranges from 1.6 in persons aged 55–64 years to 1.0 in 
persons aged 85 years or older.40 Note that the contribution of atherothromboembolism to ischemic 
stroke is limited to 50 percent;41 however, this should not influence the gender ratio, unless this per-
centage differs highly between men and women. With regard to peripheral arterial disease, research 
performed previously within the Rotterdam Study has demonstrated that the prevalences in 5-year 
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age categories are similar for men and women.7 Gender differences in cardiovascular events such as 
myocardial infarction may be attributable to differences in exposure to risk factors, differences in the 
development of atherosclerosis, differences in “trigger” factors given equal severity of atherosclerosis, 
or a combination of these processes. The present findings underscore the role of the development of 
atherosclerosis in gender differences in the occurrence of coronary events.
To explain the differential gender effects across vascular sites, we should search for risk factors 
that have different effects on atherosclerosis in men and women but also have varying effects on 
atherosclerosis in different vascular beds. As demonstrated by our study, traditional cardiovascular 
disease risk factors do not seem to provide an explanation. Cardiovascular risk factors are considered 
to be generally the same for both genders, with the exception of diabetes mellitus, HDL cholesterol, 
and triglycerides, which have been found to have stronger effects among women.42 Furthermore, 
low density lipoprotein particle size may be of particular importance for coronary heart disease in 
men.43 In general, risk factors for atherosclerosis in different vascular beds are the same as those that 
predispose to disease in each individual vascular bed.44-47 The impact of these risk factors may vary 
according to vascular site; for instance, smoking and diabetes have a larger impact on peripheral arte-
rial disease than the other risk factors.48 Although the risk factors are generally the same, differences 
in vascular anatomy, leading to regional disturbances of blood flow, and local changes in the arterial 
wall that affect interaction with blood components may still cause differences between the vascular 
sites. Not much is known about risk factors for atherosclerosis that simultaneously differ between 
men and women and between vascular sites. Finding these factors may provide clues as to why men 
have substantially more atherosclerosis than women in the coronary arteries but not in the aorta 
and peripheral vessels. This may help to elucidate the reason for the gender gap in coronary heart 
disease.
In conclusion, our study illustrates that the gender difference in coronary calcification is impres-
sive, that it is particularly high in younger participants, and that it remains present at older ages. In 
younger participants, the multivariable-adjusted male:female odds ratio in the coronary arteries was 
close to 8. In the carotid arteries, the gender difference was also substantial, reaching 3 overall, but in 
the aorta and the peripheral vessels the male:female odds ratio remained close to the null value of 1. 
Presently known risk factors do not fully explain why the gender difference in cardiovascular disease 
varies in the different vascular beds. We believe that investigation of the causes of the site-specific 
gender differences may shed more light on the gender gap in coronary heart disease.
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The objective of this thesis was to expand the knowledge on inflammatory markers and inflammatory 
genes that may play a part in the pathophysiology of cardiovascular disease. Most studies described 
were conducted within the framework of the Rotterdam Study, a population-based cohort study 
among men and women aged 55 years and over. In the present chapter, methodological aspects will 
be addressed, the main findings of this thesis will be placed in the context of ongoing research in the 
field of inflammation and cardiovascular disease, and potential clinical implications and directions for 
future research will be discussed.
Methodological considerations
Methodological considerations pertaining to the separate studies have been described in the specific 
chapters. Here, general methodological considerations will be discussed with regard to observational 
studies and genetic association studies.
Observational studies1
Observational studies include cohort studies, in which subjects are classified according to their expo-
sure status and followed over time to ascertain disease incidence; case-control studies, in which sub-
jects are selected according to their disease status and further classified according to their exposure 
status; and cross-sectional studies, which include as subjects all persons in the population at the time 
of ascertainment or a representative sample of all such persons, and have an objective limited to de-
scribing the population at that time. The latter two designs may also be applied within the framework 
of a cohort study. In follow-up studies, the design may be retrospective or prospective. A retrospective 
design enables the researcher to identify large groups in the past and to follow them up over long 
periods of time until the present moment. However, the available data may not be of desired qual-
ity. Using a prospective design, the researcher has full control of the data collection. However, large 
groups need to be followed over many years to examine disease frequencies. The Rotterdam Study is 
an observational, prospective cohort study, and therefore has the advantages of careful and appropri-
ate data collection. The designs of the studies described in this thesis were either prospective, with 
the ability to assess temporal relationships, or cross-sectional.
A disadvantage of observational studies is that they may be subject to bias. Types of bias include 
selection bias, information bias and confounding bias. Selection bias occurs when the relation be-
tween exposure and disease is different for those who participate and those who should be theoreti-
cally eligible for the study, including those who do not participate. Examples of studies that may be 
prone to selection bias in this thesis are the studies involving coronary calcification (chapters 2.2, 3.2, 
4.1 and 6.1). A subgroup of the Rotterdam study was used for these studies, which was not completely 
random, and this resulted in slight differences in baseline characteristics between participants and 
non-participants. However, we have no reason to believe that this would have affected the relation 
between the exposure and the disease in participants or non-participants, and therefore deem distor-
tion of the results unlikely.
Information bias occurs when misclassification of the outcome occurs that is related to the de-
terminant, or vice versa. This has been termed differential misclassification. In the Rotterdam Study, 
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exposure data were collected before the disease onset, and missing values were mostly caused by 
periodic absence of research assistants or technical problems. Therefore, differential misclassification 
of the exposure is unlikely. Furthermore, disease outcomes were assessed by persons blinded to the 
exposure status, which makes differential misclassification of the outcome unlikely as well.
Confounding bias may occur when the apparent effect of the exposure of interest is distorted 
because the effect of an extraneous factor is mistaken for or mixed with the actual exposure ef-
fect. This implies that a confounder is associated with both the exposure and the exposure effect. 
When investigating the association of biomarkers such as C-reactive protein (CRP) with coronary 
heart disease (chapter 2.1), many confounders of the association are present. The analyses can be 
adjusted for known confounders. However, confounders unknown to the researcher may still lead to 
a distortion of the results. Such “residual confounding” is difficult to solve in observational studies. 
A way to avoid these problems is to perform a double-blind, randomized controlled trial, in which 
participants are randomized to therapeutic measures influencing the exposure of interest or placebo 
and followed for the occurrence of events. Clinical trials may lead to different conclusions than ob-
servational studies.
Another issue that may pose problems in observational studies is causal inference. To determine 
whether an observed association is causal, a criterion that can be used is that of temporality: if the 
putative cause did not precede the effect, that is indisputable evidence that the observed association 
is not causal. In some cases, it may not be straightforward to establish whether the cause preceded 
the effect. For example, it may not be clear whether CRP plays an etiologic part in the development of 
atherothrombotic disease or whether it merely reflects the inflammatory state, and in this case the se-
verity of the atherosclerotic burden, already present in the individual at the time of CRP measurement 
(chapter 2.1). To solve this problem of reverse causation, a different study design should be chosen. 
Within the observational setting, a “Mendelian randomization” approach could be chosen. Alterna-
tively, an interventional approach could be chosen to provide more insight into causality, such as 
performing a randomized controlled clinical trial aimed to assess whether CRP reduction per se low-
ers risk, preferentially with agents that do not have alternative known beneficial effects. The extent 
to which Mendelian randomization and randomized trials are able to prove causality are discussed in 
more detail below.
Genetic association studies
To perform genetic association studies, candidate genes can be selected, and the association be-
tween variation in these genes and disease occurrence can be investigated. Genes may be selected 
on the basis of their presumed roles in disease pathophysiology and variants in these genes, such as 
single nucleotide polymorphisms (SNPs), may be selected because of their functional implications.2 
On the other hand, genetic variants may be selected because they “tag” gene haplotypes.3 A hap-
lotype is a set of SNPs, on a single chromatid, that are statistically associated. It is thought that the 
identification of a few alleles of a haplotype block can unambiguously identify all other polymorphic 
sites in its region. In this thesis, a presumably functional genetic variant is investigated in chapter 2.3: 
the complement factor H (CFH) Tyr402His SNP may alter the CRP binding site of CFH. In chapter 4.1, 
tagging SNPs are determined and FGG-FGA haplotypes, which may influence fibrinogen structure 
and function, are investigated.
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Genetic variants may also influence blood levels of biomarkers. Investigation of such variants may 
provide solutions for problems encountered with causal inference in observational studies, such as 
residual confounding and reverse causation. If the blood level of a biomarker truly increases risk of 
disease, then carriage of a genetic variant that exposes individuals to a long-term elevation of this 
biomarker should confer an increased risk of disease proportional to the difference in biomarker lev-
el attributable to the variant. This implies that if non-genetic observational studies were unbiased, 
the increase in risk estimated from these studies should be consistent with the increase in risk con-
ferred by carriage of the genetic variant. This approach should circumvent the problem of residual 
confounding, because the inheritance of a genetic variant associated with different biomarker levels 
should be subject to the random assortment of maternal and paternal alleles at the time of gamete 
formation. It should also circumvent the problem of reverse causation, because the genetic variant of 
interest is present in an individual before the disease occurs.4 An application of this study design can 
be found in chapter 2.1 of this thesis, where CRP haplotypes are investigated in relation to CRP serum 
levels and coronary heart disease.
The above approach, known as “Mendelian randomization”, has gained interest lately. Although it 
may solve several problems, it is based on multiple assumptions and therefore entails some problems 
of its own.5 The first assumption is that the genetic variant is only associated with the biomarker of 
interest and not with other factors that may play a part in the disease process. Another assumption 
is that the genetic variant is only associated with the quantity but not the quality of the biomarker 
of interest. Both assumptions may not always hold true. Furthermore, it is assumed that there is no 
“canalisation” or compensation for the altered gene expression, in this case different biomarker lev-
els due to the genetic variant, during development. However, given the complexity of the pathways 
involved and the multifactorial nature of cardiovascular disease, such compensation may not be un-
likely in some cases. These issues should be borne in mind and dealt with when performing Mende-
lian randomization studies.
Genetic association studies in general may have several other shortcomings.6 An association found 
between a single genetic variant and a disease outcome may have been caused by linkage disequi-
librium with another genetic variant. A more comprehensive approach is obtained by constructing 
gene haplotypes that capture the common variation across a gene, as described above. Furthermore, 
large sample sizes are needed to provide enough statistical power to detect the effect of a genetic 
variant on diseases with a multifactorial origin. Such diseases are thought to result from variations in a 
large spectrum of genes with small individual effects. For example, as demonstrated in chapter 2.1, for 
CRP haplotypes, we were able to detect a relative risk of coronary heart disease of 1.21 with a power 
of 80% in our study; the true effect may actually have been smaller and thus have gone undetected. 
Finally, reproducibility of the results of genetic association studies may pose problems; lack of repro-
ducibility may result from effect modification or population stratification, or, again, from insufficient 
statistical power.
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Main findings in the context of ongoing research
Inflammation and atherothrombotic disease
C-reactive protein
Although proof of a causal role of CRP in cardiovascular disease has to be awaited, several pathophysi-
ological mechanisms involving CRP have been suggested. CRP is involved in endothelial dysfunc-
tion, inducing the expression of adhesion molecules such as intercellular cell adhesion molecule 1 
(ICAM-1), vascular cell adhesion molecule (VCAM) and E-selectin. Also, it appears to be involved in re-
cruitment of monocytes, infiltration of monocytes into the vessel wall and subsequent development 
into foam cells. Foam cell formation might be caused in part by uptake of CRP-opsonized native LDL. 
CRP exposure increases vascular smooth muscle cell proliferation and migration. Finally, CRP is able 
to activate the classical route of complement activation, which leads to the production of a variety of 
pro-inflammatory molecules.
Numerous epidemiologic studies have reported that CRP is an independent risk factor for cardio-
vascular disease, and a meta-analysis using more than 7000 cases has demonstrated that the multi-
variable-adjusted odds ratio for coronary heart disease in the highest versus the lowest tertile of CRP 
is 1.45 (95% CI 1.25-1.68).7 Our results, presented in chapter 2.1 and showing that CRP serum level is an 
independent risk factor for coronary heart disease, are in agreement with these studies. To explore the 
potential causality of the CRP-coronary heart disease association, in chapter 2.1, we determined CRP 
gene haplotypes and investigated their associations with CRP serum level and coronary heart disease. 
Although haplotypes were associated with CRP serum level, they were not associated with coronary 
events. A possible explanation for this is that lack of power prevented us from demonstrating an as-
sociation that may have been of small magnitude given the multifactorial origin of cardiovascular dis-
ease. Several other studies have attempted to replicate these findings. Some have found significant 
associations between CRP haplotypes and cardiovascular disease, while others have failed to do so.8-10 
Again, lack of power may underlie these inconsistent results.
With regard to atherosclerosis, epidemiologic studies support independent relations between 
CRP and carotid plaques11-13 and low ankle-arm index.14-16 In general, associations between CRP and 
coronary calcification and CRP and intima-media thickness have been less consistent.11,12,14,17-22 This 
population-based study shows graded associations of CRP with extent and progression of atheroscle-
rosis. However, the strength of the associations depends on the applied measure of atherosclerosis. 
We found an independent, graded association between CRP and extent and progression of carotid 
plaques and AAI. Furthermore, CRP was independently related to the highest level of carotid IMT, 
while the association with change in IMT was not significant. Although there was an independent, 
graded relation between CRP and aortic calcification, no independent association was found with 
progression of aortic calcification, nor with the amount of coronary calcification. A possible expla-
nation for the less consistent findings with progression is, that more random variation is present in 
measures of progression of atherosclerosis than in measures of burden of atherosclerosis. This results 
from the fact that progression is derived from at least two measurements, which both have their 
own random variation, while measures of burden of atherosclerosis consist of only one measurement. 
Consequently, associations of determinants with these measures of progression may be more difficult 
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to demonstrate; a phenomenon that has previously been demonstrated for progression of intima-
media thickness. In general, little is known about determinants of progression of calcification, but a 
similar problem may be present here. Our findings are generally supported by previous studies on 
the relation between CRP and quantity of atherosclerosis. The inconsistency in the literature on the 
relation between CRP and atherosclerosis may, at least partly, be explained by differences in applied 
measures of atherosclerosis and lack of quantification.
Complement factor H
Linkage studies for age-related macular degeneration have mapped a gene at chromosome 1q32, 
and through both fine-mapping and a whole genome association study, the Y402H variant of CFH 
gene was identified as the dominant susceptibility factor for age-related macula degeneration with 
ORs ranging from 2.5 to 7.4.23-25 The pathophysiological processes pertaining to CFH are the follow-
ing. The complement system contains several plasma and membrane-associated proteins that are 
organized in three activation pathways: the classical, the lectin and the alternative pathway. CFH is a 
plasma protein that plays an important part in the inhibition of the alternative pathway; it restricts the 
action of complement to activating surfaces by binding to C3b, accelerating the decay of the alterna-
tive pathway C3-convertase (C3bBb) and acting as a cofactor for the factor I-mediated proteolytic in-
activation of C3b. This mechanism allows for activation of the early complement cascade by opsoniza-
tion and may thereby play a protective role, however, complement activation is limited to the C3 level, 
and does not lead to full complement activation with cell lysis and ensuing inflammation. As such, 
CFH may play a part in the pathophysiology of atherosclerosis. The complement system contributes 
to inflammation in the arterial intima, and thus may exert unfavourable effects on atherosclerosis. 
Research in coronary artery specimens suggests that interaction of CFH with proteoglycans may be 
the mechanism by which complement activation in the superficial layer of the coronary intima is con-
trolled.26 Within the Rotterdam Study cohort, we demonstrated a 1.8-fold odds ratio for myocardial 
infarction among those individuals harboring the His allele of Y402H (chapter 2.3). There have been 
a few studies that have attempted to replicate these findings; Pai et al. demonstrated a protective ef-
fect of the His allele in women, but not in men,27 while other studies failed to demonstrate significant 
associations.28-30 Underlying reasons for these discrepancies may include smaller sample size, leading 
to low power and leaving room for a modest association, and use of atherosclerosis as the outcome 
instead of hard events. Furthermore, we cannot exclude the possibility that the association between 
Y402H and coronary heart disease is a false positive finding.
Binding of CRP to CFH has been suggested to augment the ability of CFH to down-regulate the 
effect of complement in atherosclerotic lesions. Furthermore, the CFH Tyr402His polymorphism has 
been suggested to influence the ability of CFH to bind CRP.31 In chapter 2.4, we have demonstrated 
that the combined presence of unfavorable CRP and CFH genetic profiles is associated with risk of 
myocardial infarction. Unfortunately, we did not have an independent replication cohort at our dis-
posal to consolidate the findings. Our paper may stimulate other research groups to investigate this 
association.
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Lipoprotein-associated phospholipase A2
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker that has gained atten-
tion recently because it may play a part in the pathophysiology of cardiovascular disease. Lp-PLA2 
is an enzyme that circulates in the blood, and, in humans, is bound predominantly to LDL. Oxidative 
modification to the phospholipid component of LDL provides the substrate for the enzyme; follow-
ing LDL oxidation, Lp-PLA2 acts rapidly to hydrolyze one of the fatty moieties of the phospholipid to 
produce two inflammatory molecules- oxidized fatty acids and lysophosphatidylcholine. Given that 
the majority of oxidized LDL resides within the intima, the products of Lp-PLA2 are generated within 
the vessel wall where the inflammatory processes of atherosclerosis occur. Both oxidized fatty acids 
and lysophosphatidylcholine are highly soluble, diffuse throughout atheroma, and affect the various 
cell types involved in atherosclerosis.
Overall, epidemiologic studies suggest that Lp-PLA2 is an independent risk factor for cardiovas-
cular disease.32-35 Research performed within the Rotterdam Study has led to the same conclusion.36 
Studies on Lp-PLA2 and coronary atherosclerosis seem to lean into the same direction.37-42 However, in 
the Rotterdam Study, the association between Lp-PLA2 and coronary calcification was not indepen-
dent of cholesterol (chapter 3.2). Furthermore, results from the Rotterdam Study have also suggested 
that the association of Lp-PLA2 with extracoronary atherosclerosis is not independent of cholesterol 
(chapter 3.3). Extracoronary atherosclerosis has been studied less extensively in the literature.43,44
As such, an issue of interest is whether the effect of Lp-PLA2 on cardiovascular events is truly inde-
pendent of LDL-cholesterol, to which it is bound. Until now, findings generally seem to support an inde-
pendent role for Lp-PLA2 in cardiovascular risk prediction. Another issue of interest is that Lp-PLA2 has 
been suggested to have both pro-atherogenic and anti-atherogenic properties. In humans, given that 
high levels of Lp-PLA2 are associated with cardiovascular events, evidence is building up that the pro-
atherogenic properties of Lp-PLA2 outweigh the anti-atherogenic properties. However, research on ge-
netic variation in the Lp-PLA2 gene appears to yield inconclusive results with regard to this matter.45-50
Fibrinogen
Apart from being an inflammatory marker, fibrinogen is an important coagulation factor, acting as 
an adhesive protein essential for platelet aggregation as well as forming insoluble fibrin fibers in the 
final stage of the blood coagulation cascade. Several prospective epidemiological studies have dem-
onstrated an independent association between fibrinogen level and cardiovascular disease. This has 
recently been confirmed in a large, individual participant meta-analysis.51 Changes in the structure 
of the fibrin network may also represent a pathophysiological mechanism contributing to the pro-
gression of atherosclerosis.52,53 A correlation has been demonstrated between fibrin structure and 
coronary disease, and a possible underlying mechanism is the relationship between fibrin structure 
and hypofibrinolysis. Fibrin structure is in part determined by genetic influences. Therefore, genetic 
variants altering fibrinogen structure and function and consequently fibrin structure may provide an 
opportunity to further investigate the involvement of fibrinogen in atherogenesis. As such,we have 
demonstrated that FGG and FGA fibrinogen haplotypes were not associated with coronary events, 
coronary calcification or extracoronary atherosclerosis (chapter 4.1).
With regard to replication of these findings, until now, we are only aware of two other studies on 
fibrinogen haplotypes and coronary events. Uitte de Willige et al. found no association between FGG 
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gene haplotypes and myocardial infarction in the “Study of Myocardial Infarctions Leiden”(SMILE), 
which is in agreement with our study.54 Mannila et al. studied the association between fibrinogen 
gene haplotypes and myocardial infarction in the Stockholm Coronary Artery Risk Factor (SCARF) 
study, and found that FGG and FGA haplotypes were associated with risk of myocardial infarction.55 
The discrepancy with the Rotterdam Study may have arisen because of differences in study popula-
tion and the fact that the SCARF study was designed to study determinants of premature myocardial 
infarction, whereas the Rotterdam Study was designed to examine myocardial infarction in a general 
population.
Heat shock protein 27
Heat shock proteins (HSPs) from the HSP60 and HSP70 families have been most widely investigated 
in relation to atherosclerosis.56,57 Recently, cardiovascular attention has also focused on HSP27.58 The 
pathophysiological role of HSP27 has been suggested to include chaperoning activity, inhibition of 
F-actin polymerization, protection against apoptosis and involvement in the presentation of oxidized 
proteins to the proteosome degradation machinery. Using atherosclerotic carotid endarterectomy 
samples and control endarteries, Martin-Ventura et al demonstrated that HSP27 secretion correlates 
negatively with atherosclerotic plaque complexity by comparing the complicated versus the non-
complicated adjacent area from the same specimen and control endarteries. They also reported re-
duced HSP27 plasma levels in atherosclerotic patients compared with healthy subjects.59 Park et al. 
used the same strategy but examined the tissue compartment, and also reported that HSP27 expres-
sion is increased in the normal-appearing vessel adjacent to atherosclerotic plaque compared to both 
the plaque core area and the reference arteries.60 By contrast, however, they reported that HSP27 plas-
ma level was increased in acute coronary syndrome patients compared to normal reference subjects.
In this thesis, we performed a prospective, nested case-control study within the Women’s Health 
Study to examine whether baseline levels of HSP27 among initially healthy individuals are associated 
with future cardiovascular event rates. No association was found between baseline HSP27 plasma 
level and risk of cardiovascular events (chapter 4.2). Further, although HSP27 was inversely associated 
with age, it was not associated with other established cardiovascular risk factors. To explain these 
results, we have to consider the possibility that HSP27 plasma level might not closely reflect the se-
cretion of HSP27 from atherosclerotic plaques. If we address the hypothesis that HSP27 may be de-
graded by culprit atherosclerotic plaque,61 it is unlikely that variations in HSP27 plasma level could 
be detected until the disease is advanced, as demonstrated in patients with a mean age of nearly 70 
years with carotid atherosclerosis.59 Another possibility is that HSP27 plasma level rises in the acute 
phase of ischemic events, as shown for HSP70,62 in which case raised plasma level would not precede 
cardiovascular disease. This would help to explain the positive results found by Park et al., who used 
acute coronary syndrome patients and drew blood within 24 hours from presentation to the emer-
gency department.60
Inflammation and heart failure
While heart failure was once merely considered to be a cardiocirculatory impairment, now it is known 
that the neuroendocrine system is involved. Furthermore, multiple lines of evidence support the “cy-
tokine hypothesis,” which suggests that inflammation plays an important role in the development 
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and progression of heart failure. Pathophysiologically, many aspects of the syndrome of heart failure 
can be explained by the known biological effects of proinflammatory cytokines. When expressed at 
sufficiently high concentrations, such as those observed in heart failure, cytokines are sufficient to 
mimic some aspects of the heart failure phenotype, including progressive left ventricular dysfunction, 
pulmonary edema, left ventricular remodeling, and cardiomyopathy. Thus, heart failure may progress, 
at least in part, as a result of the toxic effects exerted by endogenous cytokine cascades on the heart 
and the peropheral circulation. Consequently, circulating markers of inflammation, such as tumor ne-
crosis factor alpha, interleukin 6, and C-reactive protein, may be useful in establishing the diagnosis, 
gauging prognosis, and evaluating the response to therapy in patients with heart failure.63
In this thesis, first, we examined the associations of established cardiovascular risk factors with 
echocardiographic parameters in asymptomatic persons (chapter 5.1). Ventricular systolic and dia-
stolic dysfunction was present in participants that had not been diagnosed with heart failure or myo-
cardial infarction. Higher age, higher BMI, lower systolic and higher diastolic blood pressure were 
most consistently associated with worse systolic function. Higher age and higher diastolic blood pres-
sure were most consistently associated with lower E/A ratio. This was generally in line with previous 
studies.64-68 Furthermore, chapter 5.2 demonstrates an association of selected structural and diastolic 
echocardiographic parameters with all-cause mortality in our study population. This is also in line 
with previous studies.69-73 The above results underline the importance of insight into the identification 
of individuals with preclinical ventricular dysfunction who may benefit from early treatment.
Subsequently, we explored the role of inflammation in heart failure. Chapter 5.3 describes the as-
sociation of CRP serum levels with incident heart failure. Positive associations had already been found 
in the Cardiovascular Health Study, the Framingham Study and the Health ABC study.74-76 Sex-specific 
relative risks of developing heart failure were not provided in these studies. We found that in men, 
the association of CRP with heart failure was partly explained by presence of coronary heart disease, 
whereas in women, it was partly explained by hypertension and body mass index. The reason for 
this may lie in the fact that men are known to have coronary artery disease as an underlying factor 
for heart failure more frequently than women, and women are more likely to have hypertension as 
an underlying factor, and both coronary heart disease and hypertension are associated with CRP. In 
chapter 5.4 we investigated the association of Lp-PLA2 and heart failure in a random subcohort of the 
Rotterdam Study. Our findings suggest that Lp-PLA2 activity is independently associated with risk of 
heart failure. To our knowledge, no other studies have examined this association. Altogether, our find-
ings support the hypothesis that inflammation plays a role in the development of heart failure.
Prevalence of atherosclerosis in men and women in the Rotterdam Study
The gender difference in coronary heart disease occurrence is not completely understood, and cannot 
be fully explained by risk factors such as lifestyle, lipid profile and blood pressure. The hypothesis that 
estrogen carries a cardio protective effect is being debated and could not be proven in large random-
ized controlled trials on estrogen therapy. Although the gender difference is also present to a much 
smaller extent for stroke and peripheral artery disease, it is most prominent for coronary heart dis-
ease. This suggests that gender differences in cardiovascular disease differ according to vascular sites. 
Autopsy studies support such a differential gender effect. Although studies have been performed 
in living populations to examine gender differences in atherosclerosis at single vascular sites,77-80 no 
Chapter 7
226
studies have been performed in living populations to compare gender differences in atherosclerosis 
at different sites of the vascular tree.
In chapter 6.1 of this thesis, we have demonstrated that the gender difference in atherosclerosis 
in the coronary vessels is large, that it is particularly high in younger participants, and that it remains 
present at older age. The gender difference in the coronary vessels is strikingly larger than in the other 
studied vascular beds. The gender difference in carotid atherosclerosis is also substantial, yet smaller, 
and less consistent. Remarkably, the difference in the aorta and the lower extremity vessels is virtually 
absent. The difference in gender ratio between sites is not explained by differences in cardiovascular 
risk factors.
Clinical implications and future research topics
In this thesis, we have investigated the roles of CRP and Lp-PLA2 in cardiovascular disease. In gen-
eral, the role of CRP has been most widely investigated; CRP has been reported to be independently 
and consistently associated with cardiovascular events in men and women, in healthy persons and 
in cardiovascular disease patients, and in strata of Framingham risk.81 Furthermore, several studies 
have reported that CRP has additional value to established cardiovascular risk factors in cardiovascu-
lar risk stratification.82-85 As a result, the Centers for Disease Control and Prevention and the American 
Heart Association have issued a statement supporting the usefulness of CRP in cardiovascular risk 
stratification.86 Nonetheless, the role of CRP in cardiovascular risk stratification remains controversial. 
Literature-based meta-analyses have demonstrated significant, independent associations of CRP with 
coronary heart disease.7,87 In the future, an individual-based meta-analysis of CRP serum levels and risk 
of cardiovascular disease could provide more precise risk estimates, carefully adjusted for potential 
confounders, stratified on potential effect modifiers and adjusted for regression dilution. However, an 
independent association with cardiovascular disease does not prove usefulness for risk stratification. 
Furthermore, in contrast with the above, several papers have reported a lack of additional value of 
CRP to established risk factors in cardiovascular risk stratification.88-90 This discrepancy may at least in 
part be due to the fact that no consensus has yet been reached as to the strategy that is most appro-
priate to investigate the added value of biomarkers to established cardiovascular risk factors for risk 
stratification. A strategy that is often used is comparison of the area under the ROC curve for models 
containing established cardiovascular risk factors with models additionally containing the biomarker 
of interest.91 The ROC curve is a plot of sensitivity versus 1–specificity that offers a summary of sen-
sitivity and specificity across a range of cut points for a continuous predictor. Perfect discrimination 
is achieved if the scores for all the cases are higher than those for all the non-cases, with no overlap. 
The appropriateness of this method for the above issue has been questioned.92 A biomarker with an 
odds ratio of 3 may have little effect on the area under the ROC curve, yet an increased level could 
shift estimated 10-year cardiovascular risk for an individual considerably, which may lead to different 
treatment recommendations.92
Apart from usefulness in risk stratification, another issue that is still controversial and warrants 
further investigation is the potential etiologic role of CRP in cardiovascular disease. Although basic 
research suggests several pathophysiological mechanisms through which CRP may act as a causal 
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agent,93 the possibility exists that CRP is merely a marker that reflects the degree of inflammation 
present. Of course, it should be kept in mind that CRP merely being a marker would not exclude the 
possibility that inflammation in itself is a causal agent. A randomized controlled clinical trial using an 
intervention that selectively reduces CRP could potentially provide more insight into the nature of the 
CRP-cardiovascular disease association. Unfortunately, no such selective intervention currently exists. 
Although statins are known to lower CRP, they also have major effects on lipid profile and glucose 
metabolism. Interestingly, patients with acute coronary syndromes who have low CRP levels after 
statin therapy have been shown to have better clinical outcomes than those with higher CRP levels, 
regardless of the resultant level of LDL cholesterol.94 The JUPITER trial, presently ongoing, will evaluate 
the potential benefits and risks of statin therapy among those with normal LDL cholesterol but raised 
CRP.95 However, the basis for the trial does not depend on a causal relationship of CRP with coronary 
heart disease, but only whether CRP is a useful indicator for people at increased risk not identified by 
traditional risk factors. Mendelian randomization may be a suitable alternative to gain more insight 
into the role of CRP in cardiovascular disease. Cohort studies applying this method may be pooled to 
obtain adequate statistical power. However, when applying the Mendelian randomization approach, 
the above-mentioned limitations of this method should be kept in mind.
Lp-PLA2 has generally been studied less extensively. Although the body of evidence is not as vast 
as for CRP, a large number of observational epidemiological studies have reported generally positive 
associations between circulating mass and activity levels of Lp-PLA2 and risk of cardiovascular dis-
ease. Few studies have been large enough to provide reliable estimates in different subgroups. More 
insight is needed into the precise nature of the association, including the influence of confounders 
such as cholesterol and effect modifiers such as gender, and this may be provided by an individual-
based meta-analysis, which is on the way.96 Also, adequate data on the additional value of Lp-PLA2 
to established cardiovascular risk factors for cardiovascular risk stratification are needed. Should, in 
the end, Lp-PLA2 prove to be useful in risk stratification, then guidelines should be formulated stat-
ing which type of assay (mass or activity) is most appropriate, which Lp-PLA2 cut-off points should 
be used for risk stratification in clinical practice, and in which subject categories these cut-off points 
should be applied for risk stratification. On the other hand, in contrast to CRP, selective inhibitors of 
Lp-PLA2 have been developed and are currently under investigation.97 Although this research is still 
in a relatively early phase, in the future, it may provide us with the opportunity to investigate the 
pathophysiological effects of Lp-PLA2 by means of a randomized clinical trial.
Finally, HSPs are plausible candidates for a role in atherogenesis. HSP60 and HSP70 families and 
antibodies against these HSPs have been most widely investigated in relation to atherosclerosis; sev-
eral of these factors have been associated with carotid disease and ischemic stroke,98-100 with presence 
and severity of coronary atherosclerosis,101,102 and with restenosis after percutaneous transluminal 
coronary angioplasty.103 They have also been associated with aortic disease and peripheral vascular 
disease.104-106 The Women’s Health Study is the first prospective study to examine the association of 
HSP27 with cardiovascular disease. Therefore, confirmation of the findings by other prospective stud-
ies is warranted. However, given the potential mechanisms of action, measuring HSP27 in persons in 
whom advanced cardiovascular disease is present may be a more appropriate method to examine the 
role of HSP27 in cardiovascular disease.
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In this thesis, we have performed genetic association studies concerning CFH genotype and fibrino-
gen FGG/FGA haplotypes and risk of cardiovascular disease. Our findings need to be confirmed in 
other study populations. As described above, reproducibility of genetic association studies remains 
problematic.6 The direction that is currently gaining attention in genetic research is the application of 
genome wide association studies in population-based cohorts. Such studies investigate direct gene 
associations with large numbers of markers. SNPs are known to occur with sufficient frequency in 
the human genome to allow testing on this scale and genotyping platforms are now available to 
analyze upwards of 500K SNPs. Improvements in the efficiency of the design can be made by care-
ful SNP selection, taking advantage of the background patterns of linkage disequilibrium (LD) and 
focusing genotyping on a subset of “tag SNPs”, acting as proxies for nearby correlated variants. The 
International Haplotype Map (HapMap) project offers a comprehensive view of the structure of LD 
throughout the genome in multiple populations.107 This, coupled with recent improvements in the 
efficiency of high-throughput genotyping platforms, has paved the way for effective whole genome 
association experiments. Several issues need to be addressed when using this approach. The primary 
concern is one of statistical power to observe an effect of a specific size. A number of 1000 cases 
and 1000 controls may be a realistic standard for detection of genes of moderate effect sizes; this is 
relatively large compared with most genetic case-control studies.108 Another issue in genome-wide 
experiments is the choice of source tissue. Although the amount of DNA required is relatively small, 
the experiments are exquisitely sensitive to DNA quality. Consequently, quality of the sample source 
material may be as important as concerns over study design and sample size.108 Furthermore, as the 
density of GW-SNP genotyping platforms continues to increase, the data volume and consequently 
data storage poses a challenge. Also, available tools for data management and analysis of GW-SNP 
data are relatively scarce.109 A few exist or are under development, such as PLINK and GenABEL. A 
large number of test statistics will be generated when performing the analysis, and a major problem is 
how to best evaluate results taking this large number of tests into account. Ways to deal with multiple 
testing include applying Bonferroni’s correction or the slightly less conservative Sidak’s correction; the 
false discovery rate (FDR) method, which calculates the proportion of null results among significant 
results and is appropriate for situations in which multiple “hits” are expected in large-scale experi-
ments; or permutation testing.109 As genome wide association studies will continue to gain popularity, 
the above-mentioned issues will need to be dealt with adequately.
In this thesis, we have examined the distribution of echocardiographic parameters in the Rotterdam 
Study population and the associations of these parameters with established cardiovascular risk fac-
tors and with mortality. Insight into echocardiographic parameters is important, because it has been 
recognized that preclinical ventricular dysfunction may be present even when heart failure has not 
yet become clinically manifest,110 and preclinical ventricular dysfunction has several characteristics 
rendering it a suitable target for screening. It has a natural history that is known to be of progressive 
nature, eventually resulting in overt heart failure, and as such it is a recognizable early asymptomatic 
stage of this condition. Heart failure is an important health problem that is gaining further momen-
tum with the aging of the population and increased survival of patients with coronary heart disease. 
Also, preclinical ventricular dysfunction is prone to therapeutic interventions that reduce morbidity 
and mortality from heart failure.111,112 It should be noted here that the lack of a clear association of 
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asymptomatic systolic dysfunction with all-cause mortality in our study may in part have been caused 
by selection bias in our study; mean follow-up was 3.0 years, and participants who came to the re-
search center may have been less likely to die in the first years of follow-up, because they were still 
relatively healthy. This may have attenuated the association.
When considering whether screening community-dwelling individuals for preclinical ventricular 
dysfunction is appropriate some issues still need attention.113 We found that moderate left ventricular 
systolic function was present in 2.8% of men and 1.7% of women without prevalent heart failure, 
myocardial infarction or atrial fibrillation and flutter, while poor systolic function was present in 1.1% 
and 0.4% of men and women, respectively. Global systolic function was qualitatively assessed from 
two-dimensional images by trained echocardiographers in our study. This approach reflects the rou-
tine practice in echocardiography laboratories and its reproducibility and accuracy has been shown 
to be as good as those of quantitative methods;114,115 as such, we believe the measurement of systolic 
function was performed appropriately in our study. This low prevalence of moderate and poor left 
ventricular function does not provide additional support for screening. However, it should be kept 
in mind that in general, prevalence of asymptomatic left ventricular dysfunction varies widely across 
studies, in part because of differences in study populations and in definitions of asymptomatic left 
ventricular dysfunction.
Furthermore, appropriate screening tools should be applied. Although echocardiography is a 
strategy that detects ventricular dysfunction accurately in asymptomatic patients, when considering 
screening its costs- relative to its benefits- need to be investigated. Options that are cheaper may 
also be investigated; these include electrocardiograms and natriuretic peptides such as brain natri-
uretic peptide (BNP). The drawback of electrocardiography is that it may have low specificity and a 
low positive predictive value,116 while the opposite is essential when screening large populations of 
asymptomatic individuals with a low prevalence of disease. Although BNP is useful for ruling out heart 
failure as the cause of symptoms, the capacity of BNP level to identify persons with ventricular systolic 
dysfunction may be limited,117 and low sensitivities and specificities have been reported using various 
cut-points.113
In this thesis, we have found associations of CRP and Lp-PLA2 with incident heart failure, and these 
findings support the hypothesis that inflammation plays a role in the development of heart failure. 
Inflammatory biomarkers that have been investigated most extensively in this regard are tumor ne-
crosis factor and interleukin-6.63 In addition to their potential as heart failure biomarkers, inflamma-
tory cytokines have been investigated as targets of heart failure therapy. Results for therapies directed 
against specific cytokines (such as tumor necrosis factor alpha) have thus far been disappointing.63 
Although one interpretation of these findings is that inflammatory mediators are not viable targets 
in heart failure, the countervailing point of view is that we simply have not targeted proinflammatory 
mediators with agents that can be used safely in the context of heart failure or that targeting a single 
component of the inflammatory cascade is not sufficient in a disease as complex as heart failure. 
Despite the unfavorable beginning with targeted anti-inflammatory approaches, strategies that use 
agents that have a broad spectrum of anti-inflammatory properties and immunomodulatory strate-
gies that activate antiinflammatory pathways are currently being evaluated. Well-designed clinical 
trials are needed to provide more insight into this matter.
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Finally, in this thesis, we have demonstrated that the gender difference in atherosclerosis in the cor-
onary vessels is strikingly larger than in the other studied vascular bed, and that the difference in 
gender ratio between sites is not explained by differences in cardiovascular risk factors. To explain 
the differential gender effect across vascular sites, we should search for risk factors that have differ-
ent effects on atherosclerosis in men and women but also have varying effects on atherosclerosis in 
different vascular beds. Cardiovascular risk factors are considered to be generally the same for both 
genders, with the exception of diabetes mellitus, HDL cholesterol and triglycerides, which have been 
found to have stronger effects among women,118 and LDL particle size, which may be of particular im-
portance for coronary heart disease in men.119 Furthermore, risk factors for atherosclerosis in different 
vascular beds are generally the same as those that predispose to disease in each individual vascular 
bed,120-123 although the impact of these risk factors may vary according to vascular site; for instance, 
smoking and diabetes have a larger impact on peripheral arterial disease than the other risk factors.124 
As such, it seems that to explain the gender difference, we should search for risk factors other than the 
established cardiovascular risk factors. Besides risk factors, differences in vascular anatomy, leading to 
regional disturbances of blood flow, and local changes in the arterial wall that affect interaction with 
blood components may cause differences between the vascular sites.
Not much is known about factors that simultaneously differ between men and women and be-
tween vascular sites. Finding them may provide clues as to why men have substantially more athero-
sclerosis than women in the coronary arteries but not in the aorta and peripheral vessels. This may 
help to elucidate the reason for the gender gap in coronary heart disease.
Main conclusions
Summarizing, the main conclusions of this thesis with respect to inflammation and cardiovascular 
disease are as follows.
CRP serum level is clearly and independently associated with coronary events. However, the strength 
of its association with atherosclerosis depends on the applied measure of atherosclerosis. An asso-
ciation between CRP gene haplotypes and coronary events could not be demonstrated. However, a 
causal role for CRP in coronary heart disease could not be excluded because of insufficient statistical 
power.
The CFH Tyr402His polymorphism is associated with increased risk of myocardial infarction, as is 
the combined presence of unfavorable CRP and CFH genetic profiles, which points towards an inter-
action between CRP and the alternative complement system in coronary heart disease.
Lp-PLA2 activity is associated with coronary and extra-coronary atherosclerosis, but these associa-
tions are not independent of cholesterol.
Both CRP serum level and Lp-PLA2 activity are associated with increased risk of heart failure, which 
supports the hypothesis that inflammation plays a part in the development of heart failure.
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Summary
Cardiovascular disease remains the leading cause of death in the western world. Of note is that a 
considerable part of the cases occurs in individuals that have none of the established cardiovascular 
risk factors. This prompts a search for remaining, unknown risk factors. In the last ten years, it has been 
recognized that inflammation plays an important role in cardiovascular disease. Insight into the role 
of inflammatory markers and genes in atherosclerosis may therefore provide a further understanding 
of the pathophysiology and may aid in identifying individuals at high risk.  
In this thesis, we examined the role of emerging inflammatory markers and genes in cardiovascu-
lar disease within a population-based cohort setting. Most studies were conducted within the Rot-
terdam Study, a study among 7983 men and women aged 55 years and over living in a well-defined 
suburb of Rotterdam, the Netherlands. Inflammatory markers and genetic variations were assessed in 
the participants and associations with coronary events, coronary calcification, extracoronary athero-
sclerosis and heart failure were investigated.
Part I focuses on inflammation, atherosclerosis and coronary events. First, the associations between 
C-reactive protein (CRP) serum level, CRP gene haplotypes and risk of coronary heart disease were 
examined (chapter 2.1). CRP serum level was associated with higher risk of coronary heart disease, 
and CRP gene haplotypes were associated with CRP serum level. However, CRP gene haplotypes were 
not associated with coronary heart disease. These findings do not provide evidence for a causal role 
for CRP in coronary heart disease. In chapter 2.2 the association of CRP serum level with measures of 
atherosclerosis was evaluated. An independent, graded association of CRP with extent and progres-
sion of carotid plaques and ankle-arm index was found. CRP was independently related to the highest 
level of carotid intima-media thickness, while the association with change in intima-media thickness 
was not significant. Although there was an independent, graded relation between CRP and aortic 
calcification, no independent association was found with progression of aortic calcification, nor with 
the amount of coronary calcification. In short, graded associations of CRP with extent and progression 
of atherosclerosis were present, but the strength of the associations depended on the applied mea-
sure of atherosclerosis. Chapter 2.3 addresses the role of complement factor H (CFH) in myocardial 
infarction. An association was demonstrated between the His allele of the Tyr402His single nucleotide 
polymorphism of the CFH gene and increased risk of myocardial infarction. This finding underlines 
the importance of the alternative complement pathway in coronary heart disease. Binding of CRP to 
CFH has been suggested to augment the ability of CFH to down-regulate the effect of complement in 
atherosclerotic lesions. In chapter 2.4, we demonstrated that the combined presence of unfavorable 
CRP and CFH genetic profiles is associated with risk of myocardial infarction.
Chapter 3 is a review on the emerging biomarker lipoprotein-associated phospholipase A2 (Lp-
PLA2) and cardiovascular disease. It addresses cohort studies that have examined Lp-PLA2 in relation 
to incident cardiovascular events, studies on Lp-PLA2 and measures of atherosclerosis, and studies 
on the Lp-PLA2 gene and cardiovascular disease. Overall, these studies suggest an independent, 
pro-atherogenic role for Lp-PLA2 in cardiovascular disease. Still, several issues remain to be further 
addressed and these are also discussed. In the Rotterdam Study, an association between Lp-PLA2 
activity and coronary calcification was found, but this association was not independent of cholesterol 
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(chapter 3.2). The same was true for the association of Lp-PLA2 activity with extracoronary athero-
sclerosis, also found in the Rotterdam Study (chapter 3.3).
In chapter 4.1, we addressed the role of genetic variants altering fibrinogen structure and func-
tion, and consequently fibrin structure, in atherogenesis. FGG and FGA fibrinogen haplotypes were 
not associated with coronary events, coronary calcification or extracoronary atherosclerosis. In chap-
ter 4.2, we examined whether baseline levels of heat shock protein 27 (HSP27) are associated with 
future cardiovascular events among initially healthy individuals, by means of a nested case-control 
study within the Women’s Health Study, a prospective study of initially healthy women. However, no 
such association could be demonstrated.
Part II focuses on inflammation and heart failure. First, the associations of established cardiovascular 
risk factors with echocardiographic parameters were examined in asymptomatic persons (chapter 
5.1). Ventricular systolic and diastolic dysfunction was present in participants that had not been di-
agnosed with heart failure or myocardial infarction. Higher age, higher BMI, lower systolic and higher 
diastolic blood pressure were most consistently associated with worse systolic function. Higher age 
and higher diastolic blood pressure were most consistently associated with lower E/A ratio. In chapter 
5.2, an association of selected structural and diastolic echocardiographic parameters with all-cause 
mortality was demonstrated.
Subsequently, the role of inflammation in heart failure was explored. Chapter 5.3 describes the 
positive association of CRP serum level with incident heart failure. In men, the association was partly 
explained by presence of coronary heart disease, whereas in women, it was partly explained by hy-
pertension and body mass index. The reason for this may lie in the fact that men are known to have 
coronary artery disease as an underlying factor for heart failure more frequently than women, and 
women are more likely to have hypertension as an underlying factor, and both coronary heart disease 
and hypertension are associated with CRP. In chapter 5.4, an independent association of Lp-PLA2 
activity with heart failure was demonstrated. Altogether, these findings support the hypothesis that 
inflammation plays a role in the development of heart failure.
Finally, in Part III, differences in prevalence of atherosclerosis between the genders are illustrated 
within the Rotterdam Study. We demonstrated that the gender difference in atherosclerosis in the 
coronary vessels is large, that it is particularly high in younger participants, and that it remains present 
at older age (chapter 6.1). The gender difference in the coronary vessels was found to be strikingly 
larger than in the other studied vascular beds. The gender difference in carotid atherosclerosis was 
also substantial, yet smaller, and less consistent. Remarkably, the difference in the aorta and the lower 
extremity vessels was virtually absent. The difference in gender ratio between sites was not explained 
by differences in cardiovascular risk factors. These findings underline the need for investigation of the 
causes of the site-specific gender differences in atherosclerosis, which may shed more light on the 
gender gap in coronary heart disease.
In chapter 7, the general discussion, methodological considerations with regard to the studies in this 
thesis are described; this includes aspects of observational studies and genetic association studies. 
Also, the main findings are reviewed in the context of ongoing research. Clinical implications, such as 
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usefulness of biomarkers for risk stratification, are addressed. Furthermore, future research directions 
including clinical trials and genome-wide association studies are discussed.
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Samenvatting 
Hart- en vaatziekten vormen nog steeds de belangrijkste doodsoorzaak in de westerse wereld. Een 
aanzienlijk deel van de gevallen betreft individuen bij wie geen van de bekende cardiovasculaire 
risicofactoren aanwezig is. Dit vormt een aanleiding om op zoek te gaan naar nieuwe, onbekende 
risicofactoren. In de afgelopen tien jaar is onderkend dat ontsteking een belangrijke rol speelt in hart- 
en vaatziekten. Inzicht in de rol van inflammatoire markers en genen in atherosclerose zou kunnen 
resulteren in een beter begrip van de pathofysiologie en zou daardoor de identificatie van individuen 
met een verhoogd risico kunnen vergemakkelijken.
In dit proefschrift hebben we de rol van in opkomst zijnde inflammatoire markers en genen in 
hart- en vaatziekten bestudeerd in een populatiegebaseerde setting. De meeste studies zijn uitge-
voerd binnen het Erasmus Rotterdam Gezondheid Onderzoek (ERGO), een studie in 7983 mannen 
en vrouwen van 55 jaar en ouder, wonend in de Rotterdamse wijk Ommoord. Inflammatoire markers 
en genetische varianten zijn bepaald in de deelnemers en hun verband met gevallen van coronaire 
hartziekte, coronaire calcificatie, extracoronaire atherosclerose en hartfalen is onderzocht.
Deel I is gericht op inflammatie, atherosclerose en coronaire hartziekte. Eerst is het verband tussen 
C-reactief proteïne (CRP) serum waarden, CRP gen haplotypes en het risico op coronaire hartziekte 
bestudeerd (hoofdstuk 2.1). CRP serum waarden waren geassocieerd met een hoger risico op coro-
naire hartziekten, en CRP gen haplotypes waren geassocieerd met CRP serum waarden. Echter, CRP 
gen haplotypes waren niet geassocieerd met coronaire hartziekten. Deze bevindingen ondersteunen 
een causale rol van CRP in het ontstaan van hart -en vaatziekten niet. In hoofdstuk 2.2 is het verband 
tussen CRP serum waarden en maten van atherosclerose onderzocht. Een onafhankelijk en gegra-
deerd verband is gevonden tussen CRP en mate van ernst en progressie van zowel carotisplaques als 
enkel-arm index. CRP vertoonde een onafhankelijk verband met de grootste intima-media dikte. De 
associatie met verandering van intima-media dikte was echter niet significant. Hoewel er onafhan-
kelijke, gegradeerde associatie was tussen CRP en aortacalcificatie, is er geen onafhankelijk verband 
gevonden met progressie van aortacalcificatie, noch met mate van coronaire calcificatie. Kortom, er 
waren gegradeerde associaties met mate en progressie van atherosclerose, doch de sterkte van de 
associaties hing af van de maat van atherosclerose die toegepast werd. Hoofdstuk 2.3 richt zich op 
de rol van complement factor H (CFH) in het ontstaan van een myocardinfarct. Een verband tussen het 
His allel van het Tyr402His genetische polymorfisme van het CFH gen en een verhoogd risico op het 
optreden van een myocardinfarct werd aangetoond. Deze bevinding onderstreept het belang van de 
alternatieve complement route bij het optreden van coronaire hartziekte. Mogelijk versterkt binding 
van CRP aan CFH het vermogen van CFH om het effect van complement in atherosclerotische lesies 
te verzwakken. In hoofdstuk 2.4 is aangetoond dat de gecombineerde aanwezigheid van zowel on-
gunstige genetische CRP varianten als de bovengenoemde ongunstige genetische CFH variant geas-
socieerd is met een verhoogd risico op het optreden van een myocardinfarct.
Hoofdstuk 3.1 is een overzicht van de literatuur over de in opkomst zijnde biomarker lipoproteï-
ne-gebonden fosfolipase A2 (Lp-PLA2) in relatie tot hart - en vaatziekten. Cohort studies die Lp-PLA2 
in relatie tot gevallen van hart - en vaatziekte hebben bestudeerd, worden besproken, net als studies 
over Lp-PLA2 en maten van atherosclerose, en studies over het Lp-PLA2 gen en cardiovasculaire aan-
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doeningen. In het algemeen suggereren deze studies dat Lp-PLA2 een onafhankelijke, pro-atheroge-
ne rol speelt in het ontstaan van hart-en vaatziekten. Toch zijn er enkele zaken die verdere aandacht 
behoeven; deze worden tevens besproken. In het ERGO onderzoek werd een verband gevonden tus-
sen Lp-PLA2 activiteit en coronaire calcificatie (hoofdstuk 3.2). Dit verband was echter niet onaf-
hankelijk van cholesterol. Dit gold ook voor het verband tussen Lp-PLA2 activiteit en extracoronaire 
atherosclerose, tevens aangetoond in het ERGO onderzoek (hoofdstuk 3.3).
Varianten in het fibrinogeen gen zijn van invloed op de structuur en functie van fibrinogeen, en 
derhalve ook op de structuur van fibrine. In hoofdstuk 4.1 werd onderzocht of deze varianten een 
rol spelen bij de atherogenese. De resultaten lieten zien dat FGG en FGA fibrinogeen haplotypes niet 
geassocieerd waren met het optreden van gevallen van coronaire hartziekte, noch met coronaire 
calcificatie, noch met extracoronaire atherosclerose. In hoofdstuk 4.2 werd onderzocht of baseline 
waarden van ‘heat shock’ eiwit 27 (HSP27) geassocieerd zijn met het toekomstige optreden van ge-
vallen van cardiovasculaire aandoeningen. Dit werd gedaan binnen de ‘Women’s Health Study’, een 
prospectieve studie in aanvankelijk gezonde vrouwen. Een dergelijk verband kon echter niet worden 
aangetoond
Deel II is gericht op inflammatie en hartfalen. Eerst werden de verbanden bestudeerd tussen cardio-
vasculaire risicofactoren en structurele, systolische en diastolische echocardiografische parameters 
in asymptomatische personen (hoofdstuk 5.1). Ventriculaire systolische en diastolische dysfunctie 
was aanwezig in deelnemers zonder hartfalen of myocardinfarct in hun voorgeschiedenis. Hogere 
leeftijd, hogere BMI, lagere systolische en hogere diastolische bloeddruk waren meest consistent ge-
associeerd met een slechtere systolische functie. Hogere leeftijd en hogere diastolische bloeddruk 
waren meest consistent geassocieerd met een lagere E/A ratio. In hoofdstuk 5.2 werd een verband 
aangetoond tussen bepaalde structurele en diastolische echocardiografische parameters en algehele 
mortaliteit.
Hierna werd de rol van inflammatie in het ontstaan van hartfalen onderzocht. In hoofdstuk 5.3 
werd een positief verband aangetoond tussen CRP serum waarden en incident hartfalen. In mannen 
werd het verband gedeeltelijk verklaard door de aanwezigheid van coronaire hartziekten, terwijl het 
in vrouwen gedeeltelijk werd verklaard door aanwezigheid van hypertensie en hogere body mass 
index. Een mogelijke verklaring hiervoor is dat in mannen, zoals bekend, coronaire hartziekten vaker 
de onderliggende oorzaak zijn voor hartfalen dan in vrouwen, terwijl in vrouwen, hypertensie vaker 
de onderliggende oorzaak is, en zowel coronaire hartziekten als hypertensie zijn geassocieerd met 
hogere CRP waarden. In hoofdstuk 5.4 werd een onafhankelijk verband tussen Lp-PLA2 activiteit en 
hartfalen aangetoond. Deze bevindingen ondersteunen de hypothese dat inflammatie een rol speelt 
bij het ontstaan van hartfalen.
Tenslotte worden in deel III verschillen in prevalentie van atherosclerose tussen mannen en vrouwen 
in het ERGO onderzoek geïllustreerd. We toonden aan dat het geslachtsverschil in de mate van athe-
rosclerose in de coronairvaten groot is, dat het met name indrukwekkend is in jongere deelnemers, en 
dat het blijft bestaan op oudere leeftijd (hoofdstuk 6.1). Het geslachtsverschil was opmerkelijk groter 
in de coronairvaten dan in de andere vaatbedden. In de carotisvaten was het verschil tevens substan-
tieel, echter duidelijk kleiner en minder consistent. Opmerkelijk was, dat het verschil in de aorta en 
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de vaten van de onderste extremiteit vrijwel afwezig bleek. Het verschil in de geslachtsratio tussen 
de locaties werd niet verklaard door verschillen in cardiovasculaire risicofactoren. Deze bevindingen 
onderstrepen het belang van onderzoek naar de oorzaken van de locatiegebonden geslachtsverschil-
len in atherosclerose. Deze oorzaken zouden meer inzicht kunnen verschaffen in het geslachtsverschil 
in het optreden van coronaire hartziekten.
In hoofdstuk 7, de algemene discussie, worden methodologische overwegingen met betrekking tot 
de studies in dit proefschrift beschreven, zowel wat betreft observationele studies als genetische as-
sociatie studies. Ook worden de belangrijkste bevindingen in het perspectief geplaatst van huidige 
inzichten. Klinische implicaties, zoals het nut van biomarkers voor risicostratificatie, worden bespro-
ken. Daarnaast wordt de richting van toekomstig onderzoek, waaronder klinische trials en genoom-
wijde associatie studies, bediscussieerd.
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